Sanofi (SNY) 20-F 13 Feb 25 2024 FY Annual report (foreign) Financial data

Cover page

Cover page	12 Months Ended
	Dec. 31, 2024 shares
Entity Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2024
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-31368
Entity Registrant Name	Sanofi
Entity Incorporation, State or Country Code	I0
Entity Address, Address Line One	46, avenue de la Grande Armée
Entity Address, Postal Zip Code	75017
Entity Address, City or Town	Paris
Entity Address, Country	FR
Entity Common Stock, Shares Outstanding	1,263,122,721
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Entity Central Index Key	0001121404
Business Contact
Entity Information [Line Items]
Contact Personnel Name	Roy Papatheodorou
Entity Address, Address Line One	46, avenue de la Grande Armée
Entity Address, Postal Zip Code	75017
Entity Address, City or Town	Paris
Entity Address, Country	FR
City Area Code	33
Local Phone Number	1 53 77 40 00
American Depositary Shares, each representing one half of one ordinary share, par value €2 per share
Entity Information [Line Items]
Title of 12(b) Security	American Depositary Shares, each representing one half of one ordinary share, par value €2 per share
Trading Symbol	SNY
Security Exchange Name	NASDAQ
Ordinary shares, par value €2 per share
Entity Information [Line Items]
Title of 12(b) Security	Ordinary shares, par value €2 per share
Security Exchange Name	NASDAQ

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Auditor [Line Items]
Auditor Name	PricewaterhouseCoopers Audit
Auditor Location	Neuilly-sur-Seine and Courbevoie, France
Auditor Firm ID	1347
Forvis Mazars
Auditor [Line Items]
Auditor Name	Forvis Mazars SA
Auditor Location	Neuilly-sur-Seine and Courbevoie, France
Auditor Firm ID	1334

Consolidated balance sheets

Consolidated balance sheets - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Assets
Property, plant and equipment	€ 10,091	€ 10,160		€ 9,869
Right-of-use assets	1,510	1,654		1,815
Goodwill	43,384	49,404		49,892
Other intangible assets	22,629	24,319		21,640
Investments accounted for using the equity method	316	424		677
Other non-current assets	3,753	3,218		3,095
Non-current income tax assets	560	188		242
Deferred tax assets	7,967	6,427		5,381
Non-current assets	90,210	95,794		92,611
Inventories	9,431	9,666		8,960
Accounts receivable	7,677	8,433		8,424
Other current assets	3,826	3,455		3,532
Current income tax assets	724	391		374
Cash and cash equivalents	7,441	8,710	[1]	12,736	[1]
Current assets	42,588	30,670		34,111
Non-current assets or disposal groups classified as held for sale	13,489	15		85
Total assets	132,798	126,464		126,722
Equity and liabilities
Equity attributable to equity holders of Sanofi	77,507	74,040		74,784
Equity attributable to non-controlling interests	350	313		368
Total equity	77,857	74,353		75,152
Long-term debt	11,791	14,347		14,857
Non-current lease liabilities	1,645	1,755		1,904
Non-current liabilities related to business combinations and to non-controlling interests	569	501		674
Non-current provisions and other non-current liabilities	8,096	7,602		6,341
Non-current income tax liabilities	1,512	1,842		1,979
Deferred tax liabilities	2,166	1,857		1,841
Non-current liabilities	25,779	27,904		27,596
Accounts payable	7,551	7,328		6,813
Current liabilities related to business combinations and to non-controlling interests	72	208		105
Current provisions and other current liabilities	14,241	13,741		12,021
Current income tax liabilities	697	597		574
Current lease liabilities	261	275		277
Short-term debt and current portion of long-term debt	4,209	2,045		4,174
Current liabilities	29,162	24,207		23,974
Liabilities included in disposal groups classified as held for sale	2,131	13		10
Total equity and liabilities	€ 132,798	€ 126,464		€ 126,722
[1] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).

Consolidated income statements

Consolidated income statements - EUR (€) € in Millions, shares in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	[1]	Dec. 31, 2022
Profit (loss) [abstract]
Net sales	€ 41,081	€ 37,817		€ 37,651	[1]
Other revenues	3,205	3,801	[2]	2,910	[1],[2]
Cost of sales	(13,205)	(12,628)		(11,882)	[1]
Gross profit	31,081	28,990		28,679	[1]
Research and development expenses	(7,394)	(6,507)		(6,501)	[1]
Selling and general expenses	(9,183)	(8,933)		(8,739)	[1]
Other operating income	1,089	979		1,814	[1]
Other operating expenses	(4,382)	(3,443)		(2,523)	[1]
Amortization of intangible assets	(1,749)	(1,911)		(1,804)	[1]
Impairment of intangible assets	(248)	(896)		429	[1]
Fair value remeasurement of contingent consideration	(96)	(93)		27	[1]
Restructuring costs and similar items	(1,396)	(1,030)	[3]	(1,077)	[1],[3]
Other gains and losses, and litigation	(470)	(196)		(143)	[1]
Operating income	7,252	6,960	[4]	10,162	[1],[4],[5]
Financial expenses	(1,073)	(1,293)	[4],[6]	(430)	[1],[4],[5],[6]
Financial income	519	584	[4],[6]	205	[1],[4],[5],[6]
Income before tax and investments accounted for using the equity method	6,698	6,251	[4],[7]	9,937	[1],[4],[5],[7]
Income tax expense	(1,204)	(1,017)	[7]	(1,909)	[1],[7]
Share of profit/(loss) from investments accounted for using the equity method	60	(136)		55	[1]
Net income from continuing operations	5,554	5,098		8,083	[1]
Net income excluding the exchanged/held-for-exchange Animal Health business	64	338		401	[1]
Net income	5,618	5,436		8,484	[1]
Net income attributable to non-controlling interests	58	36	[8]	113	[1],[8]
Net income attributable to equity holders of Sanofi	€ 5,560	€ 5,400		€ 8,371	[1]
Average number of shares outstanding (in shares)	1,251.4	1,251.7		1,251.9	[1]
Average number of shares after dilution (in shares)	1,256.1	1,256.4		1,256.9
Basic earnings per share excluding the exchanged/held-for-exchange Animal Health business (in euros per share)	€ 4.40	€ 4.06		€ 6.38	[1]
Diluted earnings per share (in euros per share)	4.39	4.05		6.35	[1]
Basic earnings (loss) per share from discontinued operations	0.04	0.25		0.31	[1]
Basic earnings (loss) per share	4.44	4.31		6.69	[1]
Diluted earnings (loss) per share from discontinued operations	0.04	0.25		0.31	[1]
Diluted earnings (loss) per share	€ 4.43	€ 4.30		€ 6.66	[1]
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. ( a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax) (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).

Consolidated statements of comp

Consolidated statements of comprehensive income - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Statement of comprehensive income [abstract]
Net income	€ 5,618	€ 5,436	[1]	€ 8,484	[1]
Attributable to equity holders of Sanofi	5,560	5,400	[1]	8,371	[1]
Attributable to non-controlling interests	58	36	[1],[2]	113	[1],[2]
Other comprehensive income:
Actuarial gains/(losses)	11	(168)		622
Change in fair value of equity instruments included in financial assets and financial liabilities	(20)	97		13
Tax effects	(18)	(6)		(204)
Items not subsequently reclassifiable to profit or loss (a)	(27)	(77)		431
Change in fair value of debt instruments included in financial assets	5	21		(77)
Change in fair value of cash flow hedges	(6)	(1)		7
Change in currency translation differences	2,470	(1,462)		2,332
Tax effects	19	(6)		105
Items subsequently reclassifiable to profit or loss(e)	2,488	(1,448)		2,367
Other comprehensive income from continuing operations	2,461	(1,525)		2,798
Other comprehensive income from discontinued operations	(29)	(78)		(34)
Comprehensive income	8,050	3,833		11,248
Attributable to equity holders of Sanofi	7,970	3,810		11,130
Comprehensive income, attributable to owners of parent, continuing operations	7,958	3,567		10,768
Attributable to non-controlling interests	80	23		118
Comprehensive income, attributable to owners of parent, discontinued operations	€ 12	€ 243		€ 362
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).

Consolidated statements of chan

Consolidated statements of changes in equity - EUR (€) € in Millions		Total		Attributable to equity holders of Sanofi		Share capital	Additional paid-in capital		Treasury shares	Reserves and retained earnings	Stock options and other share- based payments	Other comprehensive income	Attributable to non- controlling interests
Beginning balance at Dec. 31, 2021		€ 69,031		€ 68,681		€ 2,527	€ 532		€ (939)	€ 63,013	€ 4,405	€ (857)	€ 350
Other comprehensive income for the period		2,764		2,759						451		2,308	5
Net income for the period		8,484	[1]	8,371						8,371			113
Comprehensive income		11,248		11,130						8,822		2,308	118
Dividend paid out of earnings		(4,168)		(4,168)						(4,168)
Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi	[2]	793		793						793
Payment of dividends to non-controlling interests		(100)		0									(100)
Share repurchase program	[3]	(497)		(497)					(497)
Reduction in share capital	[3]	0				(13)	(587)		600	0
Share-based payment plans:
Exercise of stock options		35	[3]	35	[3]	1	34	[3]
Issuance of restricted shares and vesting of existing restricted shares	[3],[4]	0		0		3	(3)		130	(130)
Employee share ownership plan	[3]	153		153		4	149
Value of services obtained from employees		245		245							245
Tax effects on share-based payments		8		8							8
Other changes in non-controlling interests(d)		(10)		(10)						(10)
Ending balance at Dec. 31, 2022		€ 75,152		74,784		2,522	125		(706)	66,734	4,658	1,451	368
Share-based payment plans:
Dividends paid, ordinary shares per share (in EUR per share)		€ 3.33
Other comprehensive income for the period		€ (1,603)		(1,590)						(77)		(1,513)	(13)
Net income for the period		5,436	[1]	5,400						5,400			36
Comprehensive income		3,833		3,810						5,323		(1,513)	23
Dividend paid out of earnings		(4,454)		(4,454)						(4,454)
Payment of dividends to non-controlling interests		(59)		0									(59)
Share repurchase program	[3]	(593)		(593)					(593)
Exercise of stock options	[3]	37		37		1	36
Issuance of restricted shares and vesting of existing restricted shares	[3],[4]	0		0		3	(3)		115	(115)
Employee share ownership plan	[3]	159		159		4	155
Value of services obtained from employees		283		283							283
Tax effects on share-based payments		3		3							3
Other changes arising from issuance of restricted shares	[5]	2		2						2
Other changes in non-controlling interests		0		(1)						(1)			1
Other changes in non-controlling interests	[6]	(10)		9						9			(19)
Ending balance at Dec. 31, 2023		€ 74,353		74,040		2,530	313		(1,184)	67,499	4,944	(62)	313
Share-based payment plans:
Dividends paid, ordinary shares per share (in EUR per share)		€ 3.56
Other comprehensive income for the period		€ 2,432		2,410						(28)		2,438	22
Net income for the period		5,618		5,560						5,560			58
Comprehensive income		8,050		7,970						5,532		2,438	80
Dividend paid out of earnings		(4,704)		(4,704)						(4,704)
Payment of dividends to non-controlling interests		(44)		0									(44)
Share repurchase program	[3]	(302)		(302)					(302)
Reduction in share capital	[3]	0		0		(12)	(492)		530	(26)
Exercise of stock options	[3]	33		33		1	32
Issuance of restricted shares and vesting of existing restricted shares	[3],[4]	0		0		3	(3)		116	(116)
Employee share ownership plan	[3]	154		154		4	150
Value of services obtained from employees		305		305							305
Tax effects on share-based payments		11		11							11
Other changes arising from issuance of restricted shares	[5]	1		1						1
Ending balance at Dec. 31, 2024		€ 77,857		€ 77,507		€ 2,526	€ 0		€ (840)	€ 68,185	€ 5,260	€ 2,376	€ 350
Share-based payment plans:
Dividends paid, ordinary shares per share (in EUR per share)		€ 3.76
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation This a mount includes the valuation of the shares distributed as a dividend in kind, at a price of €14.58 per share, as of May 10, 2022 (see Note D.1.3). See Notes D.15.1., D.15.3., D.15.4. and D.15.5. This line includes the use of existing shares to fulfill vested rights under restricted share plans. This line comprises the impact of the i ssuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi lost control of EUROAPI . This line mainly comprises changes in non-controlling interests arising from divestments and acquisitions.

Consolidated statements of ch_2

Consolidated statements of changes in equity (Parenthetical) - € / shares			12 Months Ended
	May 10, 2022	May 03, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Dividends paid, ordinary shares per share (in EUR per share)			€ 3.76	€ 3.56	€ 3.33
EUROAPI
Exceptional supplementary dividend, percentage of share capital	5,800%	58%
Weighted average share price (in EUR per share)	€ 14.58

Consolidated statements of cash

Consolidated statements of cash flows - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021	[1]
Cash flows from (used in) operating activities [abstract]
Net income attributable to equity holders of Sanofi		€ 5,560	€ 5,400	[1]	€ 8,371	[1]
Net income excluding the exchanged/held-for-exchange Animal Health business	[1]	(64)	(338)		(401)
Net income attributable to non-controlling interests		58	36	[1],[2]	113	[1],[2]
Share of undistributed earnings from investments accounted for using the equity method		82	293	[1]	(45)	[1]
Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets		3,586	4,429	[1]	3,108	[1]
Gains and losses on disposals of non-current assets, net of tax	[3]	(366)	(364)	[1]	(590)	[1]
Net change in deferred taxes		(802)	(1,233)	[1]	(529)	[1]
Net change in non-current provisions and other non-current liabilities	[4]	812	105	[1]	48	[1]
Cost of employee benefits (share-based payments)		278	260	[1]	234	[1]
Impact of the workdown of acquired inventories remeasured at fair value		10	9	[1]	3	[1]
Other profit or loss items with no cash effect on cash flows generated by operating activities	[5]	68	261	[1]	120	[1]
Operating cash flow before changes in working capital from continuing operations		9,222	8,858	[1]	10,432	[1]
Adjustments to reconcile profit (loss) [abstract]
(Increase)/decrease in inventories		(477)	(866)	[1]	(918)	[1]
(Increase)/decrease in accounts receivable		(28)	(472)	[1]	(500)	[1]
Increase/(decrease) in accounts payable		789	258	[1]	340	[1]
Net change in other current assets and other current liabilities		(899)	1,493	[1]	284	[1]
Cash flows from (used in) operating activities, continuing operations	[6]	8,607	9,271	[1]	9,638	[1]
Net cash provided by/(used in) operating activities	[6]	9,081	10,258	[1]	10,526	[1]
Cash flows from (used in) operating activities, discontinued operations		474	987	[1]	888	[1]
Cash flows from (used in) investing activities [abstract]
Net cash provided by/(used in) operating activities from the discontinued Opella business		(3,195)	(2,906)	[1]	(2,103)	[1]
Acquisitions of consolidated undertakings and investments accounted for using the equity method	[7]	(1,901)	(2,535)	[1]	(987)	[1]
Acquisitions of other equity investments		(623)	(134)	[1]	(487)	[1]
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax	[8]	1,461	807	[1]	1,340	[1]
Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax	[9]	0	42	[1]	134	[1]
Net change in other non-current assets		(40)	(224)	[1]	(14)	[1]
Cash flows from (used in) investing activities, continuing operations		(4,298)	(4,950)	[1]	(2,117)	[1]
Net cash provided by/(used in) continuing investing activities		(4,407)	(6,200)	[1]	(2,075)	[1]
Cash flows from (used in) investing activities, discontinued operations	[10]	(109)	(1,250)	[1]	42	[1]
Cash flows from (used in) financing activities [abstract]
Net cash provided by/(used in) investing activities of the discontinued Opella business(i)		187	195	[1]	188	[1]
Dividends paid:
to shareholders of Sanofi		(4,704)	(4,454)	[1]	(4,168)	[1]
to non-controlling interests, excluding BMS		(38)	(56)	[1]	(97)	[1]
Payments received/(made) on changes of ownership interest in a subsidiary without loss of control		0	(3)	[1]	0	[1]
Additional long-term debt contracted		0	48	[1]	1,549	[1]
Repayments of long-term debt		(671)	(3,683)	[1]	(2,718)	[1]
Repayments of lease liabilities		(282)	(253)	[1]	(280)	[1]
Net change in short-term debt and other financial instruments	[11]	59	751	[1]	216	[1]
Acquisitions of treasury shares		(302)	(593)	[1]	(497)	[1]
Cash flows from (used in) financing activities, continuing operations		(5,751)	(8,048)	[1]	(5,807)	[1]
Net cash provided by/(used in) continuing financing activities		(5,763)	(8,052)	[1]	(5,821)	[1]
Cash flows from (used in) financing activities, discontinued operations		(12)	(4)	[1]	(14)	[1]
Impact of exchange rates on cash and cash equivalents		(13)	(32)	[1]	8	[1]
Effect of Reclassification of Discontinued Operation		(167)	0	[1]	0	[1]
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes		(1,269)	(4,026)	[1]	2,638	[1]
Cash and cash equivalents, beginning of period	[1]	8,710	12,736		10,098
Cash and cash equivalents at end of period		7,441	8,710	[1]	12,736	[1]
Cash and cash equivalents, discontinued operations		€ 167	€ 0	[1]	€ 0	[1]	€ 0
[1] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation Includes non-current financial assets. This line item includes contributions paid to pension funds (see Note D.19.1.). This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items. Including: 2024 2023 2022 • Income tax paid (3,291) (2,623) (2,452) • Interest paid (587) (559) (380) • Interest received 447 547 173 • Dividends received from non-consolidated entities 52 17 1 This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2024, it includes the net cash outflow relating to the acquisition of Inhibrx, Inc. (see Note D.1..1). For 2023, it includes the net cash outflow on the acquisitions of Provention Bio (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note D.1.) For 2024 , this line item includes the sale of the Enjaymo global rights to Recordati for pre-tax proceeds of €768 million . For 2023 and 2022 , this line item mainly comprises disposals of assets and activities related to portfolio streamlining, and disposals of equity and debt instruments. For 2022, this line item includes the net cash inflows (before taxes) of €101 million on the divestment of EUROAPI (see Note D.1.). For 2023, this line item includes the net cash outflow on the acquisition of QRIB (see Note D.1.) For 2024, this line item mainly includes a US commercial paper program for €262 million . For 2024 , 2023 and 2022 , it also includes realized foreign exchange differences on (i) cash and cash equivalents in non-functional currencies (primarily the US dollar) and (ii) derivative instruments used to manage such cash and cash equivalents.

Consolidated statements of ca_2

Consolidated statements of cash flows (Parenthetical) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Condensed Cash Flow Statements, Captions [Line Items]
Income tax paid		€ (3,291)	€ (2,623)		€ (2,452)
Interest paid		(587)	(559)		(380)
Interest received		447	547		173
Dividends received from non-consolidated entities		52	17		1
Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax	[1]	0	42	[2]	134	[2]
Net change in short-term debt and other financial instruments	[3]	59	751	[2]	216	[2]
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax	[4]	1,461	€ 807	[2]	1,340	[2]
Enjaymo global rights
Condensed Cash Flow Statements, Captions [Line Items]
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax		768
Commercial paper program in USA
Condensed Cash Flow Statements, Captions [Line Items]
Net change in short-term debt and other financial instruments		€ 262
EUROAPI
Condensed Cash Flow Statements, Captions [Line Items]
Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax					€ 101
[1] For 2022, this line item includes the net cash inflows (before taxes) of €101 million on the divestment of EUROAPI (see Note D.1.). Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). For 2024, this line item mainly includes a US commercial paper program for €262 million . For 2024 , 2023 and 2022 , it also includes realized foreign exchange differences on (i) cash and cash equivalents in non-functional currencies (primarily the US dollar) and (ii) derivative instruments used to manage such cash and cash equivalents. For 2024 , this line item includes the sale of the Enjaymo global rights to Recordati for pre-tax proceeds of €768 million . For 2023 and 2022 , this line item mainly comprises disposals of assets and activities related to portfolio streamlining, and disposals of equity and debt instruments.

Introduction

Introduction	12 Months Ended
	Dec. 31, 2024
General Information About Financial Statements [Abstract]
Introduction	Introduction Sanofi, together with its subsidiaries (collectively “Sanofi”, “the Group” or “the Company”), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. Sanofi is listed in Paris (Euronext: SAN) and New York (Nasdaq: SNY). The consolidated financial statements for the year ended December 31, 2024 , and the notes thereto, were signed off by the Sanofi Board of Directors on February 12, 2025.

Basis of preparation

Basis of preparation	12 Months Ended
	Dec. 31, 2024
Corporate information and statement of IFRS compliance [abstract]
Basis of preparation	Basis of preparation A.1. International financial reporting standards (IFRS) The consolidated financial statements cover the twelve-month periods ended December 31, 2024 , 2023 and 2022 . In accordance with Regulation No. 1606/2002 of the European Parliament and Council of July 19, 2002 on the application of international accounting standards, Sanofi has presented its consolidated financial statements in accordance with IFRS since January 1, 2005. The term “IFRS” refers collectively to international accounting and financial reporting standards (IASs and IFRSs) and to interpretations of the interpretations committees (SIC and IFRIC) with mandatory application as of December 31, 2024 . The consolidated financial statements of Sanofi as of December 31, 2024 have been prepared in compliance with IFRS as issued by the International Accounting Standards Board (IASB) and with IFRS as endorsed by the European Union as of December 31, 2024 . IFRS as endorsed by the European Union as of December 31, 2024 are available under the heading “IFRS Financial Statements” via the following web link: https://www.efrag.org/Endorsement The consolidated financial statements have been prepared in accordance with the IFRS general principles of fair presentation, going concern, accrual basis of accounting, consistency of presentation, materiality, and aggregation. A.2. New standards, amendments and interpretations A.2.1. New standards applicable from January 1, 2024 On September 22, 2022, the IASB issued an amendment to IFRS 16 (Leases) relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable from January 1, 2024 and had no impact on Sanofi's financial statements. On January 23, 2020, the IASB issued “Classification of Liabilities as Current or Non-current”, an amendment to IAS 1, and then on October 31, 2022 issued “Non-current Liabilities with Covenants”, a further amendment to IAS 1. The amendments, which are applicable from January 1, 2024, had no impact on Sanofi's financial statements. On May 25, 2023, the IASB issued " Su pplier Finance Arrangements ", amendments to IAS 7 and IFRS 7 , applicable from January 1, 2024. The amendments relate to disclosures of information about such arrangements , and have led to the following clarification: within Accounts payable , amounts representing payables that are managed via a paying agent contract under which a bank manages the settlement of Sanofi's trade accounts payable on behalf of Sanofi and that have already been paid to suppliers by the bank represented around 2% as of December 31, 2024. As those amounts are not material, Sanofi does not provide additional information in respect of those amendments. A.2.2. New pronouncements issued by the IASB and applicable from 2025 or later This note describes standards, amendments and interpretations issued by the IASB that will have mandatory application in 2025 or subsequent years, and Sanofi’s position regarding future application. On August 15, 2023, the IASB iss ued "Lack of Exchangeability", an am endment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable at the earliest from January 1, 2025 ; it will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it. On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard. On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact, and will not early adopt these amendments. On July 18, 2024, the IASB issued Volume 11 of its annual improvements to various standards, which are essentially in the nature of clarifications, applicable from January 1, 2026 at the earliest (subject to endorsement by the European Union). Sanofi does not expect any material impact, and will not early adopt these amendments. On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and IFRS 7, applicable (subject to endorsement by the European Union) from January 1, 2026. The amendments clarify the application of the ‘own use’ exemption to Power Purchase Agreements (PPAs) with physical delivery of renewable electricity, and modify the hedge accounting requirements for contracts without physical delivery (VPPAs). Sanofi does not expect any material impact and does not intend to early adopt these amendments. Renewable energy purchase contracts entered into by Sanofi as of December 31, 2024 are described in note D.21. A.3. Use of estimates and judgments The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date of the finalization of the financial statements. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include: • amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions (see Notes B.13. and D.23.); • impairment of property, plant and equipment and intangible assets (see Notes B.6. and D.5.); • the valuation of goodwill and the valuation and estimated useful life of acquired intangible assets (see Notes B.3.2., B.4., D.4. and D.5.); • the measurement of contingent consideration receivable in connection with asset divestments (see Notes B.8.5. and D.12.) and of contingent consideration payable (see Notes B.3. and D.18.); • the measurement of financial assets and liabilities at amortized cost (see Note B.8.5.); • the amount of post-employment benefit obligations (see Notes B.23. and D.19.1.); • the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks (see Notes B.12., B.19., B.20., D.19. and D.22.); and • the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences (see Notes B.22. and D.14.). Actual results could differ from these estimates. Management is also required to exercise judgment in assessing whether the criteria required under IFRS 5 (Non-Current Assets Held For Sale and Discontinued Operations) are met for (i) classifying a non-current asset or a group of assets as held for sale and (ii) presenting a discontinued operation on a separate line item in the consolidated balance sheet, income statement, statement of comprehensive income and cash flow statement. Such assessments are reviewed at the end of each reporting period each closing date to take account of changes in events and circumstances. In preparing the consolidated financial statements, Sanofi has also taken account of risks related to the effects of climate change and energy transition. As part of its Planet Care program, Sanofi has committed to move towards carbon neutrality by 2030 and net zero emissions by 2045 for its Scope 1, 2 and 3 emissions. That involves: • aiming for a 55% reduction in greenhouse gas (GHG) emissions from Sanofi’s own activities (Scopes 1 & 2) and a 30% reduction in Scope 3 GHG emissions by 2030 (versus a 2019 baseline), and a 90% reduction in GHG emissions (all scopes) by 2045. These objectives have been validated by the Science Based Target initiative (STBi); • supplying all our sites with 100% renewably-sourced electricity by 2030; • promoting an eco-friendly vehicle fleet by 2030; and • engaging the Sanofi supply chain in reducing Scope 3 emissions. The analysis of climate-related physical and transition risks facing Sanofi was updated in 2023 on the basis of three global warming scenarios out to 2030 and 2050. A number of assumptions – on issues such as carbon costs, natural disasters, water stress, raw material scarcity and logistics disruption – were built into this analysis, which also takes account of certain capital expenditures on mitigations derived from the Planet Care roadmap. In preparing the consolidated financial statements, that analysis was taken into account as follows: • the value of intangible assets and property, plant and equipment was subject to impairment testing conducted at CGU level, as described in Note D.5. Certain climate-related assumptions, such as the evolution of energy costs, transitioning to sustainable agriculture, and waste management, are already built into the forecast used for impairment testing purposes. For those assumptions not yet built into budgets, sensitivity analyses can be performed as needed; • the periodic reviews conducted on the useful lives of property, plant and equipment take account of environmental regulatory constraints, including not only GHG emissions but also physical risks; • environmental risks are covered by provisions on the basis described in Note D.19.3.; and • the credit facilities available to Sanofi as of December 31, 2024 incorporate performance objectives, including objectives related to cutting Sanofi’s carbon footprint, which could reduce the cost of debt if they are attained (see Note D.17.). It is important to bear in mind that estimating climate change related risks involves an element of unpredictability. Uncertainties may arise from factors such as changes in government policy, rapid technological change, and varied responses from stakeholders. That high level of uncertainty adds complexity to assessment of the potential impacts on our operations, and to how those impacts are reflected in our budgets. Actual impacts on Sanofi’s profits and financial position could therefore differ from initial estimates. Finally, in line with its environmental protection objectives, Sanofi has initiated projects to build eco-design into its products so as to limit their environmental impacts over their entire life cycle. Those projects will require Sanofi to redefine all of its production methods, and as such have also been built into definitions of the useful lives of Sanofi production facilities. A.4. Hyperinflation In 2024 , Sanofi continued to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial. In Argentina, the cumulative rate of inflation over the last three years is in excess of 100% , based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July 1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level. In Turkey, the cumulative rate of inflation over the last three years is in excess of 100% based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January 1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level. A.5. Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK On February 18, 2020, Sanofi and the US Department of Health and Human Services extended their research and development partnership to leverage Sanofi’s previous development work on a SARS vaccine to attempt to unlock a fast path forward for developing a COVID-19 vaccine. Under the terms of the collaboration, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services, is helping to fund the research and development undertaken by Sanofi. On April 14, 2020, Sanofi and GlaxoSmithKline (GSK) entered into a collaboration agreement to develop a recombinant COVID-19 vaccine candidate, with Sanofi contributing its S‑protein COVID-19 antigen (based on recombinant DNA technology) and GSK contributing its pandemic adjuvant technology. Sanofi is leading clinical development and the registration process for the vaccine. On July 31, 2020, the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK was selected by the US government’s Operation Warp Speed (OWS) program. Under the OWS, the US government is providing funds to support further development of the vaccine, including clinical studies and scaling-up of manufacturing capacity. Initially, the agreement also provided for the supply of 100 million doses of the vaccine. In light of the evolving context of the pandemic (including variants of the virus) and the availability of vaccines on the market, the parties decided to review the initial supply contract. At the end of 2023, the agreement was amended in respect of the supply clause, confirming that Sanofi had fulfilled its contractual obligations and setting the amount of compensation paid to Sanofi. On the basis of that signed amendment, Sanofi recognized an amount of €411 million within the line item Other revenues ; that amount was paid to Sanofi in December 2023. Sanofi has recognized the funding received from the US government as a deduction from the development expenses incurred, in accordance with IAS 20 (Accounting for Government Grants and Disclosure of Government Assistance). The amount of government aid received from the US federal government and BARDA and recognized as a deduction from development expenses and other operating expenses was €58 million in 2024, compared with €59 million in 2023 and €265 million in 2022. In September 2020, Sanofi and GSK signed pre-order contracts with the Canadian and UK governments and with the European Union for doses of the vaccine candidate. During 2021, Sanofi and GSK contractualized with the Canadian and UK governments and with the European Union on the number of doses ordered. On December 15, 2021, Sanofi and GSK announced positive preliminary data on their COVID-19 booster vaccine candidate and indicated that their Phase 3 study was to continue, based on recommendations from an independent monitoring board. On November 10, 2022, in line with the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, the European Commission approved VidPrevtyn Beta vaccine as booster for the prevention of COVID-19 in adults aged 18 years and older. Designed to provide broad protection against multiple variants, this protein-based COVID-19 booster vaccine is based on the Beta variant antigen and includes GSK’s pandemic adjuvant. VidPrevtyn Beta is indicated as a booster for active immunization against SARS-CoV-2 in adults who have previously received an mRNA or adenoviral COVID-19 vaccine. On December 21, 2022, following the European Commission approval, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved VidPrevtyn Beta vaccine for the prevention of COVID-19 in adults aged 18 and over within the UK. In accordance with IFRS 15 (see Note B.13.1.), Sanofi recognizes revenue when control over the product is transferred to the customer (for vaccines, transfer of control is determined by reference to the terms of release and acceptance of batches of vaccine). Payments received subsequent to signature of vaccine pre-order contracts relating to doses not yet delivered are customer contract liabilities (i.e. an obligation for the entity to supply goods to a customer, for which consideration has been received from the customer). They are presented within “Customer contract liabilities” in the balance sheet (see Note D.19.5.), and within “Net change in other current assets and other current liabilities” in the statement of cash flows. The pre-order contracts for Canada, the United Kingdom and the European Union expired in 2023. The customer contract liabilities, which amounted to €269 million as of December 31, 2022 and €319 million as of December 31, 2021 (see Note D.19.5., “ Current provisions and other current liabilities” ) were released to profit or loss in 2023, including an amount of €94 million classified in Other revenue in respect of doses which there was no longer an obligation to deliver as of December 31, 2023.

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Corporate information and statement of IFRS compliance [abstract]
Summary of significant accounting policies	Summary of significant accounting policies Basis of consolidation In accordance with IFRS 10 (Consolidated Financial Statements), the consolidated financial statements of Sanofi include the financial statements of entities that Sanofi controls directly or indirectly, regardless of the level of the equity interest in those entities. An entity is controlled when Sanofi has power over the entity, exposure or rights to variable returns from its involvement with the entity, and the ability to affect those returns through its power over the entity. In determining whether control exists, potential voting rights must be taken into account if those rights are substantive, in other words they can be exercised on a timely basis when decisions about the relevant activities of the entity are to be taken. Entities consolidated by Sanofi are referred to as “subsidiaries”. Entities that Sanofi controls by means other than voting rights are referred to as “consolidated structured entities”. In accordance with IFRS 11 (Joint Arrangements), Sanofi classifies its joint arrangements (i.e. arrangements in which Sanofi exercises joint control with one or more other parties) either as a joint operation (in which case, Sanofi recognizes the assets and liabilities of the operation in proportion to its rights and obligations relating to those assets and liabilities) or as a joint venture. Sanofi exercises joint control over a joint arrangement when decisions relating to the relevant activities of the arrangement require the unanimous consent of Sanofi and the other parties with whom control is shared. Sanofi exercises significant influence over an entity when it has the power to participate in the financial and operating policy decisions of that entity, but does not have the power to exercise control or joint control over those policies. In accordance with IAS 28 (Investments in Associates and Joint Ventures), the equity method is used to account for joint ventures (i.e. entities over which Sanofi exercises joint control) and for associates (i.e. entities over which Sanofi exercises significant influence). Under the equity method, the investment is initially recognized at cost, and subsequently adjusted to reflect changes in the net assets of the associate or joint venture. IAS 28 does not specify the treatment to be adopted on first-time application of the equity method to an investee following a step acquisition. Consequently, by reference to paragraph 10 of IAS 28, Sanofi has opted to apply the cost method, whereby the carrying amount of the investment represents the sum of the historical cost amounts for each step in the acquisition. As of the date on which the equity method is first applied, goodwill (which is included in the carrying amount of the investment) is determined for each acquisition step. The same applies to subsequent increases in the percentage interest in the equity-accounted investment. When the criteria of IFRS 5 are met, Sanofi recognizes the equity interest within the balance sheet line item Assets held for sale . The equity method is not applied to equity interests that are classified as held for sale assets. Transactions between consolidated companies are eliminated, as are intragroup profits. A list of the principal companies included in the consolidation in 2024 is presented in Note F. Foreign currency translation B.2.1. Accounting for foreign currency transactions in the financial statements of consolidated entities Non-current assets and inventories acquired in foreign currencies are translated into the functional currency using the exchange rate prevailing at the acquisition date. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the end of the reporting period. The gains and losses resulting from foreign currency translation are recorded in the income statement. However, foreign exchange gains and losses arising from the translation of advances between consolidated subsidiaries for which settlement is neither planned nor likely to occur in the foreseeable future are recognized in equity, in the line item Change in currency translation differences. B.2.2. Foreign currency translation of the financial statements of foreign entities Sanofi presents its consolidated financial statements in euros (€). In accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates), each subsidiary accounts for its transactions in the currency that is most representative of its economic environment (the functional currency). All assets and liabilities are translated into euros using the exchange rate of the subsidiary’s functional currency prevailing at the end of the reporting period. Income statements are translated using a weighted average exchange rate for the period, except in the case of foreign subsidiaries in a hyperinflationary economy. The resulting currency translation difference is recognized as a separate component of equity in the consolidated statement of comprehensive income, and is recognized in the income statement only when the subsidiary is sold or is wholly or partially liquidated. Business combinations and transactions with non-controlling interests B.3.1. Accounting for business combinations, transactions with non-controlling interests and loss of control Business combinations are accounted for in accordance with IFRS 3 (Business Combinations) and IFRS 10 (Consolidated Financial Statements). Business combinations are accounted for using the acquisition method. Under this method, the acquiree’s identifiable assets and liabilities that satisfy the recognition criteria of IFRS 3 (Business Combinations) are measured initially at their fair values at the date of acquisition, except for (i) non-current assets classified as held for sale (which are measured at fair value less costs to sell) and (ii) assets and liabilities that fall within the scope of IAS 12 (Income Taxes) and IAS 19 (Employee Benefits). Restructuring liabilities are recognized as a liability of the acquiree only if the acquiree has an obligation as of the acquisition date to carry out the restructuring. The principal accounting rules applicable to business combinations and transactions with non-controlling interests include: • acquisition-related costs are recognized as an expense, as a component of Operating income ; • contingent consideration is recognized in equity if the contingent payment is settled by delivery of a fixed number of the acquirer’s equity instruments; otherwise, it is recognized i n liabilities related to business combinations. Contingent consideration is recognized at fair value at the acquisition date irrespective of the probability of payment. If the contingent consideration was originally recognized as a financial liability, subsequent adjustments to the liability are recognized in profit or loss in the line item Fair value remeasurement of contingent consideration , unless the adjustment is made within the 12 months following the acquisition date and relates to facts and circumstances existing as of that date; and • goodwill may be calculated on the basis of either (i) the entire fair value of the acquiree, or (ii) a share of the fair value of the acquiree proportionate to the interest acquired. This option is elected for each acquisition individually. Purchase price allocations are performed under the responsibility of management, with assistance from an independent valuer in the case of major acquisitions. IFRS 3 does not specify an accounting treatment for contingent consideration arising from a business combination made by an entity prior to the acquisition of control in that entity and carried as a liability in the acquired entity’s balance sheet. The accounting treatment applied by Sanofi to such a liability is to measure it at fair value as of the acquisition date and to report it in the line item Liabilities related to business combinations and to non-controlling interests, with subsequent remeasurements recognized in profit or loss. This treatment is consistent with the accounting applied to contingent consideration in the books of the acquirer. Finally, management may where it deems fit elect to apply the optional test to identify concentration of fair value permitted under IFRS 3 in order to determine whether a transaction is a business combination within the meaning of IFRS 3, or merely the acquisition of an asset or of a group of similar assets. B.3.2. Goodwill The excess of the cost of an acquisition over Sanofi’s interest in the fair value of the identifiable assets and liabilities of the acquiree is recognized as goodwill at the date of the business combination. Goodwill arising on the acquisition of subsidiaries is shown in a separate balance sheet line item, whereas goodwill arising on the acquisition of investments accounted for using the equity method is recorded in Investments accounted for using the equity method. Goodwill arising on foreign operations is expressed in the functional currency of the country concerned and translated into euros using the exchange rate prevailing at the end of the reporting period. In accordance with IAS 36 (Impairment of Assets), goodwill is carried at cost less accumulated impairment (see Note B.6.). Goodwill is tested for impairment annually and whenever events or circumstances indicate that impairment might exist. Such events or circumstances include significant changes more likely than not to have an other-than-temporary impact on the substance of the original investment. Other intangible assets Other intangible assets are initially measured at acquisition cost or production cost, including any directly attributable costs of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. Intangible assets are amortized on a straight line basis over their useful lives. The useful lives of other intangible assets are reviewed at the end of each reporting period. The effect of any adjustment to useful lives is recognized prospectively as a change in accounting estimate. Amortization of other intangible assets is recognized in the income statement within Amortization of intangible assets except for amortization charged against (i) acquired or internally-developed software and (ii) other rights of an industrial or operational nature, which is recognized in the relevant classification of expense by function. Sanofi does not own any intangible assets with an indefinite useful life, other than goodwill. Intangible assets (other than goodwill) are carried at cost less accumulated amortization and accumulated impairment, if any, in accordance with IAS 36 (see Note B.6.). B.4.1. Research and development not acquired in a business combination Internally generated research and development Under IAS 38, research expenses are recognized in profit or loss when incurred. Internally generated development expenses are recognized as an intangible asset if, and only if, all the following six criteria can be demonstrated: (a) the technical feasibility of completing the development project; (b) Sanofi’s intention to complete the project; (c) Sanofi’s ability to use the project; (d) the probability that the project will generate future economic benefits; (e) the availability of adequate technical, financial and other resources to complete the project; and (f) the ability to measure the development expenditure reliably. Due to the risks and uncertainties relating to regulatory approval and to the research and development process, the six criteria for capitalization are usually considered not to have been met until the product has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical studies, are generally expensed as incurred within Research and development expenses . Some industrial development expenses (such as those incurred in developing a second-generation synthesis process) are incurred after marketing approval has been obtained, in order to improve the industrial process for an active ingredient. To the extent that the six IAS 38 criteria are considered as having been met, such expenses are recognized as an asset in the balance sheet within Other intangible assets as incurred. Similarly, some clinical studies, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS 38, in which case the related expenses are recognized as an asset in the balance sheet within Other intangible assets . Separately acquired research and development Payments for separately acquired research and development are capitalized within Other intangible assets provided that they meet the definition of an intangible asset: a resource that is (i) controlled by Sanofi, (ii) expected to provide future economic benefits for Sanofi, and (iii) identifiable (i.e. it is either separable or arises from contractual or legal rights). Under paragraph 25 of IAS 38, the first condition for capitalization (the probability that the expected future economic benefits from the asset will flow to the entity) is considered to be satisfied for separately acquired research and development. Consequently, upfront and milestone payments to third parties related to pharmaceutical products for which marketing approval has not yet been obtained are recognized as intangible assets, and amortized on a straight line basis over their useful lives beginning when marketing approval is obtained. Payments under research and development arrangements relating to access to technology or to databases, and payments made to purchase generics dossiers, are also capitalized, and amortized over the useful life of the intangible asset. Subcontracting arrangements, payments for research and development services, and continuous payments under research and development collaborations which are unrelated to the outcome of that collaboration, are expensed over the service term. B.4.2. Other intangible assets not acquired in a business combination Licenses other than those related to pharmaceutical products and research projects, in particular software licenses, are capitalized at acquisition cost, including any directly attributable cost of preparing the software for its intended use. Software licenses are amortized on a straight line basis over their useful lives for Sanofi ( three to five years ). Internally generated costs incurred to develop or upgrade software are capitalized if the IAS 38 recognition criteria are satisfied, and amortized on a straight line basis over the useful life of the software from the date on which the software is ready for use. B.4.3. Other intangible assets acquired in a business combination Other intangible assets acquired in a business combination (in-process research and development, technology platforms, and currently marketed products) that are reliably measurable are identified separately from goodwill, measured at fair value, and capitalized within Other intangible assets in accordance with IFRS 3 (Business Combinations) and IAS 38 (Intangible Assets). The related deferred tax liability is also recognized if a deductible or taxable temporary difference exists. In-process research and development acquired in a business combination is amortized on a straight line basis over its useful life from the date of receipt of marketing approval. Rights to technology platforms and to products currently marketed by Sanofi are amortized on a straight line basis over their useful lives, determined (in particular for marketed products) on the basis of cash flow forecasts which take into account the patent protection period of the marketed product. Property, plant and equipment owned and leased B.5.1. Property, plant and equipment owned Property, plant and equipment is initially measured and recognized at acquisition cost, including any directly attributable cost of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. The component-based approach to accounting for property, plant and equipment is applied. Under this approach, each component of an item of property, plant and equipment with a cost which is significant in relation to the total cost of the item and which has a different useful life from the other components must be depreciated separately. After initial measurement, property, plant and equipment is carried at cost less accumulated depreciation and impairment, except for land which is carried at cost less impairment. Subsequent costs are not recognized as assets unless (i) it is probable that future economic benefits associated with those costs will flow to Sanofi and (ii) the costs can be measured reliably. Borrowing costs attributable to the financing of items of property, plant and equipment, and incurred during the construction period, are capitalized as part of the acquisition cost of the item. Government grants relating to property, plant and equipment are deducted from the acquisition cost of the asset to which they relate. The depreciable amount of items of property, plant and equipment, net of any residual value, is depreciated on a straight line basis over the useful life of the asset. The useful life of an asset is usually equivalent to its economic life. The customary useful lives of property, plant and equipment are as follows: Buildings 15 to 40 years Fixtures 10 to 20 years Machinery and equipment 5 to 15 years Other 3 to 15 years Useful lives and residual values of property, plant and equipment are reviewed annually. The effect of any adjustment to useful lives or residual values is recognized prospectively as a change in accounting estimate. Depreciation of property, plant and equipment is recognized as an expense in the income statement, in the relevant classification of expense by function. B.5.2. Property, plant and equipment leased Leases contracted by Sanofi have been accounted for in accordance with IFRS 16 (Leases). Sanofi recognizes a right-of-use asset and a lease liability for all of its lease contracts, except for (i) leases relating to low-value assets and (ii) short-term leases (12 months or less). Payments made in respect of leases not recognized on the balance sheet are recognized as an operating expense on a straight line basis over the lease term. On commencement of a lease, the liability for future lease payments is discounted at the incremental borrowing rate, which is a risk-free rate adjusted to reflect the specific risk profile of each Sanofi entity. Because lease payments are spread over the lease term, Sanofi applies a discount rate based on the duration of those payments. The payments used to determine the liability for future lease payments exclude non-lease components, but include fixed payments that Sanofi expects to make to the lessor over the estimated lease term. After commencement of the lease, the liability for future lease payments is reduced by the amount of the lease payments made, and increased to reflect interest on the liability. In the event of a reassessment or modification of future lease payments, the lease liability is remeasured. The right-of-use asset – which is initially measured at cost including direct costs of the lessee, prepayments made at or prior to the commencement date, less lease incentives received and restoration costs – is depreciated on a straight line basis over the lease term, and tested for impairment as required. Sanofi recognizes deferred taxes in respect of right-of-use assets and lease liabilities. Leasehold improvements are depreciated over their economic life, which is capped at the lease term as determined under IFRS 16. Impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method B.6.1. Impairment of property, plant and equipment and intangible assets In accordance with IAS 36 (Impairment of Assets), assets that generate separate cash flows and assets included in cash- generating units (CGUs) are assessed for impairment when events or changes in circumstances indicate that the asset or CGU may be impaired. A CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. Under IAS 36, each CGU or group of CGUs to which goodwill is allocated must (i) represent the lowest level within the entity at which the goodwill is monitored for internal management purposes, and (ii) not be larger than an operating segment determined in accordance with IFRS 8 (Operating Segments), before application of the IFRS 8 aggregation criteria (see Note B.26.). Quantitative and qualitative indications of impairment (primarily relating to the status of the research and development portfolio, pharmacovigilance, patent litigation, and the launch of competing products) are reviewed at the end of each reporting period. If there is any internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset or CGU. Other intangible assets not yet available for use (such as capitalized in-process research and development), and CGUs or groups of CGUs that include goodwill, are tested for impairment annually whether or not there is any indication of impairment, and more frequently if any event or circumstance indicates that they might be impaired. Such assets are not amortized. When there is an internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset and recognizes an impairment loss if the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of the asset is the higher of its fair value less costs to sell or its value in use. To determine value in use, Sanofi uses estimates of future cash flows generated by the asset or CGU, prepared using the same methods as those used in the initial measurement of the asset or CGU on the basis of medium-term strategic plans. In the case of goodwill, estimates of future cash flows are based on a six-year strategic plan and a terminal value. In the case of other intangible assets, the period used is based on the economic life of the asset. Estimated cash flows are discounted at long-term market interest rates that reflect the best estimate by Sanofi of the time value of money, the risks specific to the asset or CGU, and economic conditions in the geographical regions in which the business activity associated with the asset or CGU is located. Certain assets and liabilities that are not directly attributable to a specific CGU are allocated between CGUs on a basis that is reasonable, and consistent with the allocation of the corresponding goodwill. Impairment losses arising on property, plant and equipment, software and certain rights, are recognized within the appropriate income statement line item according to the origin of the impairment. Impairment losses arising on other intangible assets (products, trademarks, technology platforms, acquired R&D) are recognized within Impairment of intangible assets in the income statement. B.6.2. Impairment of investments accounted for using the equity method In accordance with IAS 28 (Investments in Associates and Joint Ventures), Sanofi determines whether investments accounted for using the equity method may be impaired based on indicators such as default in contractual payments, significant financial difficulties, probability of bankruptcy, or a prolonged or significant decline in quoted market price. If an investment is impaired, the amount of the impairment loss is determined by applying IAS 36 (see Note B.6.1.) and recognized in Share of profit/(loss) from investments accounted for using the equity method. B.6.3. Reversals of impairment losses charged against property, plant and equipment, intangible assets, and investments accounted for using the equity method At the end of each reporting period, Sanofi assesses whether events or changes in circumstances indicate that an impairment loss recognized in a prior period in respect of an asset (other than goodwill) or an investment accounted for using the equity method can be reversed. If this is the case, and the recoverable amount as determined based on the revised estimates exceeds the carrying amount of the asset, Sanofi reverses the impairment loss only to the extent of the carrying amount that would have been determined had no impairment loss been recognized for the asset. Reversals of impairment losses in respect of other intangible assets are recognized within the income statement line item Impairment of intangible assets , while reversals of impairment losses in respect of investments accounted for using the equity method are recognized within the income statement line item Share of profit/(loss) from investments accounted for using the equity method . Impairment losses taken against goodwill are never reversed, unless the goodwill is part of the carrying amount of an investment accounted for using the equity method. Assets held for sale and liabilities related to assets held for sale and discontinued operations In accordance with IFRS 5 (Non-Current Assets Held for sale and Discontinued Operations), non-current assets and groups of assets are classified as held for sale in the balance sheet if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Within the meaning of IFRS 5, the term “sale” also includes exchanges for other assets. Non-current assets or asset groups held for sale must be available for immediate sale in their present condition, subject only to terms that are usual and customary for sales of such assets, and a sale must be highly probable. Criteria used to determine whether a sale is highly probable include: • the appropriate level of management must be committed to a plan to sell; • an active program to locate a buyer and complete the plan must have been initiated; • the asset must be actively marketed for sale at a price that is reasonable in relation to its current fair value; • completion of the sale should be foreseeable within the 12 months following the date of reclassification to Assets held for sale ; and • actions required to complete the plan should indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Before initial reclassification of the non-current asset (or asset group) to Assets held for sale , the carrying amounts of the asset (or of all the assets and liabilities in the asset group) must be measured in accordance with the applicable standards. Subsequent to reclassification to Assets held for sale , the non-current asset (or asset group) is measured at the lower of carrying amount or fair value less costs to sell, with any write-down recognized by means of an impairment loss. Once a non-current asset has been reclassified as held for sale or exchange, it is no longer depreciated or amortized. From the date of reclassification: • property, plant and equipment, right-of-use assets and intangible assets are no longer subject to individual depreciation, amortization or impairment; and • the share of profits and losses from investments accounted for using the equity method is no longer recognized. In a disposal of an equity interest leading to loss of control, all the assets and liabilities of the entity involved are classified as held for sale assets or liabilities within the balance sheet line items Assets held for sale or Liabilities related to assets held for sale , provided that the disposal satisfies the IFRS 5 classification criteria. The profit or loss generated by a held for sale asset group is reported in a separate line item in the income statement for the current period and for the comparative periods presented, provided that the asset group: • represents a separate major line of business or geographical area of operations; or • is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or • is a subsidiary acquired exclusively with a view to resale. In accordance with IFRS 10, intragroup balances and transactions relating to held for sale entities are eliminated. In the absence of any specific accounting treatment under IFRS 5, Sanofi has opted to eliminate transactions between discontinued operations and continuing operations so as to reflect the impact of such transactions consistently with the way they are presented in the income statement after effective loss of control. Events or circumstances beyond Sanofi’s control may extend the period to complete the sale or exchange beyond one year without precluding classification of the asset (or disposal group) in Assets held for sale provided that there is sufficient evidence that Sanofi remains committed to the planned sale or exchange. Finally, in the event of changes to a plan of sale that requires an asset no longer to be classified as held for sale, IFRS 5 specifies the following treatment: • the assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods; • each asset is measured at the lower of (a) its carrying amount before the asset was reclassified as held for sale, adjusted for any depreciation, amortization or revaluation that would have been recognized if the asset had not been reclassified as held for sale, or (b) its recoverable amount at the date of reclassification; • the backlog of depreciation, amortization and impairment not recognized while non-current assets were classified as held for sale must be reported in the same income statement line item that was used to report impairment losses arising on initial reclassification of assets as held for sale and gains or losses arising on the sale of such assets. In the consolidated income statement, those impacts are reported within the line item Other gains and losses, and litigation ; • the net income of a business previously classified as discontinued or as held for sale or exchange and reported on a separate line in the income statement must be reclassified and included in net income from continuing operations, for all periods presented; and • in addition, segment information relating to the income statement and the statement of cash flows (acquisitions of non- current assets) must be disclosed in the notes to the financial statements in accordance with IFRS 8 (Operating Segments), and must also be restated for all prior periods presented. Financial instruments B.8.1. Non-derivative financial assets In accordance with IFRS 9 (Financial Instruments) and IAS 32 (Financial Instruments: Presentation), Sanofi has adopted the classification of non-derivative financial assets described below. The classification used depends on (i) the characteristics of the contractual cash flows (i.e. whether they represent interest or principal) and (ii) the business model for managing the asset applied at the time of initial recognition. Financial assets at fair value through other comprehensive income These mainly comprise: • quoted and unquoted equity investments that Sanofi does not hold for trading purposes and that management has designated at “fair value through other comprehensive income” on initial recognition. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such instruments are derecognized, the previously-recognized changes in fair value remain within Other comprehensive income , as does the gain or loss on divestment. Dividends received are recognized in profit or loss for the period, within the line item Financial income ; and • debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items Financial income or Financial expenses . Financial a	Other operating income and expenses B.16.1. Other operating income Other operating income includes the share of profits that Sanofi is entitled to receive from alliance partners in respect of product marketing agreements. It also includes revenues generated under certain agreements, which may include partnership, co-promotion arrangements and licenses not included in Other revenues . This line item also includes realized and unrealized foreign exchange gains and losses on operating activities (see Note B.8.3.), and operating gains on disposals not regarded as major disposals (see Note B.20.). B.16.2. Other operating expenses Other operating expenses mainly comprise the share of profits that alliance partners are entitled to receive from Sanofi under product marketing agreements. Fair value remeasurement of contingent consideration Changes in the fair value of contingent consideration that was (i) already carried in the books of an acquired entity, or (ii) granted in connection with a business combination and initially recognized as a liability in accordance with IFRS 3, are reported in profit or loss. Such adjustments are reported separately in the income statement, in the line item Fair value remeasurement of contingent consideration . This line item also includes changes in the fair value of contingent consideration receivable in connection with a divestment and classified as a financial asset at fair value through profit or loss. Finally, it includes the effect of the unwinding of discount, and of exchange rate movements where the asset or liability is expressed in a currency other than the functional currency of the reporting entity. Restructuring costs and similar items Restructuring costs are expenses incurred in connection with the transformation or reorganization of Sanofi’s operations or support functions. Such costs include collective redundancy plans, compensation to third parties for early termination of contracts, and commitments made in connection with transformation or reorganization decisions. They also include accelerated depreciation charges arising from site closures (including closures of leased sites), and losses on asset disposals resulting from such decisions. In addition, this line item includes expenses incurred in connection with programs implemented as part of the transformation strategy announced in December 2019 and recently renewed in October 2023, and intended primarily to deliver a global information systems solution, further supported by the implementation from 2021 of Sanofi’s n ew digital strategy . Other gains and losses, and litigation The line item Other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount which Sanofi believes it necessary to report separately in the income statement in order to improve the relevance of the financial statements, such as: • gains and losses on major disposals of property, plant and equipment, of intangible assets, of assets (or groups of assets and liabilities) held for sale, or of a business within the meaning of IFRS 3, other than those considered to be restructuring costs; • impairment losses and reversals of impairment losses on assets (or groups of assets and liabilities) held for sale, other than those considered to be restructuring costs; • gains on bargain purchases; • costs relating to major litigation; and • pre-tax separation costs associated with the process of disinvesting from operations in the event of a major divestment.

Principal alliances

Principal alliances	12 Months Ended
	Dec. 31, 2024
Related Party [Abstract]
Principal alliances	C/ Principal alliances C.1. Alliance arrangements with Regeneron Pharmaceuticals, Inc. (Regeneron) Collaboration agreements on human therapeutic antibodies In November 2007, Sanofi and Regeneron signed two agreements (amended in November 2009) relating to human therapeutic antibodies: (i) the Discovery and Preclinical Development Agreement, and (ii) the License and Collaboration Agreement, relating to clinical development and commercialization. Under the License and Collaboration Agreement, Sanofi had an option to develop and commercialize antibodies discovered by Regeneron under the Discovery and Preclinical Development Agreement. Discovery and development Because Sanofi decided not to exercise its option to extend the Discovery and Preclinical Development Agreement, that agreement expired on December 31, 2017. As a result of Sanofi’s exercise of an option with respect to an antibody under the Discovery and Preclinical Development Agreement, such antibody became a “Licensed Product” under the License and Collaboration Agreement, pursuant to which Sanofi and Regeneron co-develop the antibody with Sanofi initially being wholly responsible for funding the development program. On receipt of the first positive Phase 3 study results for any antibody being developed under the License and Collaboration Agreement, the subsequent development costs for that antibody are split 80% Sanofi, 20% Regeneron. Amounts received from Regeneron under the License and Collaboration Agreement are recognized by Sanofi as a reduction in the line item Research and development expenses . Co-development with Regeneron of the antibodies Dupixent, Kevzara and REGN3500 (SAR440340 - itepekimab) is ongoing under the License and Collaboration Agreement as of December 31, 2024. Once a product begins to be commercialized, and provided that the share of quarterly results under the agreement represents a profit, Sanofi is entitled to an additional portion of Regeneron’s profit-share (capped at 20% of Regeneron’s share of quarterly profits since April 1, 2022, and at 10% until March 31, 2022) until Regeneron has paid 50% of the cumulative development costs incurred by the parties in the collaboration (see Note D.21.1.). On the later of (i) 24 months before the scheduled launch date or (ii) the first positive Phase 3 study results, Sanofi and Regeneron share the commercial expenses of the antibodies co-developed under the License and Collaboration Agreement. Commercialization Sanofi is the lead party with respect to the commercialization of all co-developed antibodies, and Regeneron has certain option rights to co-promote the antibodies. Regeneron has exercised its co-promotion rights in the United States and in certain other countries. Sanofi recognizes all sales of the antibodies. Profits and losses arising from commercial operations in the United States are split 50 /50. Outside the United States, Sanofi is entitled to between 55% and 65% of profits depending on sales of the antibodies, and bears 55% of any losses. The share of profits and losses due to or from Regeneron under the agreement is recognized within the line items Other operating income or Other operating expenses , which are components of Operating income . In addition, Regeneron is entitled to receive payments contingent on the attainment of specified levels of aggregate sales on all antibodies outside the United States, on a rolling twelve-month basis. The opposite entry for that liability is capitalized within Other intangible assets on the balance sheet. Two payments of $50 million each were made in 2022, following attainment first of $2.0 billion and then of $2.5 billion in sales of all antibodies outside the United States on a rolling twelve-month basis. The final milestone payment of $50 million , payable to Regeneron in the event that $3.0 billion in sales on a rolling twelve-month basis is attained, was made in 2023 . Amendments to the collaboration agreements In January 2018, Sanofi and Regeneron signed a set of amendments to their collaboration agreements, including an amendment that allowed for the funding of additional programs on Dupixent and REGN3500 (SAR440340 – itepekimab) with an intended focus on extending the current range of indications, finding new indications, and improving co-morbidity between multiple pathologies. Effective April 1, 2020, Sanofi and Regeneron signed a Cross License and Commercialization Agreement for Praluent, whereby Sanofi obtained sole ex-US rights to Praluent, and Regeneron obtained sole US rights to Praluent along with a right to 5% royalties on Sanofi’s sales of Praluent outside the United States. Each party is solely responsible for funding the development, manufacturing and commercialization of Praluent in their respective territories. Although each party has sole responsibility for supplying Praluent in its respective territory, Sanofi and Regeneron entered into agreements to support manufacturing needs for each other. Effective September 30, 2021, Sanofi and Regeneron signed an amendment to their collaboration agreement in order to specify allocations of responsibilities and associated resources between the two parties in connection with the co-promotion of Dupixent in certain countries. The terms of the collaboration relating to REGN3500 (SAR440340 – itepekimab) are unchanged. Effective July 1, 2022, Sanofi and Regeneron signed an amendment to their collaboration agreement in order to increase the additional portion of Regeneron’s quarterly profit-share attributable to Sanofi from 10% to 20% with retroactive impact as of April 1, 2022. Immuno-oncology (IO) collaboration agreements On July 1, 2015, Sanofi and Regeneron signed two agreements – the IO Discovery and Development Agreement and the IO License and Collaboration Agreement (IO LCA) – relating to new antibody cancer treatments in the field of immuno-oncology. The Amended IO Discovery Agreement, effective from December 31, 2018, was terminated through a Letter Amendment dated March 16, 2021 in which Sanofi formalized its opt-out from the BCMAxCD3 and MUC16xCD3 programs. LIBTAYO (cemiplimab) Under the 2015 IO LCA as amended in January 2018, Sanofi and Regeneron committed funding of no more than $1,640 million , split on a 50 /50 basis ( $820 million per company), for the development of REGN2810 (cemiplimab, trademark Libtayo), a PD-1 inhibitor antibody. The funding was raised to $1,840 million by way of amendment effective on September 30, 2021. Regeneron was responsible for the commercialization of Libtayo in the United States, and Sanofi in all other territories. Sanofi has exercised its option to co-promote Libtayo in the United States. In 2021, Regeneron exercised its option to co-promote Libtayo in certain other countries. The IO LCA also provided for a one-time milestone payment of $375 million by Sanofi to Regeneron in the event that sales of a PD-1 product were to exceed, in the aggregate, $2 billion in any consecutive 12-month period. Under the IO LCA Sanofi and Regeneron shared equally in profits and losses generated by the commercialization of collaboration products, except that Sanofi was entitled to an additional portion of Regeneron’s profit-share (capped at 10% of Regeneron’s share of quarterly profits) until Regeneron had paid 50% of the cumulative development costs incurred by the parties under the IO Discovery Agreement, as amended. In June 2022, Sanofi and Regeneron restructured their IO LCA. Under the terms of the Amended and Restated IO LCA, Regeneron holds exclusive worldwide licensing rights to Libtayo with effect from July 1, 2022. In July 2022, Sanofi received as consideration an upfront payment of $900 million ( €856 million ), which was recognized within Other operating income on the date of receipt. The same line item also includes a regulatory milestone payment of $100 million ( €96 million ) following the US FDA approval in November 2022 of Libtayo in combination with chemotherapy as a first line treatment for NSCLC (non-small cell lung cancer). In addition, Sanofi is entitled to royalties of 11% and to milestone payments ( €116 million in 2023, €111 million in 2022) linked to global net sales of Libtayo; those royalties are recognized within Other operating income in line with the pattern of sales . All of the cash inflows relating to the above items ( €117 million in 2024, €196 million in 2023, €952 million in 2022) are presented within Net cash provided by/(used in) operating activities in the consolidated statement of cash flows. The amendment to the terms of the IO LCA resulted in Sanofi recognizing an accelerated amortization charge of €226 million in 2022 ; this was allocated to the Libtayo product rights included within the residual carrying amount of the intangible asset recognized in July 2015 to reflect rights to an antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) under the Sanofi/Regeneron alliance. The transaction also includes time-limited transitional services agreements with Regeneron which include manufacturing, distribution (for which Sanofi acts as agent), and promotion. Investor agreement In 2014 and 2020, Sanofi and Regeneron amended the investor agreement entered into by the two companies in 2007. Under the terms of the amendments, Sanofi accepted various restrictions, including “standstill” provisions that contractually prohibit Sanofi from seeking to directly or indirectly exert control of Regeneron or acquiring more than 30% of Regeneron’s capital stock (consisting of the outstanding shares of common stock and the shares of Class A stock). This prohibition remains in place until the earlier of (i) the later of the fifth anniversaries of the expiration or earlier termination of the Zaltrap collaboration agreement with Regeneron (related to the development and commercialization of Zaltrap) or the collaboration agreement with Regeneron on monoclonal antibodies (see “Collaboration agreements on human therapeutic antibodies” above), each as amended or (ii) other specified events. Starting in 2018 Sanofi began to sell shares of Regeneron stock and announced on May 29, 2020 the closing of its sale of 13 million shares of Regeneron common stock in a registered offering and a private sale to Regeneron (see Note D.1.). Pursuant to subsequent sales in 2022, Sanofi no longer holds any shares of Regeneron stock, as of December 31, 2024. C.2. Agreements on the commercialization of Beyfortus (nirsevimab, previously MEDI8897) in the US On March 1, 2017, Sanofi and AstraZeneca entered into an agreement to develop and commercialize a monoclonal antibody (MEDI8897, nirsevimab) for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants. Under the terms of the agreement, Sanofi made an upfront payment of € 120 million in March 2017, a development milestone payment of € 30 million in the third quarter of 2019, a regulatory milestone payment of €25 million associated with the approval of Beyfortus (nirsevimab) by the EMA in Europe in November 2022, and a regulatory milestone payment of €65 million associated with the approval of Beyfortus (nirsevimab) by the US FDA in July 2023. In addition, Sanofi could pay AstraZeneca up to €375 million if sales objectives are met . Those amounts are recognized as a component of the value of the intangible asset when payment becomes probable. In 2024, payments of €25 million and of € 50 million were made, and an amount of € 100 million was recognized as an accrued expense further to a contractual threshold being met. The agreement also specifies that AstraZeneca is responsible for development and manufacturing, and Sanofi for commercialization. Sanofi recognizes the sales and cost of sales (purchases of finished products from AstraZeneca) and shares the Alliance’s commercial profits (i) 50 / 50 in major territories and (ii) based on 25% of net sales in other territories. The share of commercial profits and losses due to or from AstraZeneca is recognized as a component of operating income, within the line items Other operating income or Other operating expenses . In addition, Sanofi and AstraZeneca share development costs 50 /50, with Sanofi’s portion recognized within the income statement line item Research and development expenses . On April 9, 2023, Sanofi and AstraZeneca simplified their contractual agreements for the development and commercialization of Beyfortus (nirsevimab) in the US. Sanofi thereby obtained control of all commercial rights to Beyfortus (nirsevimab) in the US, and ended the sharing of commercial profits between the two partners in that territory. In line with the terms of the revised agreements and in accordance with IAS 38, Sanofi recognized an intangible asset of €1.6 billion for the fair value of the additional US rights. On the same date, AstraZeneca and Sobi ended their participation agreement, signed in 2018, which transferred the economic rights for the US territory to Sobi. Sanofi simultaneously entered into an agreement with Sobi relating to direct royalties on US net sales of Beyfortus (nirsevimab). In line with the terms of that agreement, on April 9, 2023 Sanofi recognized a financial liability amounting to €1.6 billion . That liability is classified as a financial liability at amortized cost under IFRS 9. Other than royalty payments, subsequent movements in the liability comprise (i) the unwinding of discount and (ii) changes in estimates of future cash outflows for royalty payments. Those movements will be recognized in the income statement within Net financial income/(expenses) in accordance with paragraph B.5.4.6 of IFRS 9. As of December 31, 2024 the liability was remeasured by an amount of € 291 million . As of December 31, 2023 the liability was remeasured by an amount of €541 million , reflecting the strong success of the US launch of Beyfortus, which led to sales forecasts being revised upward from the initial estimate. The resulting adjustment was recognized within Financial expenses . For territories other than the US (except for China, which is now considered a “major market,” with profits/losses shared 50 /50 with AstraZeneca), the existing agreement between AstraZeneca and Sanofi continues to govern the principal terms of the collaboration: Sanofi recognizes the sales and cost of sales and shares the Alliance’s commercial profits with AstraZeneca. In May 2023, data from the HARMONIE Phase 3b study confirmed that nirsevimab prevents infant hospitalizations due to RSV with consistent and high efficacy. Beyfortus was approved in Europe in November 2022, in the United States in July 2023, and in a number of other countries (including China and Japan) in 2024.

Principal changes in the scope

Principal changes in the scope of consolidation in 2023	12 Months Ended
	Dec. 31, 2024
Business Combination [Abstract]
Principal changes in the scope of consolidation in 2023	Presentation of the financial statements D.1. Significant transactions D.1.1. Significant transactions of 2024 D.1.1.1. Acquisition of Inhibrx, Inc On May 30, 2024 , Sanofi completed the acquisition of Inhibrx, Inc (“ Inhibrx”), adding SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lungs with progressive tissue deterioration. SAR447537 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals. The transaction did not meet the criteria for a business combination under IFRS 3, and consequently was accounted for as an acquisition of a group of assets. The acquisition price was $2,035 million . Of that amount (plus acquisition-related costs), $1,885 million was allocated to in- process development in respect of SAR447537 and recognized within Other intangible assets in accordance with IAS 38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed in the transaction. In addition, Sanofi awarded the former shareholders of Inhibrx an unquoted, non-negotiable Contingent Value Right (CVR) certificate that entitles them to a deferred cash payment of $5.00 per Inhibrx share, subject to attainment of a specified regulatory milestone before June 30, 2027. The nominal value of that off balance sheet commitment is $300 million . The impact of this acquisition, as reflected within the line item Acquisitions of consolidated undertakings and investments accounted for using the equity method in the consolidated statement of cash flows, is a net cash outflow of $2,035 million . D.1.1.2. Project to divest a controlling interest in Opella On October 21, 2024, Sanofi and Clayton, Dubilier & Rice (CD&R) entered into exclusive negotiations for the transfer of a controlling interest in Opella (in which Sanofi will remain a significant shareholder), leading to the signature of a f ully-funded unilateral put option agreement . On closing of the transaction, Sanofi would retain an equity interest of approximately 50% in the new entity which will indirectly own the Opella scope of companies, comprising Opella Healthcare and its subsidiaries. The put option agreement is based on a valuation of Opella, determined by the parties, of approximately €16 billion . On February 3, 2025, Sanofi exercised the put option agreement, confirming its intention to sign the share purchase agreement appended to the put option agreement. At the current stage of the ongoing discussions with CD&R, further heads of agreement have been agreed and appended to the put option agreement, including but not limited to: (i) a future shareholder agreement setting forth governance arrangements for the new entity; (ii) an investment agreement governing the structure of the target entity (in which Sanofi and CD&R will hold equity interests in the proportions specified in the contract) and conferring control of the relevant activities of Opella on CD&R, in accordance with the requirements of IFRS 10 (see below); and (iii) an amended version of the Separation Agreement of July 24, 2024, specifying the arrangements for the separation of the Opella activities from Sanofi. Under the terms of that agreement, certain Opella activities will not be transferred on the effective date of loss of control upon closing of the transaction . These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements and (ii) sales made by the dedicated entity Opella Russie, the equity interests in which will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term . As regards the product liability claims described in Note D.22. "Legal and arbitral proceedings", and in particular the ongoing litigation relating to Zantac in the United States, the Separation Agreement specifies that Sanofi will indemnify Opella, without limitation as to amount, for all liabilities resulting from the marketing of any Zantac brand product containing ranitidine as an active pharmaceutical ingredient, including product liability claims. In addition, under the same Separation Agreement, Sanofi retains the worldwide rights to the Gold Bond product. The assets associated with those rights, and the liabilities recognized in respect of the ongoing Gold Bond litigation in the United States, are retained by Sanofi. Gold Bond will continue to be marketed in the United States through the retained subsidiary Gold Bond LLC. All social processes have been conducted, and are now completed. The proposed transaction remains subject to obtaining customary regulatory approvals from the competent authorities. Closing of the transaction is expected in the second quarter of 2025 at the earliest. Following the closing of the transaction, Sanofi will lose control of Opella. The analysis of where power resides is based primarily on the agreement reached on the key terms of the future shareholder agreement between CD&R and Sanofi, as appended to the put option agreement signed on October 21, 2024, under which CD&R will hold a majority of voting rights in shareholder meetings of the newly-constituted entity that will indirectly own Opella, with the exception of certain decisions that must be made jointly, those being primarily decisions of a protective nature relating to fundamental changes to the nature of the activities carried on by the new entity. In addition, CD&R will have a majority on the governance body of the new entity, giving CD&R power over that entity and consequently over decisions related to the activities of Opella, thereby leading to the loss of control by Sanofi over Opella based on the criteria for assessment of control specified in IFRS 10 and the Basis of Conclusions thereto. BpiFrance is expected to participate as a minority shareholder with a c.2% stake in Opella, which does not change the analysis of control set forth above. With effect from the date of closing of the transaction, Sanofi will exercise significant influence over Opella. The share of profits or losses from the retained interest in Opella will then be reported within the line item Share of profit/(loss) from investments accounted for using the equity method in the Sanofi income statement. Completion of the transaction is considered highly probable. In accordance with the classification and presentation requirements of IFRS 5 (see Note B.7.), all assets of Opella and all liabilities directly related to those assets are classified from October 21, 2024 in the line items Assets held for sale and Liabilities related to assets held for sale , respectively, in the consolidated balance sheet (see Notes D.8. and D.36.). Opella (formerly known as Consumer Healthcare) constituted an operating segment of Sanofi until October 21, 2024 (see Note D.35., "Segment Information"). Consequently, Opella meets the definition of a discontinued operation under IFRS 5 (see Note B.7.), as a result of which the net income from this business is presented separately within the line item Net income from discontinued operations in the consolidated income statement. This presentation in a separate income statement line item applies to operations for the year ended December 31, 2024, and on a consistent basis for the comparative periods presented. The cash flows arising from operating, investing and financing activities of the Opella business are also presented in separate line items in the consolidated statements of cash flows for the year ended December 31, 2024 and for the comparative periods presented. For detailed information about the contribution of the Opella business to the consolidated financial statements refer to Note D.36., “Information related to Opella ”. D.1.1.3. Enjaymo divestment On November 29, 2024, Sanofi entered into a definitive agreement with Recordati for the sale of Sanofi's global rights to Enjaymo and the transfer of specific employees. Under this agreement, Sanofi received an upfront payment of $825 million and will be eligible for milestone payments of up to $250 million based on sales. This agreement led to the de-recognition of assets relating to the Enjaymo activity, including goodwill of €276 million . The gain arising on the divestment is immaterial. The impact of the disposal in the consolidated cash flow statement, as reflected in the line item Proceeds from disposals of tangible, intangible and other non-current assets net of tax , is a pre-tax cash inflow of € 768 million . D.1.2. Significant transactions of 2023 Acquisition of Provention Bio, Inc. On March 13, 2023, Sanofi entered into a merger agreement with Provention Bio, Inc. (Provention), a US-based publicly traded biopharmaceutical company developing therapies to prevent and intercept immune-mediated diseases including type 1 diabetes. Under the terms of the agreement, Sanofi acquired the outstanding shares of Provention common stock for $25.00 per share in an all-cash transaction valued at approximately $2.8 billion . The acquisition of Provention was completed on April 27, 2023, with Sanofi holding all of the shares of Provention on expiration of the tender offer. Sanofi applied the optional test to identify concentration of fair value under paragraph B7A of IFRS 3. The transaction was accounted for as an acquisition of a group of assets, given that the principal asset (teplizumab-mzwv, commercialized in the United States under the name Tzield) concentrates substantially all of the fair value of the acquired set of activities and assets. Under the terms of a share purchase agreement entered into by Sanofi and Provention in February 2023, Sanofi already held an equity interest in Provention, representing approximately 3% of Provention’s share capital. On the date Sanofi obtained control of Provention, that equity interest was remeasured at a price of $ 25.00 per share, representing a total amount of $ 68 million . The impact of the remeasurement was recognized in Other comprehensive income . The acquisition price for the shares not already held was $ 2,806 million . Out of the total price (including the fair value of the shares already held), $ 2,810 million was allocated to Tzield and recognized within Other intangible assets . The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction, after taking account of the previously-held shares and acquisition-related costs. The impact of this acquisition as reflected within the line item Acquisitions of consolidated undertakings and investments accounted for using the equity method in the consolidated statement of cash flows is a net cash outflow of $ 2,722 million . Acquisition of QRIB Intermediate Holdings, LLC On July 28, 2023, Sanofi announced that it had acquired QRIB Intermediate Holdings, LLC (QRIB), the owner of Qunol, a market- leading US-based health & wellness brand. The acquisition strengthened Opella's operations in the Vitamin, Mineral and Supplements (VMS) category. The acquisition of QRIB by Sanofi was completed on September 29, 2023, at a purchase price of $1,419 million . The final purchase price allocation led to the recognition of goodwill of €484 million , determined as follows: (€ million) Fair value at acquisition date Other intangible assets 774 Other current and non-current assets and liabilities 80 Cash and cash equivalents 8 Deferred taxes, net (3) Net assets of QRIB Intermediate Holdings, LLC 859 Goodwill 484 Purchase price 1,343 The other acquired intangible assets identified consist of the Qunol brand. Goodwill mainly represents the expected future profits attributable to the development of the VMS platform in the United States as a result of the integration of QRIB into the Sanofi group. The entire amount of goodwill is deductible for tax purposes over a period of 15 years . The imp act of this acquisition is reflected in Net cash provided by/(used in) investing activities of the discontinued Opella business in the consolidated statement of cash flows, and represents a net cash outflow of $ 1,410 million . Net assets related to this acquisition, including associated goodwill, are part of Opella's net assets and are therefore reclassified to Assets held for sale and Liabilities related to assets held for sale (see Note D.36.). D.1.3. Significant transactions of 2022 Acquisition of Amunix Pharmaceuticals, Inc. On February 8, 2022, Sanofi acquired the entire share capital of the immuno-oncology company Amunix Pharmaceuticals, Inc. (Amunix), thereby gaining access to Amunix’s innovative ProXTen technology and a promising pipeline of immunotherapies. The acquisition price of Amunix comprises a fixed cash payment of €970 million , plus contingent consideration in the form of milestone payments based on attainment of certain future development objectives of up to $225 million , the fair value of which as of the acquisition date was €156 million . In accordance with IFRS 3, this contingent purchase consideration was recognized in Liabilities related to business combinations and non-controlling interests (see Note D.18.). The final purchase price allocation led to the recognition of €609 million of goodwill, determined as follows: (€ million) Fair value at acquisition date Other intangible assets 493 Other current and non-current assets and liabilities (13) Cash and cash equivalents 118 Deferred taxes, net (81) Net assets of Amunix 517 Goodwill 609 Purchase price 1,126 Other intangible assets comprise ProXTen, an innovative universal protease-releasable masking technology platform for the discovery and development of transformative cytokine therapies and T-cell engager (TCE) immunotherapies for patients with cancer. In 2023, an impairment loss was taken against the ProXTen platform, in line with a strategic decision to de-prioritize certain R&D programs (see Note D.5., "Impairment of intangible assets and property, plant and equipment"). The license agreement entered into with Vir Biotechnology, Inc. in September 2024 led to the derecognition of the ProXTen intangible asset for its full value, after recognizing a partial reversal of the impairment recognized in 2023. Goodwill mainly represents the value of Amunix’s upstream research and development pipeline of immuno-oncology therapies based on next-generation conditionally activated biologics, especially when combined with Sanofi’s existing oncology portfolio. The goodwill generated on this acquisition does not give rise to any deduction for income tax purposes. Amunixhas no commercial operations. T he impact of this acquisition as reflected within the line item Acquisitions of consolidated undertakings and investments accounted for using the equity method in the consolidated statement of cash flows is a cash outflow of €852 million . EUROAPI - Loss of control and accounting implications On March 17, 2022, the Sanofi Board of Directors approved a decision to put to a shareholder vote the proposed distribution in kind of approximately 58% of the share capital of EUROAPI, thereby confirming Sanofi’s commitment (announced in February 2020) to discontinue its active pharmaceutical ingredient operations. As part of the same corporate action and on the same date, Sanofi entered into an investment agreement with EPIC Bpifrance, which undertook to acquire from Sanofi – via the French Tech Souveraineté fund – a 12% equity interest in EUROAPI at a price not exceeding €150 million and to be determined on the basis of the volume weighted average price (VWAP) of EUROAPI shares on the Euronext Paris regulated market over the thirty-day period starting from the date of initial listing, i.e. May 6, 2022. On completion of those transactions, Sanofi holds an equity interest of 30.1% in EUROAPI, which it has undertaken to retain for at least two years from the date of the distribution, subject to the customary exceptions. With effect from that date, Sanofi exercises significant influence over EUROAPI as a result of (i) its equity interest, and (ii) having one representative on the EUROAPI Board of Directors. On May 3, 2022, the General Meeting of Sanofi shareholders approved the decision of the Board of Directors to distribute approximately 58% of the share capital of EUROAPI in the form of an exceptional dividend in kind. On May 10, 2022, the payment date of the dividend in kind in the days following the admission to listing of EUROAPI shares, those Sanofi shareholders who had retained their Sanofi shares received 1 EUROAPI share per 23 Sanofi shares, representing in total 57.88% of the share capital of EUROAPI. As of that date, Sanofi lost control over the EUROAPI entities, based on an assessment of the criteria specified in IFRS 10 (Consolidated financial statements). The assets and liabilities of EUROAPI, which since March 17, 2022 had been presented as assets and liabilities held for sale within the Sanofi balance sheet in accordance with IFRS 5 (Non-Current Assets Held for sale), were deconsolidated. In addition, because EUROAPI operations do not constitute a discontinued operation under IFRS 5, the contribution from EUROAPI has not been presented within separate line items in the income statement and statement of cash flows or in information for prior comparative periods. The contribution of EUROAPI operations to the consolidated net sales of Sanofi in the year ended December 31, 2021 was €486 million. The principal consequences of the deconsolidation of EUROAPI are described below: • the derecognition of the carrying amount of all the assets and liabilities of EUROAPI, representing a net amount of €1,227 million as of May 10, 2022. This includes goodwill of €164 million, determined in accordance with IAS 36 (“Impairment of Assets”), which was historically allocated to the Pharmaceuticals cash generating unit (CGU), and which for the purposes of the deconsolidation was allocated using an alternative method based on the relative values of goodwill as of the date of consolidation (the “notional goodwill method”). That method was considered more appropriate to the capital-intensive nature of EUROAPI operations than the method based on the relative values of EUROAPI operations and the retained portion of the CGU; • a reduction in Equity attributable to equity holders of Sanofi reflecting the distribution in kind, measured at €793 million based on the weighted average price of €14.58 per share as of the date of delivery of the EUROAPI shares to Sanofi shareholders and corresponding to the fair value of the distribution in accordance with IFRIC 17 (Distribution of Non-Cash Assets to Owners); • a cash inflow of €150 million from the divestment of 12% of the share capital of EUROAPI to EPIC Bpifrance as of the settlement date of the shares, i.e. June 17, 2022; • the recognition in the balance sheet within the line item Investments accounted for using the equity method , of the retained 30.1% equity interest in EUROAPI at an amount of €413 million, determined on the basis of the weighted average price of €14.58 per share and representing the fair value of the equity interest in accordance with IFRS 10; • the reclassification within the net gain/loss on deconsolidation of unrealized foreign exchange losses amounting to €35 million arising on EUROAPI subsidiaries, in accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates); • the recognition of transaction-related costs and of the effects of undertakings made under agreements entered into with EUROAPI setting out the principles and terms of the legal reorganization carried out ahead of the date of deconsolidation. The principal undertakings made to EUROAPI relate to compensation for: – environmental remediation obligations on non-operational chemical sites in France transferred to EUROAPI, amounting to €14 million, and – regulatory compliance costs relating to certain state-of-the-art active pharmaceutical ingredients of EUROAPI, capped at €15 million. These elements collectively resulted in a pre-tax loss on deconsolidation of €3 million, presented within the line item Other gains and losses, and litigation in the income statement. The tax effect of the deconsolidation was a net gain of €111 million, presented within the line item Income tax expense in the income statement. The cash impact of the deconsolidation of EUROAPI, presented within the line item Disposals of consolidated undertakings and investments accounted for using the equity method in the statement of cash flows, was a net cash inflow of €101 million. Sanofi has entered into an agreement with EUROAPI for the manufacture and supply of active pharmaceutical ingredients, intermediates and other substances, which took effect on October 1, 2021 and expires five years after the loss of control. Under the terms of the agreement, Sanofi committed to target annual net sales of approximately €300 million for a list of specified active ingredients until the agreement expires in 2026. As of December 31, 2022, that commitment amounted to €1.1 billion. As of the date of deconsolidation, the 30.1% equity interest in EUROAPI is accounted for using the equity method in accordance with IAS 28 (Investments in Associates and Joint Ventures), and the share of EUROAPI profits or losses arising from application of the equity method is excluded from “Business operating income”, the non-IFRS financial indicator used internally by Sanofi to measure the performance of its operating segments.

Principal changes in the scop_2

Principal changes in the scope of consolidation in 2022 and 2021	12 Months Ended
	Dec. 31, 2024
Business Combination [Abstract]
Principal changes in the scope of consolidation in 2022 and 2021	Presentation of the financial statements D.1. Significant transactions D.1.1. Significant transactions of 2024 D.1.1.1. Acquisition of Inhibrx, Inc On May 30, 2024 , Sanofi completed the acquisition of Inhibrx, Inc (“ Inhibrx”), adding SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lungs with progressive tissue deterioration. SAR447537 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals. The transaction did not meet the criteria for a business combination under IFRS 3, and consequently was accounted for as an acquisition of a group of assets. The acquisition price was $2,035 million . Of that amount (plus acquisition-related costs), $1,885 million was allocated to in- process development in respect of SAR447537 and recognized within Other intangible assets in accordance with IAS 38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed in the transaction. In addition, Sanofi awarded the former shareholders of Inhibrx an unquoted, non-negotiable Contingent Value Right (CVR) certificate that entitles them to a deferred cash payment of $5.00 per Inhibrx share, subject to attainment of a specified regulatory milestone before June 30, 2027. The nominal value of that off balance sheet commitment is $300 million . The impact of this acquisition, as reflected within the line item Acquisitions of consolidated undertakings and investments accounted for using the equity method in the consolidated statement of cash flows, is a net cash outflow of $2,035 million . D.1.1.2. Project to divest a controlling interest in Opella On October 21, 2024, Sanofi and Clayton, Dubilier & Rice (CD&R) entered into exclusive negotiations for the transfer of a controlling interest in Opella (in which Sanofi will remain a significant shareholder), leading to the signature of a f ully-funded unilateral put option agreement . On closing of the transaction, Sanofi would retain an equity interest of approximately 50% in the new entity which will indirectly own the Opella scope of companies, comprising Opella Healthcare and its subsidiaries. The put option agreement is based on a valuation of Opella, determined by the parties, of approximately €16 billion . On February 3, 2025, Sanofi exercised the put option agreement, confirming its intention to sign the share purchase agreement appended to the put option agreement. At the current stage of the ongoing discussions with CD&R, further heads of agreement have been agreed and appended to the put option agreement, including but not limited to: (i) a future shareholder agreement setting forth governance arrangements for the new entity; (ii) an investment agreement governing the structure of the target entity (in which Sanofi and CD&R will hold equity interests in the proportions specified in the contract) and conferring control of the relevant activities of Opella on CD&R, in accordance with the requirements of IFRS 10 (see below); and (iii) an amended version of the Separation Agreement of July 24, 2024, specifying the arrangements for the separation of the Opella activities from Sanofi. Under the terms of that agreement, certain Opella activities will not be transferred on the effective date of loss of control upon closing of the transaction . These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements and (ii) sales made by the dedicated entity Opella Russie, the equity interests in which will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term . As regards the product liability claims described in Note D.22. "Legal and arbitral proceedings", and in particular the ongoing litigation relating to Zantac in the United States, the Separation Agreement specifies that Sanofi will indemnify Opella, without limitation as to amount, for all liabilities resulting from the marketing of any Zantac brand product containing ranitidine as an active pharmaceutical ingredient, including product liability claims. In addition, under the same Separation Agreement, Sanofi retains the worldwide rights to the Gold Bond product. The assets associated with those rights, and the liabilities recognized in respect of the ongoing Gold Bond litigation in the United States, are retained by Sanofi. Gold Bond will continue to be marketed in the United States through the retained subsidiary Gold Bond LLC. All social processes have been conducted, and are now completed. The proposed transaction remains subject to obtaining customary regulatory approvals from the competent authorities. Closing of the transaction is expected in the second quarter of 2025 at the earliest. Following the closing of the transaction, Sanofi will lose control of Opella. The analysis of where power resides is based primarily on the agreement reached on the key terms of the future shareholder agreement between CD&R and Sanofi, as appended to the put option agreement signed on October 21, 2024, under which CD&R will hold a majority of voting rights in shareholder meetings of the newly-constituted entity that will indirectly own Opella, with the exception of certain decisions that must be made jointly, those being primarily decisions of a protective nature relating to fundamental changes to the nature of the activities carried on by the new entity. In addition, CD&R will have a majority on the governance body of the new entity, giving CD&R power over that entity and consequently over decisions related to the activities of Opella, thereby leading to the loss of control by Sanofi over Opella based on the criteria for assessment of control specified in IFRS 10 and the Basis of Conclusions thereto. BpiFrance is expected to participate as a minority shareholder with a c.2% stake in Opella, which does not change the analysis of control set forth above. With effect from the date of closing of the transaction, Sanofi will exercise significant influence over Opella. The share of profits or losses from the retained interest in Opella will then be reported within the line item Share of profit/(loss) from investments accounted for using the equity method in the Sanofi income statement. Completion of the transaction is considered highly probable. In accordance with the classification and presentation requirements of IFRS 5 (see Note B.7.), all assets of Opella and all liabilities directly related to those assets are classified from October 21, 2024 in the line items Assets held for sale and Liabilities related to assets held for sale , respectively, in the consolidated balance sheet (see Notes D.8. and D.36.). Opella (formerly known as Consumer Healthcare) constituted an operating segment of Sanofi until October 21, 2024 (see Note D.35., "Segment Information"). Consequently, Opella meets the definition of a discontinued operation under IFRS 5 (see Note B.7.), as a result of which the net income from this business is presented separately within the line item Net income from discontinued operations in the consolidated income statement. This presentation in a separate income statement line item applies to operations for the year ended December 31, 2024, and on a consistent basis for the comparative periods presented. The cash flows arising from operating, investing and financing activities of the Opella business are also presented in separate line items in the consolidated statements of cash flows for the year ended December 31, 2024 and for the comparative periods presented. For detailed information about the contribution of the Opella business to the consolidated financial statements refer to Note D.36., “Information related to Opella ”. D.1.1.3. Enjaymo divestment On November 29, 2024, Sanofi entered into a definitive agreement with Recordati for the sale of Sanofi's global rights to Enjaymo and the transfer of specific employees. Under this agreement, Sanofi received an upfront payment of $825 million and will be eligible for milestone payments of up to $250 million based on sales. This agreement led to the de-recognition of assets relating to the Enjaymo activity, including goodwill of €276 million . The gain arising on the divestment is immaterial. The impact of the disposal in the consolidated cash flow statement, as reflected in the line item Proceeds from disposals of tangible, intangible and other non-current assets net of tax , is a pre-tax cash inflow of € 768 million . D.1.2. Significant transactions of 2023 Acquisition of Provention Bio, Inc. On March 13, 2023, Sanofi entered into a merger agreement with Provention Bio, Inc. (Provention), a US-based publicly traded biopharmaceutical company developing therapies to prevent and intercept immune-mediated diseases including type 1 diabetes. Under the terms of the agreement, Sanofi acquired the outstanding shares of Provention common stock for $25.00 per share in an all-cash transaction valued at approximately $2.8 billion . The acquisition of Provention was completed on April 27, 2023, with Sanofi holding all of the shares of Provention on expiration of the tender offer. Sanofi applied the optional test to identify concentration of fair value under paragraph B7A of IFRS 3. The transaction was accounted for as an acquisition of a group of assets, given that the principal asset (teplizumab-mzwv, commercialized in the United States under the name Tzield) concentrates substantially all of the fair value of the acquired set of activities and assets. Under the terms of a share purchase agreement entered into by Sanofi and Provention in February 2023, Sanofi already held an equity interest in Provention, representing approximately 3% of Provention’s share capital. On the date Sanofi obtained control of Provention, that equity interest was remeasured at a price of $ 25.00 per share, representing a total amount of $ 68 million . The impact of the remeasurement was recognized in Other comprehensive income . The acquisition price for the shares not already held was $ 2,806 million . Out of the total price (including the fair value of the shares already held), $ 2,810 million was allocated to Tzield and recognized within Other intangible assets . The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction, after taking account of the previously-held shares and acquisition-related costs. The impact of this acquisition as reflected within the line item Acquisitions of consolidated undertakings and investments accounted for using the equity method in the consolidated statement of cash flows is a net cash outflow of $ 2,722 million . Acquisition of QRIB Intermediate Holdings, LLC On July 28, 2023, Sanofi announced that it had acquired QRIB Intermediate Holdings, LLC (QRIB), the owner of Qunol, a market- leading US-based health & wellness brand. The acquisition strengthened Opella's operations in the Vitamin, Mineral and Supplements (VMS) category. The acquisition of QRIB by Sanofi was completed on September 29, 2023, at a purchase price of $1,419 million . The final purchase price allocation led to the recognition of goodwill of €484 million , determined as follows: (€ million) Fair value at acquisition date Other intangible assets 774 Other current and non-current assets and liabilities 80 Cash and cash equivalents 8 Deferred taxes, net (3) Net assets of QRIB Intermediate Holdings, LLC 859 Goodwill 484 Purchase price 1,343 The other acquired intangible assets identified consist of the Qunol brand. Goodwill mainly represents the expected future profits attributable to the development of the VMS platform in the United States as a result of the integration of QRIB into the Sanofi group. The entire amount of goodwill is deductible for tax purposes over a period of 15 years . The imp act of this acquisition is reflected in Net cash provided by/(used in) investing activities of the discontinued Opella business in the consolidated statement of cash flows, and represents a net cash outflow of $ 1,410 million . Net assets related to this acquisition, including associated goodwill, are part of Opella's net assets and are therefore reclassified to Assets held for sale and Liabilities related to assets held for sale (see Note D.36.). D.1.3. Significant transactions of 2022 Acquisition of Amunix Pharmaceuticals, Inc. On February 8, 2022, Sanofi acquired the entire share capital of the immuno-oncology company Amunix Pharmaceuticals, Inc. (Amunix), thereby gaining access to Amunix’s innovative ProXTen technology and a promising pipeline of immunotherapies. The acquisition price of Amunix comprises a fixed cash payment of €970 million , plus contingent consideration in the form of milestone payments based on attainment of certain future development objectives of up to $225 million , the fair value of which as of the acquisition date was €156 million . In accordance with IFRS 3, this contingent purchase consideration was recognized in Liabilities related to business combinations and non-controlling interests (see Note D.18.). The final purchase price allocation led to the recognition of €609 million of goodwill, determined as follows: (€ million) Fair value at acquisition date Other intangible assets 493 Other current and non-current assets and liabilities (13) Cash and cash equivalents 118 Deferred taxes, net (81) Net assets of Amunix 517 Goodwill 609 Purchase price 1,126 Other intangible assets comprise ProXTen, an innovative universal protease-releasable masking technology platform for the discovery and development of transformative cytokine therapies and T-cell engager (TCE) immunotherapies for patients with cancer. In 2023, an impairment loss was taken against the ProXTen platform, in line with a strategic decision to de-prioritize certain R&D programs (see Note D.5., "Impairment of intangible assets and property, plant and equipment"). The license agreement entered into with Vir Biotechnology, Inc. in September 2024 led to the derecognition of the ProXTen intangible asset for its full value, after recognizing a partial reversal of the impairment recognized in 2023. Goodwill mainly represents the value of Amunix’s upstream research and development pipeline of immuno-oncology therapies based on next-generation conditionally activated biologics, especially when combined with Sanofi’s existing oncology portfolio. The goodwill generated on this acquisition does not give rise to any deduction for income tax purposes. Amunixhas no commercial operations. T he impact of this acquisition as reflected within the line item Acquisitions of consolidated undertakings and investments accounted for using the equity method in the consolidated statement of cash flows is a cash outflow of €852 million . EUROAPI - Loss of control and accounting implications On March 17, 2022, the Sanofi Board of Directors approved a decision to put to a shareholder vote the proposed distribution in kind of approximately 58% of the share capital of EUROAPI, thereby confirming Sanofi’s commitment (announced in February 2020) to discontinue its active pharmaceutical ingredient operations. As part of the same corporate action and on the same date, Sanofi entered into an investment agreement with EPIC Bpifrance, which undertook to acquire from Sanofi – via the French Tech Souveraineté fund – a 12% equity interest in EUROAPI at a price not exceeding €150 million and to be determined on the basis of the volume weighted average price (VWAP) of EUROAPI shares on the Euronext Paris regulated market over the thirty-day period starting from the date of initial listing, i.e. May 6, 2022. On completion of those transactions, Sanofi holds an equity interest of 30.1% in EUROAPI, which it has undertaken to retain for at least two years from the date of the distribution, subject to the customary exceptions. With effect from that date, Sanofi exercises significant influence over EUROAPI as a result of (i) its equity interest, and (ii) having one representative on the EUROAPI Board of Directors. On May 3, 2022, the General Meeting of Sanofi shareholders approved the decision of the Board of Directors to distribute approximately 58% of the share capital of EUROAPI in the form of an exceptional dividend in kind. On May 10, 2022, the payment date of the dividend in kind in the days following the admission to listing of EUROAPI shares, those Sanofi shareholders who had retained their Sanofi shares received 1 EUROAPI share per 23 Sanofi shares, representing in total 57.88% of the share capital of EUROAPI. As of that date, Sanofi lost control over the EUROAPI entities, based on an assessment of the criteria specified in IFRS 10 (Consolidated financial statements). The assets and liabilities of EUROAPI, which since March 17, 2022 had been presented as assets and liabilities held for sale within the Sanofi balance sheet in accordance with IFRS 5 (Non-Current Assets Held for sale), were deconsolidated. In addition, because EUROAPI operations do not constitute a discontinued operation under IFRS 5, the contribution from EUROAPI has not been presented within separate line items in the income statement and statement of cash flows or in information for prior comparative periods. The contribution of EUROAPI operations to the consolidated net sales of Sanofi in the year ended December 31, 2021 was €486 million. The principal consequences of the deconsolidation of EUROAPI are described below: • the derecognition of the carrying amount of all the assets and liabilities of EUROAPI, representing a net amount of €1,227 million as of May 10, 2022. This includes goodwill of €164 million, determined in accordance with IAS 36 (“Impairment of Assets”), which was historically allocated to the Pharmaceuticals cash generating unit (CGU), and which for the purposes of the deconsolidation was allocated using an alternative method based on the relative values of goodwill as of the date of consolidation (the “notional goodwill method”). That method was considered more appropriate to the capital-intensive nature of EUROAPI operations than the method based on the relative values of EUROAPI operations and the retained portion of the CGU; • a reduction in Equity attributable to equity holders of Sanofi reflecting the distribution in kind, measured at €793 million based on the weighted average price of €14.58 per share as of the date of delivery of the EUROAPI shares to Sanofi shareholders and corresponding to the fair value of the distribution in accordance with IFRIC 17 (Distribution of Non-Cash Assets to Owners); • a cash inflow of €150 million from the divestment of 12% of the share capital of EUROAPI to EPIC Bpifrance as of the settlement date of the shares, i.e. June 17, 2022; • the recognition in the balance sheet within the line item Investments accounted for using the equity method , of the retained 30.1% equity interest in EUROAPI at an amount of €413 million, determined on the basis of the weighted average price of €14.58 per share and representing the fair value of the equity interest in accordance with IFRS 10; • the reclassification within the net gain/loss on deconsolidation of unrealized foreign exchange losses amounting to €35 million arising on EUROAPI subsidiaries, in accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates); • the recognition of transaction-related costs and of the effects of undertakings made under agreements entered into with EUROAPI setting out the principles and terms of the legal reorganization carried out ahead of the date of deconsolidation. The principal undertakings made to EUROAPI relate to compensation for: – environmental remediation obligations on non-operational chemical sites in France transferred to EUROAPI, amounting to €14 million, and – regulatory compliance costs relating to certain state-of-the-art active pharmaceutical ingredients of EUROAPI, capped at €15 million. These elements collectively resulted in a pre-tax loss on deconsolidation of €3 million, presented within the line item Other gains and losses, and litigation in the income statement. The tax effect of the deconsolidation was a net gain of €111 million, presented within the line item Income tax expense in the income statement. The cash impact of the deconsolidation of EUROAPI, presented within the line item Disposals of consolidated undertakings and investments accounted for using the equity method in the statement of cash flows, was a net cash inflow of €101 million. Sanofi has entered into an agreement with EUROAPI for the manufacture and supply of active pharmaceutical ingredients, intermediates and other substances, which took effect on October 1, 2021 and expires five years after the loss of control. Under the terms of the agreement, Sanofi committed to target annual net sales of approximately €300 million for a list of specified active ingredients until the agreement expires in 2026. As of December 31, 2022, that commitment amounted to €1.1 billion. As of the date of deconsolidation, the 30.1% equity interest in EUROAPI is accounted for using the equity method in accordance with IAS 28 (Investments in Associates and Joint Ventures), and the share of EUROAPI profits or losses arising from application of the equity method is excluded from “Business operating income”, the non-IFRS financial indicator used internally by Sanofi to measure the performance of its operating segments.

Financial instruments

Financial instruments	12 Months Ended
	Dec. 31, 2024
DisclosureOfFinancialRiskAbstract [Abstract]
Disclosure of financial risk management [text block]	D.2. Capital and financial risk management information D.2.1. Capital management information In order to maintain or adjust the capital structure, Sanofi can adjust the amount of dividends paid to shareholders, repurchase its own shares, issue new shares, or issue securities giving access to its capital. The following objectives are defined under the terms of Sanofi’s share repurchase programs: • the implementation of any stock option plan giving entitlement to purchase shares in the Sanofi parent company (see Note D.15.); • the allotment or sale of shares to employees under statutory profit sharing schemes and employee savings plans; • the consideration-free allotment of shares (i.e. restricted share plans) (see Note D.15.); • the cancellation of some or all of the repurchased shares (see Note D.15.); • market-making in the secondary market by an investment services provider under a liquidity contract in compliance with the ethical code recognized by the Autorité des marchés financiers (AMF); • the delivery of shares on the exercise of rights attached to securities giving access to the capital by redemption, conversion, exchange, presentation of a warrant or any other means; • the delivery of shares (in exchange, as payment, or otherwise) in connection with mergers and acquisitions; • the execution by an investment services provider of purchases, sales or transfers by any means, in particular via off-market trading; or • any other purpose that is or may in the future be authorized under the applicable laws and regulations. Sanofi is not subject to any constraints on equity capital imposed by third parties. Sanofi defines “Net debt” as (i) the sum of short-term debt, long-term debt and interest rate derivatives and currency derivatives used to hedge debt, minus (ii) the sum of cash and cash equivalents and interest rate derivatives and currency derivatives used to hedge cash and cash equivalents (see Note D.17.). D.2.2. Financial risk management Credit risk Credit risk is the risk that customers (wholesalers, distributors, pharmacies, hospitals, clinics or government agencies) may fail to pay their debts; for Sanofi, that risk is mainly concentrated on amounts receivable from wholesalers in the United States. Sanofi manages credit risk by vetting customers in order to set credit limits and risk levels, and asking for guarantees or insurance where necessary; performing controls; and monitoring qualitative and quantitative indicators of accounts receivable balances, such as the period of credit taken and overdue payments. Sales generated by Sanofi with its biggest customers are disclosed in Note D.35. Market risks Please refer to "Item 11. Quantitative and Qualitative Disclosures about Market Risk" of this Annual Report on Form 20-F, and to Notes D.17 and D.20. below.

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2024
Property, plant and equipment [abstract]
Property, plant and equipment	Property, plant and equipment D.3.1. Property, plant and equipment owned Property, plant and equipment owned by Sanofi is comprised of the following items: (€ million) Land Buildings Machinery and equipment Fixtures, fittings and other Property, plant and equipment in process Total Gross value at January 1, 2022 240 7,170 11,648 2,655 3,097 24,810 Changes in scope of consolidation (17) (294) (1,480) (163) (150) (2,104) Acquisitions and other increases — 11 54 41 1,642 1,748 Disposals and other decreases (1) (161) (240) (155) (2) (559) Currency translation differences 17 122 144 29 35 347 Transfers (a) (2) 480 722 108 (1,626) (318) Gross value at December 31, 2022 237 7,328 10,848 2,515 2,996 23,924 Changes in scope of consolidation — (11) (29) (7) (4) (51) Acquisitions and other increases — 27 47 36 1,583 1,693 Disposals and other decreases (2) (50) (340) (100) (10) (502) Currency translation differences (5) (94) (71) (30) (45) (245) Transfers (a) (2) 481 457 86 (1,071) (49) Gross value at December 31, 2023 228 7,681 10,912 2,500 3,449 24,770 Changes in scope of consolidation — — — — — — Acquisitions and other increases — 13 36 36 1,632 1,717 Disposals and other decreases (3) (209) (510) (173) (79) (974) Currency translation differences 13 163 126 30 17 349 Transfers (a) (1) 335 764 142 (1,235) 5 Opella reclassification (b) (36) (539) (866) (154) (211) (1,806) Gross value at December 31, 2024 201 7,444 10,462 2,381 3,573 24,061 Accumulated depreciation & impairment at January 1, 2022 (9) (4,190) (8,340) (2,115) (128) (14,782) Changes in scope of consolidation — 201 1,202 130 — 1,533 Depreciation expense — (356) (622) (164) — (1,142) Impairment losses, net of reversals (1) (50) (58) (2) (75) (186) Disposals and other decreases — 133 201 153 31 518 Currency translation differences — (52) (69) (22) 5 (138) Transfers (a) — 89 49 5 (1) 142 Accumulated depreciation & impairment at December 31, 2022 (10) (4,225) (7,637) (2,015) (168) (14,055) Changes in scope of consolidation — 5 16 3 — 24 Depreciation expense — (321) (620) (139) — (1,080) Impairment losses, net of reversals — (30) (46) (4) (50) (130) Disposals and other decreases — 48 334 98 8 488 Currency translation differences 2 45 44 21 — 112 Transfers (a) — (22) 36 (1) 18 31 Accumulated depreciation & impairment at December 31, 2023 (8) (4,500) (7,873) (2,037) (192) (14,610) Changes in scope of consolidation — — — — — — Depreciation expense — (325) (580) (136) — (1,041) Impairment losses, net of reversals — (47) (23) (3) (32) (105) Disposals and other decreases 1 197 507 172 37 914 Currency translation differences 1 (77) (95) (18) — (189) Transfers (a) — 9 5 4 (3) 15 Opella reclassification (b) 6 333 599 97 11 1,046 Accumulated depreciation & impairment at December 31, 2024 — (4,410) (7,460) (1,921) (179) (13,970) Carrying amount at December 31, 2022 227 3,103 3,211 500 2,828 9,869 Carrying amount at December 31, 2023 220 3,181 3,039 463 3,257 10,160 Carrying amount at December 31, 2024 201 3,034 3,002 460 3,394 10,091 (a) This line mainly comprises property, plant and equipment in process brought into service during the period, and reclassification of assets (other than Opella assets) to Assets held for sale . (b) This line comprises property, plant and equipment owned by Opella, reclassified to Assets held for sale as of December 31, 2024 in accordance with IFRS 5 (see Note D.1.) . The table below sets forth acquisitions and capitalized interest for the years ended December 31, 2024 , 2023 and 2022 : (€ million) 2024 2023 2022 Acquisitions 1,717 1,693 1,748 Biopharma (operating segment) 1,554 1,592 1,678 of which Manufacturing & Supply 1,114 1,188 1,129 Opella (discontinued operation, see Note D.1.) 163 101 70 of which Manufacturing & Supply 135 90 63 Of which capitalized interest 51 26 17 Off balance sheet commitments relating to property, plant and equipment as of December 31, 2024 , 2023 and 2022 are set forth below: (€ million) 2024 2023 2022 Firm orders of property, plant and equipment 422 638 861 Property, plant and equipment pledged as security for liabilities 21 16 — The table below sets forth the net impairment losses recognized in each of the last three financial periods: (€ million) 2024 2023 2022 Net impairment losses on property, plant and equipment (a) 105 130 186 (a) These amounts mainly comprise impairment losses recognized as a result of decisions taken during the periods presented, relating primarily to shutdowns or changes in use of industrial sites. D.3.2. Property, plant and equipment leased – right-of-use assets Right-of-use assets relating to property, plant and equipment leased by Sanofi are analyzed in the table below: (€ million) Right-of-use assets Gross value at January 1, 2022 2,745 Changes in scope of consolidation (26) Acquisitions and other increases 292 Disposals and other decreases (232) Currency translation differences 101 Transfers (a) (8) Gross value at December 31, 2022 2,872 Acquisitions and other increases 247 Disposals and other decreases (314) Currency translation differences (58) Transfers (a) (75) Gross value at December 31, 2023 2,672 Acquisitions and other increases 442 Disposals and other decreases (375) Currency translation differences 89 Transfers(a) (60) Opella reclassification (b) (155) Gross value at December 31, 2024 2,613 Accumulated depreciation & impairment at January 1, 2022 (797) Changes in scope of consolidation 14 Depreciation and impairment charged in the period (341) Disposals and other decreases 82 Currency translation differences (17) Transfers (a) 2 Accumulated depreciation & impairment at December 31, 2022 (1,057) Depreciation and impairment charged in the period (292) Disposals and other decreases 276 Currency translation differences 21 Transfers (a) 34 Accumulated depreciation & impairment at December 31, 2023 (1,018) Depreciation and impairment charged in the period (315) Disposals and other decreases 183 Currency translation differences (30) Transfers (a) 38 Opella reclassification (b) 39 Accumulated depreciation & impairment at December 31, 2024 (1,103) Carrying amount at December 31, 2022 1,815 Carrying amount at December 31, 2023 1,654 Carrying amount at December 31, 2024 1,510 (a) This line also includes the effect of the reclassification of assets (other than Opella assets) to Assets held for sale . (b) This line comprises the Opella right-of-use assets, reclassified to Assets held for sale as of December 31, 2024 in accordance with IFRS 5 (see Note D.1.) . Leased assets comprised offices and industrial premises ( 90% ) and the vehicle fleet ( 10% ) as of December 31, 2024 . Annual lease costs on short term leases and low value asset leases amounted to €16 million in the year ended December 31, 2024 , €19 million in the year ended December 31, 2023 , and €26 million in the year ended December 31, 2022 . Variable lease payments, sub-leasing activities, and sale-and-leaseback transactions were immaterial. Total cash outflows on leases (excluding annual lease costs on short term leases and low value asset leases) were €348 million in the year ended December 31, 2024 , €315 million in the year ended December 31, 2023 , and €389 million in the year ended December 31, 2022 . A maturity analysis of the lease liability is disclosed in Note D.17.2. Commitments related to short-term leases and low value asset leases, including future payments for lease contracts committed but not yet commenced, are disclosed in Note D.21.

Goodwill and other intangible a

Goodwill and other intangible assets	12 Months Ended
	Dec. 31, 2024
Intangible assets and goodwill [abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets Movements in goodwill comprise: (€ million) Goodwill Balance at January 1, 2022 48,056 Acquisitions during the period 609 Other movements during the period (a) (258) Currency translation differences 1,485 Balance at December 31, 2022 49,892 Acquisitions during the period (c) 475 Other movements during the period (a) (90) Currency translation differences (873) Balance at December 31, 2023 49,404 Acquisitions during the period — Other movements during the period (a) (351) Currency translation differences 1,586 Opella reclassification (b) (7,255) Balance at December 31, 2024 43,384 (a) This line mainly comprises the amount of goodwill allocated to divested operations in accordance with paragraph 86 of IAS 36, including in 2024 the allocated goodwill relating to the divestment of the Enjaymo activity to Recordati (see Note D.1.). For 2022, this line includes the loss of control of EUROAPI (see Note D.1.). (b) The Opella goodwill is presented within Assets held for sale (see Note D.1.). (c) The final purchase price allocation for QRIB Intermediate Holdings, LLC resulted in the recognition of intangible assets (other than goodwill) of €774 million as of the acquisition date (September 29, 2023) and of goodwill measured at €484 million as of the acquisition date (see Note D.1.). In accordance with IAS 36, goodwill is allocated to groups of Cash Generating Units (CGUs) at a level corresponding to the Biopharma operating segment (see Note D.35.). For the purpose of annual impairment testing of goodwill, the recoverable amount was determined on the basis of value in use, as derived from discounted estimates of the future cash flows in accordance with the policies described in Note B.6.1. Acquisition of Amunix Pharmaceuticals, Inc. (2022) The final purchase price allocation for Amunix Pharmaceuticals, Inc. resulted in the recognition of intangible assets (other than goodwill) o f €493 million as of the acquisition date (February 8, 2022), and of goodwill measured at €609 million as of the acquisition date (see Note D.1.). Movements in other intangible assets comprise: (€ million) Acquired R&D Products, trademarks and other rights Software Total other intangible assets Gross value at January 1, 2022 (a) 11,207 65,906 1,752 78,865 Changes in scope of consolidation (c) — 499 (35) 464 Acquisitions and other increases 277 195 99 571 Disposals and other decreases (72) (423) (48) (543) Currency translation differences 518 1,994 21 2,533 Transfers (b) (1,576) 1,408 (6) (174) Gross value at December 31, 2022 10,354 69,579 1,783 81,716 Changes in scope of consolidation (c) 113 3,287 1 3,401 Acquisitions and other increases (f) 1,062 1,970 80 3,112 Disposals and other decreases (262) (380) (41) (683) Currency translation differences (242) (1,584) (11) (1,837) Transfers (b) (1,253) 861 (4) (396) Gross value at December 31, 2023 9,772 73,733 1,808 85,313 Changes in scope of consolidation (c) 1,745 — — 1,745 Acquisitions and other increases (f) 1,006 444 104 1,554 Disposals and other decreases (58) (1,447) (9) (1,514) Currency translation differences 606 2,708 17 3,331 Transfers (b) (52) 66 (11) 3 Opella reclassification (a) (153) (9,156) (57) (9,366) Gross value at December 31, 2024 12,866 66,348 1,852 81,066 Accumulated amortization & impairment at January 1, 2022 (a) (3,477) (52,744) (1,237) (57,458) Changes in scope of consolidation — — 11 11 Amortization expense (e) — (2,099) (97) (2,196) Impairment losses, net of reversals (d) (1,107) 1,561 — 454 Disposals and other decreases 75 411 39 525 Currency translation differences (7) (1,567) (17) (1,591) Transfers (b) 388 (214) 5 179 Accumulated amortization & impairment at December 31, 2022 (4,128) (54,652) (1,296) (60,076) Changes in scope of consolidation (c) — 33 — 33 Amortization expense — (2,225) (120) (2,345) Impairment losses, net of reversals (d) (90) (842) — (932) Disposals and other decreases 262 326 41 629 Currency translation differences 94 1,184 9 1,287 Transfers (b) 128 268 14 410 Accumulated amortization & impairment at December 31, 2023 (3,734) (55,908) (1,352) (60,994) Amortization expense — (2,094) (106) (2,200) Impairment losses, net of reversals (d) (638) 373 1 (264) Disposals and other decreases 58 655 9 722 Currency translation differences (191) (1,928) (15) (2,134) Transfers (b) (2) (3) — (5) Opella reclassification (a) 10 6,398 30 6,438 Accumulated amortization & impairment at December 31, 2024 (4,497) (52,507) (1,433) (58,437) Carrying amount at December 31, 2022 6,226 14,927 487 21,640 Carrying amount at December 31, 2023 6,038 17,825 456 24,319 Carrying amount at December 31, 2024 8,369 13,841 419 22,629 (a) Comprises the other intangible assets of Opella, now reclassified to Assets held for sale at December 31, 2024 in accordance with IFRS 5 (see note D.1.). (b) The “Transfers” line mainly comprises (i) acquired R&D that came into commercial use during the period and (ii) reclassifications of assets (other than Opella assets) as Assets held for sale . (c) The “Changes in scope of consolidation” line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during the period (see Note D.1.) . (d) See Note D.5. (e) The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of €226 million in 2022 (see Note C.1.) . (f) This line mainly comprises: In 2023: – the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April 2023 in respect of the agreements on Beyfortus (nirsevimab) (see Note C.2.); – an upfront payment of $500 million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co- commercialization of TEV’574;and – an upfront payment of $175 million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli. In 2024: – an upfront payment of $500 million for the rights acquired under the agreement with Novavax relating to the co-exclusive license agreement for the co-commercialization of a COVID-19 vaccine and the development of a combined flu-COVID-19 vaccine; and – an upfront payment of $300 million for the rights acquired under an agreement with Corxel Pharmaceuticals for the development and commercialization rights to aficamten in China. “Products, trademarks and other rights” mainly comprise: • “marketed products”, with a carrying amount of €12.7 billion as of December 31, 2024 (versus €16.6 billion as of December 31, 2023 and €12.7 billion as of December 31, 2022 ) and a weighted average amortization period of approximately 10 years; and • “technology platforms”, with a carrying amount of €1.1 billion as of December 31, 2024 (versus € 1.2 billion as of December 31, 2023 and € 2.2 billion as of December 31, 2022 ) and a weighted average amortization period of approximately 18 years. The table below provides information about the principal “marketed products”, which were recognized in connection with major acquisitions made by Sanofi and represented 95% of the carrying amount of that item as of December 31, 2024 : (€ million) Gross value Accumulated amortization & impairment December 31, 2024 Amortization period (years) (a) Residual amortization period (years) (b) Carrying amount at December 31, 2023 Carrying amount at December 31, 2022 Genzyme (c) 10,600 (10,541) 59 10 2 208 621 Boehringer Ingelheim (c) 3,520 (1,756) 1,764 17 10 1,806 2,037 Aventis (c) 34,175 (34,136) 39 9 10 43 58 Chattem (c) 1,406 (924) 482 23 10 501 574 Protein Sciences (c) 886 (505) 381 13 6 420 498 Ablynx (c) 1,966 (883) 1,083 14 8 1,220 1,357 Bioverativ (c) 8,375 (4,026) 4,349 13 8 5,152 4,836 Rezurock 2,033 (520) 1,513 12 9 1,580 1,702 Tzield 2,714 (375) 2,339 12 11 2,405 — Beyfortus 2,288 (201) 2,087 17 16 1,870 180 Qunol 790 (91) 699 10 8 722 — Total: principal marketed products incl. Opella products presented in "Assets held for sale" 68,753 (53,958) 14,795 15,927 11,863 Total: principal marketed products excl. Opella products presented in "Assets held for sale" 60,214 (48,212) 12,002 13,055 9,429 (a) Weighted averages. The amortization periods for these products vary between 1 and 25 years. (b) Weighted averages. (c) Commercialized products derived from the acquisition of these companies. In the case of Bioverativ, the product Enjaymo was sold to Recordati in 2024 (see Note D.1.). During 2023 , some of the acquired research and development came into commercial use, and started being amortized from the date of marketing approval; the main item involved was ALTUVIIIO (efanesoctocog alfa) which extends protection from bleeds and treats acute hemorrhages in people with hemophilia A. The main asset brought into service during 2022 was Enjaymo (sutimlimab-jome), a treatment for cold agglutinin disease. Amortization of other intangible assets is recognized in the income statement within the line item Amortization of intangible assets , except for amortization of software and other rights of an industrial or operational nature which is recognized in the relevant classification of expense by function. An analysis of amortization of software is shown in the table below: (€ million) 2024 2023 (a) 2022 (a) Cost of sales 16 14 9 Research and development expenses 1 3 1 Selling and general expenses 87 100 82 Other operating expenses 1 2 4 Net income from discontinued operations 1 1 1 Total 106 120 97 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation .

Impairment of intangible assets

Impairment of intangible assets and property, plant and equipment	12 Months Ended
	Dec. 31, 2024
Impairment Of Assets [Abstract]
Impairment of intangible assets and property, plant and equipment	Impairment of intangible assets and property, plant and equipment Goodwill When testing goodwill annually for impairment, the recoverable amount is determined for the Biopharma segment on the basis of value in use, as derived from discounted estimates of the future cash flows in accordance with the policies described in Note B.6.1. The value in use of the Biopharma segment was determined by applying an after-tax discount rate to estimated future after-tax cash flows; the rate used for impairment testing of the Biopharma segment in 2024 was 7.25% . The pre-tax discount rate applied to estimated pre-tax cash flows is calculated by iteration from the previously-determined value in use; the rate used for the Biopharma segment was 9.8% . The assumptions used in testing goodwill for impairment are reviewed annually. Apart from the discount rate, the principal assumptions used in 2024 were as follows: • the perpetual growth rate applied to future cash flows for the Biopharma segment was zero ; and • Sanofi also applies assumptions on the probability of success of current research and development projects, and more generally on its ability to renew the product portfolio in the longer term. Value in use (determined as described above) is compared with the carrying amount, and this comparison is then subject to sensitivity analyses by reference to key parameters including: • changes in the discount rate; • changes in the perpetual growth rate; and • fluctuations in operating margin. No impairment of the goodwill would need to be recognized in the event of a reasonably possible change in the assumptions used in 2024 . No impairment losses were recognized against goodwill in the years ended December 31, 2024 , 2023 or 2022 . Other intangible assets When there is evidence that an asset may have become impaired, the asset’s value in use is calculated by applying an after-tax discount rate to the estimated future after-tax cash flows from that asset. For the purposes of impairment testing, the tax cash flows relating to the asset are determined using a notional tax rate incorporating the notional tax benefit that would result from amortizing the asset if its value in use were regarded as its depreciable amount for tax purposes. Applying after-tax discount rates to after-tax cash flows gives the same values in use as would be obtained by applying pre-tax discount rates to pre-tax cash flows. The after-tax discount rates used in 2024 for impairment testing of other intangible assets were obtained by adjusting Sanofi’s weighted average cost of capital to reflect specific country and business risks, giving after-tax discount rates in a range from 7.25% to 8.25% . In most instances, there are no market data that would enable fair value less costs to sell to be determined other than by means of developing a similar estimate based on future cash flows. Consequently, recoverable amount is in substance equal to value in use. The estimates used to determine value in use are sensitive to assumptions specific to the nature of the asset and to Sanofi's activities. Apart from the discount rate, the principal assumptions used in 2024 were as follows: • mid-term and long-term forecasts; • perpetual growth or attrition rates, when applicable; and • probability of success of current research and development projects. The assumptions used in testing intangible assets for impairment are reviewed at least annually. In 2024 , 2023 and 2022 , impairment testing of other intangible assets (excluding software) resulted in the recognition of net impairment losses as shown below (the table presents all net impairments of the Group including Opella, over all periods): (€ million) 2024 2023 2022 Impairment of other intangible assets, net of reversals (excluding software) 265 932 (454) Marketed products (167) — (1,561) Biopharma (a) (167) — (1,526) Opella — — (35) Research and development projects and technology platforms (b)(c)(d) 415 896 1,107 Others 17 36 — (a) For 2024, this comprises a reversal of €167 million in connection with the disposal of Enjaymo. For 2022, this amount mainly comprises a reversal of €2,154 million of impairment losses taken against Eloctate and BIVV001 (assets belonging to the Eloctate franchise), consisting of €1,554 million for marketed products and €600 million for research and development projects respectively. In 2019, the launch of competing products for Eloctate led Sanofi to update its sales forecasts for products belonging to the franchise, as a result of which impairment losses of €2.8 billion were recognized against the assets in question. The reversal reflects the approval by the FDA on February 22, 2023 of ALTUVIIIO (the commercial name of efanesoctocog alpha, corresponding to the BIVV001 project), which was submitted in 2022. (b) For 2024, the monitoring of impairment indicators for other intangible assets led to the recognition of net impairment losses of €415 million , comprising (i) impairment losses of €640 million against various research and development projects - including a €239 million loss resulting from the decision taken in February 2025 to discontinue a phase 3 clinical study investigating of a vaccine candidate to prevent invasive E.coli disease - and (ii) an impairment reversal of €225 million recognized in connection with the disposal of the ProXTen technology platform. (c) For 2023, this amount mainly comprises an impairment loss of €833 million , reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and ProXTen technology platforms. (d) For 2022, this amount mainly comprises: – an impairment loss of €1,586 million taken against the development project for SAR444245 (non-alpha interleukin-2), recognized following revised cash flow projections reflecting unfavorable developments in the launch schedule; – the €600 million reversal relating to the BIVV001 project (see above). As required by IFRS 5, the other intangible assets of Opella were measured in accordance with IAS 36 immediately before their reclassification as assets held for sale; this assessment did not result in any impairment of their carrying amount being recognized. Property, plant and equipment Impairment losses taken against property, plant and equipment are disclosed in Note D.3. Risks and opportunities related to climate change Sanofi has identified specific plausible scenarios to assess climate risks and opportunities liable to impact its activities in the medium and longer term. These include: • an Aggressive Mitigation scenario, based on global collaboration to start reducing emissions immediately to meet Paris Agreement goals (limit temperature increase to 1.5°C above pre-industrial levels), generating risks related to transitioning to a lower carbon economy and entailing extensive policy, legal, technology, and market changes to address mitigation and adaptation requirements; • a No Climate Action scenario (leading to global warming of 4°C above pre-industrial levels by 2100), with event-driven physical risks resulting from climate change or longer term shifts in climate patterns leading to potential financial implications such as direct damage to assets and indirect impacts from supply chain disruption; changes in water availability, and in the sourcing or quality of resources; food security; and extreme temperature changes affecting premises, operations, supply chain, transport needs, and employee safety; and • a Most Likely scenario, encompassing fragmented regional efforts to start reducing emissions but not at a sufficient level to meet Paris Agreement g oals (emissions continue to increase but at a slowed rate, leading to a 2.8°C temperature increase). The importance and likelihood of such risks have been assessed and have not led Sanofi to identify any material impact that could generate a risk of impairment of the assets of Sanofi’s CGUs.

Investments accounted for using

Investments accounted for using the equity method	12 Months Ended
	Dec. 31, 2024
Interests In Other Entities [Abstract]
Investments accounted for using the equity method	Investments accounted for using the equity method Investments accounted for using the equity method comprise associates and joint ventures (see Note B.1.), and are set forth below. (€ million) % interest 2024 2023 2022 EUROAPI (a) 29.6 82 162 392 Infraserv GmbH & Co. Höchst KG (b) 31.2 102 90 97 MSP Vaccine Company (c) 50.0 81 96 104 Other investments — 51 76 84 Total 316 424 677 (a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€ 2.88 as of December 31, 2024, and € 5.73 as of December 31, 2023) . (b) Joint venture. (c) Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV . The table below shows Sanofi’s overall share of (i) profit or loss and (ii) other comprehensive income from investments accounted for using the equity method, showing the split between associates and joint ventures in accordance with IFRS 12 (the amounts for each individual associate or joint venture are not material): 2024 2023 2022 (€ million) Joint ventures Associates Joint ventures Associates Joint ventures Associates Share of profit/(loss) from investments accounted for using the equity method (a) 134 (74) 101 (237) 73 (18) Share of other comprehensive income from investments accounted for using the equity method 3 (5) (7) 7 (3) (1) Total 137 (79) 94 (230) 70 (19) (a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€ 2.88 as of December 31, 2024, and € 5.73 as of December 31, 2023). The financial statements include arm’s length transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below: (€ million) 2024 2023 2022(a) Sales (d) 103 157 131 Royalties and other income (d) 71 14 21 Accounts receivable and other receivables (b) 184 249 330 Other assets (c) 189 — — Purchases and other expenses (including research expenses) (d) 600 573 472 Accounts payable and other liabilities 160 190 258 (a) In 2022, these items include Sanofi's transactions with EUROAPI from May 10, 2022 (see Note D.1.). (b) Includes loans to joint ventures and associates. (c) In October 2024, Sanofi raised its investment in EUROAPI by € 200 million in the form of a perpetual subordinated hybrid bon d. The fair value of this investment as of December 31, 2024 is € 189 million. (d) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. There were no funding commitments to associates and joint ventures as of December 31, 2024 , December 31, 2023 or December 31, 2022 . For off balance sheet commitments of an operational nature involving joint ventures, see Note D.21.1.

Other non-current assets

Other non-current assets	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Other non-current assets	Other non-current assets Other non-current assets comprise: (€ million) 2024 2023 2022 Equity instruments at fair value through other comprehensive income (D.7.1.) 1,559 1,088 936 Debt instruments at fair value through other comprehensive income (D.7.2.) 357 346 329 Other financial assets at fair value through profit or loss (D.7.3.) 1,027 808 823 Pre-funded pension obligations (Note D.19.1.) 156 271 269 Long-term prepaid expenses 152 114 286 Long-term loans and advances and other non-current receivables (a) 502 591 452 Derivative financial instruments (Note D.20.) — — — Total 3,753 3,218 3,095 (a) As of December 31, 2024 , this line includes: – Loan of € 149 million to the BioAtrium joint venture which matures on December 1, 2031, of which €156 million was recognized in "Other current assets" as of December 31, 2022; – a receivable under a sub-lease amounting to € 116 million ( € 181 million before discounting), versus € 132 million (or € 195 million before discounting) as of December 31, 2023 . D.7.1. Equity instruments at fair value through other comprehensive income Quoted equity instruments The line “Equity instruments at fair value through other comprehensive income” includes equity investments quoted in an active market with a carrying amount of €467 million as of December 31, 2024 , €470 million as of December 31, 2023 and €387 million as of December 31, 2022 . The movement i n quoted equity investments included in the “Equity instruments at fair value through other comprehensive income” category in the year ended December 31, 2024 was mainly due to Sanofi taking a non-controlling equity interest in Novavax in May 2024. The main changes during previous years in quoted equity investments included in the “Equity instruments at fair value through other comprehensive income” category are described below: • In 2023 : t here were no material movements in quoted equity investments during the year ended December 31, 2023. • In 2022 : – the sale in June 2022 of the residual equity interest in Regeneron (see Note C.1.) for $ 174 million , the entire loss on which was recorded within Other comprehensive income , and – the acquisition of an equity interest in Innovent Biologics, in connection with a strategic collaboration agreement to intensify development in oncology medicines signed in August 2022, which had a fair value of €250 million as of that date and €228 million as of December 31, 2022. A 10% decline in stock prices of the quoted equity investments included within “Equity instruments at fair value through other comprehensive income” would have had a pre-tax impact of €47 million on Other comprehensive income as of December 31, 2024 . Unquoted equity instruments The line item “Equity instruments at fair value through other comprehensive income” also includes equity investments not quoted in an active market with a carrying amount of €1,092 million as of December 31, 2024 , €618 million as of December 31, 2023 and €549 million as of December 31, 2022 . The change in unquoted equity investments included in the “Equity instruments at fair value through other comprehensive income” category during the year ended December 31, 2024 was mainly due to an investment in EUROAPI in the form of a perpetual subordinated hybrid bond of which the value at inception date was €200 million and the value as of December 31, 2024 is €189 million , and various equity stakes acquired through the Sanofi Ventures fund. In addition, commitments relating to equity investments classified in this asset category amounted to €360 million as of December 31, 2024 (versus €65 million as of December 31, 2023). The figure as of December 31, 2024 includes €300 million relating to an equity interest of approximately 16% in Orano Med, a new entity valued at €1.9 billion focused on the discovery, design, and clinical development of next-generation radioligand therapies (RLTs) based on lead-212 (212Pb) alpha-emitting isotopes. D.7.2. Debt instruments at fair value through other comprehensive income The “Debt instruments at fair value through other comprehensive income” category includes quoted euro-denominated senior bonds amounting to €357 million as of December 31, 2024 , including €110 million of securities obtained in exchange for financial assets held to meet obligations to employees under post-employment benefit plans. Sanofi held €346 million of quoted senior bonds as of December 31, 2023 and €329 million as of December 31, 2022 . As regards debt instruments held to meet obligations to employees under post-employment benefit plans, an increase of 10 basis points in market interest rates as of December 31, 2024 would have had a pre-tax impact of €1 million on Other comprehensive income . As regards other quoted debt instruments, an increase of 10 basis points in market interest rates as of December 31, 2024 would have had a pre-tax impact of €1 million on Other comprehensive income . Other comprehensive income recognized in respect of “Equity instruments at fair value through other comprehensive income” and “Debt instruments at fair value through other comprehensive income” represented unrealized after-tax gains of €342 million for the year ended December 31, 2024 , versus unrealized after-tax gains of €349 million for the year ended December 31, 2023 and of € 256 million for the year ended December 31, 2022 . An analysis of the change in gains and losses recognized in Other comprehensive income , and of items reclassified to profit or loss, is presented in Note D.15.7. D.7.3. Other financial assets at fair value through profit or loss The “Other financial assets at fair value through profit or loss” category mainly includes: • a portfolio of financial investments (amounting to €688 million as of December 31, 2024 ) held to fund a deferred compensation plan provided to certain employees (versus €572 million as of December 31, 2023 and €512 million as of December 31, 2022 ); • unquoted securities not meeting the definition of equity instruments amounting to €165 million as of December 31, 2024 (versus €132 million as of December 31, 2023 and €115 million as of December 31, 2022 ). In addition, commitments relating to unquoted securities classified in this asset category amount to €168 million as of December 31, 2024 (compared to €159 million as of December 31, 2023). • contingent consideration receivable by Sanofi following the sale of Enjaymo (see note D.1) based on the probability of achieving certain levels of future sales, and discounted. If the discount rate were to increase by one percentage point, the fair value of the contingent consideration would decrease by approximately 7% . Changes in the fair value of this contingent consideration are recognized within the income statement line item Fair value remeasurement of contingent consideration (see note B.18.). As of December 31, 2024, the contingent consideration amounted to € 104 million , recorded entirely as a non- current asset; and • up to December 31, 2023, contingent consideration receivable by Sanofi following the dissolution of the Sanofi Pasteur MSD (SPMSD) joint venture, based on a percentage of MSD’s future sales during the 2017-2024 period of specified products previously distributed by SPMSD (see Note D.12.). Changes in the fair value of this contingent consideration are recognized in the income statement within the line item Fair value remeasurement of contingent consideration (see Note B.18.). As of December 31, 2024 , the contingent consideration asset amounted to €113 million (entirely recognized as a current asset), versus €214 million (non-current portion: €104 million ) as of December 31, 2023 and €303 million (non current portion: €196 million ) as of December 31, 2022

Assets held for sale or exchang

Assets held for sale or exchange and liabilities related to assets held for sale or exchange	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Assets held for sale or exchange and liabilities related to assets held for sale or exchange	Assets held for sale and liabilities related to assets held for sale Assets held for sale, and liabilities related to assets held for sale, comprise: (€ million) December 31, 2024 December 31, 2023 December 31, 2022 Opella (D.36.) 13,489 — — Other — 15 85 Assets held for sale 13,489 15 85 Opella (D.36.) 2,131 — — Other — 13 10 Liabilities related to assets held for sale 2,131 13 10

Inventories

Inventories	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Inventories	Inventories Inventories comprise the following: 2024 2023 2022 (€ million) Gross value Allowances Carrying amount Gross value Allowances Carrying amount Gross value Allowances Carrying amount Raw materials 1,588 (135) 1,453 1,676 (126) 1,550 1,613 (139) 1,474 Work in process 5,777 (481) 5,296 5,869 (553) 5,316 5,663 (678) 4,985 Finished goods 2,899 (217) 2,682 3,045 (245) 2,800 2,748 (247) 2,501 Total 10,264 (833) 9,431 10,590 (924) 9,666 10,024 (1,064) 8,960 Allowances include write-downs of products on hand pending marketing approval, except in specific circumstances where it is possible to estimate that recovery of the value of inventories as of the end of the reporting period is highly probable. No inventories were pledged as security for liabilities as of December 31, 2024 (versus zero as of December 31, 2023 and €3 million as of December 31, 2022 ).

Accounts receivable

Accounts receivable	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Accounts receivable	Accounts receivable Accounts receivable break down as follows: (€ million) December 31, 2024 December 31, 2023 December 31, 2022 Gross value 7,777 8,528 8,537 Allowances (100) (95) (113) Carrying amount 7,677 8,433 8,424 The impact of allowances against accounts receivable in 2024 was a net expense of €19 million (versus a net expense of €8 million in 2023 and a net amount of less than €1 million in 2022 ). The gross value of overdue receivables was € 650 million as of December 31, 2024 , versus € 689 million as of December 31, 2023 and € 452 million as of December 31, 2022 . (€ million) Overdue accounts gross value Overdue by <1 month Overdue by 1 to 3 months Overdue by 3 to 6 months Overdue by 6 to 12 months Overdue by > 12 months December 31, 2024 650 316 194 87 9 44 December 31, 2023 689 269 154 123 62 81 December 31, 2022 452 118 161 87 35 51 Amounts overdue by more than one month relate mainly to public-sector customers. Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse . The amount of receivables derecognized was €14 million as of December 31, 2024 ( €761 million as of December 31, 2023 and €131 million as of December 31, 2022 ). The residual guarantees relating to such transfers were immaterial as of December 31, 2024 .

Other current assets

Other current assets	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Other current assets	Other current assets An analysis of Other current assets is set forth below: (€ million) 2024 2023 2022 Tax receivables, other than corporate income taxes 782 768 660 Prepaid expenses 895 768 714 Other receivables (a) 1,446 1,448 1,289 Currency derivatives measured at fair value (see Note D.20.) 217 201 206 Other financial assets at fair value through profit or loss 115 112 146 Other current financial assets (b) 371 158 517 Total 3,826 3,455 3,532 (a) This line mainly comprises advance payments to suppliers, and receivables relating to Sanofi's activities as agent under a transitional services agreement. (b) This item mainly comprises bank loans and receivables maturing in less than one year with high-grade counterparties .

Financial assets and liabilitie

Financial assets and liabilities measured at fair value	12 Months Ended
	Dec. 31, 2024
Fair Value Measurement [Abstract]
Financial assets and liabilities measured at fair value	Financial assets and liabilities measured at fair value Under IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a fair value hierarchy with the following levels: • level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging); • level 2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; and • level 3: valuation techniques in which not all important inputs are derived from observable market data. The valuation techniques used are described in Note B.8.5. The table below shows the balance sheet amounts of assets and liabilities measured at fair value. 2024 2023 2022 Level in the fair value hierarchy Level in the fair value hierarchy Level in the fair value hierarchy (€ million) Note Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Financial assets measured at fair value Quoted equity investments D.7.1. 467 — — 470 — — 387 — — Unquoted equity investments D.7.1. — — 1,092 — — 618 — — 549 Quoted debt securities D.7.2. 357 — — 346 — — 329 — — Unquoted debt securities not meeting the definition of equity instruments D.7.3. — — 339 — — 132 — — 115 Contingent consideration relating to divestments D.7.3. & D.11. — — 286 — — 214 — — 303 Financial assets held to meet obligations under deferred compensation plans D.7.3. & D.11. 688 — — 572 — — 512 — — Non-current derivatives D.7. — — — — — — — — — Current derivatives D.11. — 217 — — 201 — — 206 — Mutual fund investments D.13. 4,161 — — 5,349 — — 9,537 — — Total financial assets measured at fair value 5,673 217 1,717 6,737 201 964 10,765 206 967 Financial liabilities measured at fair value Bayer contingent purchase consideration arising from the acquisition of Genzyme D.18. — — — — — — — — 26 MSD contingent consideration (European vaccines business) D.18. — — 72 — — 127 — — 204 Shire contingent consideration arising from the acquisition of Translate Bio D.18. — — 568 — — 441 — — 380 Contingent consideration arising from acquisition of Amunix D.18. — — — — — 137 — — 165 Other contingent consideration arising from business combinations and acquisitions D.18. — — 1 — — 4 — — 4 Non-current derivatives D.20. — 121 — — 164 — — 232 — Current derivatives D.19.5 — 337 — — 127 — — 94 — Total financial liabilities measured at fair value — 458 641 — 291 709 — 326 779 No transfers between the different levels of the fair value hierarchy occurred during 2024 .

Cash and cash equivalents

Cash and cash equivalents	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Cash and cash equivalents	Cash and cash equivalents (€ million) 2024 2023 2022 Cash 1,270 1,461 1,385 Cash equivalents (a) 6,171 7,249 11,351 Cash and cash equivalents 7,441 8,710 12,736 (a) As of December 31, 2024 , cash equivalents mainly comprised the following: (i) €4,161 million invested in euro and US dollar denominated money-market mutual funds ( December 31, 2023 : €5,349 million ; December 31, 2022 : €9,537 million ); (ii) €1,293 million of term deposits ( December 31, 2023 : €1,191 million ; December 31, 2022 : €1,167 million ) and (iii) zero commercial paper ( December 31, 2023 : zero ; December 31, 2022 : zero ). Cash equivalents also include €446 million held by captive insurance and reinsurance companies in accordance with insurance regulations ( December 31, 2023 : €476 million ; December 31, 2022 : €439 million ).

Net deferred tax position

Net deferred tax position	12 Months Ended
	Dec. 31, 2024
Income Taxes [Abstract]
Net deferred tax position	Net deferred tax position An analysis of the net deferred tax position is set forth below: (€ million) 2024 2023 2022 Deferred taxes on: Consolidation adjustments (intragroup margin in inventory) 1,927 1,525 1,388 Provision for pensions and other employee benefits 787 853 850 Remeasurement of other acquired intangible assets (2,079) (a) (2,795) (3,269) Recognition of acquired property, plant and equipment at fair value (10) (21) (24) Equity interests in subsidiaries and investments in other entities (b) (1,044) (1,023) (617) Tax losses available for carry-forward 971 1,526 1,506 Stock options and other share-based payments 103 84 92 Accrued expenses and provisions deductible at the time of payment (c) 2,277 1,994 1,859 Other (d) 2,869 2,427 1,755 Net deferred tax asset/(liability) 5,801 4,570 3,540 ( a ) A s of December 31, 2024 , includes remeasurements of the acquired intangible assets of Bioverativ ( €987 million ), Principia (€ 648 million ), Ablynx (€ 178 million ) and Genzyme ( €15 million ). (b) In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a deferred tax liability on the reserves of French and foreign subsidiaries (approximately € 64.9 billion ) which it regards as likely to be distributed in the foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2024 , Sanofi took into account changes in the ownership structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of the European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December 31, 2023, this line includes a deferred tax liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Opella business, as announced in October 2023 (see Note D.30.). (c) Includes deferred tax assets related to restructuring provisions, amounting to €319 million as of December 31, 2024 , €286 million as of December 31, 2023 , and €256 million as of December 31, 2022 . (d) Includes deferred taxes arising on the spread tax deduction of R&D expenses, amounting to € 2,053 million as of December 31, 2024 , € 1,331 million as of December 31, 2023 , and €742 million as of December 31, 2022 . The reserves of Sanofi subsidiaries that would be taxable if distributed but for which no distribution is planned, and for which no deferred tax liability has therefore been recognized, totaled €10.5 billion as of December 31, 2024 , compared with €10.0 billion as of December 31, 2023 and €10.6 billion as of December 31, 2022 . Most of Sanofi’s tax loss carry-forwards are available indefinitely. For a description of policies on the recognition of deferred tax assets, refer to Note B.22. For each tax consolidation, the recognition of deferred tax assets is determined on the basis of profit forecasts that are consistent with Sanofi’s medium-term strategic plan, and taking into consideration the tax consequences of the strategic opportunities available to Sanofi within the period of availability of tax loss carry-forwards and the specific circumstances of each tax consolidation. Deferred tax assets relating to tax loss carry-forwards as of December 31, 2024 amounted to €3,010 million , of which €2,039 million were not recognized (primarily composed of prior period tax liabilities following progress of reviews with tax authorities and capital losses ). This compares with €2,729 million as of December 31, 2023 (of which €1,203 million were not recognized) and €2,650 million as of December 31, 2022 (of which €1,144 million were not recognized). The table below shows when tax losses available for carry-forward are due to expire: (€ million) Tax losses available for carry-forward (a) 2025 1 2026 17 2027 12 2028 30 2029 187 2030 and later 9,565 Total as of December 31, 2024 9,812 Total as of December 31, 2023 8,933 Total as of December 31, 2022 8,503 (a) Excluding tax loss carry-forwards on asset disposals. Such carry-forwards amounted to €40 million as of December 31, 2024 , €5 million as of December 31, 2023 and €5 million as of December 31, 2022 . Use of tax loss carry-forwards is limited to the entity in which they arose. In jurisdictions where tax consolidations are in place, tax losses can be netted against taxable income generated by entities in the same tax consolidation. Deferred tax assets not recognized because their future recovery was not regarded as probable given the expected results of the entities in question and unagreed tax positions amounted to €2,117 million in 2024 , €1,261 million in 2023 and €1,197 million in 2022 .

Consolidated shareholders_ equi

Consolidated shareholders’ equity	12 Months Ended
	Dec. 31, 2024
Share Capital, Reserves And Other Equity Interest [Abstract]
Consolidated shareholders' equity	Consolidated shareholders’ equity D.15.1. Share capital As of December 31, 2024 , the share capital w as €2,526,245,442 , consisting of 1,263,122,721 shar es with a par value of €2 . Treasury shares held by Sanofi are as follows: Number of shares (million) % of share capital for the period December 31, 2024 9.53 0.755% December 31, 2023 13.45 1.063% December 31, 2022 8.20 0.650% January 1, 2022 11.02 0.872% Treasury shares are deducted from shareholders’ equity. Gains and losses on disposals of treasury shares are recorded directly in equity and are not recognized in net income for the period. Movements in the share capital of the Sanofi parent company over the last three years are set forth below: Date Transaction Number of shares December 31, 2021 1,263,560,695 During 2022 Capital increase by exercise of stock subscription options (a) 490,373 During 2022 Capital increase by issuance of restricted shares (b) 1,499,987 Board meeting of July 27, 2022 Capital increase reserved for employees 2,027,057 Board meeting of December 14, 2022 Reduction in share capital by cancellation of treasury shares (6,742,380) December 31, 2022 1,260,835,732 During 2023 Capital increase by exercise of stock subscription options (a) 504,956 During 2023 Capital increase by issuance of restricted shares (b) 1,330,558 Board meeting of July 27, 2023 Capital increase reserved for employees 2,128,723 December 31, 2023 1,264,799,969 During 2024 Capital increase by exercise of stock subscription options (a) 398,569 During 2024 Capital increase by issuance of restricted shares (b) 1,479,787 Board meeting of July 24, 2024 Capital increase reserved for employees 2,244,396 Board meeting of December 4, 2024 Reduction in share capital by cancellation of treasury shares (5,800,000) December 31, 2024 1,263,122,721 (a) Shares issued on exercise of Sanofi stock subscription options. (b) Shares vesting under restricted share plans and issued in the period . For the disclosures about the management of capital required under IFRS 7, refer to Note D.2. D.15.2. Restricted share plans Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. The principal characteristics of those plans are as follows: 2024 2023 2022 Type of plan Performance share plans Performance share plans Performance share plans Performance share plans Performance share plans Performance share plans Date of Board meeting approving the plan April 30, 2024 December 4, 2024 May 25, 2023 December 13, 2023 May 3, 2022 December 14, 2022 Service period 3 years 3 years 3 years 3 years 3 years 3 years Total number of shares awarded (a) 4,505,145 97,100 3,838,434 65,129 3,344,432 109,981 Of which with no market condition 2,888,502 6,649 2,425,047 944 2,000,627 10,335 Fair value per share awarded (b) €81.84 €79.51 €87.69 €77.42 €91.19 €79.17 Of which with market condition 1,616,643 90,451 1,413,387 64,185 1,343,805 99,646 Fair value per share awarded other than to the Chief Executive Officer (c) €72.79 €75.11 €83.74 €74.50 €86.65 €69.60 Fair value per share awarded other than to the Chief Executive Officer - additional shares (d) €13.50 €32.09 €43.60 €34.90 €49.00 €54.70 Fair value per share awarded to the Chief Executive Officer (c) €72.38 — €82.17 — €84.46 — Fair value of plan at the date of grant (€ million) 346 7 326 5 294 8 (a) Includes shares awarded in an additional tranche subject to a higher level of market conditions: 139,665 additional shares awarded in April 2024 and 8,229 awarded in December 2024 (versus 121,097 awarded in May 2023 and 5,838 awarded in December 2023 ). (b) Market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period. (c) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period. (d) Additional tranche subject to a higher level of market conditions: 139,665 additional shares awarded in April 2024 and 8,229 awarded in December 2024 (versus 121,097 awarded in May 2023 , 5,838 awarded in December 2023 , 114,874 awarded in May 2022 and 9,066 awarded in December 2022 ). The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below: 2024(a) 2023(a) 2022(a) Total expense for restricted share plans (€ million) 260 231 206 Number of shares not yet fully vested as of December 31 10,914,134 9,773,084 9,245,513 Under 2024 plans 4,454,299 — — Under 2023 plans 3,501,088 3,780,513 — Under 2022 plans 2,958,747 3,099,158 3,330,801 Under 2021 plans — 2,893,413 3,097,531 Under 2020 plans — — 2,817,181 (a) Includes shares awarded in an additional tranche subject to a higher level of market conditions: 147,894 additional shares awarded in 2024 , versus 126,935 awarded in 2023 and 123,940 awarded in 2022 . D.15.3. Capital increases The characteristics of the employee share ownership plans awarded in the form of a capital increase reserved for employees in 2024 , 2023 and 2022 are summarized in the table below: 2024 2023 2022 Date of Board meeting approving the plan January 31, 2024 February 2, 2023 February 3, 2022 Subscription price (€) (a) 72.87 79.58 80.21 Subscription period June 4-24, 2024 June 5-23, 2023 June 9-29, 2022 Number of shares subscribed 2,124,445 2,009,306 1,909,008 Number of shares issued immediately as employer’s contribution 119,951 119,417 118,049 (a) Subscription price representing 80% of the average of the opening quoted market prices of Sanofi shares during the 20 trading days preceding May 30, 2024, May 31, 2023 and June 6, 2022, respectively . The table below sets forth the expense recognized for each plan: (€ million) 2024 2023 2022 Expense recognized 45 52 39 of which employer’s contribution 11 12 11 D.15.4. Repurchase of Sanofi shares The Annual General Meetings of Sanofi shareholders held on April 30, 2024, May 25, 2023 and May 3, 2022 each authorized a share repurchase program for a period of 18 months . The following repurchases have been made under those programs: (in number of shares and € million) Year of authorization 2024 2023 2022 Number of shares Value Number of shares Value Number of shares Value 2024 program — — — — — — 2023 program 3,215,460 302 2,584,540 230 — — 2022 program — — 4,000,204 363 1,510,000 137 2021 program — — — — 3,976,992 360 D.15.5. Reductions in share capital Reductions in share capital for the accounting periods presented are described in the table included at Note D.15.1. above. Those reductions have no impact on shareholders’ equity. D.15.6. Currency translation differences Currency translation differences comprise the following: (€ million) 2024 2023 2022 Attributable to equity holders of Sanofi 2,408 (31) 1,499 Attributable to non-controlling interests (17) (37) (37) Total 2,391 (68) 1,462 The balance as of December 31, 2024 includes an after-tax amount of €(679) million relating to hedges of net investments in foreign operations (refer to Note B.8.3. for a description of the relevant accounting policy), compared with € (574) million as of December 31, 2023 and € (580) million as of December 31, 2022 . This balance also includes an amount of €(300) million relating to translation differences of Opella, the assets and liabilities of which are presented in Assets held for sale and Liabilities related to assets held for sale as of December 31, 2024. The movement in Currency translation differences is mainly attributable to the US dollar. D.15.7. Other comprehensive income Movements within other comprehensive income are shown below: (€ million) 2024 2023 2022 Actuarial gains/(losses): • Actuarial gains/(losses) excluding investments accounted for using the equity method (see Note D.19.1.) 13 (171) 650 • Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes (2) — 4 • Tax effects (27) 18 (212) Equity instruments included in financial assets and financial liabilities: • Change in fair value (excluding investments accounted for using the equity method) (21) 97 (4) • Change in fair value (investments accounted for using the equity method, net of taxes) — — — • Equity risk hedging instruments designated as fair value hedges — — 17 • Tax effects 9 (21) (4) Items not subsequently reclassifiable to profit or loss (a) (28) (77) 451 Debt instruments included in financial assets: • Change in fair value (excluding investments accounted for using the equity method) (b) 5 21 (77) • Tax effects — (4) 15 Cash flow and fair value hedges: • Change in fair value (excluding investments accounted for using the equity method) (c) (3) 1 5 • Change in fair value (investments accounted for using the equity method, net of taxes) (3) (2) 2 ▪ Tax effects 2 — (1) Change in currency translation differences: • Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method) (d) 2,560 (1,551) 2,643 • Currency translation differences (investments accounted for using the equity method) (d) 3 3 (11) • Hedges of net investments in foreign operations (d) (121) 8 (354) • Tax effects 17 (2) 91 Items subsequently reclassifiable to profit or loss (e) 2,460 (1,526) 2,313 (a) Items not subsequently reclassifiable to profit or loss and attributable to Opella: € (1) million in 2024, immaterial amount in 2023 and € 20 million in 2022. (b) Amounts reclassified to profit or loss were immaterial in 2024 , 2023 and 2022 . (c) Amounts reclassified to profit or loss: €1 million in 2024 , €1 million in 2023 and € 2 million in 2022 . (d) Amounts reclassified to profit or loss: € 5 million in 2024 , € (56) million in 2023 and € (40) million in 2022 (including € (35) million relating to the deconsolidation of EUROAPI). Currency translation differences arise from the translation into euros of the financial statements of foreign subsidiaries, and are mainly due to the appreciation of the dollar against the euro. (e) Items subsequently reclassifiable to profit or loss and attributable to Opella (currency translation differences): € (28) million in 2024, € (78) million in 2023, € (54) million in 2022 . D.15.8. Stock options Stock option plans awarded and measurement of stock option plans No stock options were awarded during 2024 , 2023 or 2022 . Stock subscription option plans Details of the terms of exercise of stock subscription options granted under the various plans are presented below in Sanofi share equivalents. These plans were awarded to certain corporate officers and employees of Sanofi companies. The table shows all Sanofi stock subscription option plans still outstanding or under which options were exercised in the year ended December 31, 2024 : Source Date of grant Number of options granted Start date of exercise period Expiry date Exercise price (€) Number of options outstanding as of 12/31/2024 Sanofi 03/05/2014 1,009,250 03/06/2018 03/05/2024 73.48 — Sanofi 06/24/2015 435,000 06/25/2019 06/24/2025 89.38 159,250 Sanofi 05/04/2016 402,750 05/05/2020 05/04/2026 75.90 136,000 Sanofi 05/10/2017 378,040 05/11/2021 05/10/2027 88.97 257,010 Sanofi 05/02/2018 220,000 05/03/2022 05/02/2028 65.84 168,784 Sanofi 04/30/2019 220,000 05/01/2023 04/30/2029 76.71 213,400 Total 934,444 The exercise of all outstanding stock subscription options would increase shareholders’ equity by approximately €75 million . The exercise of each option results in the issuance of one share. Summary of stock option plans A summary of stock options outstanding at each balance sheet date, and of movements during the relevant periods, is presented below: Number of options Weighted average exercise price per share (€) Total (€ million) Options outstanding at January 1, 2022 2,337,968 77.13 180 Options exercisable 1,949,184 78.15 152 Options exercised (490,373) 71.39 (35) Options cancelled (a) (9,626) 80.56 (1) Options outstanding at December 31, 2022 1,837,969 78.64 144 Options exercisable 1,624,569 78.89 128 Options exercised (504,956) 73.65 (37) Options outstanding at December 31, 2023 1,333,013 80.53 107 Options exercisable 1,333,013 80.53 107 Options exercised (398,569) 81.38 (32) Options outstanding at December 31, 2024 934,444 80.16 75 Options exercisable 934,444 80.16 75 (a) Mainly due to the grantees leaving Sanofi . The table below provides summary information about options outstanding and exercisable as of December 31, 2024 : Outstanding Exercisable Range of exercise prices per share Number of options Weighted average residual life (years) Weighted average exercise price per share (€) Number of options Weighted average exercise price per share (€) From €60.00 to €70.00 per share 168,784 3.34 65.84 168,784 65.84 From €70.00 to €80.00 per share 349,400 3.17 76.39 349,400 76.39 From €80.00 to €90.00 per share 416,260 1.64 89.13 416,260 89.13 Total 934,444 934,444 D.15.9. Number of shares used to compute diluted earnings per share Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares. (million) 2024 2023 2022 Average number of shares outstanding 1,251.4 1,251.7 1,251.9 Adjustment for stock options with dilutive effect 0.1 0.2 0.3 Adjustment for restricted shares 4.6 4.5 4.7 Average number of shares used to compute diluted earnings per share 1,256.1 1,256.4 1,256.9 In 2024 , 2023 and 2022 , all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect.

Non-controlling interests

Non-controlling interests	12 Months Ended
	Dec. 31, 2024
Interests In Other Entities [Abstract]
Non-controlling interests	N on-controlling interests Non-controlling interests did not represent a material component of Sanofi’s consolidated financial statements in the years ended December 31, 2024 , 2023 and 2022

Debt, cash and cash equivalents

Debt, cash and cash equivalents and lease liabilities	12 Months Ended
	Dec. 31, 2024
Financial Instruments [Abstract]
Debt, cash and cash equivalents and lease liabilities	Debt, cash and cash equivalents and lease liabilities D.17.1. Debt, cash and cash equivalents Changes in Sanofi's financial position during the period were as follows: (€ million) 2024 2023 2022 Long-term debt 11,791 14,347 14,857 Short-term debt and current portion of long-term debt 4,209 2,045 4,174 Interest rate and currency derivatives used to manage debt 137 139 187 Total debt 16,137 16,531 19,218 Cash and cash equivalents (7,441) (8,710) (12,736) Interest rate and currency derivatives used to manage cash and cash equivalents 76 (28) (45) Net debt (a) 8,772 7,793 6,437 (a) Net debt does not include lease liabilities, which amounted to €1,906 million as of December 31, 2024 , € 2,030 million as of December 31, 2023 , and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.) . “Net debt” is a non-IFRS financial measure used by management and investors to measure Sanofi’s overall net indebtedness. Reconciliation of carrying amount to value on redemption Value on redemption (€ million) Carrying amount at December 31, 2024 Amortized cost Adjustment to debt measured at fair value December 31, 2024 December 31, 2023 December 31, 2022 Long-term debt 11,791 30 119 11,940 14,546 15,143 Short-term debt and current portion of long-term debt 4,209 4 5 4,218 2,045 4,178 Interest rate and currency derivatives used to manage debt 137 (124) 13 (18) (48) Total debt 16,137 34 — 16,171 16,573 19,273 Cash and cash equivalents (7,441) (7,441) (8,710) (12,736) Interest rate and currency derivatives used to manage cash and cash equivalents 76 76 (28) (45) Net debt 8,772 34 — 8,806 7,835 6,492 a) Principal financing transactions during the year The table below shows the movement in total debt during the period: Cash flows from financing activities Non-cash items (€ million) December 31, 2023 Repayments New borrowings Other cash flows (a) Currency translation differences (b) Reclassification from non-current to current Other items (c) December 31, 2024 Long-term debt 14,347 (67) — — 63 (2,599) 47 11,791 Short-term debt and current portion of long-term debt 2,045 (605) — 242 9 2,599 (81) 4,209 Interest rate and currency derivatives used to manage debt 139 — — (132) 146 — (16) 137 Total debt 16,531 (672) — 110 218 — (50) 16,137 (a)These amounts mainly comprise €262 million related to the US commercial paper program. (b) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone. (c) These amounts mainly comprise changes in accrued interest balances, and fair value adjustments. Sanofi did not carry out any bond issues in 2024. One bond issue was redeemed in 2024: the €600 million issue from April 2016, which was redeemed at maturity on April 5, 2024. Sanofi exercised an extension option on one of its two syndicated credit facilities linked to social and environmental indicators, thereby extending the maturity of that €4 billion facility (put in place in March 2023) to March 6, 2030. Consequently, as of December 31, 2024, Sanofi had two syndicated credit facilities to provide liquidity for the purposes of current operations, each of them linked to environmental and social indicators: • a €4 billion facility maturing December 6, 2027, with no further extension option available; and • a €4 billion facility maturing March 6, 2030, with no further extension option available . In line with Sanofi’s commitment to embed sustainable development in the “Play to Win” strategy, those two revolving credit facilities build in an adjustment mechanism that links the credit spread to the attainment of two sustainable development performance indicators: • for the facility maturing in December 2027: (i) Sanofi’s contribution to polio eradication, and (ii) the reduction in Sanofi’s carbon footprint; and • for the facility maturing in March 2030: (i) Sanofi’s contribution to improving access to essential medicines in low-income and intermediate-income countries via its Sanofi Global Health non-profit unit, and (ii) the reduction in Sanofi’s carbon footprint. The table below shows the movement in total debt during prior periods: Cash flows from financing activities Non-cash items (€ million) December 31, 2022 Repayments New borrowings Other cash flows (a) Currency translation differences (b) Reclassification from non-current to current Other items (c) December 31, 2023 Long-term debt 14,857 (12) 48 — (30) (604) 88 14,347 Short-term debt and current portion of long-term debt 4,174 (3,672) — 903 (21) 604 57 2,045 Interest rate and currency derivatives used to manage debt 187 — — (8) 29 — (69) 139 Total debt 19,218 (3,684) 48 895 (22) — 76 16,531 (a) These amounts mainly comprise €946 million related to the US commercial paper program. (b) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone. (c) These amounts mainly comprise changes in accrued interest balances, and fair value adjustments. Cash flows from financing activities Non-cash items (€ million) December 31, 2021 Repayments New borrowings Other cash flows Currency translation differences (a) Reclassification from non-current to current Other items (b) December 31, 2022 Long-term debt 17,123 (11) 1,549 — 56 (3,632) (228) 14,857 Short-term debt and current portion of long-term debt 3,183 (2,707) — 43 20 3,632 3 4,174 Interest rate and currency derivatives used to manage debt (56) — — (373) 366 7 243 187 Total debt 20,250 (2,718) 1,549 (330) 442 7 18 19,218 (a) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone. (b) These amounts include changes in accrued interest balances and fair value adjustments. b) Net debt by type, at value on redemption 2024 2023 2022 (€ million) Non- current Current Total Non- current Current Total Non- current Current Total Bond issues 11,876 2,716 14,592 14,416 718 15,134 15,044 3,817 18,861 Other bank borrowings 64 1,290 1,354 130 1,118 1,248 99 187 286 Other borrowings — 3 3 — 6 6 — 6 6 Bank credit balances — 209 209 — 203 203 — 168 168 Interest rate and currency derivatives used to manage debt — 13 13 — (18) (18) — (48) (48) Total debt 11,940 4,231 16,171 14,546 2,027 16,573 15,143 4,130 19,273 Cash and cash equivalents — (7,441) (7,441) — (8,710) (8,710) — (12,736) (12,736) Interest rate and currency derivatives used to manage cash and cash equivalents — 76 76 — (28) (28) — (45) (45) Net debt (a) 11,940 (3,134) 8,806 14,546 (6,711) 7,835 15,143 (8,651) 6,492 (a) Net debt does not include lease liabilities (see the maturity schedule in Note D.17.2.) Bond issues denominated in euros carried out by Sanofi are as follows: Issuer ISIN code Issue date Maturity Annual interest rate Amount (€ million) Type Sanofi FR0013505104 March 2020 April 2025 1.000% 1,000 EMTN program Sanofi FR0014009KS6 April 2022 April 2025 0.875% 850 Standalone Prospectus Sanofi FR0012969038 September 2015 September 2025 1.500% 750 EMTN program Sanofi FR0013324340 March 2018 March 2026 1.000% 1,500 EMTN program Sanofi FR0012146801 September 2014 September 2026 1.750% 1,510 EMTN program Sanofi FR0013201639 September 2016 January 2027 0.500% 1,150 EMTN program Sanofi FR0013144003 April 2016 April 2028 1.125% 700 EMTN program Sanofi FR0013409844 March 2019 March 2029 0.875% 650 EMTN program Sanofi FR0014009KQ0 April 2022 April 2029 1.250% 650 Standalone Prospectus Sanofi FR0013324357 March 2018 March 2030 1.375% 2,000 EMTN program Sanofi FR0013505112 March 2020 April 2030 1.500% 1,000 EMTN program Sanofi FR0013409851 March 2019 March 2034 1.250% 500 EMTN program Sanofi FR0013324373 March 2018 March 2038 1.875% 1,250 EMTN program Bond issues denominated in US dollars carried out by Sanofi under the public bond issue program (shelf registration statement) registered with the US Securities and Exchange Commission (SEC) comprise: Issuer ISIN code Issue date Maturity Annual interest rate Amount ($ million) Type Sanofi US801060AD60 June 2018 June 2028 3.625% 1,000 SEC registered The “Other borrowings” line mainly comprises participating shares issued between 1983 and 1987, of which 57,844 remain outstanding, with a nominal amount of €9 million . In order to manage its liquidity needs for current operations, as of December 31, 2024 Sanofi had: • a syndicated credit facility of €4 billion , drawable in euros and in US dollars, maturing December 6, 2027; and • a syndicated credit facility of €4 billion , drawable in euros and in US dollars, maturing March 6, 2030. Sanofi also has two commercial paper programs: • a €6 billion Negotiable European Commercial Paper program in France, with an average drawdown of €0.1 billion and a maximum drawdown of €0.4 billion during 2024. As of December 31, 2024, this program was not being utilized; and • a $10 billion Commercial Paper program in the United States, with an average drawdown of $5.8 billion and a maximum drawdown of $8.9 billion during 2024, and an amount of $1.3 billion drawn down as of December 31, 2024. The financing in place as of December 31, 2024 at the level of the holding company (which manages most of Sanofi’s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking spreads or fees to the credit rating. c) Debt by maturity, at value on redemption December 31, 2024 Current Non-current (€ million) Total 2025 2026 2027 2028 2029 2030 and later Bond issues 14,592 2,716 3,010 1,150 1,666 1,300 4,750 Other bank borrowings 1,354 1,290 32 1 1 1 29 Other borrowings 3 3 — — — — — Bank credit balances 209 209 — — — — — Interest rate and currency derivatives used to manage debt 13 13 — — — — — Total debt 16,171 4,231 3,042 1,151 1,667 1,301 4,779 Cash and cash equivalents (7,441) (7,441) — — — — — Interest rate and currency derivatives used to manage cash and cash equivalents 76 76 — — — — — Net debt (a) 8,806 (3,134) 3,042 1,151 1,667 1,301 4,779 (a) Net debt does not include lease liabilities, which amounted to € 1,906 million as of December 31, 2024; € 2,030 million as of December 31, 2023; and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.). As of December 31, 2024 , the main undrawn confirmed general-purpose credit facilities at holding company level amounted to €8 billion , half of which expired in 2027 and the other half of which expires in 2030. As of December 31, 2024 , no single counterparty represented more than 6% of Sanofi’s undrawn confirmed credit facilities. December 31, 2023 Current Non-current (€ million) Total 2024 2025 2026 2027 2028 2029 and later Bond issues 15,134 718 2,600 3,010 1,150 1,606 6,050 Other bank borrowings 1,248 1,118 98 1 1 1 29 Other borrowings 6 6 — — — — — Bank credit balances 203 203 — — — — — Interest rate and currency derivatives used to manage debt (18) (18) — — — — — Total debt 16,573 2,027 2,698 3,011 1,151 1,607 6,079 Cash and cash equivalents (8,710) (8,710) — — — — — Interest rate and currency derivatives used to manage cash and cash equivalents (28) (28) — — — — — Net debt 7,835 (6,711) 2,698 3,011 1,151 1,607 6,079 December 31, 2022 Current Non-current (€ million) Total 2023 2024 2025 2026 2027 2028 and later Bond issues 18,861 3,817 600 2,600 4,160 — 7,684 Other bank borrowings 286 187 61 — — — 38 Other borrowings 6 6 — — — — — Bank credit balances 168 168 — — — — — Interest rate and currency derivatives used to manage debt (48) (48) — — — — — Total debt 19,273 4,130 661 2,600 4,160 — 7,722 Cash and cash equivalents (12,736) (12,736) — — — — — Interest rate and currency derivatives used to manage cash and cash equivalents (45) (45) — — — — — Net debt 6,492 (8,651) 661 2,600 4,160 — 7,722 d) Debt by interest rate, at value on redemption The table below splits net debt between fixed and floating rate, and by maturity, as of December 31, 2024 . The figures shown are values on redemption, before the effects of derivative instruments: (€ million) Total 2025 2026 2027 2028 2029 2030 and later Fixed-rate debt 14,592 2,716 3,010 1,150 1,666 1,300 4,750 of which euro 13,626 of which US dollar 966 % fixed-rate 90% Floating-rate debt 1,566 1,502 32 1 1 1 29 of which euro — of which US dollar 1,221 % floating-rate 10% Debt 16,158 4,218 3,042 1,151 1,667 1,301 4,779 Cash and cash equivalents (7,441) (7,441) — — — — — of which euro (2,945) of which US dollar (4,204) % floating-rate 100% Net debt 8,717 (3,223) 3,042 1,151 1,667 1,301 4,779 Sanofi issues debt in two currencies, the euro and the US dollar, and also invests its cash and cash equivalents in those currencies. Sanofi also operates cash pooling arrangements to manage the surplus cash and short-term liquidity needs of foreign subsidiaries located outside the euro zone. To optimize the cost of debt or reduce the volatility of debt and manage its exposure to financial foreign exchange risk, Sanofi uses derivative instruments (interest rate swaps, currency swaps, foreign exchange swaps and forward contracts) that alter the fixed/floating rate split and the currency split of its net debt: (€ million) Total 2025 2026 2027 2028 2029 2030 and later Fixed-rate debt 11,098 (778) 3,010 1,150 1,666 1,300 4,750 of which euro 11,098 of which US dollar — % fixed-rate 69% Floating-rate debt 5,074 5,010 32 1 1 1 29 of which euro 174 of which US dollar 3,507 % floating-rate 31% Debt 16,171 4,231 3,042 1,151 1,667 1,301 4,779 Cash and cash equivalents (7,365) (7,365) — — — — — of which euro (3,987) of which US dollar (1,005) of which Singapore dollar (822) % floating-rate 100% Net debt 8,806 (3,134) 3,042 1,151 1,667 1,301 4,779 The table below shows the fixed/floating rate split of net debt at value on redemption after taking account of derivative instruments as of December 31, 2023 and December 31, 2022 : (€ million) 2023 % 2022 % Fixed-rate debt 11,382 69% 16,386 85% Floating-rate debt 5,191 31% 2,886 15% Debt 16,573 100% 19,273 100% Cash and cash equivalents (8,738) (12,781) Net debt 7,835 6,492 The weighted average interest rate on debt as of December 31, 2024 was 1.7% before derivative instruments and 2.1% after derivative instruments. Cash and cash equivalents were invested as of December 31, 2024 at an average rate of 4.2% before derivative instruments and 4.1% after derivative instruments. The projected full-year sensitivity of net debt to interest rate fluctuations for 2025 is as follows: Change in short-term interest rates Impact on pre-tax net income (€ million) Impact on pre-tax income/(expense) recognized directly in equity (€ million) +100 bp 34 — +25 bp 8 — -25 bp (8) — -100 bp (34) — e) Debt by currency, at value on redemption The table below shows net debt by currency at December 31, 2024 , before and after derivative instruments contracted to convert the foreign-currency net debt of exposed entities into their functional currency: (€ million) Before derivative instruments After derivative instruments Euro 10,681 7,285 US dollar (2,017) 2,502 Singapore dollar (3) (822) Hungarian forint — (641) Chinese yuan renminbi (10) 226 Other currencies 65 256 Net debt 8,717 8,806 The table below shows net debt by currency at December 31, 2023 and 2022 , after derivative instruments contracted to convert the foreign currency net debt of exposed entities into their functional currency: (€ million) 2023 2022 Euro 6,852 10,489 US dollar 1,169 (2,404) Other currencies (186) (1,593) Net debt 7,835 6,492 f) Market value of net debt The market value of Sanofi’s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows: (€ million) 2024 2023 2022 Market value 8,165 7,086 5,227 Value on redemption 8,806 7,835 6,492 The fair value of net debt is determined by reference to quoted market prices at the balance sheet date in the case of quoted instruments (level 1 in the IFRS 7 hierarchy, see Note D.12.), and by reference to the fair value of interest rate and currency derivatives used to manage net debt (level 2 in the IFRS 7 hierarchy, see Note D.12.). g) Future contractual cash flows relating to debt and related derivatives The table below shows the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt: December 31, 2024 Payments due by period (€ million) Total 2025 2026 2027 2028 2029 2030 and later Debt 17,077 4,328 3,226 1,288 1,780 1,388 5,067 Principal 16,049 4,105 3,047 1,151 1,667 1,300 4,779 Interest (a) 1,028 223 179 137 113 88 288 Net cash flows related to derivative instruments 161 71 34 34 21 1 — Total 17,238 4,399 3,260 1,322 1,801 1,389 5,067 (a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2024 . Future contractual cash flows are shown on the basis of the carrying amount in the balance sheet at the reporting date, without reference to any subsequent management decision that might materially alter the structure of Sanofi’s debt or its hedging policy. The tables below show the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt as of December 31, 2023 and 2022 : December 31, 2023 Payments due by period (€ million) Total 2024 2025 2026 2026 2028 2029 and later Debt 17,710 2,153 2,912 3,187 1,285 1,719 6,454 Principal 16,468 1,917 2,703 3,011 1,151 1,607 6,079 Interest (a) 1,242 236 209 176 134 112 375 Net cash flows related to derivative instruments 143 47 32 23 24 16 1 Total 17,853 2,200 2,944 3,210 1,309 1,735 6,455 (a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2023 . December 31, 2022 Payments due by period (€ million) Total 2023 2024 2025 2026 2026 2028 and later Debt 20,408 4,206 868 2,803 3,184 1,283 8,064 Principal 18,932 3,928 661 2,601 3,011 1,151 7,580 Interest (a) 1,476 278 207 202 173 132 484 Net cash flows related to derivative instruments 209 24 60 38 31 31 25 Total 20,617 4,230 928 2,841 3,215 1,314 8,089 (a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2022 . D.17.2. Lease liabilities A maturity analysis of lease liabilities as of December 31, 2024 , 2023 and 2022 is set forth below: Undiscounted future minimum lease payments (€ million) Total Less than 1 year From 1 to 3 years From 3 to 5 years More than 5 years Discounting effect Total lease liabilities as of December 31, 2024 (a) 1,906 377 498 386 819 (174) Total lease liabilities as of December 31, 2023 2,030 291 448 360 989 (58) Total lease liabilities as of December 31, 2022 2,181 320 515 436 1,129 (219) (a) 2024 amounts exclude Opella discontinued operations, while 2023 and 2022 include them. Lease liabilities include leases relating to real estate assets located at Cambridge, MA (United States), which have a lease term of 15 years .

Liabilities related to business

Liabilities related to business combinations and to non-controlling interests	12 Months Ended
	Dec. 31, 2024
Business Combination [Abstract]
Liabilities related to business combinations and to non-controlling interests	Liabilities related to business combinations and to non-controlling interests For a description of the nature of the liabilities reported in the line item Liabilities related to business combinations and to non-controlling interests , refer to Note B.8.5. The principal acquisitions are described in Notes D.1. and D.2. The liabilities related to business combinations and to non-controlling interests shown in the table below are level 3 instruments under the IFRS 7 fair value hierarchy (see Note D.12.). Movements in liabilities related to business combinations and to non-controlling interests are shown below: (€ million) Bayer contingent consideration arising from the acquisition of Genzyme MSD contingent consideration (European Vaccines business) Shire contingent consideration arising from the acquisition of Translate Bio Contingent consideration arising from acquisition of Amunix Other Total (a) Balance at January 1, 2022 59 269 354 — 32 714 New transactions — — — 156 — 156 Payments made (29) (79) — — (28) (136) Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (b) (9) 14 2 (2) — 5 Other movements — — — — — — Currency translation differences 5 — 24 11 — 40 Balance at December 31, 2022 26 204 380 165 4 779 New transactions — — — — — — Payments made (21) (77) — (69) — (167) Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (b) (5) — 74 45 — 114 Other movements — — — — — — Currency translation differences — — (13) (4) — (17) Balance at December 31, 2023 — 127 441 137 4 709 New transactions — — — — — — Payments made — (70) — — (1) (71) Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (b) — 16 94 — 1 109 Other movements — — — (137) (3) (139) Currency translation differences — (1) 33 — — 33 Balance at December 31, 2024 — 72 568 — 1 641 (a) Portion due after more than one year: €569 million as of December 31, 2024 ( €501 million as of December 31, 2023 and €674 million as of December 31, 2022 ); portion due within less than one year: €72 million as of December 31, 2024 ( €208 million as of December 31, 2023 and €105 million as of December 31, 2022 ). (b) Amounts reported within the income statement line item Fair value remeasurement of contingent consideration , and mainly comprising unrealized gains and losses . As of December 31, 2024 , Liabilities related to business combinations and to non-controlling interests mainly comprised: • the MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture, which amounted to €72 million as of December 31, 2024 , €127 million as of December 31, 2023 and €204 million as of December 31, 2022 (see Note D.12.). The fair value of this contingent consideration is determined by applying the royalty percentage stipulated in the contract to discounted sales proje ctions; • a contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi’s acquisition of Translate Bio in September 2021. In a business combination carried out in December 2016 and predating the acquisition of control by Sanofi, Translate Bio (then called Rana Therapeutics, Inc.) acquired from Shire the intellectual property rights relating to the latter’s Messenger RNA Therapeutics (MRT) program. As of December 31, 2024 , Shire was entitled to receive the following potential payments: – milestone payments contingent on the launch of products based on MRT technology, and on the attainment of a specified level of sales of those products, and – a percentage of sales of those products . The fair value of the Shire liability was measured at €568 million as of December 31, 2024 , compared with €441 million as of December 31, 2023 and €380 million as of December 31, 2022 ; it was determined by applying the contractual terms to development and sales projections which were weighted to reflect the probability of success, and discounted. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately 13% ; • Following the exclusive licensing agreement on the ProXTen technology platform entered into with Vir Biotechnology in September 2024 , Inc., Sanofi no longer has any contingent consideration liability arising from the acquisition of Amunix in 2022 . The fair value of that contingent consideration liability was € 137 million as of December 31, 2023 and €165 million as of December 31, 2022. • The Bayer contingent consideration liability arising from Sanofi’s acquisition of Genzyme in 2011 was extinguished during 2023 in accordance with the contractual terms. T he table below sets forth the maximum amount of contingent consideration payable in respect of already-marketed products: December 31, 2024 Payments due by period (€ million) Total Less than 1 year From 1 to 3 years From 3 to 5 years More than 5 years Commitments relating to contingent consideration in connection with business combinations 72 72 — — — The nominal amount of contingent consideration was €133 million as of December 31, 2023 and €604 million as of December 31, 2022 .

Provisions, income tax liabilit

Provisions, income tax liabilities and other liabilities	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Provisions, income tax liabilities and other liabilities	Provisions, income tax liabilities and other liabilities The line item Non current provisions and other non-current liabilities comprises the following: (€ million) 2024 2023 2022 Provisions 5,762 5,262 5,822 Other non-current liabilities (a) 2,334 2,340 519 Total 8,096 7,602 6,341 (a) Includes derivative financial instruments: € 121 million as of December 31, 2024 , €164 million as of December 31, 2023 , €232 million as of December 31, 2022 . The figure as of December 31, 2024 includes € 2,007 million for the liability in respect of royalties payable to Sobi on net sales of Beyfortus (nirsevimab) in the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is € 1,140 million; the nominal value of payments estimated to be due after more than five years is € 2,792 million. Non-current income tax liabilities are described in Note D.19.4., and other current liabilities in Note D.19.5. The table below sets forth movements in non-current provisions for the reporting periods presented: (€ million) Provisions for pensions and other post- employment benefits (D.19.1.) Provisions for other long-term benefits Restructuring provisions (D.19.2.) Other provisions (D.19.3.) Total Balance at January 1, 2022 2,947 935 524 2,024 6,430 Changes in scope of consolidation (96) (28) — (76) (200) Increases in provisions 193 (a) 40 521 531 1,285 Provisions utilized (275) (a) (119) (12) (122) (528) Reversals of unutilized provisions (66) (a) (20) (11) (191) (288) Transfers 10 4 (265) (23) (274) Net interest related to employee benefits, and unwinding of discount 43 4 5 12 64 Currency translation differences 63 28 (1) 23 113 Actuarial gains and losses on defined-benefit plans (780) — — — (780) Balance at December 31, 2022 2,039 844 761 2,178 5,822 Increases in provisions 141 (a) 185 315 311 952 Provisions utilized (162) (a) (107) (25) (114) (408) Reversals of unutilized provisions (21) (a) (190) (159) (388) (758) Transfers (1) — (361) (210) (572) Net interest related to employee benefits, and unwinding of discount 70 3 23 24 120 Currency translation differences (23) (17) — (25) (65) Actuarial gains and losses on defined-benefit plans 171 — — — 171 Balance at December 31, 2023 2,214 718 554 1,776 5,262 Changes in scope of consolidation — — — 11 11 Increases in provisions 145 (a) 199 548 730 1,622 Provisions utilized (173) (a) (118) (20) (135) (446) Reversals of unutilized provisions (108) (a) — (8) (126) (242) Transfers (89) — (270) (157) (516) Net interest related to employee benefits, and unwinding of discount 65 2 19 36 122 Currency translation differences 43 34 (3) 42 116 Actuarial gains and losses on defined-benefit plans (13) — — — (13) Opella reclassification (b) (92) (14) (21) (27) (154) Balance at December 31, 2024 1,992 821 799 2,150 5,762 (a) In the case of “Provisions for pensions and other post-employment benefits”, the “Increases in provisions” line corresponds to rights vesting in employees during the period, and past service cost; the “Provisions utilized” line corresponds to contributions paid into pension funds and to beneficiaries; and the “Reversals of unutilized provisions” line corresponds to plan curtailments, settlements and amendments. (b) The liabilities of Opella, which in 2022 and 2023 were presented in the relevant balance sheet line item for each class of liability, were reclassified in 2024 to Liabilities related to assets held for sale in accordance with IFRS 5 (see Note D.1.) . D.19.1. Provisions for pensions and other post-employment benefits Sanofi offers its employees pension plans and other post-employment benefit plans. The specific features of the plans (benefit formulas, fund investment policy and fund assets held) vary depending on the applicable laws and regulations in each country where the employees work. These employee benefits are accounted for in accordance with IAS 19 (see Note B.23.). Sanofi’s pension obligations in four major countries represented approximately 88% of the total value of the defined-benefit obligation and approximately 87% of the total value of plan assets as of December 31, 2024 . The features of the principal defined- benefit plans in each of those four countries are described below. France Lump-sum retirement benefit plans All employees working for Sanofi in France are entitled on retirement to a lump-sum payment, the amount of which depends both on their length of service and on the rights guaranteed by collective and internal agreements. The employee’s final salary is used in calculating the amount of these lump-sum retirement benefits. These plans represent approximately 38% of Sanofi’s total obligation in France. Defined-benefit pension plans These plans provide benefits from the date of retirement. Employees must fulfil a number of criteria to be eligible for these benefits. All of these plans are now closed. These plans represent approximately 62% of Sanofi’s total obligation in France. Germany Top-up defined-benefit pension plan The benefits offered under this pension plan are wholly funded by the employer (there are no employee contributions) via a Contractual Trust Agreement (CTA), under which benefits are estimated on the basis of a career average salary. Employees are entitled to receive an annuity under this plan if their salary exceeds the social security ceiling. The amount of the pension is calculated by reference to a range of vesting rates corresponding to salary bands. The plan also includes disability and death benefits. This plan represents approximately 61% of Sanofi’s total obligation in Germany. Sanofi-Aventis plus (SAV plus) A top-up pension plan (SAV plus) replaced a previous top-up defined-benefit plan. New entrants joining the plan after April 1, 2015 contribute to a defined-contribution plan that is partially funded via the company’s CTA. All employees whose salary exceeds the social security ceiling are automatically covered by the plan. The employer’s contribution is 14% of the amount by which the employee’s salary exceeds the social security ceiling. Multi-employer plan (Pensionskasse) This is a defined-benefit plan treated as a defined-contribution plan, in accordance with the accounting policies described in Note B.23. Currently, contributions cover the level of annuities. Only the portion relating to the future revaluation of the annuities is included in the defined-benefit pension obligation. The obligation relating to this revaluation amounted to €682 million as of December 31, 2024 , versus €744 million as of December 31, 2023 and €652 million as of December 31, 2022 . This plan represents approximately 26% of Sanofi’s total defined-benefit obligation in Germany. United States Defined-benefit pension plans In the United States, there are two types of defined-benefit plan: • “qualified” plans within the meaning of the Employee Retirement Income Security Act of 1974 (ERISA), which provide guaranteed benefits to eligible employees during retirement, and in the event of death or disability. Employees can elect to receive a reduced annuity, in exchange for an annuity to be paid in the event of their death to a person designated by them. An annuity is also granted under the plan if the employee dies before retirement age. Eligible employees do not pay any contributions. These plans are closed to new entrants, and the vesting of rights for future service periods is partially frozen. These plans represent approximately 57% of Sanofi’s total obligation in the United States; • “non-qualified” plans within the meaning of ERISA provide top-up retirement benefits to some eligible employees depending on the employee’s level of responsibility and subject to a salary cap. These plans represent approximately 16% of Sanofi’s total obligation in the United States. Healthcare cover and life insurance Sanofi companies provide some eligible employees with healthcare cover and life insurance during the retirement period (the company’s contributions are capped at a specified level). These plans represent approximately 27% (or €381 million ) of Sanofi’s total obligation and 3% (or €20 million ) of total plan assets in the United States. United Kingdom Defined-benefit pension plans Sanofi operates a number of pension plans in the United Kingdom that reflect past acquisitions. The most significant arrangements are defined-benefit plans that have been closed since October 1, 2015. With effect from that date, employees can no longer pay into these plans. Under these defined-benefit plans, an annuity is paid from the retirement date. This annuity is calculated on the basis of the employee’s length of service as of September 30, 2015, and of the employee’s final salary (or salary on the date he or she leaves Sanofi). The rates used for the vesting of rights vary from member to member. For most members, rights vest at the rate of 1.25 % or 1.50% of final salary for each qualifying year of service giving entitlement. The notional retirement age varies according to the category to which the member belongs, but in most cases retirement is at age 65 . Members may choose to retire before or after the notional retirement age ( 60 years), in which case the amount of the annual pension is adjusted to reflect the revised estimate of the length of the retirement phase. Pensions are usually indexed to the Retail Price Index (RPI). Members paid a fixed-percentage contribution into their pension plan (the percentage varied according to the employee category), and the employer topped up the contribution to the required amount. These plans represent approximately 100% of Sanofi’s total obligation in the United Kingdom. In November 2024, a bulk annuity purchase transaction, commonly known as a “buy-in”, was executed for the main defined benefit pension scheme in the United Kingdom covering the majority of uninsured pension liabilities. Through this transaction, and in conjunction with the previous pensioner buy-in executed in 2021, the main defined benefit pension plan in the United Kingdom is largely insured against investment, longevity, interest rate and inflation risks. Pension obligations will be funded by the insurer’s annuity payments and the buy-in policies are held as an asset of the pension scheme. The pension scheme retains full legal responsibility to pay the benefits to plan participants using insurance payments. The insurance contract is deemed to be the present value of the matched obligations. The variation of €(204) million of the fair value of assets held by the pension scheme generated by the purchase of the qualifying insurance policy is booked in the other comprehensive income. After the end of the reporting period, Sanofi completed a further buy-in covering the remaining uninsured liabilities meaning all members of the scheme are now fully insured by the transaction, except those arising from guaranteed minimum pensions equalization. For service periods subsequent to October 1, 2015, employees belong to a new defined-contribution plan. Actuarial assumptions used to measure Sanofi’s obligations Actuarial valuations of Sanofi’s benefit obligations were computed by management with assistance from external actuaries as of December 31, 2024 , 2023 and 2022 . Those calculations were based on the following financial and demographic assumptions: 2024 2023 2022 France Germany US UK France Germany US UK France Germany US UK Discount rate (a)(b) 2.95% to 3.40% 2.95% to 3.40% 5.45% 5.50% 2.95% to 3.15% 2.95% to 3.15% 4.75% 4.50% 3.55% to 3.75% 3.55% to 3.75% 4.90% 4.75% General inflation rate (c) 2.10% 2.10% — 3.20% 2.20% 2.20% — 3.05% 2.50% 2.50% — 3.25% Pension benefit indexation 2.10% 2.10% — 3.00% 2.20% 2.20% — 2.90% 2.50% 2.50% — 3.00% Healthcare cost inflation rate (d) — — 4.00% to 5.93% — — — 4.00% to 9.75% — — — 3.29% to 6.56% — Retirement age 62 to 67 63 55 to 70 60 to 65 62 to 67 63 55 to 70 60 to 65 62 to 67 63 55 to 70 60 to 65 Mortality table TGH/ TGF 05 Heubeck RT 2018 G RP2012 Proj. MP2021 White Collar SAPS S3 TGH/ TGF 05 Heubeck RT 2018 G RP2012 Proj. MP2021 White Collar SAPS S3 TGH/ TGF 05 Heubeck RT 2018 G RP2012 Proj. MP2021 White Collar SAPS S3 (a) The discount rates used were based on market rates for high quality corporate bonds with a duration close to that of the expected benefit payments under the plans. The benchmarks used to determine discount rates were the same for all periods presented. (b) The rate depends on the duration of the plan ( 0 to 7 years, 7 to 10 years, or more than 10 years). (c) Inflation for the euro zone is determined using a multi-criterion method. (d) No post-employment healthcare benefits are provided in France since 2020, Germany and UK . Weighted average duration of obligation for pensions and other long-term benefits in principal countries The table below shows the duration of Sanofi’s obligations in the principal countries: 2024 2023 2022 (years) France Germany US UK France Germany US UK France Germany US UK Weighted average duration 11 12 10 11 10 12 11 13 10 12 11 13 Sensitivity analysis The table below shows the sensitivity of Sanofi’s obligations for pensions and other post-employment benefits to changes in key actuarial assumptions: (€ million) Pensions and other post-employment benefits, by principal country Measurement of defined-benefit obligation Change in assumption France Germany US UK Discount rate -0.50% +90 +190 +103 +161 General inflation rate +0.50% +56 +267 — +95 Pension benefit indexation +0.50% +57 +264 — +93 Healthcare cost inflation rate +0.50% — — +41 +43 Mortality table +1 year +56 +86 +59 +118 The table below reconciles the net obligation in respect of Sanofi’s pension and other post-employment benefit plans with the amounts recognized in the consolidated financial statements: Pensions and other post-employment benefits (€ million) 2024 2023 2022 Measurement of the obligation: Beginning of period 8,930 8,651 12,175 Current service cost 138 140 193 Interest cost 335 346 206 Actuarial losses/(gains) due to changes in demographic assumptions (45) (34) (219) Actuarial losses/(gains) due to changes in financial assumptions (380) 157 (3,006) Actuarial losses/(gains) due to experience adjustments (4) 256 177 Plan amendments, curtailments or settlements not specified in the terms of the plan (b) (181) (36) (229) Plan settlements specified in the terms of the plan (59) (40) (84) Benefits paid (502) (483) (463) Changes in scope of consolidation and transfers 4 (14) (114) Currency translation differences 181 (13) 15 Opella reclassification (188) — — Obligation at end of period 8,229 8,930 8,651 Fair value of plan assets: Beginning of period 6,993 6,899 9,651 Interest income on plan assets 271 276 163 Difference between actual return and interest income on plan assets (c) (416) 197 (2,398) Administration costs (13) (7) (6) Plan settlements specified in the terms of the plan (58) (40) (84) Plan settlements not specified in the terms of the plan (71) (17) (161) Contributions from plan members 5 6 6 Employer’s contributions 127 122 238 Benefits paid (456) (446) (426) Changes in scope of consolidation and transfers (20) (8) (32) Currency translation differences 132 11 (52) Opella reclassification (97) — — Fair value of plan assets at end of period 6,397 6,993 6,899 Net amount shown in the balance sheet: Net obligation 1,832 1,937 1,752 Effect of asset ceiling 4 6 18 Net amount shown in the balance sheet at end of period 1,836 1,943 1,770 Amounts recognized in the balance sheet: Pre-funded obligations (see Note D.7.) (a) (156) (271) (269) Obligations provided for 1,992 2,214 2,039 Net amount recognized at end of period 1,836 1,943 1,770 Benefit cost for the period: (d) Current service cost 138 140 193 (Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan (110) (22) (68) Net interest (income)/cost 64 71 43 Contributions from plan members (5) (6) (6) Administration costs and taxes paid during the period 13 7 6 Expense recognized directly in profit or loss 100 190 168 Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses) (b) (13) 171 (650) Expense/(gain) for the period 87 361 (482) (a) For 2023, this line includes €66 million of assets in the United Kingdom (versus €99 million for 2022); those amounts are not subject to any asset ceiling, in accordance with IFRIC 14. (b) Amounts recognized in Other comprehensive income (see Note D.15.7.). (c) In 2024, this line includes the effects of the partial buy-in in the United Kingdom for €(204) million . (d) Benefit cost for the total Group including Opella on all the periods . The tables below show Sanofi’s net liability in respect of pension plans and other post-employment benefits by geographical region: (€ million) Pensions and other post-employment benefits by geographical region December 31, 2024 France Germany US UK Other Total Measurement of obligation 1,228 2,651 1,427 1,994 929 8,229 Fair value of plan assets 667 2,239 744 1,891 856 6,397 Effect of asset ceiling — — — — (4) (4) Net amount shown in the balance sheet at end of period 561 412 683 103 77 1,836 (€ million) Pensions and other post-employment benefits by geographical region December 31, 2023 France Germany US UK Other Total Measurement of obligation 1,322 2,911 1,528 2,174 995 8,930 Fair value of plan assets 675 2,401 825 2,235 857 6,993 Effect of asset ceiling — — — — (6) (6) Net amount shown in the balance sheet at end of period 647 510 703 (61) 144 1,943 (€ million) Pensions and other post-employment benefits by geographical region December 31, 2022 France Germany US UK Other Total Measurement of obligation 1,324 2,730 1,546 2,080 971 8,651 Fair value of plan assets 697 2,317 860 2,175 850 6,899 Effect of asset ceiling — — — — (18) (18) Net amount shown in the balance sheet at end of period 627 413 686 (95) 139 1,770 The adoption in April 2023 of pension reforms in France (including the raising of the retirement age from 62 to 64 years) qualifies as a plan amendment within the meaning of IAS 19, and resulted in the recognition of an immaterial amount in the income statement and the balance sheet for the year ended December 31, 2023. The table below shows the fair value of plan assets relating to Sanofi’s pension and other post-employment plans, split by asset category: 2024 2023 2022 Securities quoted in an active market 63.1% 84.9% 84.4% Cash and cash equivalents 0.8% 0.8% 0.7% Equity instruments 19.3% 22.3% 21.7% Bonds and similar instruments 35.8% 54.3% 52.4% Real estate 2.9% 3.4% 4.0% Derivatives (0.2%) —% 0.1% Commodities 1.1% 0.9% 0.9% Other 3.4% 3.2% 4.6% Other securities 36.9% 15.1% 15.6% Hedge funds —% —% —% Insurance policies 36.9% 15.1% 15.6% Total 100.0% 100.0% 100.0% Sanofi has a long-term objective of maintaining or increasing the extent to which its pension obligations are covered by assets. To this end, Sanofi uses an asset-liability management strategy, matching plan assets to its pension obligations. This policy aims to ensure the best fit between the assets held on the one hand, and the associated liabilities and expected future payments to plan members on the other. To meet this aim, Sanofi operates a risk monitoring and management strategy (mainly focused on interest rate risk and inflation risk), while investing a growing proportion of assets in high-quality bonds with comparable maturities to those of the underlying obligations and in contracts entered into with leading insurance companies to fund certain post-employment benefit obligations. The tables below show the service cost for Sanofi’s pension and other post-employment benefit plans, by geographical region: (€ million) Pensions and other post-employment benefits by geographical region Service cost for 2024 France Germany US UK Other Total Current service cost 48 30 22 — 38 138 (Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan (82) — (20) — (8) (110) Net interest cost/(income) including administration costs and taxes paid during the period 13 20 36 (1) 9 77 Contributions from plan members — — — — (5) (5) Expense/(gain) recognized directly in profit or loss (21) 50 38 (1) 34 100 Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses) (31) (134) (46) 212 (14) (13) Expense/(gain) for the period (52) (84) (8) 211 20 87 (€ million) Pensions and other post-employment benefits by geographical region Service cost for 2023 France Germany US UK Other Total Current service cost 50 30 20 — 40 140 (Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan (20) — 1 — (3) (22) Net interest cost/(income) including administration costs and taxes paid during the period 22 15 35 (5) 11 78 Contributions from plan members — — — — (6) (6) Expense/(gain) recognized directly in profit or loss 52 45 56 (5) 42 190 Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses) 3 98 26 44 — 171 Expense/(gain) for the period 55 143 82 39 42 361 (€ million) Pensions and other post-employment benefits by geographical region Service cost for 2022 France Germany US UK Other Total Current service cost 61 44 50 — 38 193 (Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan (60) 2 1 (6) (5) (68) Net interest cost/(income) including administration costs and taxes paid during the period 10 7 30 (7) 9 49 Contributions from plan members — — — — (6) (6) Expense/(gain) recognized directly in profit or loss 11 53 81 (13) 36 168 Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses) (156) (204) (382) 130 (38) (650) Expense/(gain) for the period (145) (151) (301) 117 (2) (482) An analysis of the “Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)” line in the preceding tables is set forth below: (€ million) 2024 2023 2022 France Germany US UK France Germany US UK France Germany US UK Actuarial gains/(losses) arising during the period 29 135 47 (212) (3) (98) (25) (44) 156 205 382 (131) Comprising: Gains/(losses) on experience adjustments (a) 18 46 (42) (472) 16 (54) (7) (12) (120) (620) (287) (1,328) Gains/(losses) on demographic assumptions — — 11 50 — — 18 11 — — 129 54 Gains/(losses) on financial assumptions 11 89 78 210 (19) (44) (36) (43) 276 825 540 1,143 (a) Experience adjustments are mainly due to the effect on plan assets of trends in the financial markets . The net pre-tax actuarial loss (excluding investments accounted for using the equity method) recognized directly in equity is presented below: (€ million) 2024 2023 2022 Net pre-tax actuarial loss (2,258) (2,259) (2,090) The present value of Sanofi’s obligations in respect of pension and other post-employment benefit plans at the end of each reporting period is shown below: (€ million) 2024 2023 2022 Present value of wholly or partially funded obligations in respect of pension and other post-employment benefit plans 7,192 7,693 7,463 Present value of unfunded obligations 1,037 1,237 1,188 Total 8,229 8,930 8,651 The total expense for pensions and other post-employment benefits ( €100 million in 2024 ) is allocated between income statement line items as follows: (€ million) 2024 2023 2022 Cost of sales 32 33 53 Research and development expenses 17 28 51 Selling and general expenses 42 57 78 Other operating (income)/expenses, net 4 5 (2) Restructuring costs (64) (9) (59) Financial expenses 60 67 42 Net income from discontinued operations 9 9 5 Total 100 190 168 The estimated amounts of employer’s contributions to plan assets in 2025 are as follows: (€ million) France Germany US UK Other Total Employer’s contributions in 2024 (estimate): 2025 — — 2 48 27 77 The table below shows the expected timing of benefit payments under pension and other post-employment benefit plans for future years: (€ million) France Germany US UK Other Total Estimated future benefit payments 2025 94 210 97 126 38 565 2026 59 210 98 130 41 538 2027 71 208 100 134 40 553 2028 75 207 103 139 42 566 2029 81 209 107 143 44 584 2030 to 2034 497 893 543 785 241 2,959 The table below shows estimates as of December 31, 2024 for the timing of future payments in respect of unfunded pension and other post-employment benefit plans: Payments due by period (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Estimated payments 1,035 67 122 131 715 D.19.2. Restructuring provisions The table below shows movements in restructuring provisions classified in non-current and current liabilities: (€ million) 2024 2023 2022 Balance, beginning of period 1,132 1,233 1,118 Of which: • Classified in non-current liabilities 554 761 524 • Classified in current liabilities 578 472 594 Change in provisions recognized in profit or loss for the period 999 435 636 Provisions utilized (a) (582) (561) (522) Transfers (33) 3 — Unwinding of discount 19 31 5 Currency translation differences 1 (9) (4) Opella reclassification (b) (84) — — Balance, end of period 1,452 1,132 1,233 Of which: • Classified in non-current liabilities 799 554 761 • Classified in current liabilities 653 578 472 (a) Provisions utilized mainly correspond to payments related to employees affected by separation programs. (b) This line comprises the restructuring provisions of Opella, reclassified to Liabilities related to assets held for sale as of December 31, 2024 (see Note D.1.). Provisions for employee termination benefits as of December 31, 2024 amounted to €1,318 million (compared with € 968 million as of December 31, 2023 and €1,039 million as of December 31, 2022 ). The provisions apply mainly to France, and relate to various voluntary redundancy programs: • a greement under the Job Management and Career Paths (GEPP) scheme affecting several French legal entities, signed on February 28, 2022 and announced in April 2022 as part of the “Play to Win” strategy. The agreement provides internal transfer and outplacement opportunities for employees whose jobs are undergoing transformation, and also includes an end- of-career paid leave program and an external retraining program. The plan began to be implemented in 2022 . The provisions charged in 2023 reflect adjustments to the job profiles deemed to be "sensitive"; the reversals recognized during 2023 are due mainly to the Borne Law, which raises the retirement age to 64 and hence disqualifies some participants eligible under previous legislation (in light of the maximum period for portage workers). In 2024 , the agreement was renewed to cover the years 2024 to 2026 , and the new provisions charged in 2024 relate mainly to scope extensions in the job profiles affected by transformations; • a voluntary redundancy program announced in 2024 in connection with the reorganization of R&D operations to make Sanofi a leader in immunology, including an end-of-career paid leave plan and an end-of-career transition plan; and • collectively-agreed separation programs involving a number of legal entities announced at the end of June 2020 as part of the rollout of the “Play to Win” strategy; these include an end-of-career paid leave plan and an external retraining program, and were still ongoing during 2024 . The same applies to Sanofi-Aventis Recherche & Développement, which announced a voluntary redundancy program associated with R&D reorganization in 2020 , and implemented that program in 2021 . The provision includes the present values of: • gross annuities for self-funded plans; • employer’s social security charges on early retirement annuities for all plans (outsourced and self-funded); and • the levy charged on those annuities under the “Fillon” law (only for plans with termination of employment contracts). The average residual portage periods under these plans were 2.18 years, 2.22 years and 2.60 years as of December 31, 2024 , 2023 and 2022 , respectively. The main other countries covered by restructuring provisions are Germany, Japan and the United States. The timing of future termination benefit payments is as follows: December 31, 2024 Benefit payments by period (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Employee termination benefits • France 862 312 416 126 8 • Other countries 456 304 144 7 1 Total 1,318 616 560 133 9 December 31, 2023 Benefit payments by period (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Employee termination benefits • France 611 215 315 79 2 • Other countries 357 302 47 7 1 Total 968 517 362 86 3 December 31, 2022 Benefit payments by period (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Employee termination benefits • France 804 185 412 207 — • Other countries 235 189 36 8 2 Total 1,039 374 448 215 2 D.19.3. Other provisions Other provisions include provisions for risks and litigation relating to environmental, tax, commercial and product liability matters. (€ million) 2024 2023 2022 Environmental risks 474 493 526 Product liability risks, litigation and other 1,676 1,283 1,652 Total 2,150 1,776 2,178 Provisions for environmental risks relate primarily to contingencies arising from business divestitures, and include remediation costs relating to such environmental risks. Identified environmental risks are covered by provisions estimated on the basis of the costs Sanofi believes it will be obliged to meet over a period not exceeding (other than in exceptional cases) 30 years. Sanofi expects that €67 million of those provisions will be utilized in 2025 , and €203 million over the period from 2026 through 2029 . As regards greenhouse gas emission quotas, which relate to Sanofi production facilities in France and Ireland, in the absence of specific IFRS pronouncements Sanofi has adopted the "net liability approach". That involves recognizing a liability at the balance sheet date if actual emissions exceed the quotas held, in accordance with IAS 37 and French GAAP ( Plan Comptable Général, Article 615-1s). Quotas are managed as a production cost, and as such are recognized in inventory at a zero value (if received free of charge) and at acquisition cost (if bought on the market). As of December 31, 2024 , a provision of €1 million has been recognized. “Product liability risks, litigation and other” mainly comprises provisions for risks relating to product liability (including IBNR provisions as described in Note B.12.), government investigations, regulatory or antitrust law claims, contingencies arising from business divestitures (other than environmental risks), and remediation costs related to leases. The main pending legal and arbitral proceedings and government investigations are described in Note D.22. A full risk and litigation assessment is performed with the assistance of Sanofi’s legal advisers, and provisions are recorded as required by circumstances in accordance with the principles described in Note B.12. D.19.4. Non-current income tax liabilities Non-current income tax liabilities amounted to € 1,512 million as of December 31, 2024 (versus € 1,842 million as of December 31, 2023 and € 1,979 million as of December 31, 2022 ) . These amounts include uncertainties over income tax treatment totalling €1,512 million as of December 31, 2024 , versus €1,595 million as of December 31, 2023 and €1,520 million as of December 31, 2022 . Until December 31, 2023 , this line item includes the residual liability due after more than one year arising from the estimated tax charge on deemed repatriation attributable to the accumulated earnings of non-US operations ( € 247 million as of December 31, 2023 and € 459 million as of December 31, 2022 ) . The expense was initially recognized in 2018 at an amount of $1,092 million , and payment is being made over eight years through 2025 . As of December 31, 2024 , the residual liability is included in the line item Current income tax liabilities . A US legal restructuring resulted in a capital loss of € 3 billion recognized in the 2020 final tax filing. One-third of the capital loss has been used against 2020 capital gains and the remaining balance will be eligible to carry back for three years . Due to management’s judgement about potential alternative interpretations of the prevailing tax law, no tax benefit has been recognized on this transaction in accordance with IFRIC 23. D.19.5. Current provisions and other current liabilities Current provisions and other current liabilities comprise th

Derivative financial instrument

Derivative financial instruments and market risks	12 Months Ended
	Dec. 31, 2024
Financial Instruments [Abstract]
Derivative financial instruments and market risks	Derivative financial instruments and market risks The table below shows the fair value of derivative instruments as of December 31, 2024 , 2023 and 2022 : (€ million) Non- current assets Current assets Total assets Non-current liabilities Current liabilities Total liabilities Market value at December 31, 2024 (net) Market value at December 31, 2023 (net) Market value at December 31, 2022 (net) Currency derivatives — 217 217 — (330) (330) (113) 75 112 operating — 81 81 — (111) (111) (30) 22 22 financial — 136 136 — (219) (219) (83) 53 90 Interest rate derivatives — — — (121) (7) (128) (128) (165) (232) Equity derivatives — — — — — — — — Total — 217 217 (121) ( 337) (458) (241) ( 90) ( 120) Objectives of the use of derivative financial instruments Sanofi uses derivative instruments to manage operating exposure to movements in exchange rates, and financial exposure to movements in interest rates and exchange rates (where the debt or receivable is not contracted in the functional currency of the borrower or lender entity). On occasion, Sanofi uses equity derivatives in connection with the management of its portfolio of equity investments. Sanofi performs periodic reviews of its transactions and contractual agreements in order to identify any embedded derivatives, which are accounted for separately from the host contract in accordance with IFRS 9. Sanofi had no material embedded derivatives as of December 31, 2024 , 2023 or 2022 . Counterparty risk For a description of counterparty risk, refer to “Item 11. — Quantitative and Qualitative Disclosures about Market Risk”. a) Currency derivatives used to manage operating risk exposures For a description of Sanofi’s objectives, policies and procedures for the management of operating foreign exchange risk, refer to “Item 11. — Quantitative and Qualitative Disclosures about Market Risk”. The table below shows operating currency hedging instruments in place as of December 31, 2024 , with the notional amount translated into euros at the relevant closing exchange rate: December 31, 2024 Of which derivatives designated as cash flow hedges Of which derivatives not eligible for hedge accounting (€ million) Notional amount Fair value Notional amount Fair value Of which recognized in equity Notional amount Fair value Forward currency sales 7,521 (67) — — — 7,521 (67) of which US dollar 3,974 (59) — — — 3,974 (59) of which Chinese yuan renminbi 703 (5) — — — 703 (5) of which Pound sterling 368 (1) — — — 368 (1) of which Japanese yen 241 2 — — — 241 2 of which Turkish lira 216 (23) — — — 216 (23) Forward currency purchases 4,796 37 — — — 4,796 37 of which US dollar 2,660 24 — — — 2,660 24 of which Singapore dollar 484 3 — — — 484 3 of which Chinese yuan renminbi 451 2 — — — 451 2 of which Turkish lira 203 19 — — — 203 19 of which Canadian dollar 126 — — — — 126 — Total 12,317 (30) — — — 12,317 (30) The table below shows operating currency hedging instruments in place as of December 31, 2023 , with the notional amount translated into euros at the relevant closing exchange rate: December 31, 2023 Of which derivatives designated as cash flow hedges Of which derivatives not eligible for hedge accounting (€ million) Notional amount Fair value Notional amount Fair value Of which recognized in equity Notional amount Fair value Forward currency sales 6,112 30 — — — 6,112 30 of which US dollar 2,981 35 — — — 2,981 35 of which Chinese yuan renminbi 788 7 — — — 788 7 of which Singapore dollar 419 (1) — — — 419 (1) of which Japanese yen 339 (6) — — — 339 (6) of which Korean won 192 (4) — — — 192 (4) Forward currency purchases 4,246 (8) — — — 4,246 (8) of which US dollar 2,022 (12) — — — 2,022 (12) of which Singapore dollar 876 — — — — 876 — of which Chinese yuan renminbi 364 (1) — — — 364 (1) of which Korean won 137 2 — — — 137 2 of which Japanese yen 123 1 — — — 123 1 Total 10,358 22 — — — 10,358 22 The table below shows operating currency hedging instruments in place as of December 31, 2022 , with the notional amount translated into euros at the relevant closing exchange rate: December 31, 2022 Of which derivatives designated as cash flow hedges Of which derivatives not eligible for hedge accounting (€ million) Notional amount Fair value Notional amount Fair value Of which recognized in equity Notional amount Fair value Forward currency sales 5,403 49 — — — 5,403 49 of which US dollar 2,732 56 — — — 2,732 56 of which Chinese yuan renminbi 576 2 — — — 576 2 of which Japanese yen 240 (5) — — — 240 (5) of which Singapore dollar 180 1 — — — 180 1 of which Korean won 179 (14) — — — 179 (14) Forward currency purchases 3,459 (27) — — — 3,459 (27) of which US dollar 2,047 (21) — — — 2,047 (21) of which Singapore dollar 375 (7) — — — 375 (7) of which Chinese yuan renminbi 142 — — — — 142 — of which Korean won 130 4 — — — 130 4 of which Taiwan dollar 84 — — — — 84 — Total 8,862 22 — — — 8,862 22 b) Currency and interest rate derivatives used to manage financial exposure For a description of Sanofi’s objectives, policies and procedures for the management of financial foreign exchange risk and interest rate risk, refer to “Item 11. — Quantitative and Qualitative Disclosures about Market Risk”. The table below shows financial currency hedging instruments in place, with the notional amount translated into euros at the relevant closing exchange rate: 2024 2023 2022 (€ million) Notional amount Fair value Expiry Notional amount Fair value Expiry Notional amount Fair value Expiry Forward currency sales 10,377 (195) 10,279 111 7,559 66 of which US dollar 8,923 (a) (176) 2025 6,628 101 2024 6,114 59 2023 of which Japanese yen 371 4 2025 157 (1) 2024 111 — 2023 of which Chinese yuan renminbi 235 (1) 2025 513 4 2024 203 2 2023 Forward currency purchases 6,884 112 7,055 (58) 4,997 24 of which US dollar 4,397 (b) 123 2025 3,073 (52) 2024 2,011 (4) 2023 of which Singapore dollar 819 2 2025 2,696 (10) 2024 2,154 22 2023 of which Hungarian forint 641 (9) 2025 99 1 2024 59 1 2023 Total 17,261 (83) 17,334 53 12,556 90 (a) Includes forward sales with a notional amount of $3,615 million expiring in 2025 , designated as a hedge of Sanofi’s net investment in Bioverativ. As of December 31, 2024 , the fair value of these forward contracts represented a liability of €88 million ; the opposite entry was recognized in "Other comprehensive income", with the impact on financial income and expense being immaterial. (b) Includes forward purchases with a notional amount of $ 1,000 million expiring in 2025 , designated as a fair value hedge of the exposure of $ 1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of December 31, 2024 , the fair value of the contracts was an asset of € 75 million , the opposite entry for €0.2 million of which was debited to “Other comprehensive income” under the cost of hedging accounting treatment. The table below shows interest rate hedging instruments in place as of December 31, 2024 : Notional amounts by expiry date as of December 31, 2024 Of which designated as fair value hedges Of which designated as cash flow hedges (€ million) 2025 2026 2027 2028 2029 2030 and later Total Fair value Notional amount Fair value Notional amount Fair value Of which recognized in equity Interest rate swaps pay capitalized SOFR USD/ receive 1.03% — — — 483 — — 483 (47) 483 (47) — — — pay capitalized SOFR USD/ receive 1.32% — — — 483 — — 483 (43) 483 (43) — — — pay capitalized Ester/receive 0.69% 850 — — — — — 850 (7) 850 (7) — — — pay capitalized Ester/receive 0.92% — — — — 650 650 (31) 650 (31) — — — Total 850 — — 966 650 — 2,466 (128) 2,466 (128) — — — The table below shows interest rate hedging instruments in place as of December 31, 2023 : Notional amounts by expiry date as of December 31, 2023 Of which designated as fair value hedges Of which designated as cash flow hedges (€ million) 2024 2025 2026 2027 2028 2029 and later Total Fair value Notional amount Fair value Notional amount Fair value Of which recognized in equity Interest rate swaps pay capitalized SOFR USD/ receive 1.03% — — — — 453 — 453 (49) 453 (49) — — — pay capitalized SOFR USD/ receive 1.32% — — — — 453 — 453 (43) 453 (43) — — — pay capitalized Ester/receive 0.69% — 850 — — — — 850 (28) 850 (28) — — — pay capitalized Ester/receive 0.92% — — — — — 650 650 (44) 650 (44) — — — pay capitalized Ester/receive 3.43% 999 — — — — — 999 (1) 999 (1) — — — Total 999 850 — — 906 650 3,405 (165) 3,405 (165) — — — The table below shows interest rate hedging instruments in place as of December 31, 2022 : Notional amounts by expiry date as of December 31, 2022 Of which designated as fair value hedges Of which designated as cash flow hedges (€ million) 2023 2024 2025 2026 2027 2028 and later Total Fair value Notional amount Fair value Notional amount Fair value Of which recognized in equity Interest rate swaps pay capitalized SOFR USD/ receive 1.03% — — — — — 467 467 (62) 467 (62) — — — pay capitalized SOFR USD/ receive 1.32% — — — — — 467 467 (56) 467 (56) — — — pay capitalized Ester/ receive 0.69% — — 850 — — — 850 (43) 850 (43) — — — pay capitalized Ester/ receive 0.92% — — — — — 650 650 (71) 650 (71) — — — Total — — 850 — — 1,584 2,434 (232) 2,434 (232) — — — c) Actual or potential effects of netting arrangements The table below is prepared in accordance with the accounting policies described in Note B.8.3.: (€ million) 2024 2023 2022 Derivative financial assets Derivative financial liabilities Derivative financial assets Derivative financial liabilities Derivative financial assets Derivative financial liabilities Gross carrying amounts before offset (a) 217 (458) 201 (291) 206 (326) Gross amounts offset (in accordance with IAS 32) (b) — — — — — — Net amounts as reported in the balance sheet (a) - (b) = (c) 217 (458) 201 (291) 206 (326) Effects of other netting arrangements (not fulfilling the IAS 32 criteria for offsetting) (d) Financial instruments (201) 201 (171) 171 (160) 160 Fair value of financial collateral N/A N/A N/A N/A N/A N/A Net exposure (c) + (d) 16 (257) 30 (120) 46 (166)

Off balance sheet commitments

Off balance sheet commitments	12 Months Ended
	Dec. 31, 2024
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Off balance sheet commitments	Off balance sheet commitments The off balance sheet commitments presented below are shown at their nominal value. D.21.1. Off balance sheet commitments relating to operating activities Off balance sheet commitments relating to Sanofi ’s operating activities, not including as of December 31, 2024 the commitments of the Opella held-for-sale operation, comprise the following: December 31, 2024 Payments due by period (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced (a) 554 28 34 41 451 Irrevocable purchase commitments (b) • given (c) 3,683 1,152 1,195 442 894 • received (391) (288) (96) (7) — Research and development license agreements - commitments given • commitments related to R&D and other commitments (d) 84 42 29 6 7 • contingent milestone payments in connection with development programs in progress (e) 4,230 941 635 470 2,184 Total - net commitments given 8,160 1,875 1,797 952 3,536 (a) Includes the variable portion of future lease payments not recognized as lease liabilities as of December 31, 2024 ; the equivalent amount of these commitments as of December 31, 2023 was € 221 million. During 2023 , Sanofi signed a 15-year lease which will take effect in 2025 and to which Sanofi is committed for a minimum period of 12 years , corresponding to a commitment of $ 0.2 billion. The lease includes two extension options of five years each. During 2024 , Sanofi signed a 12-year lease in France which will take effect in 2027, representing a commitment of € 0.2 billion. (b) These comprise irrevocable commitments to suppliers of (i) property, plant and equipment, net of down-payments (see Note D.3.) and (ii) goods and services. As of December 31, 2023 , irrevocable commitments amounted to €6,141 million given (including €754 million related to Opella) and € 550 million received (zero related to Opella). (c) Irrevocable purchase commitments given as of December 31, 2024 include € 749 million of commitments to joint ventures. This line also includes (i) the commitment to EUROAPI as described in Note D.1. and amounting to € 535 million as of December 31, 2024, and (ii) commitments related to long-term renewable energy purchase contracts lasting between 15 and 20 years giving rise to the physical supply of electricity mainly in France for an estimated total annual volume of 329 GWh. (d) Commitments related to research and development, and other commitments, amounted to € 381 million as of December 31, 2023 . (e) This line only includes contingent milestone payments on development projects in progress. The equivalent amount as of December 31, 2023 was € 4,886 million . In pursuance of its strategy, Sanofi may acquire technologies and rights to products. Such acquisitions may be made in various contractual forms: acquisitions of shares, loans, license agreements, joint development, and co-marketing. These arrangements generally involve upfront payments on signature of the agreement, development milestone payments, and royalties. Some of these complex agreements include undertakings to fund research programs in future years and payments contingent upon achieving specified development milestones, the granting of approvals or licenses, or the attainment of sales targets once a product is commercialized. The “Research and development license agreements” line comprises future service commitments to fund research and development or technology, and contingent milestone payments regarded as reasonably achievable (i.e. all potential milestone payments relating to projects in the development phase, for which the future financial consequences are known or probable and for which there is a sufficiently reliable estimate). This line excludes: • commitments given relating to (i) projects in the research phase, amounting to €14.4 billion as of December 31, 2024 and €16.8 billion as of December 31, 2023 and (ii) payments contingent upon the attainment of sales targets once a product is commercialized, amounting to €15.2 billion as of December 31, 2024 and €17.9 billion as of December 31, 2023 ); • commitments received amounting to €13.0 billion as of December 31, 2024 ( €10.0 billion as of December 31, 2023 ), mainly comprising research, development and commercialization agreements with partners further to the acquisitions of (i) Ablynx ( €0.7 billion as of December 31, 2024 , versus €0.9 billion as of December 31, 2023 ); (ii) Kymab (€ 0.3 billion as of December 31, 2024 , versus € 0.2 billion as of December 31, 2023 ) and (iii) Provention Bio (€ 0.4 billion as of December 31, 2024 , versus € 0.3 billion as of December 31, 2023 ), plus contingent consideration receivable based on attainment of regulatory and sales milestones for commercialized products under the terms of licenses or rights assignment agreements amounting to € 11.2 billion as of December 31, 2024 (€ 8.5 billion as of December 31, 2023). The major agreements entered into by Sanofi in 2024 are described below: • On May 10, 2024 , Sanofi entered into a co-exclusive licensing agreement with Novavax. The terms of the agreement include (i) a co-exclusive license to co-commercialize Novavax’s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea, where Novavax has existing partnership agreements); (ii) a sole license to Novavax’s adjuvanted COVID-19 vaccine for use in combination with Sanofi’s flu vaccines; and (iii) a non-exclusive license to use the Matrix-M adjuvant in vaccine products. Novavax received an upfront payment of $ 500 million and could receive up to $ 700 million contingent on attainment of development, regulatory and commercialization milestones, representing up to $1.2 billion in total. Starting in 2025, Sanofi will recognize sales of Novavax’s adjuvanted COVID-19 vaccine and will bear certain R&D, regulatory and commercialization expenses. Novavax will receive double-digit tiered royalties on Sanofi sales of COVID-19 vaccines and combined influenza/COVID-19 vaccines. Novavax is also entitled to additional launch and sales milestone payments of up to $ 200 million, plus single-digit royalties for each additional Sanofi vaccine product developed under a non-exclusive license using Novavax’s Matrix-M adjuvant technology. In addition, Sanofi took a minority equity interest of less than 5% in Novavax. Outside of the collaboration, each party may develop and commercialize their own flu and COVID-19 vaccines and their own adjuvanted products at their own cost. • On September 12, 2024 , Sanofi entered into an exclusive licensing agreement with RadioMedix, Inc. and Orano Med for AlphaMedix (SAR447873), a late-stage project currently being evaluated for the treatment of adult patients with unresectable or metastatic progressive somatostatin-receptor expressing neuroendocrine tumors (NETs), a rare cancer. Under the licensing agreement, Sanofi will be responsible for the global commercialization of AlphaMedix, while Orano Med will be responsible for the manufacturing of AlphaMedix through its global industrial platform currently under development. Under the terms of the agreement, RadioMedix and Orano Med received an upfront payment of € 100 million and could receive up to € 220 million based on sales milestones, as well as being eligible for tiered sales-based royalties. • On December 20, 2024 , Sanofi entered into an exclusive licensing agreement with Corxel Pharmaceuticals (CORXEL) to develop and commercialize aficamten in China, Hong Kong, Macao and Taiwan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). Aficamten is an investigational, next-in-class selective small molecule cardiac myosin inhibitor discovered and developed globally by Cytokinetics. Sanofi will now acquire CORXEL’s rights relating to aficamten in China, Hong Kong, Macao and Taiwan for an undisclosed amount. Cytokinetics remains eligible to receive up to $ 150 million in development and commercial milestone payments from Sanofi as well as royalties in the low-to- high teens on future sales of aficamten in China, Hong Kong, Macao and Taiwan. Cytokinetics is now also eligible to receive additional undisclosed payments in connection with the execution of the agreement between Sanofi and CORXEL. The amount reported for commitments as of December 31, 2024 also includes commitments under agreements entered into by Sanofi in prior years. The main such agreements are described below; for a full description of each agreement, refer to the Annual Report on Form 20-F for the year in which the agreement was entered into. The major agreements entered into by Sanofi in 2023 are described below: • expan ded collaboration with Scribe Therapeutics signed in September 2022, and an exclusive license agreement on CasX- Editor(XE) genome editing technology associated with guide RNAs for multiple targets including sickle cell disease and other genomic diseases; • agreement with Janssen Pharmaceuticals, Inc. (Janssen) to develop and commercialize a vaccine candidate against extra intestinal pathogenic strains of E. coli developed by Janssen. In February 2025, a scheduled review of the E.mbrace phase 3 study conducted by independent data monitoring committee (IDMC) determined that the vaccine candidate was not sufficiently effective at preventing invasive E. coli disease (IED) compared to placebo. As a result of the IDMC's determination, the E.mbrace study is being discontinued (see Note D.5.); • collaboration agreement with Teva Pharmaceuticals to co-develop and co-commercialize TEV’574 (duvakitug), for which positive Phase 2b clinical study results in patients with ulcerative colitis and Crohn’s disease were announced on December 17, 2024. In addition, by acquiring all of the outstanding shares of Provention Bio, Inc. on April 27, 2023 (see Note D.1.), Sanofi assumed commitments amounting to € 946 million made by that company to various partners under collaboration agreements previously entered into. The principal agreements entered into by Sanofi in earlier years are listed below: • Exscientia (2022): an innovative license agreement and research collaboration to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilizing actual patient samples; • ABL Bio (2022) : a licensing and collaboration agreement for the development of ABL301, a bispecific antibody intended as a treatment for alpha-synucleinopathies; • Adagene Inc., a company specializing in the discovery and development of antibody-based therapies (2022) : collaboration and exclusive license agreement; • Blackstone (2022) : a strategic risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to € 300 million to accelerate the global pivotal studies and clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa, to treat patients with multiple myeloma. That amount will be paid to Sanofi on the basis of development expenses incurred. In addition, Sanofi may pay royalties on future sales of this solution; • IGM Biosciences Inc. (2022) : an exclusive collaboration agreement to create, develop, manufacture and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets; • Atomwise (2022) : a collaboration agreement that will leverage Atomwise's ATOMNET platform to identify and synthesize up to five drug targets; • Scribe Therapeutics (2022) : a research collaboration to leverage Scribe's CRISPR by Design platform and to obtain a non- exclusive license to CasX-Editor(XE) genome editing technology for multiple oncology targets; • Insilico Medicine (2022) : a strategic research collaboration to leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new therapeutic targets; • Innate Pharma SA (2022) : an expanded collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7-H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform; • Kymera (2020): agreement to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; • Nurix Therapeutics (2020): collaboration to develop novel targeted protein degradation therapies; and • Denali Therapeutics Inc. (2018): collaboration agreement on the development of multiple molecules with the potential to treat a range of systemic inflammatory diseases such as ulcerative colitis. Sanofi did not discontinue any collaboration agreement that would have resulted in a significant reduction in commitments as of December 31, 2024 . In addition, under the collaboration agreement with Regeneron on monoclonal antibodies (see Note C.1.), Sanofi is entitled to receive an additional share of quarterly profits (capped at 10% of Regeneron’s share of quarterly profits until March 31, 2022, and thereafter at 20% ), until Regeneron has paid 50% of the cumulative development costs incurred by the parties to the alliance. As of December 31, 2024 this represented total commitments received of € 1.6 billion (versus € 2.1 billion as of December 31, 2023 ), against cumulative development costs of € 9.7 billion . Sanofi entered into an agreement with Royalty Pharma in December 2014 relating to development programs, under which Royalty Pharma bore a portion of the remaining development costs of the project on a quarterly basis in return for royalties on future sales. The products in development under that agreement have been launched in territories including the United States and Europe, marking the end of the joint development programs. On February 27, 2017, Sanofi and Lonza announced a strategic partnership in the form of a joint venture (BioAtrium AG) to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland. An initial investment of approximately €0.3 billion to finance construction of the facility, split 50 / 50 between the two partners, has now been made in full. In addition, Sanofi could pay BioAtrium AG in the region of €0.6 billion over the 2025-2031 period as its share of operating expenses and the cost of producing future batches. In February 2014, pursuant to the “Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits” (still effective as of December 31, 2024 ), Sanofi Pasteur and the World Health Organization (WHO) signed a bilateral “Standard Material Transfer Agreement” (SMTA 2). This agreement stipulates that Sanofi Pasteur will, during declared pandemic periods, (i) donate 7.5% of its real-time production of pandemic vaccines against any strain with potential to cause a pandemic, and (ii) reserve a further 7.5% of such production on affordable terms. The agreement cancels and replaces all preceding commitments to donate pandemic vaccines to the WHO. Sanofi has also entered into power purchase agreements in furtherance of its sustainability strategy. The characteristics of the principal power purchase agreements in place as of December 31, 2024 are summarized below: Country Type of Energy Annual Volume Start Date Term Type of Contract Accounting Treatment France Solar 8 GWh 2025 20 years PPA (a) Own use procurement contract (b) Wind 46 GWh 2025 20 years Wind 29 GWh 2025 20 years Wind 21 GWh 2025 20 years Wind 32 GWh 2025 20 years Wind 22 GWh 2025 20 years Solar 6 GWh 2025 20 years Solar 6 GWh 2025 20 years Solar 7 GWh 2025 20 years Wind 21 GWh 2025 15 years Wind 40 GWh 2025 15 years Germany Wind 70 GWh 2025 18 years Belgium Wind 20 GWh 2026 15 years (a) PPA (Power Purchase Agreement): long-term renewable energy contract resulting in physical supply of electricity at a predetermined fixed price for the entire duration of the contract. (b) At the current stage of analysis with reference to IFRS 10 (Consolidated Financial Statements), IFRS 16 (Leases) and IFRS 9 (Financial Instruments), Sanofi has concluded that it can apply the own use exception as permitted by paragraph 2.4 of IFRS 9. These contracts help secure the objective of 100% electricity from renewable sources supply across all Sanofi operations by 2030. D.21.2. Off balance sheet commitments relating to financing activities Credit facilities Undrawn credit facilities are as follows: December 31, 2024 Expiry (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years General-purpose credit facilities 8,000 — 4,000 — 4,000 As of December 31, 2024 , total credit facilities amounted to €8,000 million (versus €8,000 million as of December 31, 2023 and €8,000 million as of December 31, 2022 ). Guarantees The table below shows the amount of guarantees given and received: (€ million) 2024 2023 2022 Guarantees given: 4,298 3,936 3,815 • Guarantees provided to banks in connection with credit facilities 1,130 1,067 1,007 • Other guarantees given 3,168 2,869 2,808 Guarantees received (1,288) (1,272) (1,229) D.21.3. Off balance sheet commitments relating to asset acquisitions and divestments, and to changes in the scope of consolidation As of December 31, 2024 , Sanof i had received commitments amounting in aggregate to € 0.5 billion in respect of (i) divestments of assets relating to transactions not yet finalized as of that date and (ii) contingent consideration arising under past agreements. Off balance sheet commitments of a financing nature with associates and joint ventures are disclosed in N ote D.6. Off-balance sheet commitments relating to securities classified in the categories Equity instruments at fair value through other comprehensive income and Unquoted debt securities not meeting the definition of equity instruments are respectively disclosed in Notes D .7.1. and D.7.3.. The maximum amount of contingent consideration relating to business combinations is disclosed in Note D.18.

Legal and arbitral proceedings

Legal and arbitral proceedings	12 Months Ended
	Dec. 31, 2024
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Legal and arbitral proceedings	Legal and arbitral proceedings Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures. Provisions related to legal and arbitral proceedings are recorded in accordance with the principles described in Note B.12. Most of the issues raised by these claims are highly complex and subject to substantial uncertainties; therefore, the probability of loss and an estimation of damages are difficult to ascertain. Contingent liabilities are cases for which either we are unable to make a reasonable estimate of the expected financial effect that will result from ultimate resolution of the proceeding, or a cash outflow is not probable. In either case, a brief description of the nature of the contingent liability is disclosed and, where practicable, an estimate of its financial effect, an indication of the uncertainties relating to the amount and timing of any outflow, and the possibility of any reimbursement are provided in application of paragraph 86 of IAS 37. In the cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed, we have indicated our losses or the amount of provision accrued that is the estimate of the probable loss. In a limited number of ongoing cases, while we are able to make a reasonable estimate of the expected loss or range of the possible loss and have accrued a provision for such loss, we believe that publication of this information on a case-by-case basis or by class would seriously prejudice the Company’s position in the ongoing legal proceedings or in any related settlement discussions. Accordingly, in those cases, we have disclosed information with respect to the nature of the contingency but have not disclosed our estimate of the range of potential loss, in accordance with paragraph 92 of IAS 37. These assessments can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Our assessments are based on estimates and assumptions that have been deemed reasonable by management. We believe that the aggregate provisions recorded for the above matters are adequate based upon currently available information. However, given the inherent uncertainties related to these cases and involved in estimating contingent liabilities, we could in the future incur judgments that could have a material adverse effect on our net income in any particular period. Long term provisions are disclosed in Note D.19. They include: • provisions for product liability risks, litigation and other amount to €1,676 million in 2024 . These provisions are mainly related to product liabilities, government investigations, competition law, regulatory claims, warranties in connection with certain contingent liabilities arising from business divestitures other than environmental matters and other claims; • provisions for environmental risks and remediation amount to €474 million in 2024 , the majority of which are related to contingencies that have arisen from business divestitures. a) Products Sanofi Pasteur Hepatitis B Vaccine Product Litigation Since 1996, more than 180 lawsuits have been filed in various French civil courts against Sanofi Pasteur (a French subsidiary of Sanofi) and/or Sanofi Pasteur MSD SNC (a joint venture company with Merck & Co., Inc. now terminated), for which past ongoing litigation is now managed by the originating party. In such lawsuits, the plaintiffs allege that they suffer from a variety of neurological disorders and autoimmune diseases, including multiple sclerosis and Guillain-Barré syndrome, as a result of receiving the hepatitis B vaccine. In January 2018, the Appeal Court of Bordeaux found a causal link between hepatitis B vaccine and multiple sclerosis. In July 2019, the French Supreme Court (Cour de cassation) cancelled the judgment of the Appeal Court of Bordeaux and referred the case back to the Appeal Court of Toulouse. On March 30, 2022, the Appeal Court of Toulouse dismissed all the plaintiffs' claims. As of December 31, 2024 , there were four ongoing lawsuits related to Sanofi Pasteur hepatitis B vaccine. Taxotere Product Litigation in the US A number of lawsuits have been filed against affiliates of Sanofi under US state law for personal injuries allegedly sustained in connection with the use of Taxotere. The actions are held in several jurisdictions around the country. In 2021, there were two bellwether trials as part of a federal multi-district litigation in the Eastern District of Louisiana both resulting in jury verdicts in Sanofi's favor. Throughout 2024, Sanofi entered into a number of settlement agreements or agreements in principle with many plaintiffs’ firms encompassing nearly all the remaining cases. These agreements, still a work in progress, require the consent of the individual plaintiffs and will take some time to conclude, in order to ensure that certain threshold participation requirements are met. At the end of the settlement process, Sanofi expects approximately 100 plaintiffs to opt out of the settlement and litigation will continue. It is not possible, at this stage, to assess with certainty the outcome of these lawsuits. Zantac Litigation in the US In September 2019, the US Food and Drug Administration (FDA) announced it was investigating the claims of an online pharmacy’s Citizen Petition that the medication Zantac (the brand name for ranitidine) used for stomach heartburn contains or can generate the chemical N-Nitrosodimethylamine (NDMA), an alleged human carcinogen. As a precautionary measure, Sanofi initiated a voluntary recall of branded over-the-counter Zantac in October 2019. Concurrent with the FDA investigation, multiple personal injury lawsuits and class actions alleging that Zantac causes various cancers and seeking damages for either alleged personal injuries or alleged economic injuries were filed. Federal court cases were coordinated into a Multi-Districts Litigation (MDL) in the Southern District of Florida in February 2020. On December 6, 2022, the MDL Court granted Sanofi and other defendants’ Daubert and summary judgment motions. As a result, the Court entered final judgment in all cases involving plaintiffs’ five designated cancers and dismissed the class action cases. Based on the preliminary estimates, more than 12,000 plaintiffs have filed notices to appeal the Daubert ruling in the Eleventh Circuit. The MDL Court subsequently dismissed all pending cases alleging a non-designated cancer for failure to serve expert reports. Other cases are pending in various state courts. The majority of the state court plaintiffs have cases pending in Delaware, where a hearing on defendants’ Daubert motions to exclude plaintiffs’ experts took place in January 2024. In May 2024, the State of Delaware court decided not to exclude plaintiffs’ experts from the cases. Sanofi has appealed this decision to the Delaware Supreme Court which has granted review, and a decision is expected in June 2025. To date, there have been five trials against other defendants, but none against Sanofi as yet. In March 2024, Sanofi reached agreement in principle with a number of plaintiffs’ lawyers to resolve Zantac personal injury cases pending against it in all US state courts outside of Delaware. This agreement would resolve approximately 75% of nearly 4,400 cases. The agreement requires the consent of individual plaintiffs and will take some time to conclude. Overall, as of December 31, 2024, there were around 1,623 product liability “complaints” filed. These complaints encompass 24,922 individual product liability “plaintiffs” who have all filed against Sanofi. The vast majority of these plaintiffs participated in the MDL Court’s census registry program, allege cancers that the plaintiffs’ leadership decided not to designate and pursue in the MDL, and have since filed their complaints in state courts. Additional cases may be filed. In addition, in November 2019, Sanofi received a Civil Investigative Demand (CID) related to this issue from the Arizona Attorney General. Sanofi provided responses in December 2019 and July 2020 and has not received any follow-up requests. In June 2020, the New Mexico Attorney General filed a complaint against Sanofi, the previous marketing authorization holders for branded Zantac, a dozen generic manufacturers, and several retailers. The complaint brings claims for alleged violations of the New Mexico Unfair Practices Act, violations of the New Mexico False Advertising Act, violations of the New Mexico Public Nuisance Statute, common law public nuisance, and negligence. Trial in the case is scheduled for September 2025. In June 2020, Sanofi received a notice from the US Department of Justice Civil Division and US Attorney’s Office for the Eastern District of Pennsylvania of an investigation into allegations that pharmaceutical manufacturers violated the False Claims Act, 31 U.S.C. § 3729, in relation to the drug Zantac and ranitidine hydrochloride through alleged failure to disclose to the federal government information about the potential presence of NDMA. In response to the notice, Sanofi provided information and documents including applications and communications with FDA, in August 2020. Sanofi has not received any subsequent requests from the federal government. In November 2020, the Mayor and City Council of Baltimore filed a complaint against Sanofi, the previous marketing authorization holders for branded Zantac, generic manufacturers, and several retailers. The complaint alleges violations of the Maryland Consumer Protection statute, public nuisance, and negligence. Trial in the case is scheduled for September 2026. In January 2021, Sanofi had been served with the Center for Environmental Health’s Second Amended Complaint alleging Proposition 65 violations. The case which was pending in California Superior Court in Alameda County was settled in 2024 and is now concluded. It is not possible, at this stage, to assess with certainty the outcome of these lawsuits. Zantac Litigation in Canada Between 2019 and 2022, seven proposed class actions naming some or all of Sanofi Consumer Health Inc., Sanofi-Aventis Canada Inc., Chattem (Canada) Inc., Sanofi and Sanofi Pasteur Limited as Defendants, relating to ranitidine were filed in courts in various Canadian provinces. The cases allege that proposed class members suffered personal injury from the ingestion of ranitidine, and seek damages in unspecified amounts, disgorgement of profits, restitution in the amount of the purchase price of Zantac and subrogated damages on behalf of provincial health insurers for health care costs related to ranitidine use. Between 2021-2024, a total of 122 individual claims naming Sanofi Consumer Health Inc., Sanofi-Aventis Canada Inc., Sanofi Pasteur Limited and Chattem (Canada) Inc. were filed in Ontario and British Columbia. In May 2023, in the proceedings pending before the Supreme Court of British Columbia, the court dismissed the action, ruling that there is no scientific support for the plaintiffs' claims. The Superior Court of Quebec has stayed the corresponding proposed Zantac class proceedings in Quebec until the result of the US Multi-District Litigation (MDL) appeal is announced or October 15, 2025 (whichever comes first). It is not possible, at this stage, to assess with certainty the outcome of the remaining lawsuits. Talc Product Litigation in the US Over the last few years, Sanofi affiliates have been named in product liability actions in the United States regarding the alleged presence of asbestos in talc products originating from past acquisitions. A certain number of these claims were also dismissed during that time. As of December 31, 2024, there were approximately 700 ongoing product liability actions. To date, no cases have proceeded to trial. It is not possible, at this stage, to assess with certainty the outcome of these lawsuits. Depakine Product Litigation in France Civil proceedings As of December 31, 2024 , 79 families had brought a civil claim involving 133 people exposed in utero to sodium valproate against a French affiliate of Sanofi seeking indemnification under French law for personal injuries allegedly suffered by children in connection with the use of sodium valproate (Depakine) by their mothers during pregnancy to treat their epilepsy. These actions are being held in several jurisdictions in France. Forty lawsuits are in progress on the merits, the most advanced of which was tried at the level of the French Supreme Court, which in November 2019 issued a ruling sending the case before the Paris Appeal Court to rule on Sanofi’s argument on the compliance of the product with mandatory regulations, as well as on the question of defectiveness of the product and the assessment of damages. In January 2023, the Paris Appeal Court ordered a stay in the proceedings until the submission of the second expert opinion report as part of the criminal investigation (see below). Seven first instance rulings on the merits were handed down in 2022 by the Judicial Tribunal of Nanterre. In three cases, the Court declared the judicial expert report null and void and the Court dismissed one claim in another case. Concerning three other cases relating to births that occurred between 2005 and 2009, the Court held, on the basis of a non- fault liability, that Sanofi was liable in light of the wording of the patient information leaflet. Provisional compensation amounts were set in the range of €0.1 million to €0.5 million . To date, four first instance cases have ruled in favour of plaintiffs and two first instance rulings excluded Sanofi’s liability. All the judgments have been appealed and are still pending. In the class action lawsuit filed in May 2017 by the APESAC (Association des Parents d’Enfants souffrant du Syndrome de l’Anti- Convulsivant) against the French affiliate, the Judicial Tribunal of Paris ruled on January 5, 2022 that a class is admissible, retaining Sanofi’s liability between 1984 and January 2006 for malformations and between 2001 and January 2006 for neuro- developmental disorders (NDD). This decision is based on the conclusions of a criminal expert report within the frame of ongoing criminal proceedings, for which the Chambre de l’Instruction of the Appeal Court of Paris had ordered a counter-expertise (see below). The APESAC, Sanofi and its insurers appealed the Judicial Tribunal of Paris’ ruling related to the class action. On July 21, 2021, the Judicial Tribunal of Créteil (France) dismissed a claim for damages brought against Sanofi regarding a child born in 1995. The Judicial Tribunal considered that the risk of occurrence of NDD in children born to a mother exposed to sodium valproate during pregnancy was not demonstrated by the state of scientific knowledge at the time of her pregnancy. This decision was appealed and the proceeding is now pending before the Appeal Court of Paris, which had ordered a stay in the proceeding until the end of the criminal investigation. Several questions on the Product Liability Directive have been referred to the Court of Justice of the European Union (CJEU ), which will have an impact on the pending Depakine cases. A ruling from the CJEU is expected between September and December 2025. Since July 2020, a collective redress has been filed against the French affiliate representing as of December 2024 approximately 76 f amilies (with 288 claimants including 111 people exposed in utero), seeking indemnification for a prejudice of anxiety. I n August 2024, the court denied Sanofi’s request related to the stay of proceeding pending the CJEU ruling and rejected Sanofi's statute of limitation arguments. In September 2024, Sanofi filed an appeal. Criminal investigation A criminal investigation was initiated in May 2015 before the Paris Civil Court. In January 2020, the French affiliate of Sanofi was indicted for aggravated deception and involuntary injuries and in July 2020 for involuntary manslaughter. In July 2020, a judicial supervision of the affiliate was ordered, together with the implementation of financial guarantees. In November 2020, the Health Authority ( ANSM) was similarly indicted for involuntary injuries and involuntary manslaughters. On March 9, 2022, the Chambre de l’Instruction of the Appeal Court of Paris (Cour d’appel) ruled that certain complaints for involuntary manslaughter and several others for aggravated deception and involuntary injuries were time-barred. The Public Prosecutor, as well as the civil parties, have brought the matter before the Chambre Criminelle of the Supreme Court (Cour de cassation) . In September 2022, the investigating judges appointed two experts for a counter-expertise following the Chambre de l’Instruction’s ruling handed down end of 2021. Since 2022, several individual medical assessments have been ordered by the investigating judge. In June 2023, the Chambre Criminelle of the French Supreme Court ( Cour de cassation ) confirmed the Paris Court of Appeal’s decision ( Chambre de l’Instruction ) dated March 2022 which had ruled that certain complaints for involuntary manslaughter and several others for aggravated deception and involuntary injuries were time-barred. In August 2023, Sanofi received the counter expertise report and sent its comments in November 2023. Public compensation scheme In 2017, the French government set up a public compensation scheme to indemnify patients for damages suffered in connection with the prescription of sodium valproate and its derivatives. The scheme was further amended through the 2020 Finance Law, with notably the introduction of presumptions of failure to inform the mother since 1982 for malformations and since 1984 for NDD. The scheme was amended again through the 2021 Finance Law in order to increase the maximum premium applicable in the event of refusal to make an offer (or making an insufficient offer) where this would be deemed unjustified by a court ruling. The committee of the compensation scheme has issued several final opinions holding the French affiliate liable for damages either in full or in part along with the French State, and, in some cases, healthcare practitioners. The French affiliate disagreed with the committee’s conclusions and has accordingly not offered indemnification to the claimants who have received compensation from the ONIAM (Office National d’Indemnisation des Accidents Médicaux) . The ONIAM is now seeking reimbursement from Sanofi, which has filed legal actions to oppose ONIAM’s payment orders. Administrative Actions In July 2020, March and June 2021, the Montreuil Administrative Court held the French State liable in five administrative proceedings initiated by families against the State. In March 2021, the Administrative Court did not find any failure to inform the mother regarding the risk of neurodevelopmental disorders for births in 1999 and in 2002, based on the state of scientific knowledge at the time. However, regarding the risk of malformations, liabilities were retained against the State, the healthcare professionals and Sanofi, notably for discrepancy between the SmPC (Summary of the Product Characteristics) and the patient leaflet. In other cases involving births in 2005-2008, the State was held liable both for malformations and neurodevelopmental disorders but partially exonerated, taking into account the roles of healthcare practitioners and Sanofi. Given that the French affiliate was not a party to these administrative proceedings, its arguments (including several requests from the French affiliate to the Health Authorities to reinforce warnings to healthcare professionals and patients in relation to Depakine) were not considered. All rulings were appealed by the claimants. Sanofi has filed requests for voluntary intervention in these proceedings to present its arguments before the Administrative Court of Appeal, which has been granted for some of them. In one proceeding, the claimants decided to withdraw their claims. In January 2025, the Paris Administrative Court of Appeal handed down five rulings. In cases concerning births in 2006 onwards, the Court retained the State’s liability and no fault from Sanofi due to the reiterated variation requests of the medicine’s information documents. In a case concerning births in 1999 and 2002, the Court retained the State’s liability with a 50% liability retained for Sanofi. It i s not possible, at this stage, to make a reliable assessment of the outcome of these cases. Depakine Product Litigation in other EU countries, in the UK and Switzerland In Switzerland, eleven families have filed a civil claim for damages concerning seventeen people exposed in utero. Some of them also involve the claimants’ physicians. In November 2022, one action was declared time-barred by the judge. The claimant appealed this court decision on the merit. In November 2024, the court confirmed the first instance judgment. The claimant appealed against this court decision to the Federal Tribunal (last Instance). In Spain, there are seven ongoing actions relating to fifteen children. In March 2022, in one trial, the Court ordered Sanofi to indemnify four patients. Sanofi appealed this decision. In January 2023, in another trial filed by one patient, the Appeal Court confirmed the first instance's decision and dismissed the claim. As of December 2024, two actions are pending in front of the Supreme Court and five are at the first instance stage. In Belgium, there are two civil proceedings (currently on hold) and a criminal complaint against X and against Sanofi. In the criminal complaint, the court ruled in September 2024 that the action was time-barred. Claimants have appealed. In Ireland, there are two cases in Pre-Action stage and two civil claims ongoing. In the United Kingdom, there is one case in the Pre-Action stage in Great Britain and one civil claim ongoing in Northern Ireland. It is not possible, at this stage, to assess reliably the outcome of these cases. Dengvaxia (Philippines) From early 2018 up to present date, several claims have been filed in the Philippines by parents of deceased children whose deaths were allegedly due to vaccination with Dengvaxia. In early March 2019 and in 2020 and 2022, the Philippine Department of Justice (DOJ) prosecution panel announced it had found probable cause to indict several Sanofi employees/former employees and former Government officials for “reckless imprudence” resulting in homicides. Since then, several criminal actions have been filed in court as a result of this finding and are pending at various stages of the legal procedure. Petitions for Review to the DOJ Secretary have been filed and the said petitions remain pending. Meanwhile, the majority of the respondents have challenged the jurisdiction of the lower court where the first eight cases had been assigned and this issue was filed with the Supreme Court. There are several claims that have not yet been filed in any court despite resolutions by the DOJ that there is probable cause. In July 2024, the Court dismissed the first eight criminal cases, ruling the prosecution failed to establish the elements of “reckless imprudence” resulting in homicide. Remaining cases are still pending at various stages. b) Patents Ramipril Canada Patent Litigation Sanofi was involved in a number of legal proceedings involving companies which market generic Altace (ramipril) in Canada. In 2004, Sanofi unsuccessfully brought Notice of Compliance proceedings (NOC proceedings) at the end of which eight manufacturers obtained marketing authorizations from the Canadian Minister of Health for generic versions of ramipril in Canada. Sanofi filed unsuccessful patent infringement actions against all those companies and ultimately Sanofi was liable for damages under Section 8. Sanofi made payment in complete satisfaction of those awards. In June 2011, Apotex commenced an action in the Ontario Superior Court of Justice asserting damages under the Ontario Statute of Monopolies, the UK Statute of Monopolies, and the Trade-marks Act (the “Ontario Action”). At the request of the parties, in June 2021 the Court ordered that the action be stayed in view of the lower court’s decision in March in the Apotex vs. Lilly case. In the Lilly case, the Court dismissed Apotex’s Statute of Monopolies claim by way of summary judgment. In April 2023, the Canadian Supreme Court denied Apotex’s application for leave to appeal in the Lilly case and based on the Supreme Court decision, Apotex’s claim no longer has any basis. O n February 6, 2025, Apotex formally discontinued the case against Sanofi. Sanofi continues to pursue recovery of appropriate costs. Praluent (alirocumab)-related Amgen Patent Litigation in the US In 2014, Amgen filed four separate complaints against Sanofi and Regeneron in the US District Court for the District of Delaware (“District Court”) asserting patent infringement relating to Sanofi and Regeneron’s Praluent product. Together these complaints alleged that Praluent infringed seven patents for antibodies targeting PCSK9 and sought injunctive relief and unspecified damages. In February 2021, the Federal Circuit affirmed the District Court’s ruling invalidating the Amgen asserted patent claims. In November 2021, Amgen filed a petition with the US Supreme Court, asking it to overturn the Federal Circuit decision. On November 4, 2022, the US Supreme Court granted Amgen’s petition for review. In May 2023, the Supreme Court issued a unanimous decision in favor of Sanofi and Regeneron regarding the patent infringement actions filed in 2014 by Amgen relating to Sanofi and Regeneron’s Praluent product. Sanofi is in the process of seeking certain legal costs from Amgen, which is pending before the District of Delaware Court. Praluent (alirocumab)-related Amgen Patent Litigation in Europe In June 2023, Amgen filed an action for infringement of EP 3 666 797 against Sanofi and Regeneron concerning Praluent in the Munich Local Division of the Unified Patent Court. Amgen seeks a permanent injunction and unspecified damages and compensation from March 1, 2023. In June 2023, Sanofi filed a revocation action attacking the validity of EP 3 666 797 in the Munich Central Division of the Unified Patent Court. In this action, a decision on the Amgen patent’s validity was issued in July 2024, revoking Amgen’s patent, hence supporting Sanofi’s position. Amgen has appealed this decision, and the appeal is underway. Amgen’s action for infringement in the Munich Local Division of the Unified Patent Court is suspended pending this appeal. Sanofi and Regeneron have also attacked the validity of the same EP 3 666 797 patent at the European Patent Office. These proceedings are ongoing and a first instance oral hearing at the Opposition Division of the European Patent Office is scheduled in March-April 2025. Plavix Litigation (Commonwealth) in Australia In August 2007, GenRX (a subsidiary of Apotex) obtained registration of a generic clopidogrel bisulfate product on the Australian Register of Therapeutic Goods. At the same time, GenRX filed a patent invalidation action with the Federal Court of Australia, seeking revocation of Sanofi’s Australian enantiomer patent claiming clopidogrel salts (a “nullity action”). In September 2007, Sanofi obtained a preliminary injunction from the Federal Court preventing commercial launch of this generic clopidogrel bisulfate product until judgment on the substantive issues of patent validity and infringement. In August 2008, the Australian Federal Court confirmed that the claim in Sanofi’s Australian enantiomer patent directed to clopidogrel bisulfate (the salt form in Plavix) was valid and the patent infringed. On appeal, the Full Federal Court of Australia held in September 2009 that all claims in the patent are invalid. Sanofi’s appeal to the Australia High Court was denied in March 2010. On conclusion of the proceedings in 2010, the Sanofi patent was invalidated. In April 2013, the Australian Department of Health and Ageing (“Commonwealth”) filed an application before the Federal Court of Australia seeking payment of damages from Sanofi related to the Apotex preliminary injunction. Sanofi and BMS settled the patent litigation with Apotex in November 2014. In April 2020, the Commonwealth’s claim was dismissed. In May 2020, the Commonwealth filed a Notice of Appeal to the Full Court of the Federal Court. On appeal, the Commonwealth reduced its claim to a range of AUD223.3 million ( €137.8 million ) to AUD280.2 million ( €172.9 million ) which, inclusive of interest to December 31, 2023, ranges from AUD360.5 million ( €218.0 million ) to AUD487.5 million ( €294.3 million ). In June 2023, the Full Court of the Federal Court of Australia unanimously dismissed the Commonwealth’s appeal following its application seeking payment of damages from Sanofi/BMS related to the preliminary injunction. O n July 24, 2023, the Commonwealth filed an application for special leave to appeal to the High Court of Australia, which was granted on December 18, 2023. On December 11, 2024, the High Court of Australia dismissed the appeal from the June 2023 decision of the Full Court of the Federal Court of Australia. The only outstanding issue in this matter is the enforcement of the costs order. c) Other litigation Plavix (clopidogrel) – Attorney General Action in Hawaii In March 2014, the Hawaii Attorney General (AG) filed a complaint that sets forth allegations related to the sale and marketing of and variability of response to Plavix. The Hawaii AG specifically alleged that Plavix had a diminished effect in patients of certain genetic backgrounds and that Sanofi and BMS had failed to make an earlier disclosure of this information. In February 2021, the Court issued its decision, imposing penalties in the total amount of $834 million against both Sanofi and Bristol Myers Squibb (BMS), with $417 million being apportioned to each company. In June 2021, Sanofi and BMS appealed this judgment. The appeal was transferred directly to the Hawaii Supreme Court. In March 2023, the Hawaii Supreme Court vacated the judgment and ordered a new trial. A second trial was concluded in October 2023 and in 2024 a judgment was rendered against the defendants for $916 million ( $458 million against Sanofi) . Sanofi and BMS have appealed this decision to the Hawaii Supreme Court. Plavix (clopidogrel)-related litigation in France In France, in the claim concerning allegations that Sanofi’s communication and promotional practices inhibited the entry on the market of generics of clopidogrel (the active ingredient of Plavix), the French Antitrust Authority issued its decision on May 14, 2013, imposing on Sanofi a fine of €40.6 million . This decision was confirmed by the Supreme Court (Cour de cassation) in 2016. As a consequence of the May 2013 ruling, claims were filed by Sandoz and by Teva in 2014 before the Commercial Court of Paris for compensation of their alleged damages: loss of margin and other ancillary damages. In June and November 2016 respectively, settlement agreements were entered into with Sandoz and Teva. Consequently, they subsequently withdrew their civil claims, jointly and severally. In September 2017, Sanofi and its French affiliate received a summons before the Paris Commercial Court from the French Caisse Nationale d’Assurance Maladie – CNAM (French Social Security) claiming €115.8 million for their alleged damages. On October 1, 2019, the Paris Commercial Court dismissed the CNAM’s action as time barred. On February 9, 2022, the Paris Court of Appeals overturned the Paris Commercial Court's ruling, finding the CNAM’s action as not time-barred and designated an expert to determine the amount of damages. The expert report was issued in March 2024. A judgment is expected in 2025. 340B Drug Pricing Program in the United States Sanofi is currently involved in several matters relating to the 340B program in the US (a federal program that requires drug manufacturers to supply certain products to certain “covered entities” at reduced prices). In 2021, Sanofi filed a lawsuit against the Department of Health and Human Services (HHS), the Health Resources

Provisions for discounts, rebat

Provisions for discounts, rebates and sales returns	12 Months Ended
	Dec. 31, 2024
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Provisions for discounts, rebates and sales returns	Provisions for discounts, rebates and sales returns Adjustments between gross sales and net sales, as described in Note B.13., are recognized either as provisions or as reductions in accounts receivable, depending on their nature. The table below shows movements in these items: (€ million) Government and State programs (a) Managed care and GPO programs (b) Chargeback incentives Rebates and discounts Sales returns Other deductions Total Balance at January 1, 2022 2,596 931 303 1,425 610 34 5,899 Provision related to current period sales 6,744 3,246 4,147 7,244 578 182 22,141 Net change in provision related to prior period sales (120) (47) (21) (138) (8) 19 (315) Payments made (6,824) (3,208) (4,093) (6,809) (599) (166) (21,699) Currency translation differences 207 99 26 83 48 1 464 Balance at December 31, 2022 (c) 2,603 1,021 362 1,805 629 70 6,490 Changes in scope of consolidation 2 — (1) (6) (2) 4 (3) Provision related to current period sales 7,758 3,590 3,861 8,177 654 256 24,296 Net change in provision related to prior period sales (74) (12) (9) (58) (25) 23 (155) Payments made (7,251) (3,446) (3,564) (7,603) (511) (278) (22,653) Currency translation differences (76) (34) (12) (46) (30) (15) (213) Balance at December 31, 2023 (c) 2,962 1,119 637 2,269 715 60 7,762 Provision related to current period sales 5,401 3,961 3,093 9,758 595 482 23,290 Net change in provision related to prior period sales (177) (5) (26) (34) (54) 14 (282) Payments made (5,599) (3,882) (3,336) (9,678) (491) (496) (23,482) Currency translation differences 143 77 36 8 41 (2) 303 Opella reclassification (d) (d) (24) — (6) (201) (30) (3) (264) Balance at December 31, 2024 (c) 2,706 1,270 398 2,122 776 56 7,328 (a) Primarily US government programs: Medicaid ( €1,193 million in 2024 , €1,421 million in 2023 , €1,307 million in 2022 ) and Medicare ( €722 million in 2024 , €1,099 million in 2023 and €775 million in 2022 ). (b) Mainly rebates and other price reductions granted to healthcare authorities in the United States (including Managed Care: €1,097 million in 2024 , €1,028 million in 2023 and € 934 million in 2022 ). (c) Provisions related to US net sales amounted to €4,823 million as of December 31, 2024 , €5,124 million as of December 31, 2023 and €4,270 million as of December 31, 2022 .

Other operating income

Other operating income	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Other operating income	Other operating income Other operating income totaled €1,089 million in 2024 , versus €979 million in 2023 and €1,814 million in 2022 . Other operating income includes (i) gains from asset divestments, amounting to € 539 million in 2024 (versus € 484 million in 2023 and € 481 million in 2022 ); and (ii) income from Sanofi’s pharmaceutical partners, amounting to € 221 million in 2024 (including € 166 million from Regeneron, see Note D.26. below and Note C.1.), compared with € 285 million in 2023 (including € 227 million from Regeneron), and € 1,179 million in 2022 . Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Other operating expenses

Other operating expenses	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Other operating expenses	Other operating expenses Other operating expenses totaled €4,382 million in 2024 , compared with €3,443 million in 2023 and €2,523 million in 2022 . Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. For 2024 , this line item includes €3,955 million of expenses related to Regeneron (see Note C.1.), compared with €3,206 million for 2023 and €2,378 million for 2022 (as shown in the table below): (€ million) 2024 2023 2022 Income & expense related to sharing of (profits)/losses under the Monoclonal Antibody Alliance (4,143) (3,321) (2,325) Additional share of profit paid by Regeneron towards development costs (a) 833 668 434 Reimbursement to Regeneron of selling expenses incurred (637) (543) (476) Total - Monoclonal Antibody Alliance (3,947) (3,196) (2,367) Immuno-Oncology Alliance — — 16 Other (mainly Zaltrap and Libtayo) 158 217 1,120 Other operating income/(expenses), net related to Regeneron (3,789) (2,979) (1,231) of which amount presented in Other operating income (Note D.25.) 166 227 1,147 (a) As of December 31, 2024, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to € 1.6 billion , compared with € 2.1 billion as of December 31, 2023 (see Note D.21.). Charges to provisions for litigation and environmental risks are also recorded within this line item.

Restructuring costs and similar

Restructuring costs and similar items	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Restructuring costs and similar items	Restructuring costs and similar items Restructuring costs and similar items amounted to € 1,396 million in 2024 , € 1,030 million in 2023 and € 1,077 million in 2022 , and were comprised of the following items: (€ million) 2024 2023 (a) 2022 (a) Employee-related expenses 963 404 471 Charges, gains or losses on assets (b) 4 273 261 Costs related to transformation programs 285 330 325 Other 144 23 20 Total 1,396 1,030 1,077 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sano fi . Restructuring costs and similar items were € 366 million higher in 2024 than 2023 . For 2024 , they mainly comprise costs relating to severance plans announced by Sanofi. For 2023 , they included the impact of pension reform in France on future annuities under the rules of each severance plan. Restructuring costs and similar items also include the effects of Sanofi's ongoing transformation projects.

Other gains and losses, and lit

Other gains and losses, and litigation	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Other gains and losses, and litigation	Other gains and losses, and litigation Other gains and losses, and litigation for 2024 represent a charge of € 470 millio n, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii (see Note D.22.) For 2023 , this line item represented a charge of €196 million related to major litigation. For 2022 , this line item represented a charge of €143 million , comprising the pre-tax loss arising on the deconsolidation of EUROAPI (see Note D.1.3.) and costs related to major litigation. Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Financial expenses and income

Financial expenses and income	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Financial expenses and income	Financial expenses and income An analysis of Financial expenses and Financial income is set forth below: (€ million) 2024 2023 (a) 2022 (a) Cost of debt (b) (599) (552) (362) Interest income (c) 413 527 239 Cost of net debt (186) (25) (123) Non-operating foreign exchange gains/(losses) 6 (2) (3) Unwinding of discounting of provisions (d) (44) (51) (17) Net interest cost related to employee benefits (64) (70) (46) Gains/(losses) on disposals of financial assets — (1) 1 Net interest expense on lease liabilities (42) (37) (40) Other (e) (224) (523) 3 Net financial income/(expenses) (554) (709) (225) comprising: Financial expenses (1,073) (1,293) (430) Financial income 519 584 205 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) Includes net gains/(losses) on interest rate and currency derivatives used to manage debt: €(45) million in 2024 , €(67) million in 2023 , €(11) million in 2022 . (c) Includes net gains on interest rate and currency derivatives used to manage cash and cash equivalents: €(25) million in 2024 , €(13) million in 2023 , €68 million in 2022 . (d) Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note D.19.). (e) Includes a financial expense of € 291 million for the remeasurement of the liability recognized in the balance sheet for estimated future royalties on Beyfortus sales in the US. In 2023 , that expense amounted to € 541 million, reflecting the successful launch of Beyfortus (see Note C.2.). T he impact of the ineffective portion of hedging relationships was immaterial in 2024 , 2023 and 2022 .

Income tax expense

Income tax expense	12 Months Ended
	Dec. 31, 2024
Income Taxes [Abstract]
Income tax expense	D.30. Income tax expense Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States. The table below shows the allocation of income tax expense between current and deferred taxes: (€ million) 2024 2023 (a) 2022 (a) Current taxes (2,152) (2,251) (2,631) Deferred taxes 948 1,234 722 Total (1,204) (1,017) (1,909) Income before tax and investments accounted for using the equity method 6,698 6,251 9,937 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. The difference between the effective tax rate and the standard corporate income tax rate applicable in France is explained as follows: (%) 2024 2023 (a) 2022 (a) Standard tax rate applicable in France 25.8 25.8 25.8 Difference between the standard French tax rate and the rates applicable to Sanofi (b) (13.3) (15.3) (6.9) Revisions to tax exposures and settlements of tax disputes 2.8 3.1 (0.8) Fair value remeasurement of contingent consideration 0.1 (0.2) Other items (c) 2.7 2.6 1.3 Effective tax rate 18.0 16.3 19.2 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France. For the year ended December 31, 2024, this line includes a tax expense of €58 million , representing the estimated impact of Pillar Two based on Sanofi’s current understanding of Pillar Two rules. (c) In determining the amount of the deferred tax liability for 2024 , 2023 and 2022 , Sanofi took into account changes in the ownership structure of certain subsidiaries . For the periods presented, the amount of deferred tax assets recognized in profit or loss that were initially subject to impairment losses at the time of a business combination is immaterial.

Share of profit_loss from inves

Share of profit/loss from investments accounted for using the equity method	12 Months Ended
	Dec. 31, 2024
Interests In Other Entities [Abstract]
Share of profit/loss from investments accounted for using the equity method	D.31. Share of profit/loss from investments accounted for using the equity method The line item Share of profit/(loss) from investments accounted for using the equity method showed net income of € 60 million in 2024 (after charging an impairment loss of € 77 million on the equity-accounted investment in EUROAPI – see Note D.6.), compared with a net loss of € 136 million for 2023 and a net gain of € 55 million for 2022. Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Net income attributable to non-

Net income attributable to non-controlling interests	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Net income attributable to non-controlling interests	D.32. Net income attributable to non-controlling interests The table below shows Net income attributable to non-controlling interests for the reporting periods presented: (€ million) 2024 2023 2022 Share of net income attributable to non-controlling interests 58 36 113 Total 58 36 113

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2024
Related Party [Abstract]
Related party transactions	D.33. Related party transactions The principal related parties are companies over which Sanofi has control or significant influence, joint ventures, key management personnel, and principal shareholders. Sanofi has not entered into any material transactions with any key management personnel. Financial relations with Sanofi’s principal shareholders fall within the ordinary course of business and were immaterial in the years ended December 31, 2024 , 2023 and 2022 . Note F.1. lists the principal companies controlled by Sanofi; those companies are fully consolidated, as described in Note B.1. Transactions between those companies, and between the parent company and its subsidiaries, are eliminated when preparing the consolidated financial statements. Transactions with companies over which Sanofi has significant influence, and with joint ventures, are presented in Note D.6. Key management personnel include corporate officers and the members of the Executive Committee (an average of 13 m embers in 2024 , 10 in 2023 and 11 in 2022 ). The table below shows, by type, the compensation paid to key management personnel: (€ million) 2024 2023 2022 Short-term benefits (a) 37 36 31 Post-employment benefits 2 2 2 Share-based payment 21 8 19 Total recognized in profit or loss 60 46 52 (a) Compensation, employer’s social security contributions, directors’ compensation, and any termination benefits (net of reversals of termination benefit obligations). The table below shows the aggregate obligation as of December 31 for each period presented for individuals who hold or have held executive positions within Sanofi during that period. (€ million) 2024 2023 2022 Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members 9 10 10 Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel 7 6 5

Disclosures about major custome

Disclosures about major customers and credit risk	12 Months Ended
	Dec. 31, 2024
Disclosure of disaggregation of revenue from contracts with customers [abstract]
Disclosure of revenue [text block]	D.34. Revenue from contracts with customers D.34.1. Analysis of net sales The table below sets forth Sanofi’s net sales for the years ended December 31, 2024 , 2023 and 2022 : (€ million) Europe United States Other countries 2024 Europe United States Other countries 2023 (a) Europe United States Other countries 2022 (a) Total Group 9,027 19,986 12,068 41,081 8,816 17,262 11,739 37,817 8,490 16,986 12,175 37,651 Immunology of which Dupixent 1,618 9,544 1,910 13,072 1,224 8,145 1,346 10,715 940 6,346 1,006 8,292 Rare diseases of which ALTUVIIIO — 617 65 682 — 155 4 159 — — — — Nexviazyme 201 361 105 667 100 272 53 425 17 158 21 196 Cablivi 93 136 20 249 98 112 17 227 94 110 7 211 Xenpozyme 46 81 24 151 31 52 8 91 15 5 1 21 Enjaymo 17 58 30 105 6 42 24 72 — 17 5 22 Neurology of which Aubagio 152 187 40 379 437 460 58 955 511 1,420 98 2,029 Oncology of which Sarclisa 134 200 137 471 111 165 105 381 88 127 79 294 Other medicines of which Rezurock 28 425 17 470 5 303 2 310 1 206 — 207 Tzield 1 52 1 54 — 25 — 25 — — — — Industrial sales 520 1 2 523 528 4 19 551 580 17 11 608 Vaccines of which Influenza Vaccines 640 1,433 482 2,555 694 1,406 569 2,669 681 1,737 559 2,977 Polio/Pertussis/ Hib Vaccines 497 679 1,565 2,741 477 721 1,568 2,766 479 787 1,594 2,860 RSV vaccines (Beyfortus) 440 1,068 178 1,686 140 407 — 547 — — — — Meningitis, travel and endemics vaccines 204 736 376 1,316 157 730 379 1,266 112 767 430 1,309 Of which total launches 960 2,998 577 4,535 491 1,533 213 2,237 215 623 113 951 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation . D.34.2. Other revenues (€ million) 2024 2023 (a) 2022 (a) VaxServe sales of non-Sanofi products 1,959 2,167 1,567 COVID-19 vaccine related revenues — 509 257 Intragroup sales from continuing to discontinued operations (b) 163 188 208 Royalties 121 107 103 Other (c) 623 534 399 Total Biopharma Other revenues 2,866 3,505 2,534 Sales / Revenues from Opella products (d) 339 296 376 Total Other revenues 3,205 3,801 2,910 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) Revenues generated by legal entities within the scope of continuing operations from the manufacture of Opella products on behalf of legal entities within the scope of discontinued operations. (c) This line mainly includes revenues received under agreements for Sanofi to provide manufacturing services to third parties. (d) Consumer Healthcare activities that will not be transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements ; (ii) sales made by the dedicated entity Opella Russie, the equity interests in which will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term ; and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).
Disclosure of disaggregation of revenue from contracts with customers [text block]	The table below sets forth Sanofi’s net sales for the years ended December 31, 2024 , 2023 and 2022 : (€ million) Europe United States Other countries 2024 Europe United States Other countries 2023 (a) Europe United States Other countries 2022 (a) Total Group 9,027 19,986 12,068 41,081 8,816 17,262 11,739 37,817 8,490 16,986 12,175 37,651 Immunology of which Dupixent 1,618 9,544 1,910 13,072 1,224 8,145 1,346 10,715 940 6,346 1,006 8,292 Rare diseases of which ALTUVIIIO — 617 65 682 — 155 4 159 — — — — Nexviazyme 201 361 105 667 100 272 53 425 17 158 21 196 Cablivi 93 136 20 249 98 112 17 227 94 110 7 211 Xenpozyme 46 81 24 151 31 52 8 91 15 5 1 21 Enjaymo 17 58 30 105 6 42 24 72 — 17 5 22 Neurology of which Aubagio 152 187 40 379 437 460 58 955 511 1,420 98 2,029 Oncology of which Sarclisa 134 200 137 471 111 165 105 381 88 127 79 294 Other medicines of which Rezurock 28 425 17 470 5 303 2 310 1 206 — 207 Tzield 1 52 1 54 — 25 — 25 — — — — Industrial sales 520 1 2 523 528 4 19 551 580 17 11 608 Vaccines of which Influenza Vaccines 640 1,433 482 2,555 694 1,406 569 2,669 681 1,737 559 2,977 Polio/Pertussis/ Hib Vaccines 497 679 1,565 2,741 477 721 1,568 2,766 479 787 1,594 2,860 RSV vaccines (Beyfortus) 440 1,068 178 1,686 140 407 — 547 — — — — Meningitis, travel and endemics vaccines 204 736 376 1,316 157 730 379 1,266 112 767 430 1,309 Of which total launches 960 2,998 577 4,535 491 1,533 213 2,237 215 623 113 951 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation

Segment information

Segment information	12 Months Ended
	Dec. 31, 2024
Operating Segments [Abstract]
Segment information	D.35. Segment information Sanofi reports segment information for the Biopharma operating segment, further to the opening of exclusive negotiations between Sanofi and Clayton, Dubilier & Rice (CD&R) on October 21, 2024 with a view to selling an equity interest in Opella, which would lead to loss of control over Opella on the effective closing date, scheduled for the second quarter of 2025 at the earliest. Prior to the opening of those exclusive negotiations, Opella (formerly Consumer Healthcare) was an operating segment of Sanofi. As a result of the announcement of the Proposed Opella Transaction ( as defined in Note D.1.1.2. Project to divest a controlling interest in Opella) , as of the fourth quarter of 2024 Opella meets the criteria for a discontinued operation under IFRS 5 ( see Note B.7 .), and the net income from this business is now presented separately within the line item Net income from discontinued operations in the consolidated income statement. This presentation in a separate line item in the income statement applies to results of operations for the current period, and for the comparative periods presented. With effect from that date, Sanofi became a dedicated Biopharma company of which the performance, based on internal management reporting, is subject to regular review by the Chief Executive Officer, Sanofi's chief operating decision-maker. The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises plus support and corporate functions, for all geographical territories. It also includes revenues generated by legal entities within the Biopharma segment (and included in the scope of continuing operations) from the manufacture of Consumer Healthcare products on behalf of legal entities within Opella; those revenues are presented within Other Revenues in the income statement. The Biopharma operating segment also includes the the purchase price of Biopharma products manufactured by legal entities within the Opella scope. The “Other” category comprises primarily, but not exclusively, Consumer Healthcare activities that will not be transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements ; (ii) sales made by the dedicated entity Opella Russie, the equity interests in which will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term ; and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights). Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. D.35.1. Segment results Sanofi reports segment results on the basis of “Business operating income”. This indicator is used internally by Sanofi’s chief operating decision maker to measure the performance of the operating segment and to allocate resources. “Business operating income” is derived from Operating income , adjusted as follows: • amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature), are eliminated; • fair value remeasurements of contingent consideration relating to business combinations (IFRS 3) or business divestments, and presented within the line item Fair value remeasurement of contingent consideration , are eliminated; • expenses arising from the remeasurement of inventories following business combinations (IFRS 3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph 2b of IFRS 3, are eliminated; • amounts reported within the line items Restructuring costs and similar items are eliminated; • other gains and losses including gains and losses on major divestments, presented within the line item Other gains and losses, and litigation , are eliminated; • other costs and provisions related to litigation, presented within the line item Other gains and losses, and litigation , are eliminated; • the share of profits/losses from investments accounted for using the equity method is added, to the extent that this relates to joint ventures and associates with which Sanofi has a strategic alliance; and • the portion of business operating income net of tax attributable to non-controlling interests is deducted; and • net income attributable to non-controlling interests related to continuing operations and excluding the effects of the above reconciliation items, is deducted. The table below shows Sanofi’s segment results for the years ended December 31, 2024 , December 31, 2023 and December 31, 2022 : 2024 (€ million) Biopharma Other Total 2024 Change vs. 2023 on a reported basis (IFRS) Change vs. 2023 at constant exchange rates (non- IFRS) 2024 Change vs. 2023 on a reported basis (IFRS) Change vs. 2023 at constant exchange rates (non- IFRS) 2024 Change vs. 2023 on a reported basis (IFRS) Change vs. 2023 at constant exchange rates (non- IFRS) Net sales 41,081 8.6% 11.3% — 41,081 8.6% 11.3% Other revenues 2,866 (18.2%) (16.3%) 339 14.5% 23.3% 3,205 (15.7%) (13.3%) Cost of sales (12,973) 4.5% 5.7% (222) 8.8% 20.1% (13,195) 4.6% 6.0% Research and development expenses (7,393) 13.7% 14.6% (1) (50.0%) (50.0%) (7,394) 13.6% 14.6% Selling and general expenses (9,113) 2.9% 4.6% (70) (11.4%) (3.8%) (9,183) 2.8% 4.5% Other operating income and expenses (3,305) 12 (3,293) Share of profit/(loss) from investments accounted for using the equity method 136 — 136 Net income attributable to non-controlling interests (14) — (14) Business operating income 11,285 1.2% 7.3% 58 152.2% 160.9% 11,343 1.5% 7.6% As % of net sales 27.5% 27.6% 2023 (a) (€ million) Biopharma Other Total Net sales 37,817 — 37,817 Other revenues 3,505 296 3,801 Cost of sales (12,415) (204) (12,619) Research and development expenses (6,505) (2) (6,507) Selling and general expenses (8,854) (79) (8,933) Other operating income and expenses (2,476) 12 (2,464) Share of profit/(loss) from investments accounted for using the equity method 101 — 101 Net income attributable to non-controlling interests (18) — (18) Business operating income 11,155 23 11,178 (a) Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. 2022 (a)(b) (€ million) Biopharma Other Total Net sales 37,651 — 37,651 Other revenues 2,534 376 2,910 Cost of sales (11,682) (197) (11,879) Research and development expenses (6,499) (2) (6,501) Selling and general expenses (8,536) (203) (8,739) Other operating income and expenses (764) 55 (709) Share of profit/(loss) from investments accounted for using the equity method 76 — 76 Net income attributable to non-controlling interests (16) — (16) Business operating income 12,764 29 12,793 (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax). The table below, presented in compliance with IFRS 8, shows a reconciliation between aggregated “Business operating income” for the segment and Income before tax and investments accounted for using the equity method : (€ million) 2024 2023 (a) 2022 (a)(h) Business operating income 11,343 11,178 12,793 Share of profit/(loss) from investments accounted for using the equity method (b) (136) (101) (76) Net income attributable to non-controlling interests (c) 14 18 16 Amortization and impairment of intangible assets (d) (1,997) (2,807) (1,375) Fair value remeasurement of contingent consideration (96) (93) 27 Expenses arising from the impact of acquisitions on inventories (e) (10) (9) (3) Restructuring costs and similar items (f) (1,396) (1,030) (1,077) Other gains and losses, and litigation (g) (470) (196) (143) Operating income 7,252 6,960 10,162 Financial expenses (1,073) (1,293) (430) Financial income 519 584 205 Income before tax and investments accounted for using the equity method 6,698 6,251 9,937 ( a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) Joint ventures and associates with which Sanofi has entered into a strategic alliance. (c) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (d) For 2024, this line includes a net impairment charge of € 248 million mainly due to a recognition of impairment losses of € 640 million against on various research and development projects – including a €239 million loss resulting from the decision taken in February 2025 to discontinue a phase 3 clinical study investigating of a vaccine candidate to prevent invasive E.coli disease - partially offset by impairment losses reversals , recognized in connection with the disposals of the ProXTen platform and Enjaymo, for € 225 million and € 167 million respectively. For 2023, this amount mainly comprises an impairment loss of €833 million , reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and ProXTen technology platforms. For 2022, this line includes a reversal of €2,154 million on Eloctate franchise products following FDA approval of ALTUVIIIO on February 22, 2023, partially offset by an impairment loss of €1,586 million on intangible assets relating to SAR444245 (non- alpha interleukin-2). (e) This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date. (f) See note D.27 . (g) See note D.28. (h) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax) . D.35.2. Other segment information Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. The tables below show the split by operating segment of (i) the carrying amount of investments accounted for using the equity method with which Sanofi has entered into a strategic alliance, (ii) acquisitions of property, plant and equipment, and (iii) acquisitions of intangible assets. The principal investments accounted for using the equity method in the Biopharma segment are the interests in MSP Vaccine Company, and Infraserv GmbH & Co. Höchst KG (see Note D.6.). Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period. Biopharma (€ million) 2024 2023 2022 Investments accounted for using the equity method (a) 234 234 248 Acquisitions of property, plant and equipment 1,733 1,619 1,529 Acquisitions of other intangible assets 1,462 1,287 574 (a) Carrying amount at the end of the reporting period. D.35.3. Information by geographical region The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with IFRS 8, the non-current assets reported below exclude right-of-use assets relating to leases as determined under IFRS 16, investments accounted for using the equity method, other non-current assets, non-current income tax assets, and deferred tax assets. 2024 (€ million) Total Europe of which France United States Other countries Net sales 41,081 9,027 1,814 19,986 12,068 Non-current assets: • property, plant and equipment owned 10,091 5,550 3,112 2,411 2,130 • goodwill 43,384 — — — — ▪ other intangible assets 22,629 3,307 — 18,711 611 (€ million) 2023 Total Europe of which France United States Other countries Net sales (a) 37,817 8,816 1,910 17,262 11,739 Non-current assets: • property, plant and equipment owned 10,160 5,659 3,085 2,322 2,179 • goodwill 49,404 — — — — • other intangible assets 24,319 5,566 — 17,850 903 (a) Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (€ million) 2022 Total Europe of which France United States Other countries Net sales (a) 37,651 8,490 1,830 16,986 12,175 Non-current assets: • property, plant and equipment owned 9,869 5,365 2,875 2,457 2,047 • goodwill 49,892 — — — — • other intangible assets 21,640 6,257 — 14,174 1,209 (a) Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. As stated in Note D.5., goodwill is not allocated by geographical region. D.35.4. Disclosures about major customers Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented 34% of net sales in 2024 . The three largest customers respectively accounted for approximately 15% , 11% and 8% of Sanofi's net sales in 2024 ( 13% , 10% and 8% in 2023 ; 13% , 9% and 8% in 2022 ).

Non-current asset held for sale

Non-current asset held for sale and discontinued operations	12 Months Ended
	Dec. 31, 2024
DisclosureOfDiscontinuedOperationsAbstract [Abstract]
Disclosure of non-current assets held for sale and discontinued operations [text block]	D.36. Information related to Opella In accordance with IFRS 5 (see Notes B.7. and D.1.), all assets of Opella and all liabilities directly related to those assets are classified as of December 31, 2024 within the line items Assets held for sale and Liabilities related to assets held for sale , respectively, in the consolidated balance sheet as of that date (see Note D.8.). An analysis of those line items is provided below: (€ million) 2024 Assets Property, plant and equipment owned 760 Right-of-use assets 116 Goodwill 7,255 Other intangible assets 2,928 Inventories 600 Accounts receivable 989 Other assets 841 Total assets held for sale 13,489 Liabilities Llease liabilities 112 Non-current provisions and other non-current liabilities 204 Accounts payable 797 Current provisions and other current liabilities 570 Other liabilities 448 Total liabilities related to assets held for sale 2,131 In accordance with IFRS 5, the Opella held for sale asset group, and the related liabilities, have been measured at the lower of carrying amount and fair value less costs to sell. This valuation did not result in the recognition of any impairment. The table below details the main items presented within Net income from discontinued operations : (€ million) 2024 2023 2022 Net sales 5,031 4,884 4,781 Operating income 305 915 494 Income before tax and investments accounted for using the equity method 288 902 485 Income tax expense (240) (585) (97) Net income from discontinued operations (Opella) 64 338 401 Net income from the Opella discontinued operation was €274 million lower in 2024 than in 2023. This year-on-year change reflects in particular the acceleration in 2024 of the transformational project to create the standalone Opella entity - transaction costs incurred in 2024 in respect of the proposed Opella transfer - and changes in gains from asset divestments within the Opella scope between the two periods. In addition, net income from the Opella discontinued operation for the year ended December 31, 2024 includes a net tax expense of €122 million relating to the tax cost of the legal restructuring of the Opella scope. For the year ended December 31, 2023, net income from the Opella discontinued operation includes a €365 million deferred tax liability recognized in respect of investments in consolidated entities in light of the proposed separation of the Opella business. The table below presents basic and diluted earnings per share from discontinued operations (Opella, in accordance with IAS 33 (Earnings per Share): (€ million) 2024 2023 2022 Net income from discontinued operations (Opella) 64 338 401 Average number of shares outstanding (million) 1,251.4 1,251.7 1,251.9 Average number of shares after dilution (million) 1,256.1 1,256.4 1,256.9 Basic earnings per share (in euros) 0.04 0.25 0.31 Diluted earnings per share (in euros) 0.04 0.25 0.31 Off balance sheet commitments relating to Opella operating activities break down as follows: December 31, 2024 Payments due by period (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Irrevocable purchase commitments 704 159 225 204 116 • given 705 160 225 204 116 • received (1) (1) Research and development license agreements - commitments given 676 6 560 77 33 Total 1,380 165 785 281 149

Principal accountants' fees and

Principal accountants' fees and services	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Principal accountants' fees and services	E/ Principal accountants’ fees and services PricewaterhouseCoopers Audit and Forvis Mazars SA served as independent auditors of Sanofi for the year ended December 31, 2024 , and PricewaterhouseCoopers Audit and Ernst & Young in 2023. The table below shows fees charged by those firms and member firms of their networks to Sanofi and consolidated subsidiaries in the years ended December 31, 2024 and 2023 . Forvis Mazars PricewaterhouseCoopers Ernst & Young 2024 2024 2023 2023 (€ million) Amount % Amount % Amount % Amount % Statutory audit of separate and consolidated financial statements (a) 11.5 93% 19.7 73% 14.7 72% 15.1 74% Limited review of sustainability statement (b) 0.6 5% 1.0 4% — —% — —% Services other than statutory audit (c) 0.2 2% 6.4 23% 5.8 28% 5.4 26% Audit-related services (d)(e) 0.2 6.4 5.8 5.3 Tax 0.0 0.0 — — Other — — — 0.1 Total 12.3 100% 27.1 100% 20.5 100% 20.5 100% (a) Includes services provided by the independent auditors of the parent company and French subsidiaries: Forvis Mazars €4.8 million in 2024 ; PricewaterhouseCoopers Audit €12.5 million in 2024 , €8.3 million in 2023 and Ernst & Young €7.9 million in 2023 . (b) For SEC purposes, these Services are classified as Other. (c) Services other than statutory audit provided by Forvis Mazars during 2024 comprised: - assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy. Services other than statutory audit provided by PricewaterhouseCoopers during 2024 comprised: - contractual audits, including on the combined financial statements of the Opella business; - additional procedures to enable reports previously signed by the firm to be incorporated by reference; and - assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy. (d) Includes services provided by the independent auditors of the parent company and French subsidiaries: Forvis Mazars: €0.1 million in 2024 ,; PricewaterhouseCoopers Audit €3.5 million in 2024 , €3.6 million in 2023 and Ernst & Young €5.2 million in 2023 . (e) Includes €0.5 million for services that can only be provided by the statutory auditors, such as comfort letters, attestation services required by regulation (which qualify as audit fees under SEC rules).

List of principal companies inc

List of principal companies included in the scope of consolidation during 2023	12 Months Ended
	Dec. 31, 2024
Interests In Other Entities [Abstract]
List of principal companies included in the scope of consolidation during 2023	F/ List of principal companies included in the scope of consolidation during 2024 F.1. Principal fully consolidated companies The table below shows Sanofi’s principal subsidiaries and their country of incorporation : Europe Financial interest (%) as of December 31, 2024 Hoechst GmbH * Germany 100.0 Sanofi-Aventis Deutschland GmbH Germany 100.0 A. Nattermann & Cie GmbH Germany 100.0 Sanofi-Aventis GmbH Austria 100.0 Sanofi Belgium Belgium 100.0 Ablynx NV Belgium 100.0 Genzyme Flanders BV Belgium 100.0 Sanofi A/S Denmark 100.0 Sanofi-Aventis SA Spain 100.0 Opella Healthcare Spain, SL Spain 100.0 Sanofi Oy Finland 100.0 Sanofi France 100.0 Sanofi Winthrop Industrie * France 100.0 Sanofi-Aventis Recherche & Développement France 100.0 Sanofi-Aventis Groupe France 100.0 Sanofi-Aventis Participations * France 100.0 Sanofi Pasteur France 100.0 Aventis Pharma SA France 100.0 Aventis Agriculture France 100.0 Sanofi Biotechnology * France 100.0 Sanofi Pasteur NVL France 100.0 Sanofi Pasteur Europe France 100.0 Opella Healthcare France 100.0 Sanofi Pasteur Merieux SAS France 100.0 Opella Healthcare International SAS France 100.0 Opella Healthcare France SAS France 100.0 Opella Healthcare Group SAS France 100.0 Genzyme Polyclonals SAS France 100.0 Sanofi-Aventis AEBE Greece 100.0 Sanofi-Aventis Private Co Ltd Hungary 99.6 Chinoin Private Co Ltd Hungary 99.6 Opella Healthcare Hungary Commercial KFT Hungary 100.0 Opella Healthcare Hungary KFT Hungary 100.0 Carraig Insurance DAC Ireland 100.0 Genzyme Ireland Limited Ireland 100.0 Sanofi-Aventis Ireland Ltd Ireland 100.0 Sanofi-aventis Holdings (Ireland) Ltd Ireland 100.0 Sanofi SRL Italy 100.0 Opella Healthcare Italy SRL Italy 100.0 Genzyme Global Sarl Luxembourg 100.0 Genzyme Luxembourg Sarl Luxembourg 100.0 Le Rock Re Luxembourg 100.0 Sanofi-aventis Norge AS Norway 100.0 Sanofi BV * Netherlands 100.0 Sanofi Foreign Participations BV * Netherlands 100.0 Europe Financial interest (%) as of December 31, 2024 Opella Healthcare Participation BV Netherlands 100.0 Sanofi-Aventis Sp zoo Poland 100.0 Opella Healthcare Poland sp.ZOO Poland 100.0 Sanofi Produtos Farmaceuticos Lda Portugal 100.0 Sanofi sro Czech Republic 100.0 Sanofi Romania SRL Romania 100.0 Opella Healthcare Romania SRL Romania 100.0 Sanofi-Aventis UK Holdings Limited United Kingdom 100.0 Aventis Pharma Limited United Kingdom 100.0 Sanofi-Synthelabo UK Ltd United Kingdom 100.0 Aventis Pharma Holdings Ltd United Kingdom 100.0 Opella Healthcare UK Limited United Kingdom 100.0 AO Sanofi Russia Russia 100.0 Opella Healthcare LLC Russia 100.0 Sanofi AB Sweden 100.0 Sanofi-Aventis (Suisse) SA Switzerland 100.0 Genzyme Global Sarl Baar Intellectual Property Branch Switzerland 100.0 Sanofi Ilac Sanayi ve Ticaret AS Turkey 100.0 Sanofi Pasteur Asi Ticaret AS Turkey 100.0 Opella Healthcare Tüketici Sağlığı Anonim Şirketi Turkey 100.0 Sanofi Saglik Urunleri Limited Sirketi Turkey 100.0 United States Financial interest (%) as of December 31, 2024 Genzyme Therapeutic Products Limited Partnership United States 100.0 Aventis Inc * United States 100.0 Sanofi US Services Inc United States 100.0 Sanofi-Aventis U.S. LLC United States 100.0 Chattem, Inc United States 100.0 Aventisub LLC United States 100.0 Genzyme Corporation * United States 100.0 Sanofi Pasteur Inc * United States 100.0 VaxServe, Inc United States 100.0 Bioverativ Inc United States 100.0 Bioverativ U.S.LLC United States 100.0 Bioverativ USA Inc United States 100.0 Bioverativ Therapeutics Inc United States 100.0 Principia Biopharma Inc United States 100.0 Sanofi Ventures LLC United States 100.0 Sanofi Bioverativ Holdings LLC United States 100.0 RPR US Ltd United States 100.0 Kadmon Pharmaceuticals LLC United States 100.0 Kadmon Corporation, LLC United States 100.0 Synthorx, Inc United States 100.0 Provention Bio United States 100.0 QRIB Intermediate Holding United States 100.0 QRI United States 100.0 Gold Bond Co LLC United States 100.0 Chattem (GB) Holding United States 100.0 Sanofi AATD, Inc United States 100.0 Translate Bio, Inc United States 100.0 Other Countries Financial interest (%) as of December 31, 2024 Sanofi-Aventis South Africa (Pty) Ltd South Africa 100.0 Sanofi-Aventis Algérie Algeria 100.0 Sanofi Arabia Trading Company Limited Saudi Arabia 100.0 Sanofi-Aventis Argentina SA Argentina 100.0 Opella Healthcare Argentina SAU Argentina 100.0 Genzyme de Argentina SA Argentina 100.0 Sanofi-Aventis Healthcare Pty Ltd Australia 100.0 Sanofi-Aventis Australia Pty Ltd Australia 100.0 Sanofi Medley Farmaceutica Ltda Brazil 100.0 Opella Healthcare Brazil Ltda Brazil 100.0 Sanofi-Aventis Canada Inc Canada 100.0 Sanofi Pasteur Limited Canada 100.0 Merieux Canada Holdings ULC (Canada) Canada 100.0 Sanofi Vaccines Chile SA Chile 100.0 Sanofi (Hangzhou) Pharmaceuticals Co Ltd China 100.0 Opella Healthcare Shanghai LTD China 100.0 Sanofi (China) Investment Co Ltd China 100.0 Sanofi (Beijing) Pharmaceuticals Co Ltd China 100.0 Sanofi (Jiangsu) Biologics Co Ltd China 100.0 Shenzhen Sanofi pasteur Biological Products Co Ltd China 100.0 Shanghai Rongheng Pharmaceutical Co Ltd China 100.0 Opella Healthcare Colombia SAS Colombia 100.0 Sanofi-Aventis de Colombia SA Colombia 100.0 Sanofi-Aventis Korea Co Ltd South Korea 100.0 Sanofi-Aventis Gulf FZE United Arab Emirates 100.0 Sanofi Egypt Egypt 99.8 Sanofi Hong-Kong Limited Hong Kong 100.0 Sanofi India Limited India 60.4 Sanofi Healthcare India Private Limited India 99.9 Sanofi-Aventis Israël Ltd Israel 100.0 Sanofi KK Japan 100.0 SSP Co Ltd Japan 100.0 Sanofi-Aventis (Malaysia) SDN BHD Malaysia 100.0 Sanofi-Aventis Maroc Morocco 100.0 Sanofi-Aventis de Mexico SA de CV Mexico 100.0 Sanofi Pasteur SA de CV Mexico 100.0 Azteca Vacunas SA de CV Mexico 100.0 Sanofi-Aventis de Panama SA Panama 100.0 Opella Healthcare Panama SA Panama 100.0 sanofi-aventis Puerto Rico Inc Puerto Rico 100.0 Sanofi-Aventis Philippines Inc Philippines 100.0 Opella Healthcare Philippines Inc Philippines 100.0 Sanofi-Aventis Singapore Pte Ltd * Singapore 100.0 Aventis Pharma (Manufacturing) Pte Ltd Singapore 100.0 Sanofi Manufacturing Pte Ltd Singapore 100.0 Sanofi Taiwan Co Ltd Taiwan 100.0 Sanofi-Aventis (Thailand) Ltd Thailand 100.0 Sanofi-Aventis de Venezuela SA Venezuela 100.0 Sanofi-aventis Vietnam Company Limited Vietnam 100.0 Sanofi Vietnam Shareholding Company Limited Vietnam 85.0 * Main significant subsidiaries as of December 31, 2024 . F.2. Principal investments accounted for using the equity method Financial interest (%) as of December 31, 2024 Haleon US, LP United States 11.7 Infraserv GmbH & Co. Höchst KG Germany 31.2 Maphar Morocco 48.3 MCM Vaccine BV Netherlands 50.0 MSP Vaccine Company (formerly MCM company) United States 50.0 EUROAPI France 29.6

Events subsequent to December 3

Events subsequent to December 31, 2023	12 Months Ended
	Dec. 31, 2024
Disclosure of non-adjusting events after reporting period [abstract]
Events subsequent to December 31, 2023	G/ Event subsequent to December 31, 2024 During the meeting of the Board of Directors on January 29, 2025, the Board authorized Sanofi to repurchase the Company's shares, for an amount not exceeding €5 billion , under the terms and conditions set by the General Meeting of April 30, 2024 in its 19th resolution. As part of this authorization, Sanofi entered into a share buyback agreement with its historical shareholder L'Oréal on February 2, 2025 for the acquisition of 2.34% of its share capital, or the equivalent of 29,556,650 shares , for a total amount of approximately €3 billion , representing a price of € 101.50 per share. The conclusion of this agreement was approved by the Board of Directors on the same day prior to the signing of said agreement and in accordance with the procedure of Articles L. 225-38 et seq. of the French Commercial Code. In addition, on February 6, 2025, Sanofi entered into a mandate with an investment services provider to repurchase its own shares for a maximum amount of €2 billion , between February 7, 2025 and December 31, 2025 at the latest.

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management and Strategy Disclosure Abstract [Abstract]
Cybersecurity Risk Management Processes For Assessing Identifying And Managing Threats	Risk Management and Strategy Sanofi has implemented a cybersecurity strategy i nvolving various dedicated personnel and resources aimed at preventing, detecting and responding to cyberattacks, as well as being able to recover promptly in the event of material impact following a cyberattack. Additionally, Sanofi has set up various cybersecurity proces ses applicable to subsidiaries within the Sanofi group. Sanofi regularly updates its cybersecurity processes to address cybersecurity trends and threats. Cybersecurity processes have been established to address material cybersecurity risks, including in connection with the following areas: • information technology and solution usage; • access control; • patch management; • security on specific environments (i.e. cloud, virtualization, SAP, automated systems, IoT, etc.); • log management; • network security; • systems security standards; • remote access; • secure development of applications; • cryptography; • mobile devices; • third-party management (including cybersecurity requirements in contracts); and • incident management. Sanofi utilizes security standards and frameworks (i.e. the NIST framework) and has established cross-functional risk control capabilities to facilitate operational implementation aligned with its cybersecurity processes. S anofi regularly analyzes its Internet-based services and performs regular penetration tests and attack simulations to assess the protections and the detections capabilities. The cybersecurity compliance status of computing assets connected to Sanofi’s network is routinely consolidated for Sanofi's business units, including within manufacturing, and research and development sites. Monthly dashboards are published and shared within Sanofi’s different business units and global functions. Sanofi implements corrective measures and improvement actions in response to these processes. Data classification and protection tools are in place, such as the implementation of a specific process and technology aimed at detecting and responding to abnormal data flows. Sanofi has set up a cybersecurity operation center in charge of detecting and responding to cybersecurity threats and attacks, as well as coordinating Sanofi-wide incident responses. Incident response trainings and simulations are run within Sanofi to seek to be better prepared in case of a cybersecurity incident. In addition, Sanofi’s employees, who are the main users of Sanofi’s digital assets, are regularly trained to face cybersecurity threats and attacks. In the event of a cyberattack, Sanofi has established a plan that includes criteria triggering the notification process for material cybersecurity incidents including from the cybersecurity operation center and the Chief Information Security Officer who can use the internal escalation channels to inform the management and the Board of Directors and, as appropriate, the relevant regulatory bodies. When dealing with third parties , our main commercial contracts include cybersecurity clauses aimed at ensuring such third parties comply with Sanofi’s cybersecurity rules and requirements, especially when providing services to and processing data from Sanofi. Additionally, Sanofi set up a vendor’s risk assessment program to evaluate the digital maturity of a vendor, which covers their business continuity as well as their related internal regulations, such as data privacy. As part of their contractual commitments major vendors and partners must report to Sanofi any cybersecurity incident that may have a significant impact for Sanofi. A dedicated process has been implemented for third parties’ networks interconnected with Sanofi’s network, aimed at limiting any propagation of a cyberattack to Sanofi’s digital assets. Sanofi’s cybersecurity risk management processes are integrated into its overall risk management system through its enterprise risk management process, which seeks to identify and address material risks to the organization. Each year, specific risk committees identify the risks that affect Sanofi’s local businesses in each country it operates and Sanofi’s global functions, such as Research and Development or Manufacturing and Supply. Although Sanofi has put in place the cybersecurity processes described above, Sanofi remains exposed to cybersecurity attacks and incidents and misuse or manipulation of any of its IT systems, which could have a material adverse effect on its business strategy, results of operations or financial condition (see “Item 3. Key Information — D. Risk Factors — Risks relating to our business — Breaches of data security, disruptions of information technology systems and cyber threats could result in financial, legal, competitive, operational, business or reputational harm ”).
Cybersecurity Risk Management Processes Integrated	Sanofi has set up a cybersecurity operation center in charge of detecting and responding to cybersecurity threats and attacks, as well as coordinating Sanofi-wide incident responses. Incident response trainings and simulations are run within Sanofi to seek to be better prepared in case of a cybersecurity incident. In addition, Sanofi’s employees, who are the main users of Sanofi’s digital assets, are regularly trained to face cybersecurity threats and attacks. In the event of a cyberattack, Sanofi has established a plan that includes criteria triggering the notification process for material cybersecurity incidents including from the cybersecurity operation center and the Chief Information Security Officer who can use the internal escalation channels to inform the management and the Board of Directors and, as appropriate, the relevant regulatory bodies.
Cybersecurity Risk Board of Directors Oversight	Governance Sanofi has appointed a Chief Information Security Officer who oversees Sanofi's information, cybersecurity, and technology security. Our current Chief Information Security Officer has been working for Sanofi in this capacity since 2014 and has seventeen years of experience in the cybersecurity industry, including eight years as the global head of cybersecurity at one of France’s largest telecommunications companies. The Chief Information Security Officer is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents through the cybersecurity operation center. He develops appropriate plans to mitigate such risks. Such plans are validated by the Chief Digital Officer and shared with the Executive Committee. The Chief Information Security Officer belongs to the digital division and directly reports to the Chief Digital Officer, a member of the Executive Committee. In addition, the Chief Information Security Officer is a permanent member of the group Risk Committee and reports on the cybersecurity risk to such group Risk Committee, to the Audit Committee and to the Executive Committee regularly. The reporting covers various matters, such as the outcomes of audits on Sanofi’s information systems, the main incidents encountered over the preceding period, Sanofi’s digital transformation or the cybersecurity strategy and framework for the coming years. The group Risk Committee , comprised of the managers of Sanofi’s Global Business Units, consolidates the risks identified by the specific committees and targets the high priority risks Sanofi is facing. The group Risk Committee then allocates each risk to the relevant Executive Committee member (i.e. the cybersecurity risk is allocated to the Chief Digital Officer as the relevant member of the Executive Committee, who manages the mitigation of such risk with the Chief Information Security Officer) and reports regularly to the Audit Committee. Following this identification and allocation process, the group Risk Committee reports on a quarterly basis to the Executive Committee on the progress of the mitigation plans. The Audit Committee controls that the cybersecurity risks are well managed and reports on such management to the Board of Directors. The Board of Directors is also informed of such risks, as well as other cybersecurity matters, through periodic reports from the Chief Digital Officer, the Head of the group Risk Committee, or the Chief Information Security Officer.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight	Chief Information Security Officer
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight	The Chief Information Security Officer is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents through the cybersecurity operation center. He develops appropriate plans to mitigate such risks. Such plans are validated by the Chief Digital Officer and shared with the Executive Committee.
Cybersecurity Risk Role of Management	The Chief Information Security Officer belongs to the digital division and directly reports to the Chief Digital Officer, a member of the Executive Committee. In addition, the Chief Information Security Officer is a permanent member of the group Risk Committee and reports on the cybersecurity risk to such group Risk Committee, to the Audit Committee and to the Executive Committee regularly. The reporting covers various matters, such as the outcomes of audits on Sanofi’s information systems, the main incidents encountered over the preceding period, Sanofi’s digital transformation or the cybersecurity strategy and framework for the coming years.
Cybersecurity Risk Management Expertise of Management Responsible	The group Risk Committee , comprised of the managers of Sanofi’s Global Business Units, consolidates the risks identified by the specific committees and targets the high priority risks Sanofi is facing. The group Risk Committee then allocates each risk to the relevant Executive Committee member (i.e. the cybersecurity risk is allocated to the Chief Digital Officer as the relevant member of the Executive Committee, who manages the mitigation of such risk with the Chief Information Security Officer) and reports regularly to the Audit Committee. Following this identification and allocation process, the group Risk Committee reports on a quarterly basis to the Executive Committee on the progress of the mitigation plans.
Cybersecurity Risk Process for Informing Management or Committees Responsible	The Audit Committee controls that the cybersecurity risks are well managed and reports on such management to the Board of Directors. The Board of Directors is also informed of such risks, as well as other cybersecurity matters, through periodic reports from the Chief Digital Officer, the Head of the group Risk Committee, or the Chief Information Security Officer.

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2024
Corporate information and statement of IFRS compliance [abstract]
International financial reporting standards (IFRS)	International financial reporting standards (IFRS) The consolidated financial statements cover the twelve-month periods ended December 31, 2024 , 2023 and 2022 . In accordance with Regulation No. 1606/2002 of the European Parliament and Council of July 19, 2002 on the application of international accounting standards, Sanofi has presented its consolidated financial statements in accordance with IFRS since January 1, 2005. The term “IFRS” refers collectively to international accounting and financial reporting standards (IASs and IFRSs) and to interpretations of the interpretations committees (SIC and IFRIC) with mandatory application as of December 31, 2024 . The consolidated financial statements of Sanofi as of December 31, 2024 have been prepared in compliance with IFRS as issued by the International Accounting Standards Board (IASB) and with IFRS as endorsed by the European Union as of December 31, 2024 . IFRS as endorsed by the European Union as of December 31, 2024 are available under the heading “IFRS Financial Statements” via the following web link: https://www.efrag.org/Endorsement The consolidated financial statements have been prepared in accordance with the IFRS general principles of fair presentation, going concern, accrual basis of accounting, consistency of presentation, materiality, and aggregation.
New standards, amendments and interpretations	New standards, amendments and interpretations A.2.1. New standards applicable from January 1, 2024 On September 22, 2022, the IASB issued an amendment to IFRS 16 (Leases) relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable from January 1, 2024 and had no impact on Sanofi's financial statements. On January 23, 2020, the IASB issued “Classification of Liabilities as Current or Non-current”, an amendment to IAS 1, and then on October 31, 2022 issued “Non-current Liabilities with Covenants”, a further amendment to IAS 1. The amendments, which are applicable from January 1, 2024, had no impact on Sanofi's financial statements. On May 25, 2023, the IASB issued " Su pplier Finance Arrangements ", amendments to IAS 7 and IFRS 7 , applicable from January 1, 2024. The amendments relate to disclosures of information about such arrangements , and have led to the following clarification: within Accounts payable , amounts representing payables that are managed via a paying agent contract under which a bank manages the settlement of Sanofi's trade accounts payable on behalf of Sanofi and that have already been paid to suppliers by the bank represented around 2% as of December 31, 2024. As those amounts are not material, Sanofi does not provide additional information in respect of those amendments.
New pronouncements issued by IASB and applicable from 2024 or later	New pronouncements issued by the IASB and applicable from 2025 or later This note describes standards, amendments and interpretations issued by the IASB that will have mandatory application in 2025 or subsequent years, and Sanofi’s position regarding future application. On August 15, 2023, the IASB iss ued "Lack of Exchangeability", an am endment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable at the earliest from January 1, 2025 ; it will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it. On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard. On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact, and will not early adopt these amendments. On July 18, 2024, the IASB issued Volume 11 of its annual improvements to various standards, which are essentially in the nature of clarifications, applicable from January 1, 2026 at the earliest (subject to endorsement by the European Union). Sanofi does not expect any material impact, and will not early adopt these amendments. On December 18, 2024, the IASB issued "Contracts referencing nature-dependent electricity", amendments to IFRS 9 and IFRS 7, applicable (subject to endorsement by the European Union) from January 1, 2026. The amendments clarify the application of the ‘own use’ exemption to Power Purchase Agreements (PPAs) with physical delivery of renewable electricity, and modify the hedge accounting requirements for contracts without physical delivery (VPPAs). Sanofi does not expect any material impact and does not intend to early adopt these amendments. Renewable energy purchase contracts entered into by Sanofi as of December 31, 2024 are described in note D.21.
Use of estimates and judgments	Use of estimates and judgments The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date of the finalization of the financial statements. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include: • amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions (see Notes B.13. and D.23.); • impairment of property, plant and equipment and intangible assets (see Notes B.6. and D.5.); • the valuation of goodwill and the valuation and estimated useful life of acquired intangible assets (see Notes B.3.2., B.4., D.4. and D.5.); • the measurement of contingent consideration receivable in connection with asset divestments (see Notes B.8.5. and D.12.) and of contingent consideration payable (see Notes B.3. and D.18.); • the measurement of financial assets and liabilities at amortized cost (see Note B.8.5.); • the amount of post-employment benefit obligations (see Notes B.23. and D.19.1.); • the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks (see Notes B.12., B.19., B.20., D.19. and D.22.); and • the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences (see Notes B.22. and D.14.). Actual results could differ from these estimates. Management is also required to exercise judgment in assessing whether the criteria required under IFRS 5 (Non-Current Assets Held For Sale and Discontinued Operations) are met for (i) classifying a non-current asset or a group of assets as held for sale and (ii) presenting a discontinued operation on a separate line item in the consolidated balance sheet, income statement, statement of comprehensive income and cash flow statement. Such assessments are reviewed at the end of each reporting period each closing date to take account of changes in events and circumstances. In preparing the consolidated financial statements, Sanofi has also taken account of risks related to the effects of climate change and energy transition. As part of its Planet Care program, Sanofi has committed to move towards carbon neutrality by 2030 and net zero emissions by 2045 for its Scope 1, 2 and 3 emissions. That involves: • aiming for a 55% reduction in greenhouse gas (GHG) emissions from Sanofi’s own activities (Scopes 1 & 2) and a 30% reduction in Scope 3 GHG emissions by 2030 (versus a 2019 baseline), and a 90% reduction in GHG emissions (all scopes) by 2045. These objectives have been validated by the Science Based Target initiative (STBi); • supplying all our sites with 100% renewably-sourced electricity by 2030; • promoting an eco-friendly vehicle fleet by 2030; and • engaging the Sanofi supply chain in reducing Scope 3 emissions. The analysis of climate-related physical and transition risks facing Sanofi was updated in 2023 on the basis of three global warming scenarios out to 2030 and 2050. A number of assumptions – on issues such as carbon costs, natural disasters, water stress, raw material scarcity and logistics disruption – were built into this analysis, which also takes account of certain capital expenditures on mitigations derived from the Planet Care roadmap. In preparing the consolidated financial statements, that analysis was taken into account as follows: • the value of intangible assets and property, plant and equipment was subject to impairment testing conducted at CGU level, as described in Note D.5. Certain climate-related assumptions, such as the evolution of energy costs, transitioning to sustainable agriculture, and waste management, are already built into the forecast used for impairment testing purposes. For those assumptions not yet built into budgets, sensitivity analyses can be performed as needed; • the periodic reviews conducted on the useful lives of property, plant and equipment take account of environmental regulatory constraints, including not only GHG emissions but also physical risks; • environmental risks are covered by provisions on the basis described in Note D.19.3.; and • the credit facilities available to Sanofi as of December 31, 2024 incorporate performance objectives, including objectives related to cutting Sanofi’s carbon footprint, which could reduce the cost of debt if they are attained (see Note D.17.). It is important to bear in mind that estimating climate change related risks involves an element of unpredictability. Uncertainties may arise from factors such as changes in government policy, rapid technological change, and varied responses from stakeholders. That high level of uncertainty adds complexity to assessment of the potential impacts on our operations, and to how those impacts are reflected in our budgets. Actual impacts on Sanofi’s profits and financial position could therefore differ from initial estimates. Finally, in line with its environmental protection objectives, Sanofi has initiated projects to build eco-design into its products so as to limit their environmental impacts over their entire life cycle. Those projects will require Sanofi to redefine all of its production methods, and as such have also been built into definitions of the useful lives of Sanofi production facilities.
Hyperinflation	Hyperinflation In 2024 , Sanofi continued to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial. In Argentina, the cumulative rate of inflation over the last three years is in excess of 100% , based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July 1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level. In Turkey, the cumulative rate of inflation over the last three years is in excess of 100% based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January 1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level.
Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK	A.5. Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK On February 18, 2020, Sanofi and the US Department of Health and Human Services extended their research and development partnership to leverage Sanofi’s previous development work on a SARS vaccine to attempt to unlock a fast path forward for developing a COVID-19 vaccine. Under the terms of the collaboration, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services, is helping to fund the research and development undertaken by Sanofi. On April 14, 2020, Sanofi and GlaxoSmithKline (GSK) entered into a collaboration agreement to develop a recombinant COVID-19 vaccine candidate, with Sanofi contributing its S‑protein COVID-19 antigen (based on recombinant DNA technology) and GSK contributing its pandemic adjuvant technology. Sanofi is leading clinical development and the registration process for the vaccine. On July 31, 2020, the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK was selected by the US government’s Operation Warp Speed (OWS) program. Under the OWS, the US government is providing funds to support further development of the vaccine, including clinical studies and scaling-up of manufacturing capacity. Initially, the agreement also provided for the supply of 100 million doses of the vaccine. In light of the evolving context of the pandemic (including variants of the virus) and the availability of vaccines on the market, the parties decided to review the initial supply contract. At the end of 2023, the agreement was amended in respect of the supply clause, confirming that Sanofi had fulfilled its contractual obligations and setting the amount of compensation paid to Sanofi. On the basis of that signed amendment, Sanofi recognized an amount of €411 million within the line item Other revenues ; that amount was paid to Sanofi in December 2023. Sanofi has recognized the funding received from the US government as a deduction from the development expenses incurred, in accordance with IAS 20 (Accounting for Government Grants and Disclosure of Government Assistance). The amount of government aid received from the US federal government and BARDA and recognized as a deduction from development expenses and other operating expenses was €58 million in 2024, compared with €59 million in 2023 and €265 million in 2022. In September 2020, Sanofi and GSK signed pre-order contracts with the Canadian and UK governments and with the European Union for doses of the vaccine candidate. During 2021, Sanofi and GSK contractualized with the Canadian and UK governments and with the European Union on the number of doses ordered. On December 15, 2021, Sanofi and GSK announced positive preliminary data on their COVID-19 booster vaccine candidate and indicated that their Phase 3 study was to continue, based on recommendations from an independent monitoring board. On November 10, 2022, in line with the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, the European Commission approved VidPrevtyn Beta vaccine as booster for the prevention of COVID-19 in adults aged 18 years and older. Designed to provide broad protection against multiple variants, this protein-based COVID-19 booster vaccine is based on the Beta variant antigen and includes GSK’s pandemic adjuvant. VidPrevtyn Beta is indicated as a booster for active immunization against SARS-CoV-2 in adults who have previously received an mRNA or adenoviral COVID-19 vaccine. On December 21, 2022, following the European Commission approval, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved VidPrevtyn Beta vaccine for the prevention of COVID-19 in adults aged 18 and over within the UK. In accordance with IFRS 15 (see Note B.13.1.), Sanofi recognizes revenue when control over the product is transferred to the customer (for vaccines, transfer of control is determined by reference to the terms of release and acceptance of batches of vaccine). Payments received subsequent to signature of vaccine pre-order contracts relating to doses not yet delivered are customer contract liabilities (i.e. an obligation for the entity to supply goods to a customer, for which consideration has been received from the customer). They are presented within “Customer contract liabilities” in the balance sheet (see Note D.19.5.), and within “Net change in other current assets and other current liabilities” in the statement of cash flows. The pre-order contracts for Canada, the United Kingdom and the European Union expired in 2023. The customer contract liabilities, which amounted to €269 million as of December 31, 2022 and €319 million as of December 31, 2021 (see Note D.19.5., “ Current provisions and other current liabilities” ) were released to profit or loss in 2023, including an amount of €94 million classified in Other revenue in respect of doses which there was no longer an obligation to deliver as of December 31, 2023.
Basis of consolidation	Basis of consolidation In accordance with IFRS 10 (Consolidated Financial Statements), the consolidated financial statements of Sanofi include the financial statements of entities that Sanofi controls directly or indirectly, regardless of the level of the equity interest in those entities. An entity is controlled when Sanofi has power over the entity, exposure or rights to variable returns from its involvement with the entity, and the ability to affect those returns through its power over the entity. In determining whether control exists, potential voting rights must be taken into account if those rights are substantive, in other words they can be exercised on a timely basis when decisions about the relevant activities of the entity are to be taken. Entities consolidated by Sanofi are referred to as “subsidiaries”. Entities that Sanofi controls by means other than voting rights are referred to as “consolidated structured entities”. In accordance with IFRS 11 (Joint Arrangements), Sanofi classifies its joint arrangements (i.e. arrangements in which Sanofi exercises joint control with one or more other parties) either as a joint operation (in which case, Sanofi recognizes the assets and liabilities of the operation in proportion to its rights and obligations relating to those assets and liabilities) or as a joint venture. Sanofi exercises joint control over a joint arrangement when decisions relating to the relevant activities of the arrangement require the unanimous consent of Sanofi and the other parties with whom control is shared. Sanofi exercises significant influence over an entity when it has the power to participate in the financial and operating policy decisions of that entity, but does not have the power to exercise control or joint control over those policies. In accordance with IAS 28 (Investments in Associates and Joint Ventures), the equity method is used to account for joint ventures (i.e. entities over which Sanofi exercises joint control) and for associates (i.e. entities over which Sanofi exercises significant influence). Under the equity method, the investment is initially recognized at cost, and subsequently adjusted to reflect changes in the net assets of the associate or joint venture. IAS 28 does not specify the treatment to be adopted on first-time application of the equity method to an investee following a step acquisition. Consequently, by reference to paragraph 10 of IAS 28, Sanofi has opted to apply the cost method, whereby the carrying amount of the investment represents the sum of the historical cost amounts for each step in the acquisition. As of the date on which the equity method is first applied, goodwill (which is included in the carrying amount of the investment) is determined for each acquisition step. The same applies to subsequent increases in the percentage interest in the equity-accounted investment. When the criteria of IFRS 5 are met, Sanofi recognizes the equity interest within the balance sheet line item Assets held for sale . The equity method is not applied to equity interests that are classified as held for sale assets. Transactions between consolidated companies are eliminated, as are intragroup profits. A list of the principal companies included in the consolidation in 2024 is presented in Note F.
Foreign currency translation	Foreign currency translation B.2.1. Accounting for foreign currency transactions in the financial statements of consolidated entities Non-current assets and inventories acquired in foreign currencies are translated into the functional currency using the exchange rate prevailing at the acquisition date. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the end of the reporting period. The gains and losses resulting from foreign currency translation are recorded in the income statement. However, foreign exchange gains and losses arising from the translation of advances between consolidated subsidiaries for which settlement is neither planned nor likely to occur in the foreseeable future are recognized in equity, in the line item Change in currency translation differences. B.2.2. Foreign currency translation of the financial statements of foreign entities Sanofi presents its consolidated financial statements in euros (€). In accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates), each subsidiary accounts for its transactions in the currency that is most representative of its economic environment (the functional currency). All assets and liabilities are translated into euros using the exchange rate of the subsidiary’s functional currency prevailing at the end of the reporting period. Income statements are translated using a weighted average exchange rate for the period, except in the case of foreign subsidiaries in a hyperinflationary economy. The resulting currency translation difference is recognized as a separate component of equity in the consolidated statement of comprehensive income, and is recognized in the income statement only when the subsidiary is sold or is wholly or partially liquidated.
Business combinations and transactions with non-controlling interests	Business combinations and transactions with non-controlling interests B.3.1. Accounting for business combinations, transactions with non-controlling interests and loss of control Business combinations are accounted for in accordance with IFRS 3 (Business Combinations) and IFRS 10 (Consolidated Financial Statements). Business combinations are accounted for using the acquisition method. Under this method, the acquiree’s identifiable assets and liabilities that satisfy the recognition criteria of IFRS 3 (Business Combinations) are measured initially at their fair values at the date of acquisition, except for (i) non-current assets classified as held for sale (which are measured at fair value less costs to sell) and (ii) assets and liabilities that fall within the scope of IAS 12 (Income Taxes) and IAS 19 (Employee Benefits). Restructuring liabilities are recognized as a liability of the acquiree only if the acquiree has an obligation as of the acquisition date to carry out the restructuring. The principal accounting rules applicable to business combinations and transactions with non-controlling interests include: • acquisition-related costs are recognized as an expense, as a component of Operating income ; • contingent consideration is recognized in equity if the contingent payment is settled by delivery of a fixed number of the acquirer’s equity instruments; otherwise, it is recognized i n liabilities related to business combinations. Contingent consideration is recognized at fair value at the acquisition date irrespective of the probability of payment. If the contingent consideration was originally recognized as a financial liability, subsequent adjustments to the liability are recognized in profit or loss in the line item Fair value remeasurement of contingent consideration , unless the adjustment is made within the 12 months following the acquisition date and relates to facts and circumstances existing as of that date; and • goodwill may be calculated on the basis of either (i) the entire fair value of the acquiree, or (ii) a share of the fair value of the acquiree proportionate to the interest acquired. This option is elected for each acquisition individually. Purchase price allocations are performed under the responsibility of management, with assistance from an independent valuer in the case of major acquisitions. IFRS 3 does not specify an accounting treatment for contingent consideration arising from a business combination made by an entity prior to the acquisition of control in that entity and carried as a liability in the acquired entity’s balance sheet. The accounting treatment applied by Sanofi to such a liability is to measure it at fair value as of the acquisition date and to report it in the line item Liabilities related to business combinations and to non-controlling interests, with subsequent remeasurements recognized in profit or loss. This treatment is consistent with the accounting applied to contingent consideration in the books of the acquirer. Finally, management may where it deems fit elect to apply the optional test to identify concentration of fair value permitted under IFRS 3 in order to determine whether a transaction is a business combination within the meaning of IFRS 3, or merely the acquisition of an asset or of a group of similar assets. B.3.2. Goodwill The excess of the cost of an acquisition over Sanofi’s interest in the fair value of the identifiable assets and liabilities of the acquiree is recognized as goodwill at the date of the business combination. Goodwill arising on the acquisition of subsidiaries is shown in a separate balance sheet line item, whereas goodwill arising on the acquisition of investments accounted for using the equity method is recorded in Investments accounted for using the equity method. Goodwill arising on foreign operations is expressed in the functional currency of the country concerned and translated into euros using the exchange rate prevailing at the end of the reporting period. In accordance with IAS 36 (Impairment of Assets), goodwill is carried at cost less accumulated impairment (see Note B.6.). Goodwill is tested for impairment annually and whenever events or circumstances indicate that impairment might exist. Such events or circumstances include significant changes more likely than not to have an other-than-temporary impact on the substance of the original investment.
Other intangible assets	Other intangible assets Other intangible assets are initially measured at acquisition cost or production cost, including any directly attributable costs of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. Intangible assets are amortized on a straight line basis over their useful lives. The useful lives of other intangible assets are reviewed at the end of each reporting period. The effect of any adjustment to useful lives is recognized prospectively as a change in accounting estimate. Amortization of other intangible assets is recognized in the income statement within Amortization of intangible assets except for amortization charged against (i) acquired or internally-developed software and (ii) other rights of an industrial or operational nature, which is recognized in the relevant classification of expense by function. Sanofi does not own any intangible assets with an indefinite useful life, other than goodwill. Intangible assets (other than goodwill) are carried at cost less accumulated amortization and accumulated impairment, if any, in accordance with IAS 36 (see Note B.6.). B.4.1. Research and development not acquired in a business combination Internally generated research and development Under IAS 38, research expenses are recognized in profit or loss when incurred. Internally generated development expenses are recognized as an intangible asset if, and only if, all the following six criteria can be demonstrated: (a) the technical feasibility of completing the development project; (b) Sanofi’s intention to complete the project; (c) Sanofi’s ability to use the project; (d) the probability that the project will generate future economic benefits; (e) the availability of adequate technical, financial and other resources to complete the project; and (f) the ability to measure the development expenditure reliably. Due to the risks and uncertainties relating to regulatory approval and to the research and development process, the six criteria for capitalization are usually considered not to have been met until the product has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical studies, are generally expensed as incurred within Research and development expenses . Some industrial development expenses (such as those incurred in developing a second-generation synthesis process) are incurred after marketing approval has been obtained, in order to improve the industrial process for an active ingredient. To the extent that the six IAS 38 criteria are considered as having been met, such expenses are recognized as an asset in the balance sheet within Other intangible assets as incurred. Similarly, some clinical studies, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS 38, in which case the related expenses are recognized as an asset in the balance sheet within Other intangible assets . Separately acquired research and development Payments for separately acquired research and development are capitalized within Other intangible assets provided that they meet the definition of an intangible asset: a resource that is (i) controlled by Sanofi, (ii) expected to provide future economic benefits for Sanofi, and (iii) identifiable (i.e. it is either separable or arises from contractual or legal rights). Under paragraph 25 of IAS 38, the first condition for capitalization (the probability that the expected future economic benefits from the asset will flow to the entity) is considered to be satisfied for separately acquired research and development. Consequently, upfront and milestone payments to third parties related to pharmaceutical products for which marketing approval has not yet been obtained are recognized as intangible assets, and amortized on a straight line basis over their useful lives beginning when marketing approval is obtained. Payments under research and development arrangements relating to access to technology or to databases, and payments made to purchase generics dossiers, are also capitalized, and amortized over the useful life of the intangible asset. Subcontracting arrangements, payments for research and development services, and continuous payments under research and development collaborations which are unrelated to the outcome of that collaboration, are expensed over the service term. B.4.2. Other intangible assets not acquired in a business combination Licenses other than those related to pharmaceutical products and research projects, in particular software licenses, are capitalized at acquisition cost, including any directly attributable cost of preparing the software for its intended use. Software licenses are amortized on a straight line basis over their useful lives for Sanofi ( three to five years ). Internally generated costs incurred to develop or upgrade software are capitalized if the IAS 38 recognition criteria are satisfied, and amortized on a straight line basis over the useful life of the software from the date on which the software is ready for use. B.4.3. Other intangible assets acquired in a business combination Other intangible assets acquired in a business combination (in-process research and development, technology platforms, and currently marketed products) that are reliably measurable are identified separately from goodwill, measured at fair value, and capitalized within Other intangible assets in accordance with IFRS 3 (Business Combinations) and IAS 38 (Intangible Assets). The related deferred tax liability is also recognized if a deductible or taxable temporary difference exists. In-process research and development acquired in a business combination is amortized on a straight line basis over its useful life from the date of receipt of marketing approval. Rights to technology platforms and to products currently marketed by Sanofi are amortized on a straight line basis over their useful lives, determined (in particular for marketed products) on the basis of cash flow forecasts which take into account the patent protection period of the marketed product.
Property, plant and equipment owned and leased	Property, plant and equipment owned and leased B.5.1. Property, plant and equipment owned Property, plant and equipment is initially measured and recognized at acquisition cost, including any directly attributable cost of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. The component-based approach to accounting for property, plant and equipment is applied. Under this approach, each component of an item of property, plant and equipment with a cost which is significant in relation to the total cost of the item and which has a different useful life from the other components must be depreciated separately. After initial measurement, property, plant and equipment is carried at cost less accumulated depreciation and impairment, except for land which is carried at cost less impairment. Subsequent costs are not recognized as assets unless (i) it is probable that future economic benefits associated with those costs will flow to Sanofi and (ii) the costs can be measured reliably. Borrowing costs attributable to the financing of items of property, plant and equipment, and incurred during the construction period, are capitalized as part of the acquisition cost of the item. Government grants relating to property, plant and equipment are deducted from the acquisition cost of the asset to which they relate. The depreciable amount of items of property, plant and equipment, net of any residual value, is depreciated on a straight line basis over the useful life of the asset. The useful life of an asset is usually equivalent to its economic life. The customary useful lives of property, plant and equipment are as follows: Buildings 15 to 40 years Fixtures 10 to 20 years Machinery and equipment 5 to 15 years Other 3 to 15 years Useful lives and residual values of property, plant and equipment are reviewed annually. The effect of any adjustment to useful lives or residual values is recognized prospectively as a change in accounting estimate. Depreciation of property, plant and equipment is recognized as an expense in the income statement, in the relevant classification of expense by function. B.5.2. Property, plant and equipment leased Leases contracted by Sanofi have been accounted for in accordance with IFRS 16 (Leases). Sanofi recognizes a right-of-use asset and a lease liability for all of its lease contracts, except for (i) leases relating to low-value assets and (ii) short-term leases (12 months or less). Payments made in respect of leases not recognized on the balance sheet are recognized as an operating expense on a straight line basis over the lease term. On commencement of a lease, the liability for future lease payments is discounted at the incremental borrowing rate, which is a risk-free rate adjusted to reflect the specific risk profile of each Sanofi entity. Because lease payments are spread over the lease term, Sanofi applies a discount rate based on the duration of those payments. The payments used to determine the liability for future lease payments exclude non-lease components, but include fixed payments that Sanofi expects to make to the lessor over the estimated lease term. After commencement of the lease, the liability for future lease payments is reduced by the amount of the lease payments made, and increased to reflect interest on the liability. In the event of a reassessment or modification of future lease payments, the lease liability is remeasured. The right-of-use asset – which is initially measured at cost including direct costs of the lessee, prepayments made at or prior to the commencement date, less lease incentives received and restoration costs – is depreciated on a straight line basis over the lease term, and tested for impairment as required. Sanofi recognizes deferred taxes in respect of right-of-use assets and lease liabilities. Leasehold improvements are depreciated over their economic life, which is capped at the lease term as determined under IFRS 16.
Impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method	Impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method B.6.1. Impairment of property, plant and equipment and intangible assets In accordance with IAS 36 (Impairment of Assets), assets that generate separate cash flows and assets included in cash- generating units (CGUs) are assessed for impairment when events or changes in circumstances indicate that the asset or CGU may be impaired. A CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. Under IAS 36, each CGU or group of CGUs to which goodwill is allocated must (i) represent the lowest level within the entity at which the goodwill is monitored for internal management purposes, and (ii) not be larger than an operating segment determined in accordance with IFRS 8 (Operating Segments), before application of the IFRS 8 aggregation criteria (see Note B.26.). Quantitative and qualitative indications of impairment (primarily relating to the status of the research and development portfolio, pharmacovigilance, patent litigation, and the launch of competing products) are reviewed at the end of each reporting period. If there is any internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset or CGU. Other intangible assets not yet available for use (such as capitalized in-process research and development), and CGUs or groups of CGUs that include goodwill, are tested for impairment annually whether or not there is any indication of impairment, and more frequently if any event or circumstance indicates that they might be impaired. Such assets are not amortized. When there is an internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset and recognizes an impairment loss if the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of the asset is the higher of its fair value less costs to sell or its value in use. To determine value in use, Sanofi uses estimates of future cash flows generated by the asset or CGU, prepared using the same methods as those used in the initial measurement of the asset or CGU on the basis of medium-term strategic plans. In the case of goodwill, estimates of future cash flows are based on a six-year strategic plan and a terminal value. In the case of other intangible assets, the period used is based on the economic life of the asset. Estimated cash flows are discounted at long-term market interest rates that reflect the best estimate by Sanofi of the time value of money, the risks specific to the asset or CGU, and economic conditions in the geographical regions in which the business activity associated with the asset or CGU is located. Certain assets and liabilities that are not directly attributable to a specific CGU are allocated between CGUs on a basis that is reasonable, and consistent with the allocation of the corresponding goodwill. Impairment losses arising on property, plant and equipment, software and certain rights, are recognized within the appropriate income statement line item according to the origin of the impairment. Impairment losses arising on other intangible assets (products, trademarks, technology platforms, acquired R&D) are recognized within Impairment of intangible assets in the income statement. B.6.2. Impairment of investments accounted for using the equity method In accordance with IAS 28 (Investments in Associates and Joint Ventures), Sanofi determines whether investments accounted for using the equity method may be impaired based on indicators such as default in contractual payments, significant financial difficulties, probability of bankruptcy, or a prolonged or significant decline in quoted market price. If an investment is impaired, the amount of the impairment loss is determined by applying IAS 36 (see Note B.6.1.) and recognized in Share of profit/(loss) from investments accounted for using the equity method. B.6.3. Reversals of impairment losses charged against property, plant and equipment, intangible assets, and investments accounted for using the equity method At the end of each reporting period, Sanofi assesses whether events or changes in circumstances indicate that an impairment loss recognized in a prior period in respect of an asset (other than goodwill) or an investment accounted for using the equity method can be reversed. If this is the case, and the recoverable amount as determined based on the revised estimates exceeds the carrying amount of the asset, Sanofi reverses the impairment loss only to the extent of the carrying amount that would have been determined had no impairment loss been recognized for the asset. Reversals of impairment losses in respect of other intangible assets are recognized within the income statement line item Impairment of intangible assets , while reversals of impairment losses in respect of investments accounted for using the equity method are recognized within the income statement line item Share of profit/(loss) from investments accounted for using the equity method . Impairment losses taken against goodwill are never reversed, unless the goodwill is part of the carrying amount of an investment accounted for using the equity method.
Assets held for sale or exchange and liabilities related to assets held for sale or exchange	Assets held for sale and liabilities related to assets held for sale and discontinued operations In accordance with IFRS 5 (Non-Current Assets Held for sale and Discontinued Operations), non-current assets and groups of assets are classified as held for sale in the balance sheet if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Within the meaning of IFRS 5, the term “sale” also includes exchanges for other assets. Non-current assets or asset groups held for sale must be available for immediate sale in their present condition, subject only to terms that are usual and customary for sales of such assets, and a sale must be highly probable. Criteria used to determine whether a sale is highly probable include: • the appropriate level of management must be committed to a plan to sell; • an active program to locate a buyer and complete the plan must have been initiated; • the asset must be actively marketed for sale at a price that is reasonable in relation to its current fair value; • completion of the sale should be foreseeable within the 12 months following the date of reclassification to Assets held for sale ; and • actions required to complete the plan should indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Before initial reclassification of the non-current asset (or asset group) to Assets held for sale , the carrying amounts of the asset (or of all the assets and liabilities in the asset group) must be measured in accordance with the applicable standards. Subsequent to reclassification to Assets held for sale , the non-current asset (or asset group) is measured at the lower of carrying amount or fair value less costs to sell, with any write-down recognized by means of an impairment loss. Once a non-current asset has been reclassified as held for sale or exchange, it is no longer depreciated or amortized. From the date of reclassification: • property, plant and equipment, right-of-use assets and intangible assets are no longer subject to individual depreciation, amortization or impairment; and • the share of profits and losses from investments accounted for using the equity method is no longer recognized. In a disposal of an equity interest leading to loss of control, all the assets and liabilities of the entity involved are classified as held for sale assets or liabilities within the balance sheet line items Assets held for sale or Liabilities related to assets held for sale , provided that the disposal satisfies the IFRS 5 classification criteria. The profit or loss generated by a held for sale asset group is reported in a separate line item in the income statement for the current period and for the comparative periods presented, provided that the asset group: • represents a separate major line of business or geographical area of operations; or • is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or • is a subsidiary acquired exclusively with a view to resale. In accordance with IFRS 10, intragroup balances and transactions relating to held for sale entities are eliminated. In the absence of any specific accounting treatment under IFRS 5, Sanofi has opted to eliminate transactions between discontinued operations and continuing operations so as to reflect the impact of such transactions consistently with the way they are presented in the income statement after effective loss of control. Events or circumstances beyond Sanofi’s control may extend the period to complete the sale or exchange beyond one year without precluding classification of the asset (or disposal group) in Assets held for sale provided that there is sufficient evidence that Sanofi remains committed to the planned sale or exchange. Finally, in the event of changes to a plan of sale that requires an asset no longer to be classified as held for sale, IFRS 5 specifies the following treatment: • the assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods; • each asset is measured at the lower of (a) its carrying amount before the asset was reclassified as held for sale, adjusted for any depreciation, amortization or revaluation that would have been recognized if the asset had not been reclassified as held for sale, or (b) its recoverable amount at the date of reclassification; • the backlog of depreciation, amortization and impairment not recognized while non-current assets were classified as held for sale must be reported in the same income statement line item that was used to report impairment losses arising on initial reclassification of assets as held for sale and gains or losses arising on the sale of such assets. In the consolidated income statement, those impacts are reported within the line item Other gains and losses, and litigation ; • the net income of a business previously classified as discontinued or as held for sale or exchange and reported on a separate line in the income statement must be reclassified and included in net income from continuing operations, for all periods presented; and • in addition, segment information relating to the income statement and the statement of cash flows (acquisitions of non- current assets) must be disclosed in the notes to the financial statements in accordance with IFRS 8 (Operating Segments), and must also be restated for all prior periods presented.
Financial instruments	Financial instruments B.8.1. Non-derivative financial assets In accordance with IFRS 9 (Financial Instruments) and IAS 32 (Financial Instruments: Presentation), Sanofi has adopted the classification of non-derivative financial assets described below. The classification used depends on (i) the characteristics of the contractual cash flows (i.e. whether they represent interest or principal) and (ii) the business model for managing the asset applied at the time of initial recognition. Financial assets at fair value through other comprehensive income These mainly comprise: • quoted and unquoted equity investments that Sanofi does not hold for trading purposes and that management has designated at “fair value through other comprehensive income” on initial recognition. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such instruments are derecognized, the previously-recognized changes in fair value remain within Other comprehensive income , as does the gain or loss on divestment. Dividends received are recognized in profit or loss for the period, within the line item Financial income ; and • debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items Financial income or Financial expenses . Financial assets at fair value through profit or loss These mainly comprise: • contingent consideration already carried in the books of an acquired entity or granted in connection with a business combination; • instruments whose contractual cash flows represent payments of interest and repayments of principal, which are managed with a view to selling the asset in the short term ; • instruments that management has designated at “fair value through profit or loss” on initial recognition; and • quoted and unquoted equity investments: equity instruments that are not held for trading and which management did not designate at “fair value through other comprehensive income” on initial recognition, and instruments that do not meet the IFRS definition of “equity instruments”. Gains and losses arising from changes in fair value are recognized in profit or loss within the line items Financial income or Financial expenses . Dividends received are recognized in profit or loss for the period, within the line item Financial income . Fair value of equity investments in unquoted entities On initial recognition of an equity investment in an entity not quoted in an active market, the fair value of the investment is the transaction price except in specific circumstances. This acquisition cost ceases to be a representative measure of the fair value of an unquoted equity investment when Sanofi identifies significant changes in the investee, or in the environment in which it operates. In such cases, an internal valuation is carried out, based mainly on growth forecasts or by reference to similar transactions contracted with third parties. Financial assets measured at amortized cost Financial assets at amortized cost comprise instruments whose contractual cash flows represent payments of interest and repayments of principal and which are managed with a view to collecting cash flows. The main assets in this category are loans and receivables. They are presented within the line items Other non-current assets , Other current assets , Accounts receivable and Cash and cash equivalents . Loans with a maturity of more than 12 months are presented in “Long-term loans and advances” within Other non-current assets . These financial assets are measured at amortized cost using the effective interest method. Impairment of financial assets measured at amortized cost The main assets involved are accounts receivable. Accounts receivable are initially recognized at the amount invoiced to the customer. Impairment losses on trade accounts receivable are estimated using the expected credit loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within Selling and general expenses in the income statement. B.8.2. Derivative instruments Derivative instruments that do not qualify for hedge accounting are initially and subsequently measured at fair value, with changes in fair value recognized in the income statement in Other operating income or in Financial income or Financial expenses , depending on the nature of the underlying economic item which is hedged. Derivative instruments that qualify for hedge accounting are measured using the policies described in Note B.8.3. below. IFRS 13 (Fair Value Measurement) requires counterparty credit risk to be taken into account when measuring the fair value of financial instruments. That risk is estimated on the basis of observable, publicly-available statistical data. Policy on offsetting In order for a financial asset and a financial liability to be presented as a net amount in the balance sheet under IAS 32, there must be: (a) a legally enforceable right to offset; and (b) the intention either to settle on a net basis, or to realize the asset and settle the liability simultaneously. B.8.3. Hedging As part of its overall market risk management policy, Sanofi enters into various hedging transactions involving derivative or non- derivative instruments; these may include forward contracts, currency swaps or options, interest rate swaps or options, cross- currency swaps, and debt placings or issues. Such financial instruments are designated as hedging instruments and recognized using the hedge accounting principles of IFRS 9 when (a) there is formal designation and documentation of the hedging relationship, of how the effectiveness of the hedging relationship will be assessed, and of the underlying market risk management objective and strategy; (b) the hedged item and the hedging instrument are eligible for hedge accounting; and (c) there is an economic relationship between the hedged item and the hedging instrument, defined on the basis of a hedge ratio that is consistent with the underlying market risk management strategy, and the residual credit risk does not dominate the value changes that result from that economic relationship. Fair value hedge A fair value hedge is a hedge of the exposure to changes in fair value of an asset, liability or firm commitment that is attributable to one or more risk components and could affect profit or loss. Changes in fair value of the hedging instrument and changes in fair value of the hedged item attributable to the hedged risk components are generally recognized in the income statement, within Other operating income for hedges related to operating activities, or within Financial income or Financial expenses for hedges related to investing or financing activities. Cash flow hedge A cash flow hedge is a hedge of the exposure to variability in cash flows from an asset, liability or highly probable forecast transaction that is attributable to one or more risk components and could affect profit or loss. Changes in fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within Other operating income for hedges related to operating activities, and within Financial income or Financial expenses for hedges related to investing or financing activities. Cumulative changes in fair value of the hedging instrument previously recognized in equity are reclassified to the income statement when the hedged transaction affects profit or loss. Those reclassified gains and losses are recognized within Other operating income for hedges related to operating activities, and within Financial income or Financial expenses for hedges related to investing or financing activities. When a forecast transaction results in the recognition of a non-financial asset or liability, cumulative changes in the fair value of the hedging instrument previously recognized in equity are incorporated in the initial carrying amount of that asset or liability. When the hedging instrument expires or is sold, terminated or exercised, the cumulative gain or loss previously recognized in equity remains separately recognized in equity and is not reclassified to the income statement, or recognized as an adjustment to the initial cost of the related non-financial asset or liability, until the forecast transaction occurs. However, if Sanofi no longer expects the forecast transaction to occur, the cumulative gain or loss previously recognized in equity is recognized immediately in profit or loss. Hedge of a net investment in a foreign operation In a hedge of a net investment in a foreign operation, changes in the fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within Financial income or Financial expenses . When the investment in the foreign operation is sold, the changes in the fair value of the hedging instrument previously recognized in equity are reclassified to the income statement within Financial income or Financial expenses . Cost of hedging As part of its market risk management policy, Sanofi may designate currency options or interest rate options as hedging instruments, the effectiveness of which is measured on the basis of changes in intrinsic value. In such cases, the time value of the option is treated as a hedging cost and accounted for as follows: • if the option includes a component that is not aligned on the critical features of the hedged item, the corresponding change in the time value is taken to profit or loss; • otherwise, the change in the time value is taken to equity within the statement of comprehensive income, and then: – if the hedged item is linked to a transaction that results in the recognition of a financial asset or liability, the change in the time value is reclassified to profit or loss symmetrically with the hedged item, or – if the hedged item is linked to a transaction that results in the recognition of a non-financial asset or liability, the change in the time value is incorporated in the initial carrying amount of that asset or liability, or – if the hedged item is linked to a period of time, the change in time value is reclassified to profit or loss on a straight line basis over the life of the hedging relationship. In the case of forward contracts and foreign exchange swaps, and of cross-currency swaps that qualify for hedge accounting on the basis of changes in spot rates, Sanofi may elect for each transaction to use the option whereby the premium/discount or foreign currency basis spread are treated in the same way as the time value of an option. Discontinuation of hedge accounting Hedge accounting is discontinued when the eligibility criteria are no longer met (in particular, when the hedging instrument expires or is sold, terminated or exercised), or if there is a change in the market risk management objective of the hedging relationship. B.8.4. Non-derivative financial liabilities Borrowings and debt Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs. Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within Financial expenses in the income statement over the term of the debt using the effective interest method. Liabilities related to business combinations and to non-controlling interests These line items record the fair value of (i) contingent consideration payable in connection with business combinations and (ii) commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests. Adjustments to the fair value of commitments to buy out equity holders of subsidiaries, including put options granted to non- controlling interests, are recognized in equity. Other non-derivative financial liabilities Other non-derivative financial liabilities include trade accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost. B.8.5. Fair value of financial instruments Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels: a. level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging); b. level 2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; and c. level 3: valuation techniques in which not all important inputs are derived from observable market data. The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments. Note Type of financial instrument Measurement principle Level in fair value hierarchy Valuation technique Method used to determine fair value Valuation model Market data Exchange rate Interest rate D.7. Financial assets measured at fair value (quoted equity instruments) Fair value 1 Market value Quoted market price N/A D.7. Financial assets measured at fair value (quoted debt instruments) Fair value 1 Market value Quoted market price N/A D.7. Financial assets measured at fair value (unquoted equity instruments) Fair value 3 Cost/ Approach based on comparables If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables. D.7. Financial assets measured at fair value (contingent consideration receivable) Fair value 3 Revenue- based approach The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. D.7. Financial assets measured at fair value held to meet obligations under post-employment benefit plans Fair value 1 Market value Quoted market price N/A D.7. Financial assets designated at fair value held to meet obligations under deferred compensation plans Fair value 1 Market value Quoted market price N/A D.7. Long-term loans and advances and other non-current receivables Amortized cost N/A N/A The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value. D.13. Investments in mutual funds Fair value 1 Market value Net asset value N/A D.13. Negotiable debt instruments, commercial paper, instant access deposits and term deposits Amortized cost N/A N/A Because these instruments have a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements. D.17.1., D.19. Debt Amortized cost (a) N/A N/A In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments). For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections. D.17.2. Lease liabilities Amortized cost N/A N/A The liability for future lease payments is discounted using the incremental borrowing rate. D.20. Forward currency contracts Fair value 2 Present value of future cash flows Mid Market < 1 year: Mid Money Market > 1 year: Mid Zero Coupon D.20. Interest rate swaps Fair value 2 Revenue- based approach Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon D.20. Cross-currency swaps Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon D.18. Liabilities related to business combinations and to non-controlling interests (CVRs) Fair value 1 Market value Quoted market price D.18. Liabilities related to business combinations and to non-controlling interests (other than CVRs) Fair value 3 Revenue- based approach Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.8.4. (a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s). B.8.6. Derecognition of financial instruments Financial assets are derecognized when the contractual rights to cash flows from the asset have ended or have been transferred and when Sanofi has transferred substantially all the risks and rewards of ownership of the asset. If Sanofi has neither transferred nor retained substantially all the risks and rewards of ownership of a financial asset, it is derecognized if Sanofi does not retain control of the asset. A financial liability is derecognized when Sanofi’s contractual obligations in respect of the liability are discharged, cancelled or extinguished. B.8.7. Risks relating to financial instruments Market risks in respect of non-current financial assets, cash equivalents, derivative instruments and debt are described in the discussions of risk factors presented in “ Item 3. Key Information — D. Risk factors” and “Item 11. Quantitative and Qualitative Disclosures about Market Risk” of Sanofi’s annual report on Form 20-F for 2024 . Credit risk is the risk that customers may fail to pay their debts. For a description of credit risk, refer to “We are subject to the risk of non-payment by our customers” within “Item 3. Key Information — D. Risk factors” and “Item 11. Quantitative and Qualitative Disclosures about Market Risk” of Sanofi’s annual report on Form 20-F for 2024 .
Inventories	Inventories Inventories are measured at the lower of cost or net realizable value. Cost is calculated using the weighted average cost method or the first-in, first-out method, depending on the nature of the inventory. The cost of finished goods inventories includes costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. During the launch phase of a new product, any inventories of that product are written down to zero pending regulatory approval, other than in specific circumstances which make it possible to estimate that there is a high probability at the end of the reporting period that the carrying amount of the inventories will be recoverable. The write-down is reversed once it becomes highly probable that marketing approval will be obtained.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents as shown in the consolidated balance sheet and statement of cash flows comprise cash, plus liquid short-term investments that are readily convertible into cash and are subject to an insignificant risk of changes in value in the event of movements in interest rates.
Treasury shares	Treasury shares In accordance with IAS 32, Sanofi treasury shares are deducted from equity, irrespective of the purpose for which they are held. No gain or loss is recognized in the income statement on the purchase, sale, impairment or cancellation of treasury shares.
Provisions for risks	Provisions for risks In accordance with IAS 37 (Provisions, Contingent Liabilities and Contingent Assets), Sanofi records a provision when it has a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources. If the obligation is expected to be settled more than 12 months after the end of the reporting period, or has no definite settlement date, the provision is recorded within Non-current provisions and other non-current liabilities . Provisions relating to the insurance programs in which Sanofi’s captive insurance company participates are based on risk exposure estimates calculated by management, with assistance from independent actuaries, using IBNR (Incurred But Not Reported) techniques. Those techniques use past claims experience, within Sanofi and in the market, to estimate future trends in the cost of claims. Contingent liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow of economic resources is remote. Sanofi estimates provisions on the basis of events and circumstances related to present obligations at the end of the reporting period and of past experience, and to the best of management’s knowledge at the date of preparation of the financial statements. Reimbursements offsetting the probable outflow of resources are recognized as assets only if it is virtually certain that they will be received. Contingent assets are not recognized. Restructuring provisions are recognized if Sanofi has a detailed, formal restructuring plan at the end of the reporting period and has announced its intention to implement this plan to those affected by it. No provisions are recorded for future operating losses. Sanofi records non-current provisions for certain obligations, such as legal or constructive obligations, where an outflow of resources is probable and the amount of the outflow can be reliably estimated. In the case of environmental risks, including at sites where operations are ongoing, Sanofi recognizes a provision where there is a violation of integrity in respect of human health or the environment resulting from past contamination at a site that requires remediation. The amount of the provision is a best estimate of the future expenditures to be incurred on the remediation plan. Where the effect of the time value of money is material, those provisions are measured at the present value of the expenditures expected to be required to settle the obligation, calculated using a discount rate that reflects an estimate of the time value of money and the risks specific to the obligation. Increases in provisions to reflect the effects of the passage of time are recognized within Financial expenses .
Revenue recognition	Revenue recognition B.13.1. Net sales Revenue arising from the sale of goods is presented in the income statement within Net sales . Net sales comprise revenue from sales of medicines, vaccines and active ingredients, net of sales returns, of customer incentives and discounts, and of certain sales-based payments paid or payable to the healthcare authorities. Analyses of net sales are provided in Note D.34.1. “ Analysis of net sales”. In accordance with IFRS 15 (Revenue from Contracts with Customers), such revenue is recognized when Sanofi transfers control over the product to the customer; control of an asset refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from that asset. For the vast majority of contracts, revenue is recognized when the product is physically transferred, in accordance with the delivery and acceptance terms agreed with the customer. For contracts entered into by Vaccines franchise, transfer of control is usually determined by reference to the terms of release (immediate or deferred) and acceptance of batches of vaccine. In the case of contracts with distributors, Sanofi does not recognize revenue when the product is physically transferred to the distributor if the products are sold on consignment, or if the distributor acts as agent. In such cases, revenue is recognized when control is transferred to the end customer, and the distributor’s commission is presented within the line item Selling and general expenses in the income statement. The amount of revenue recognized reflects the various types of price reductions or rights of return offered by Sanofi to its customers on certain products. Such price reductions and rights of return qualify as variable consideration under IFRS 15. In particular, products sold in the United States are covered by various Government and State programs (such as Medicare and Medicaid) under which products are sold at a discount. Rebates are granted to healthcare authorities, and under contractual arrangements with certain customers. Some wholesalers are entitled to chargeback incentives based on the selling price to the end customer, under specific contractual arrangements. Cash discounts may also be granted for prompt payment. Returns, discounts, incentives and rebates, as described above, are recognized in the period in which the underlying sales are recognized as a reduction of gross sales . These amounts are calculated as follows: • the amount of chargeback incentives is estimated on the basis of the relevant subsidiary’s standard sales terms and conditions, and in certain cases on the basis of specific contractual arrangements with the customer; • the amount of rebates based on attainment of sales targets is estimated and accrued as each of the underlying sales transactions is recognized; • the amount of price reductions under Government and State programs, largely in the United States, is estimated on the basis of the specific terms of the relevant regulations or agreements, and accrued as each of the underlying sales transactions is recognized; and • the amount of sales returns is calculated on the basis of management’s best estimate of the amount of product that will ultimately be returned by customers. In countries where product returns are permitted, Sanofi operates a returns policy that allows the customer to return products within a certain period either side of the expiry date (usually 12 months after the expiry date). The amount recognized for returns is estimated on the basis of past experience of sales returns. Sanofi also takes into account factors such as levels of inventory in its various distribution channels, product expiry dates, information about potential discontinuation of products, the entry of competing generics into the market, and the launch of over-the-counter medicines. Most product return clauses relate solely to date-expired products, which cannot be resold and are destroyed. Sanofi does not recognize a right of return asset in the balance sheet for contracts that allow for the return of time-expired products, since those products have no value. The estimated amounts described above are recognized in the income statement within Net sales as a reduction of gross sales, and within Other current liabilities in the balance sheet. They are subject to regular review and adjustment as appropriate based on the most recent data available to management. Sanofi believes that it has the ability to measure each of the above amounts reliably, using the following factors in developing its estimates: • the nature and patient profile of the underlying product; • the applicable regulations or the specific terms and conditions of contracts with governmental authorities, wholesalers and other customers; • historical data relating to similar contracts, in the case of qualitative and quantitative rebates and chargeback incentives; • past experience and sales growth trends for the same or similar products; • actual inventory levels in distribution channels, monitored by Sanofi using internal sales data and externally provided data; • the shelf life of Sanofi products; and • market trends including competition, pricing and demand. An analysis of provisions for discounts, rebates and sales returns is provided in Note D.23. B.13.2. Other revenues The line item Other revenues is used to recognize all revenue that falls within the scope of IFRS 15 but does not relate to sales of Sanofi products. It mainly comprises (i) royalties received from licensing intellectual property rights to third parties; (ii) VaxServe sales of products sourced from third-party manufacturers; and (iii) revenue received under agreements for Sanofi to provide manufacturing services to third parties. Royalties received under licensing arrangements are recognized over the period during which the underlying sales are recognized. VaxServe is a vaccines related entity whose operations include the distribution within the United States of vaccines and other products manufactured by third parties. VaxServe sales of products sourced from third-party manufacturers are presented within Other revenues . Other revenues is also used to recognize revenues arising from the manufacturing of Consumer Healthcare products by legal entities within the scope of continuing operations on behalf of legal entities within the scope of discontinued operations (see Note B.7.). Other revenues includes revenues associated with Consumer Healthcare operations not transferred on the effective date of loss of control of Opella. These comprise primarily, but not exclusively, Consumer Healthcare activities that will not be transferred on the effective date of loss of control of Opella, primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements ; (ii) sales made by the dedicated entity Opella Russie, the equity interests in which will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term ; and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights) .
Cost of sales	Cost of sales Cost of sales consists primarily of the industrial cost of goods sold, royalties paid for in-licensing of intellectual property, and distribution costs. The industrial cost of goods sold includes the cost of materials, depreciation of property, plant and equipment , amortization of software, personnel costs, and other expenses attributable to prod uction . This line also includes the purchase price of manufactured pharmaceutical products sourced from Opella.
Research and development	Research and development Note B.4.1. “Research and development not acquired in a business combination” and Note B.4.3. “Other intangible assets acquired in a business combination” describe the principles applied to the recognition of research and development costs. Contributions or reimbursements received from alliance partners are recorded as a reduction of Research and development expenses .
Other operating income and expenses	Other operating income and expenses B.16.1. Other operating income Other operating income includes the share of profits that Sanofi is entitled to receive from alliance partners in respect of product marketing agreements. It also includes revenues generated under certain agreements, which may include partnership, co-promotion arrangements and licenses not included in Other revenues . This line item also includes realized and unrealized foreign exchange gains and losses on operating activities (see Note B.8.3.), and operating gains on disposals not regarded as major disposals (see Note B.20.). B.16.2. Other operating expenses Other operating expenses mainly comprise the share of profits that alliance partners are entitled to receive from Sanofi under product marketing agreements.
Amortization and impairment of intangible assets	Amortization and impairment of intangible assets B.17.1. Amortization of intangible assets The expenses recorded in this line item comprise amortization charged against intangible assets (products, trademarks and technology platforms, see Note D.4.) whose contribution to Sanofi’s commercial, industrial and development functions cannot be separately identified. Amortization of software, and of other rights of an industrial or operational nature, is recognized as an expense in the income statement, in the relevant line items of expense by function. B.17.2. Impairment of intangible assets This line item records impairment losses taken against intangible assets (products, trademarks, technology platforms and acquired research), and any reversals of such impairment losses.
Fair value remeasurement of contingent consideration	Fair value remeasurement of contingent consideration Changes in the fair value of contingent consideration that was (i) already carried in the books of an acquired entity, or (ii) granted in connection with a business combination and initially recognized as a liability in accordance with IFRS 3, are reported in profit or loss. Such adjustments are reported separately in the income statement, in the line item Fair value remeasurement of contingent consideration . This line item also includes changes in the fair value of contingent consideration receivable in connection with a divestment and classified as a financial asset at fair value through profit or loss. Finally, it includes the effect of the unwinding of discount, and of exchange rate movements where the asset or liability is expressed in a currency other than the functional currency of the reporting entity.
Restructuring costs and similar items	Restructuring costs and similar items Restructuring costs are expenses incurred in connection with the transformation or reorganization of Sanofi’s operations or support functions. Such costs include collective redundancy plans, compensation to third parties for early termination of contracts, and commitments made in connection with transformation or reorganization decisions. They also include accelerated depreciation charges arising from site closures (including closures of leased sites), and losses on asset disposals resulting from such decisions. In addition, this line item includes expenses incurred in connection with programs implemented as part of the transformation strategy announced in December 2019 and recently renewed in October 2023, and intended primarily to deliver a global information systems solution, further supported by the implementation from 2021 of Sanofi’s n ew digital strategy .
Other gains and losses, and litigation	Other gains and losses, and litigation The line item Other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount which Sanofi believes it necessary to report separately in the income statement in order to improve the relevance of the financial statements, such as: • gains and losses on major disposals of property, plant and equipment, of intangible assets, of assets (or groups of assets and liabilities) held for sale, or of a business within the meaning of IFRS 3, other than those considered to be restructuring costs; • impairment losses and reversals of impairment losses on assets (or groups of assets and liabilities) held for sale, other than those considered to be restructuring costs; • gains on bargain purchases; • costs relating to major litigation; and • pre-tax separation costs associated with the process of disinvesting from operations in the event of a major divestment.
Financial expenses and income	Financial expenses and income B.21.1. Financial expenses Financial expenses mainly comprise interest charges on Sanofi's debt financing; negative changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange losses on financing and investing activities; impairment losses on financial instruments; and any reversals of impairment losses on financial instruments. Financial expenses also include expenses arising from the unwinding of discount on long-term provisions, and the net interest cost related to employee benefits. This line item does not include commercial cash discounts, which are deducted from net sales. B.21.2. Financial income Financial income includes interest and dividend income; positive changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange gains on financing and investing activities; and gains on disposals of financial assets at fair value through profit or loss.
Income tax expense	Income tax expense Income tax expense includes all current and deferred taxes of consolidated companies. Sanofi accounts for deferred taxes in accordance with IAS 12 (Income Taxes), using the methods described below: • deferred tax assets and liabilities are recognized on taxable and deductible temporary differences, and on tax loss carry- forwards. Temporary differences are differences between the carrying amount of an asset or liability in the balance sheet and its tax base; • French business taxes include a value added based component: “CVAE” (Cotisation sur la Valeur Ajoutée des Entreprises) . Given that CVAE is (i) calculated as the amount by which certain revenues exceed certain expenses and (ii) borne primarily by companies that own intellectual property rights on income derived from those rights (royalties, and margin on sales to third parties and to Sanofi entities), it is regarded as meeting the definition of income taxes specified in IAS 12, paragraph 2 (“taxes which are based on taxable profits”); • deferred tax assets and liabilities are calculated using the tax rate expected to apply in the period when the corresponding temporary differences are expected to reverse, based on tax rates enacted or substantively enacted at the end of the reporting period; • deferred tax assets are recognized in respect of deductible temporary differences, tax losses available for carry-forward and unused tax credits to the extent that future recovery is regarded as probable. The recoverability of deferred tax assets is assessed on a case-by-case basis, taking into account the profit forecasts contained in Sanofi’s medium-term business plan; • a deferred tax liability is recognized for temporary differences relating to interests in subsidiaries, associates and joint ventures, except in cases where Sanofi is able to control the timing of the reversal of the temporary differences. This applies in particular when Sanofi is able to control dividend policy and it is probable that the temporary differences will not reverse in the foreseeable future; • no deferred tax is recognized on eliminations of intragroup transfers of interests in subsidiaries, associates or joint ventures; • each tax entity calculates its own net deferred tax position. All net deferred tax asset and liability positions are then aggregated and shown in separate line items on the relevant side of the consolidated balance sheet. Deferred tax assets and liabilities are offset only if (i) Sanofi has a legally enforceable right to offset current tax assets and current tax liabilities, and (ii) the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority; • deferred taxes are not discounted, except implicitly in the case of deferred taxes on assets and liabilities which are already impacted by discounting. In addition, Sanofi has elected not to discount current taxes payable or receivable where the amounts in question are payable or receivable in the long term; and • withholding taxes on intragroup royalties and dividends, and on royalties and dividends collected from third parties, are accounted for as current income taxes. In accounting for business combinations, Sanofi complies with IFRS 3 as regards the recognition of deferred tax assets after the initial accounting period. Consequently, any deferred tax assets recognized by the acquiree after the end of that period in respect of temporary differences or tax loss carry-forwards existing at the acquisition date are recognized in profit or loss. The positions adopted by Sanofi in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, Sanofi assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information; that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice; and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of Sanofi’s best estimate and recognized as a liability; uncertain tax assets are not recognized. The amount of the liability includes any penalties and late payment interest. The line item Income tax expense includes the effects of tax reassessments and tax disputes, and any penalties and late payment interest arising from such disputes that have the characteristics of income taxes within the meaning of paragraph 2 of IAS 12 (“taxes which are based on taxable profits”). Tax exposures relating to corporate income taxes are presented separately within Non-current income tax liabilities (see Note D.19.4.). No deferred taxation is recognized on temporary differences that are liable to be subject to US global intangible low taxed income (GILTI) provisions. The related tax expense is recognized in the year in which it is declared in the tax return to the extent that it arises from the existence of non-US profits that exceed the theoretical return on investment specified in the GILTI provisions and are taxed at a rate lower than the applicable US tax rate. As a reminder, Sanofi has applied in its consolidated financial statements “International Tax Reform – Pillar Two Model Rules”, an amendment to IAS 12 issued by the IASB on May 23, 2023, and has not recognized deferred tax on temporary differences related to Pillar Two rules. In accordance with IAS 1 (Presentation of Financial Statements), current income tax assets and liabilities are presented as separate line items in the consolidated balance sheet.
Employee benefit obligations	Employee benefit obligations Sanofi offers retirement benefits to employees and retirees. Such benefits are accounted for in accordance with IAS 19 (Employee Benefits). Benefits are provided in the form of either defined contribution plans or defined benefit plans. In the case of defined contribution plans, the cost is recognized immediately in the period in which it is incurred, and equates to the amount of the contributions paid by Sanofi. For defined benefit plans, Sanofi recognizes its obligations to pay pensions and similar benefits to employees as a liability, based on an actuarial estimate of the rights vested or currently vesting in employees and retirees, using the projected unit credit method. Estimates are performed at least once a year, and rely on financial assumptions (such as discount rates, the inflation rate and the rate of salary increases) and demographic assumptions (such as life expectancy, retirement age and employee turnover). Obligations relating to other post-employment benefits (healthcare and life insurance ) offered by Sanofi companies to employees are also recognized as a liability based on an actuarial estimate of the rights vested or currently vesting in employees and retirees at the end of the reporting period. Such liabilities are recognized net of the fair value of plan assets. In the case of multi-employer defined benefit plans where plan assets cannot be allocated to each participating employer with sufficient reliability, the plan is accounted for as a defined contribution plan, in accordance with paragraph 34 of IAS 19. The benefit cost for the period consists primarily of current service cost, past service cost, net interest cost, gains or losses arising from plan settlements not specified in the terms of the plan, and the impact of plan curtailments. Net interest cost for the period is determined by applying the opening discount rate specified in IAS 19 to the net liability (i.e. the amount of the obligation, net of plan assets) recognized in respect of defined benefit plans. Past service cost is recognized immediately in profit or loss in the period in which it is incurred, regardless of whether or not the rights have vested at the time of adoption (in the case of a new plan) or of amendment (in the case of an existing plan). Actuarial gains and losses on defined benefit plans (pensions and other post-employment benefits), also referred to as “Remeasurements of the net defined benefit liability (asset)” , arise as a result of changes in financial and demographic assumptions, experience adjustments, and the difference between the actual return and the return on plan assets included in the calculation of the net interest cost. The impacts of those remeasurements are recognized in Other comprehensive income , net of deferred taxes; they are not subsequently reclassifiable to profit or loss.
Share-based payment	Share-based payment Share-based payment expense is recognized as a component of operating income, in the relevant classification of expense by function. In measuring the expense, the level of attainment of any performance conditions is taken into account. B.24.1. Stock option plans Sanofi has granted a number of equity-settled share-based payment plans (stock option plans) to some of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees. In accordance with IFRS 2 (Share-Based Payment), services received from employees as consideration for stock options are recognized as an expense in the income statement, with the opposite entry recognized in equity. The expense corresponds to the fair value of the stock option plans, and is charged to income on a straight-line basis over the four -year vesting period of the plan. The fair value of stock option plans is measured at the date of grant using the Black-Scholes valuation model, taking into account the expected life of the options. The resulting expense also takes into account the expected cancellation rate of the options. The expense is adjusted over the vesting period to reflect (i) actual cancellation rates resulting from option-holders ceasing to be employed by Sanofi and (ii) attainment of non-market performance conditions. B.24.2. Employee share ownership plans Sanofi may offer its employees the opportunity to subscribe to reserved share issues at a discount to the reference market price. Shares awarded to employees under such plans fall within the scope of IFRS 2. Consequently, an expense is recognized at the subscription date, based on the value of the discount offered to employees, with the opposite entry recognized in equity. B.24.3. Restricted share plans Sanofi may award restricted share plans to certain of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees. In accordance with IFRS 2, an expense equivalent to the fair value of such plans is recognized in profit or loss on a straight line basis over the vesting period of the plan, with the opposite entry recognized in equity. The vesting period is three years . The fair value of restricted share plans is based on the quoted market price of Sanofi shares at the date of grant, adjusted for expected dividends during the vesting period; it also takes account of any vesting conditions contingent on stock market performance, measured using the Monte-Carlo valuation model. Other vesting conditions are taken into account in the estimate of the number of shares awarded during the vesting period; that number is then definitively adjusted based on the actual number of shares awarded on the vesting date.
Earnings per share	Earnings per share Basic earnings per share is calculated using the weighted average number of shares outstanding during the reporting period, adjusted on a time-weighted basis from the acquisition date to reflect the number of own shares held by Sanofi. Diluted earnings per share is calculated on the basis of the weighted average number of ordinary shares, computed using the treasury stock method. This method assumes that (i) all outstanding dilutive options and warrants are exercised, and (ii) Sanofi acquires its own shares at the quoted market price for an amount equivalent to the cash received as consideration for the exercise of the options or warrants, plus the expense arising on unamortized stock options.
Segment information	B.26. Segment information In accordance with IFRS 8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of the segment is monitored individually using internal reports and indicators. Information about operating segments in accordance with IFRS 8 is presented in Note D.35., “Segment information”.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Corporate information and statement of IFRS compliance [abstract]
Summary of Useful Lives of Property, Plant and Equipment	The customary useful lives of property, plant and equipment are as follows: Buildings 15 to 40 years Fixtures 10 to 20 years Machinery and equipment 5 to 15 years Other 3 to 15 years
Disclosure of Detailed Information about Financial Instruments		The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments. Note Type of financial instrument Measurement principle Level in fair value hierarchy Valuation technique Method used to determine fair value Valuation model Market data Exchange rate Interest rate D.7. Financial assets measured at fair value (quoted equity instruments) Fair value 1 Market value Quoted market price N/A D.7. Financial assets measured at fair value (quoted debt instruments) Fair value 1 Market value Quoted market price N/A D.7. Financial assets measured at fair value (unquoted equity instruments) Fair value 3 Cost/ Approach based on comparables If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables. D.7. Financial assets measured at fair value (contingent consideration receivable) Fair value 3 Revenue- based approach The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. D.7. Financial assets measured at fair value held to meet obligations under post-employment benefit plans Fair value 1 Market value Quoted market price N/A D.7. Financial assets designated at fair value held to meet obligations under deferred compensation plans Fair value 1 Market value Quoted market price N/A D.7. Long-term loans and advances and other non-current receivables Amortized cost N/A N/A The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value. D.13. Investments in mutual funds Fair value 1 Market value Net asset value N/A D.13. Negotiable debt instruments, commercial paper, instant access deposits and term deposits Amortized cost N/A N/A Because these instruments have a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements. D.17.1., D.19. Debt Amortized cost (a) N/A N/A In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments). For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections. D.17.2. Lease liabilities Amortized cost N/A N/A The liability for future lease payments is discounted using the incremental borrowing rate. D.20. Forward currency contracts Fair value 2 Present value of future cash flows Mid Market < 1 year: Mid Money Market > 1 year: Mid Zero Coupon D.20. Interest rate swaps Fair value 2 Revenue- based approach Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon D.20. Cross-currency swaps Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and LIFFE interest rate futures > 1 year: Mid Zero Coupon D.18. Liabilities related to business combinations and to non-controlling interests (CVRs) Fair value 1 Market value Quoted market price D.18. Liabilities related to business combinations and to non-controlling interests (other than CVRs) Fair value 3 Revenue- based approach Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.8.4. (a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2024
Property, plant and equipment [abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment owned by Sanofi is comprised of the following items: (€ million) Land Buildings Machinery and equipment Fixtures, fittings and other Property, plant and equipment in process Total Gross value at January 1, 2022 240 7,170 11,648 2,655 3,097 24,810 Changes in scope of consolidation (17) (294) (1,480) (163) (150) (2,104) Acquisitions and other increases — 11 54 41 1,642 1,748 Disposals and other decreases (1) (161) (240) (155) (2) (559) Currency translation differences 17 122 144 29 35 347 Transfers (a) (2) 480 722 108 (1,626) (318) Gross value at December 31, 2022 237 7,328 10,848 2,515 2,996 23,924 Changes in scope of consolidation — (11) (29) (7) (4) (51) Acquisitions and other increases — 27 47 36 1,583 1,693 Disposals and other decreases (2) (50) (340) (100) (10) (502) Currency translation differences (5) (94) (71) (30) (45) (245) Transfers (a) (2) 481 457 86 (1,071) (49) Gross value at December 31, 2023 228 7,681 10,912 2,500 3,449 24,770 Changes in scope of consolidation — — — — — — Acquisitions and other increases — 13 36 36 1,632 1,717 Disposals and other decreases (3) (209) (510) (173) (79) (974) Currency translation differences 13 163 126 30 17 349 Transfers (a) (1) 335 764 142 (1,235) 5 Opella reclassification (b) (36) (539) (866) (154) (211) (1,806) Gross value at December 31, 2024 201 7,444 10,462 2,381 3,573 24,061 Accumulated depreciation & impairment at January 1, 2022 (9) (4,190) (8,340) (2,115) (128) (14,782) Changes in scope of consolidation — 201 1,202 130 — 1,533 Depreciation expense — (356) (622) (164) — (1,142) Impairment losses, net of reversals (1) (50) (58) (2) (75) (186) Disposals and other decreases — 133 201 153 31 518 Currency translation differences — (52) (69) (22) 5 (138) Transfers (a) — 89 49 5 (1) 142 Accumulated depreciation & impairment at December 31, 2022 (10) (4,225) (7,637) (2,015) (168) (14,055) Changes in scope of consolidation — 5 16 3 — 24 Depreciation expense — (321) (620) (139) — (1,080) Impairment losses, net of reversals — (30) (46) (4) (50) (130) Disposals and other decreases — 48 334 98 8 488 Currency translation differences 2 45 44 21 — 112 Transfers (a) — (22) 36 (1) 18 31 Accumulated depreciation & impairment at December 31, 2023 (8) (4,500) (7,873) (2,037) (192) (14,610) Changes in scope of consolidation — — — — — — Depreciation expense — (325) (580) (136) — (1,041) Impairment losses, net of reversals — (47) (23) (3) (32) (105) Disposals and other decreases 1 197 507 172 37 914 Currency translation differences 1 (77) (95) (18) — (189) Transfers (a) — 9 5 4 (3) 15 Opella reclassification (b) 6 333 599 97 11 1,046 Accumulated depreciation & impairment at December 31, 2024 — (4,410) (7,460) (1,921) (179) (13,970) Carrying amount at December 31, 2022 227 3,103 3,211 500 2,828 9,869 Carrying amount at December 31, 2023 220 3,181 3,039 463 3,257 10,160 Carrying amount at December 31, 2024 201 3,034 3,002 460 3,394 10,091 (a) This line mainly comprises property, plant and equipment in process brought into service during the period, and reclassification of assets (other than Opella assets) to Assets held for sale . (b) This line comprises property, plant and equipment owned by Opella, reclassified to Assets held for sale as of December 31, 2024 in accordance with IFRS 5 (see Note D.1.) .
Summary of Acquisitions and Capitalized Interest by Operating Segment	The table below sets forth acquisitions and capitalized interest for the years ended December 31, 2024 , 2023 and 2022 : (€ million) 2024 2023 2022 Acquisitions 1,717 1,693 1,748 Biopharma (operating segment) 1,554 1,592 1,678 of which Manufacturing & Supply 1,114 1,188 1,129 Opella (discontinued operation, see Note D.1.) 163 101 70 of which Manufacturing & Supply 135 90 63 Of which capitalized interest 51 26 17
Summary of Off Balance Sheet Commitments Relating to Property, Plant and Equipment	Off balance sheet commitments relating to property, plant and equipment as of December 31, 2024 , 2023 and 2022 are set forth below: (€ million) 2024 2023 2022 Firm orders of property, plant and equipment 422 638 861 Property, plant and equipment pledged as security for liabilities 21 16 —
Summary of Impairment Losses Recognised in Property, Plant and Equipment	The table below sets forth the net impairment losses recognized in each of the last three financial periods: (€ million) 2024 2023 2022 Net impairment losses on property, plant and equipment (a) 105 130 186 (a) These amounts mainly comprise impairment losses recognized as a result of decisions taken during the periods presented, relating primarily to shutdowns or changes in use of industrial sites.
Summary of Property, Plant and Equipment Leased	Right-of-use assets relating to property, plant and equipment leased by Sanofi are analyzed in the table below: (€ million) Right-of-use assets Gross value at January 1, 2022 2,745 Changes in scope of consolidation (26) Acquisitions and other increases 292 Disposals and other decreases (232) Currency translation differences 101 Transfers (a) (8) Gross value at December 31, 2022 2,872 Acquisitions and other increases 247 Disposals and other decreases (314) Currency translation differences (58) Transfers (a) (75) Gross value at December 31, 2023 2,672 Acquisitions and other increases 442 Disposals and other decreases (375) Currency translation differences 89 Transfers(a) (60) Opella reclassification (b) (155) Gross value at December 31, 2024 2,613 Accumulated depreciation & impairment at January 1, 2022 (797) Changes in scope of consolidation 14 Depreciation and impairment charged in the period (341) Disposals and other decreases 82 Currency translation differences (17) Transfers (a) 2 Accumulated depreciation & impairment at December 31, 2022 (1,057) Depreciation and impairment charged in the period (292) Disposals and other decreases 276 Currency translation differences 21 Transfers (a) 34 Accumulated depreciation & impairment at December 31, 2023 (1,018) Depreciation and impairment charged in the period (315) Disposals and other decreases 183 Currency translation differences (30) Transfers (a) 38 Opella reclassification (b) 39 Accumulated depreciation & impairment at December 31, 2024 (1,103) Carrying amount at December 31, 2022 1,815 Carrying amount at December 31, 2023 1,654 Carrying amount at December 31, 2024 1,510 (a) This line also includes the effect of the reclassification of assets (other than Opella assets) to Assets held for sale . (b) This line comprises the Opella right-of-use assets, reclassified to Assets held for sale as of December 31, 2024 in accordance with IFRS 5 (see Note D.1.) .

Goodwill and other intangible_2

Goodwill and other intangible assets (Tables)	12 Months Ended
	Dec. 31, 2024
Intangible assets and goodwill [abstract]
Schedule of Movements in Goodwill	Movements in goodwill comprise: (€ million) Goodwill Balance at January 1, 2022 48,056 Acquisitions during the period 609 Other movements during the period (a) (258) Currency translation differences 1,485 Balance at December 31, 2022 49,892 Acquisitions during the period (c) 475 Other movements during the period (a) (90) Currency translation differences (873) Balance at December 31, 2023 49,404 Acquisitions during the period — Other movements during the period (a) (351) Currency translation differences 1,586 Opella reclassification (b) (7,255) Balance at December 31, 2024 43,384 (a) This line mainly comprises the amount of goodwill allocated to divested operations in accordance with paragraph 86 of IAS 36, including in 2024 the allocated goodwill relating to the divestment of the Enjaymo activity to Recordati (see Note D.1.). For 2022, this line includes the loss of control of EUROAPI (see Note D.1.). (b) The Opella goodwill is presented within Assets held for sale (see Note D.1.). (c) The final purchase price allocation for QRIB Intermediate Holdings, LLC resulted in the recognition of intangible assets (other than goodwill) of €774 million as of the acquisition date (September 29, 2023) and of goodwill measured at €484 million as of the acquisition date (see Note D.1.).
Schedule of Movements in Other Intangible Assets	Movements in other intangible assets comprise: (€ million) Acquired R&D Products, trademarks and other rights Software Total other intangible assets Gross value at January 1, 2022 (a) 11,207 65,906 1,752 78,865 Changes in scope of consolidation (c) — 499 (35) 464 Acquisitions and other increases 277 195 99 571 Disposals and other decreases (72) (423) (48) (543) Currency translation differences 518 1,994 21 2,533 Transfers (b) (1,576) 1,408 (6) (174) Gross value at December 31, 2022 10,354 69,579 1,783 81,716 Changes in scope of consolidation (c) 113 3,287 1 3,401 Acquisitions and other increases (f) 1,062 1,970 80 3,112 Disposals and other decreases (262) (380) (41) (683) Currency translation differences (242) (1,584) (11) (1,837) Transfers (b) (1,253) 861 (4) (396) Gross value at December 31, 2023 9,772 73,733 1,808 85,313 Changes in scope of consolidation (c) 1,745 — — 1,745 Acquisitions and other increases (f) 1,006 444 104 1,554 Disposals and other decreases (58) (1,447) (9) (1,514) Currency translation differences 606 2,708 17 3,331 Transfers (b) (52) 66 (11) 3 Opella reclassification (a) (153) (9,156) (57) (9,366) Gross value at December 31, 2024 12,866 66,348 1,852 81,066 Accumulated amortization & impairment at January 1, 2022 (a) (3,477) (52,744) (1,237) (57,458) Changes in scope of consolidation — — 11 11 Amortization expense (e) — (2,099) (97) (2,196) Impairment losses, net of reversals (d) (1,107) 1,561 — 454 Disposals and other decreases 75 411 39 525 Currency translation differences (7) (1,567) (17) (1,591) Transfers (b) 388 (214) 5 179 Accumulated amortization & impairment at December 31, 2022 (4,128) (54,652) (1,296) (60,076) Changes in scope of consolidation (c) — 33 — 33 Amortization expense — (2,225) (120) (2,345) Impairment losses, net of reversals (d) (90) (842) — (932) Disposals and other decreases 262 326 41 629 Currency translation differences 94 1,184 9 1,287 Transfers (b) 128 268 14 410 Accumulated amortization & impairment at December 31, 2023 (3,734) (55,908) (1,352) (60,994) Amortization expense — (2,094) (106) (2,200) Impairment losses, net of reversals (d) (638) 373 1 (264) Disposals and other decreases 58 655 9 722 Currency translation differences (191) (1,928) (15) (2,134) Transfers (b) (2) (3) — (5) Opella reclassification (a) 10 6,398 30 6,438 Accumulated amortization & impairment at December 31, 2024 (4,497) (52,507) (1,433) (58,437) Carrying amount at December 31, 2022 6,226 14,927 487 21,640 Carrying amount at December 31, 2023 6,038 17,825 456 24,319 Carrying amount at December 31, 2024 8,369 13,841 419 22,629 (a) Comprises the other intangible assets of Opella, now reclassified to Assets held for sale at December 31, 2024 in accordance with IFRS 5 (see note D.1.). (b) The “Transfers” line mainly comprises (i) acquired R&D that came into commercial use during the period and (ii) reclassifications of assets (other than Opella assets) as Assets held for sale . (c) The “Changes in scope of consolidation” line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during the period (see Note D.1.) . (d) See Note D.5. (e) The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of €226 million in 2022 (see Note C.1.) . (f) This line mainly comprises: In 2023: – the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April 2023 in respect of the agreements on Beyfortus (nirsevimab) (see Note C.2.); – an upfront payment of $500 million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co- commercialization of TEV’574;and – an upfront payment of $175 million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli. In 2024: – an upfront payment of $500 million for the rights acquired under the agreement with Novavax relating to the co-exclusive license agreement for the co-commercialization of a COVID-19 vaccine and the development of a combined flu-COVID-19 vaccine; and – an upfront payment of $300 million for the rights acquired under an agreement with Corxel Pharmaceuticals for the development and commercialization rights to aficamten in China.
Detailed Information for Principal Marketed Products	The table below provides information about the principal “marketed products”, which were recognized in connection with major acquisitions made by Sanofi and represented 95% of the carrying amount of that item as of December 31, 2024 : (€ million) Gross value Accumulated amortization & impairment December 31, 2024 Amortization period (years) (a) Residual amortization period (years) (b) Carrying amount at December 31, 2023 Carrying amount at December 31, 2022 Genzyme (c) 10,600 (10,541) 59 10 2 208 621 Boehringer Ingelheim (c) 3,520 (1,756) 1,764 17 10 1,806 2,037 Aventis (c) 34,175 (34,136) 39 9 10 43 58 Chattem (c) 1,406 (924) 482 23 10 501 574 Protein Sciences (c) 886 (505) 381 13 6 420 498 Ablynx (c) 1,966 (883) 1,083 14 8 1,220 1,357 Bioverativ (c) 8,375 (4,026) 4,349 13 8 5,152 4,836 Rezurock 2,033 (520) 1,513 12 9 1,580 1,702 Tzield 2,714 (375) 2,339 12 11 2,405 — Beyfortus 2,288 (201) 2,087 17 16 1,870 180 Qunol 790 (91) 699 10 8 722 — Total: principal marketed products incl. Opella products presented in "Assets held for sale" 68,753 (53,958) 14,795 15,927 11,863 Total: principal marketed products excl. Opella products presented in "Assets held for sale" 60,214 (48,212) 12,002 13,055 9,429 (a) Weighted averages. The amortization periods for these products vary between 1 and 25 years. (b) Weighted averages. (c) Commercialized products derived from the acquisition of these companies. In the case of Bioverativ, the product Enjaymo was sold to Recordati in 2024 (see Note D.1.).
Amortization of Softwares Recognized in Income Statement	An analysis of amortization of software is shown in the table below: (€ million) 2024 2023 (a) 2022 (a) Cost of sales 16 14 9 Research and development expenses 1 3 1 Selling and general expenses 87 100 82 Other operating expenses 1 2 4 Net income from discontinued operations 1 1 1 Total 106 120 97 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation .

Impairment of intangible asse_2

Impairment of intangible assets and property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2024
Impairment Of Assets [Abstract]
Summary of Net Impairment Losses of Other Intangible Assets	In 2024 , 2023 and 2022 , impairment testing of other intangible assets (excluding software) resulted in the recognition of net impairment losses as shown below (the table presents all net impairments of the Group including Opella, over all periods): (€ million) 2024 2023 2022 Impairment of other intangible assets, net of reversals (excluding software) 265 932 (454) Marketed products (167) — (1,561) Biopharma (a) (167) — (1,526) Opella — — (35) Research and development projects and technology platforms (b)(c)(d) 415 896 1,107 Others 17 36 — (a) For 2024, this comprises a reversal of €167 million in connection with the disposal of Enjaymo. For 2022, this amount mainly comprises a reversal of €2,154 million of impairment losses taken against Eloctate and BIVV001 (assets belonging to the Eloctate franchise), consisting of €1,554 million for marketed products and €600 million for research and development projects respectively. In 2019, the launch of competing products for Eloctate led Sanofi to update its sales forecasts for products belonging to the franchise, as a result of which impairment losses of €2.8 billion were recognized against the assets in question. The reversal reflects the approval by the FDA on February 22, 2023 of ALTUVIIIO (the commercial name of efanesoctocog alpha, corresponding to the BIVV001 project), which was submitted in 2022. (b) For 2024, the monitoring of impairment indicators for other intangible assets led to the recognition of net impairment losses of €415 million , comprising (i) impairment losses of €640 million against various research and development projects - including a €239 million loss resulting from the decision taken in February 2025 to discontinue a phase 3 clinical study investigating of a vaccine candidate to prevent invasive E.coli disease - and (ii) an impairment reversal of €225 million recognized in connection with the disposal of the ProXTen technology platform. (c) For 2023, this amount mainly comprises an impairment loss of €833 million , reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and ProXTen technology platforms. (d) For 2022, this amount mainly comprises: – an impairment loss of €1,586 million taken against the development project for SAR444245 (non-alpha interleukin-2), recognized following revised cash flow projections reflecting unfavorable developments in the launch schedule; – the €600 million reversal relating to the BIVV001 project (see above). As required by IFRS 5, the other intangible assets of Opella were measured in accordance with IAS 36 immediately before their reclassification as assets held for sale; this assessment did not result in any impairment of their carrying amount being recognized.

Investments accounted for usi_2

Investments accounted for using the equity method (Tables)	12 Months Ended
	Dec. 31, 2024
Interests In Other Entities [Abstract]
Summary of Investments in Associates and Joint Ventures	(€ million) % interest 2024 2023 2022 EUROAPI (a) 29.6 82 162 392 Infraserv GmbH & Co. Höchst KG (b) 31.2 102 90 97 MSP Vaccine Company (c) 50.0 81 96 104 Other investments — 51 76 84 Total 316 424 677 (a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€ 2.88 as of December 31, 2024, and € 5.73 as of December 31, 2023) . (b) Joint venture. (c) Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV .
Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures	The table below shows Sanofi’s overall share of (i) profit or loss and (ii) other comprehensive income from investments accounted for using the equity method, showing the split between associates and joint ventures in accordance with IFRS 12 (the amounts for each individual associate or joint venture are not material): 2024 2023 2022 (€ million) Joint ventures Associates Joint ventures Associates Joint ventures Associates Share of profit/(loss) from investments accounted for using the equity method (a) 134 (74) 101 (237) 73 (18) Share of other comprehensive income from investments accounted for using the equity method 3 (5) (7) 7 (3) (1) Total 137 (79) 94 (230) 70 (19) (a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€ 2.88 as of December 31, 2024, and € 5.73 as of December 31, 2023).
Summary of Principal Transactions and Balances with Related Parties	The principal transactions and balances with related parties are summarized below: (€ million) 2024 2023 2022(a) Sales (d) 103 157 131 Royalties and other income (d) 71 14 21 Accounts receivable and other receivables (b) 184 249 330 Other assets (c) 189 — — Purchases and other expenses (including research expenses) (d) 600 573 472 Accounts payable and other liabilities 160 190 258 (a) In 2022, these items include Sanofi's transactions with EUROAPI from May 10, 2022 (see Note D.1.). (b) Includes loans to joint ventures and associates. (c) In October 2024, Sanofi raised its investment in EUROAPI by € 200 million in the form of a perpetual subordinated hybrid bon d. The fair value of this investment as of December 31, 2024 is € 189 million. (d) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Other non-current assets (Table

Other non-current assets (Tables)	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Summary of Other Non-current Assets	Other non-current assets comprise: (€ million) 2024 2023 2022 Equity instruments at fair value through other comprehensive income (D.7.1.) 1,559 1,088 936 Debt instruments at fair value through other comprehensive income (D.7.2.) 357 346 329 Other financial assets at fair value through profit or loss (D.7.3.) 1,027 808 823 Pre-funded pension obligations (Note D.19.1.) 156 271 269 Long-term prepaid expenses 152 114 286 Long-term loans and advances and other non-current receivables (a) 502 591 452 Derivative financial instruments (Note D.20.) — — — Total 3,753 3,218 3,095 (a) As of December 31, 2024 , this line includes: – Loan of € 149 million to the BioAtrium joint venture which matures on December 1, 2031, of which €156 million was recognized in "Other current assets" as of December 31, 2022; – a receivable under a sub-lease amounting to € 116 million ( € 181 million before discounting), versus € 132 million (or € 195 million before discounting) as of December 31, 2023 .

Assets held for sale or excha_2

Assets held for sale or exchange and liabilities related to assets held for sale or exchange (Tables)	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Summary of Assets Held for Sale or Exchange, and Liabilities Related to Assets Held for Sale or Exchange	Assets held for sale, and liabilities related to assets held for sale, comprise: (€ million) December 31, 2024 December 31, 2023 December 31, 2022 Opella (D.36.) 13,489 — — Other — 15 85 Assets held for sale 13,489 15 85 Opella (D.36.) 2,131 — — Other — 13 10 Liabilities related to assets held for sale 2,131 13 10

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Schedule of Inventories	Inventories comprise the following: 2024 2023 2022 (€ million) Gross value Allowances Carrying amount Gross value Allowances Carrying amount Gross value Allowances Carrying amount Raw materials 1,588 (135) 1,453 1,676 (126) 1,550 1,613 (139) 1,474 Work in process 5,777 (481) 5,296 5,869 (553) 5,316 5,663 (678) 4,985 Finished goods 2,899 (217) 2,682 3,045 (245) 2,800 2,748 (247) 2,501 Total 10,264 (833) 9,431 10,590 (924) 9,666 10,024 (1,064) 8,960

Accounts receivable (Tables)

Accounts receivable (Tables)	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Summary of Accounts Receivable	Accounts receivable break down as follows: (€ million) December 31, 2024 December 31, 2023 December 31, 2022 Gross value 7,777 8,528 8,537 Allowances (100) (95) (113) Carrying amount 7,677 8,433 8,424
Summary of Gross Value of Overdue Receivables	(€ million) Overdue accounts gross value Overdue by <1 month Overdue by 1 to 3 months Overdue by 3 to 6 months Overdue by 6 to 12 months Overdue by > 12 months December 31, 2024 650 316 194 87 9 44 December 31, 2023 689 269 154 123 62 81 December 31, 2022 452 118 161 87 35 51

Other current assets (Tables)

Other current assets (Tables)	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Schedule of Other Current Assets	An analysis of Other current assets is set forth below: (€ million) 2024 2023 2022 Tax receivables, other than corporate income taxes 782 768 660 Prepaid expenses 895 768 714 Other receivables (a) 1,446 1,448 1,289 Currency derivatives measured at fair value (see Note D.20.) 217 201 206 Other financial assets at fair value through profit or loss 115 112 146 Other current financial assets (b) 371 158 517 Total 3,826 3,455 3,532 (a) This line mainly comprises advance payments to suppliers, and receivables relating to Sanofi's activities as agent under a transitional services agreement. (b) This item mainly comprises bank loans and receivables maturing in less than one year with high-grade counterparties .

Financial assets and liabilit_2

Financial assets and liabilities measured at fair value (Tables)	12 Months Ended
	Dec. 31, 2024
Fair Value Measurement [Abstract]
Summary of Assets and Liabilities Measured at Fair Value	The table below shows the balance sheet amounts of assets and liabilities measured at fair value. 2024 2023 2022 Level in the fair value hierarchy Level in the fair value hierarchy Level in the fair value hierarchy (€ million) Note Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Financial assets measured at fair value Quoted equity investments D.7.1. 467 — — 470 — — 387 — — Unquoted equity investments D.7.1. — — 1,092 — — 618 — — 549 Quoted debt securities D.7.2. 357 — — 346 — — 329 — — Unquoted debt securities not meeting the definition of equity instruments D.7.3. — — 339 — — 132 — — 115 Contingent consideration relating to divestments D.7.3. & D.11. — — 286 — — 214 — — 303 Financial assets held to meet obligations under deferred compensation plans D.7.3. & D.11. 688 — — 572 — — 512 — — Non-current derivatives D.7. — — — — — — — — — Current derivatives D.11. — 217 — — 201 — — 206 — Mutual fund investments D.13. 4,161 — — 5,349 — — 9,537 — — Total financial assets measured at fair value 5,673 217 1,717 6,737 201 964 10,765 206 967 Financial liabilities measured at fair value Bayer contingent purchase consideration arising from the acquisition of Genzyme D.18. — — — — — — — — 26 MSD contingent consideration (European vaccines business) D.18. — — 72 — — 127 — — 204 Shire contingent consideration arising from the acquisition of Translate Bio D.18. — — 568 — — 441 — — 380 Contingent consideration arising from acquisition of Amunix D.18. — — — — — 137 — — 165 Other contingent consideration arising from business combinations and acquisitions D.18. — — 1 — — 4 — — 4 Non-current derivatives D.20. — 121 — — 164 — — 232 — Current derivatives D.19.5 — 337 — — 127 — — 94 — Total financial liabilities measured at fair value — 458 641 — 291 709 — 326 779

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Summary of Cash and Cash Equivalents	(€ million) 2024 2023 2022 Cash 1,270 1,461 1,385 Cash equivalents (a) 6,171 7,249 11,351 Cash and cash equivalents 7,441 8,710 12,736 (a) As of December 31, 2024 , cash equivalents mainly comprised the following: (i) €4,161 million invested in euro and US dollar denominated money-market mutual funds ( December 31, 2023 : €5,349 million ; December 31, 2022 : €9,537 million ); (ii) €1,293 million of term deposits ( December 31, 2023 : €1,191 million ; December 31, 2022 : €1,167 million ) and (iii) zero commercial paper ( December 31, 2023 : zero ; December 31, 2022 : zero ). Cash equivalents also include €446 million held by captive insurance and reinsurance companies in accordance with insurance regulations ( December 31, 2023 : €476 million ; December 31, 2022 : €439 million ).

Net deferred tax position (Tabl

Net deferred tax position (Tables)	12 Months Ended
	Dec. 31, 2024
Income Taxes [Abstract]
Summary of Net Deferred Tax Position	An analysis of the net deferred tax position is set forth below: (€ million) 2024 2023 2022 Deferred taxes on: Consolidation adjustments (intragroup margin in inventory) 1,927 1,525 1,388 Provision for pensions and other employee benefits 787 853 850 Remeasurement of other acquired intangible assets (2,079) (a) (2,795) (3,269) Recognition of acquired property, plant and equipment at fair value (10) (21) (24) Equity interests in subsidiaries and investments in other entities (b) (1,044) (1,023) (617) Tax losses available for carry-forward 971 1,526 1,506 Stock options and other share-based payments 103 84 92 Accrued expenses and provisions deductible at the time of payment (c) 2,277 1,994 1,859 Other (d) 2,869 2,427 1,755 Net deferred tax asset/(liability) 5,801 4,570 3,540 ( a ) A s of December 31, 2024 , includes remeasurements of the acquired intangible assets of Bioverativ ( €987 million ), Principia (€ 648 million ), Ablynx (€ 178 million ) and Genzyme ( €15 million ). (b) In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a deferred tax liability on the reserves of French and foreign subsidiaries (approximately € 64.9 billion ) which it regards as likely to be distributed in the foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2024 , Sanofi took into account changes in the ownership structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of the European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December 31, 2023, this line includes a deferred tax liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Opella business, as announced in October 2023 (see Note D.30.). (c) Includes deferred tax assets related to restructuring provisions, amounting to €319 million as of December 31, 2024 , €286 million as of December 31, 2023 , and €256 million as of December 31, 2022 . (d) Includes deferred taxes arising on the spread tax deduction of R&D expenses, amounting to € 2,053 million as of December 31, 2024 , € 1,331 million as of December 31, 2023 , and €742 million as of December 31, 2022 .
Summary of Tax Losses Available for Carry-forward	The table below shows when tax losses available for carry-forward are due to expire: (€ million) Tax losses available for carry-forward (a) 2025 1 2026 17 2027 12 2028 30 2029 187 2030 and later 9,565 Total as of December 31, 2024 9,812 Total as of December 31, 2023 8,933 Total as of December 31, 2022 8,503 (a) Excluding tax loss carry-forwards on asset disposals. Such carry-forwards amounted to €40 million as of December 31, 2024 , €5 million as of December 31, 2023 and €5 million as of December 31, 2022 .

Consolidated shareholders_ eq_2

Consolidated shareholders’ equity (Tables)	12 Months Ended
	Dec. 31, 2024
Share Capital, Reserves And Other Equity Interest [Abstract]
Summary of Treasury Shares Held	Treasury shares held by Sanofi are as follows: Number of shares (million) % of share capital for the period December 31, 2024 9.53 0.755% December 31, 2023 13.45 1.063% December 31, 2022 8.20 0.650% January 1, 2022 11.02 0.872%
Summary of Movements Share Capital	Movements in the share capital of the Sanofi parent company over the last three years are set forth below: Date Transaction Number of shares December 31, 2021 1,263,560,695 During 2022 Capital increase by exercise of stock subscription options (a) 490,373 During 2022 Capital increase by issuance of restricted shares (b) 1,499,987 Board meeting of July 27, 2022 Capital increase reserved for employees 2,027,057 Board meeting of December 14, 2022 Reduction in share capital by cancellation of treasury shares (6,742,380) December 31, 2022 1,260,835,732 During 2023 Capital increase by exercise of stock subscription options (a) 504,956 During 2023 Capital increase by issuance of restricted shares (b) 1,330,558 Board meeting of July 27, 2023 Capital increase reserved for employees 2,128,723 December 31, 2023 1,264,799,969 During 2024 Capital increase by exercise of stock subscription options (a) 398,569 During 2024 Capital increase by issuance of restricted shares (b) 1,479,787 Board meeting of July 24, 2024 Capital increase reserved for employees 2,244,396 Board meeting of December 4, 2024 Reduction in share capital by cancellation of treasury shares (5,800,000) December 31, 2024 1,263,122,721 (a) Shares issued on exercise of Sanofi stock subscription options. (b) Shares vesting under restricted share plans and issued in the period .
Principal Characteristics of Restricted Share Plans	Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. The principal characteristics of those plans are as follows: 2024 2023 2022 Type of plan Performance share plans Performance share plans Performance share plans Performance share plans Performance share plans Performance share plans Date of Board meeting approving the plan April 30, 2024 December 4, 2024 May 25, 2023 December 13, 2023 May 3, 2022 December 14, 2022 Service period 3 years 3 years 3 years 3 years 3 years 3 years Total number of shares awarded (a) 4,505,145 97,100 3,838,434 65,129 3,344,432 109,981 Of which with no market condition 2,888,502 6,649 2,425,047 944 2,000,627 10,335 Fair value per share awarded (b) €81.84 €79.51 €87.69 €77.42 €91.19 €79.17 Of which with market condition 1,616,643 90,451 1,413,387 64,185 1,343,805 99,646 Fair value per share awarded other than to the Chief Executive Officer (c) €72.79 €75.11 €83.74 €74.50 €86.65 €69.60 Fair value per share awarded other than to the Chief Executive Officer - additional shares (d) €13.50 €32.09 €43.60 €34.90 €49.00 €54.70 Fair value per share awarded to the Chief Executive Officer (c) €72.38 — €82.17 — €84.46 — Fair value of plan at the date of grant (€ million) 346 7 326 5 294 8 (a) Includes shares awarded in an additional tranche subject to a higher level of market conditions: 139,665 additional shares awarded in April 2024 and 8,229 awarded in December 2024 (versus 121,097 awarded in May 2023 and 5,838 awarded in December 2023 ). (b) Market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period. (c) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period. (d) Additional tranche subject to a higher level of market conditions: 139,665 additional shares awarded in April 2024 and 8,229 awarded in December 2024 (versus 121,097 awarded in May 2023 , 5,838 awarded in December 2023 , 114,874 awarded in May 2022 and 9,066 awarded in December 2022 ).
Summary of Number of Restricted Shares Not Yet Fully Vested	The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below: 2024(a) 2023(a) 2022(a) Total expense for restricted share plans (€ million) 260 231 206 Number of shares not yet fully vested as of December 31 10,914,134 9,773,084 9,245,513 Under 2024 plans 4,454,299 — — Under 2023 plans 3,501,088 3,780,513 — Under 2022 plans 2,958,747 3,099,158 3,330,801 Under 2021 plans — 2,893,413 3,097,531 Under 2020 plans — — 2,817,181 (a) Includes shares awarded in an additional tranche subject to a higher level of market conditions: 147,894 additional shares awarded in 2024 , versus 126,935 awarded in 2023 and 123,940 awarded in 2022 .
Summary of Characteristics of Employee Share Ownership Plans Awarded	The characteristics of the employee share ownership plans awarded in the form of a capital increase reserved for employees in 2024 , 2023 and 2022 are summarized in the table below: 2024 2023 2022 Date of Board meeting approving the plan January 31, 2024 February 2, 2023 February 3, 2022 Subscription price (€) (a) 72.87 79.58 80.21 Subscription period June 4-24, 2024 June 5-23, 2023 June 9-29, 2022 Number of shares subscribed 2,124,445 2,009,306 1,909,008 Number of shares issued immediately as employer’s contribution 119,951 119,417 118,049 (a) Subscription price representing 80% of the average of the opening quoted market prices of Sanofi shares during the 20 trading days preceding May 30, 2024, May 31, 2023 and June 6, 2022, respectively .
Summary of Expenses	The table below sets forth the expense recognized for each plan: (€ million) 2024 2023 2022 Expense recognized 45 52 39 of which employer’s contribution 11 12 11
Summary of Repurchases program	The following repurchases have been made under those programs: (in number of shares and € million) Year of authorization 2024 2023 2022 Number of shares Value Number of shares Value Number of shares Value 2024 program — — — — — — 2023 program 3,215,460 302 2,584,540 230 — — 2022 program — — 4,000,204 363 1,510,000 137 2021 program — — — — 3,976,992 360
Summary of Currency Translation Differences	Currency translation differences comprise the following: (€ million) 2024 2023 2022 Attributable to equity holders of Sanofi 2,408 (31) 1,499 Attributable to non-controlling interests (17) (37) (37) Total 2,391 (68) 1,462
Summary of Movements within Other Comprehensive Income	Movements within other comprehensive income are shown below: (€ million) 2024 2023 2022 Actuarial gains/(losses): • Actuarial gains/(losses) excluding investments accounted for using the equity method (see Note D.19.1.) 13 (171) 650 • Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes (2) — 4 • Tax effects (27) 18 (212) Equity instruments included in financial assets and financial liabilities: • Change in fair value (excluding investments accounted for using the equity method) (21) 97 (4) • Change in fair value (investments accounted for using the equity method, net of taxes) — — — • Equity risk hedging instruments designated as fair value hedges — — 17 • Tax effects 9 (21) (4) Items not subsequently reclassifiable to profit or loss (a) (28) (77) 451 Debt instruments included in financial assets: • Change in fair value (excluding investments accounted for using the equity method) (b) 5 21 (77) • Tax effects — (4) 15 Cash flow and fair value hedges: • Change in fair value (excluding investments accounted for using the equity method) (c) (3) 1 5 • Change in fair value (investments accounted for using the equity method, net of taxes) (3) (2) 2 ▪ Tax effects 2 — (1) Change in currency translation differences: • Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method) (d) 2,560 (1,551) 2,643 • Currency translation differences (investments accounted for using the equity method) (d) 3 3 (11) • Hedges of net investments in foreign operations (d) (121) 8 (354) • Tax effects 17 (2) 91 Items subsequently reclassifiable to profit or loss (e) 2,460 (1,526) 2,313 (a) Items not subsequently reclassifiable to profit or loss and attributable to Opella: € (1) million in 2024, immaterial amount in 2023 and € 20 million in 2022. (b) Amounts reclassified to profit or loss were immaterial in 2024 , 2023 and 2022 . (c) Amounts reclassified to profit or loss: €1 million in 2024 , €1 million in 2023 and € 2 million in 2022 . (d) Amounts reclassified to profit or loss: € 5 million in 2024 , € (56) million in 2023 and € (40) million in 2022 (including € (35) million relating to the deconsolidation of EUROAPI). Currency translation differences arise from the translation into euros of the financial statements of foreign subsidiaries, and are mainly due to the appreciation of the dollar against the euro. (e) Items subsequently reclassifiable to profit or loss and attributable to Opella (currency translation differences): € (28) million in 2024, € (78) million in 2023, € (54) million in 2022 .
Disclosure of Stock Subscription Option Plan Outstanding and Option Exercised	The table shows all Sanofi stock subscription option plans still outstanding or under which options were exercised in the year ended December 31, 2024 : Source Date of grant Number of options granted Start date of exercise period Expiry date Exercise price (€) Number of options outstanding as of 12/31/2024 Sanofi 03/05/2014 1,009,250 03/06/2018 03/05/2024 73.48 — Sanofi 06/24/2015 435,000 06/25/2019 06/24/2025 89.38 159,250 Sanofi 05/04/2016 402,750 05/05/2020 05/04/2026 75.90 136,000 Sanofi 05/10/2017 378,040 05/11/2021 05/10/2027 88.97 257,010 Sanofi 05/02/2018 220,000 05/03/2022 05/02/2028 65.84 168,784 Sanofi 04/30/2019 220,000 05/01/2023 04/30/2029 76.71 213,400 Total 934,444
Summary of Stock Options Outstanding at Each Balance Sheet Date	A summary of stock options outstanding at each balance sheet date, and of movements during the relevant periods, is presented below: Number of options Weighted average exercise price per share (€) Total (€ million) Options outstanding at January 1, 2022 2,337,968 77.13 180 Options exercisable 1,949,184 78.15 152 Options exercised (490,373) 71.39 (35) Options cancelled (a) (9,626) 80.56 (1) Options outstanding at December 31, 2022 1,837,969 78.64 144 Options exercisable 1,624,569 78.89 128 Options exercised (504,956) 73.65 (37) Options outstanding at December 31, 2023 1,333,013 80.53 107 Options exercisable 1,333,013 80.53 107 Options exercised (398,569) 81.38 (32) Options outstanding at December 31, 2024 934,444 80.16 75 Options exercisable 934,444 80.16 75 (a) Mainly due to the grantees leaving Sanofi .
Summary of Options Outstanding and Exercisable	The table below provides summary information about options outstanding and exercisable as of December 31, 2024 : Outstanding Exercisable Range of exercise prices per share Number of options Weighted average residual life (years) Weighted average exercise price per share (€) Number of options Weighted average exercise price per share (€) From €60.00 to €70.00 per share 168,784 3.34 65.84 168,784 65.84 From €70.00 to €80.00 per share 349,400 3.17 76.39 349,400 76.39 From €80.00 to €90.00 per share 416,260 1.64 89.13 416,260 89.13 Total 934,444 934,444
Summary of Number of Shares Used to Compute Diluted Earnings Per Share	(million) 2024 2023 2022 Average number of shares outstanding 1,251.4 1,251.7 1,251.9 Adjustment for stock options with dilutive effect 0.1 0.2 0.3 Adjustment for restricted shares 4.6 4.5 4.7 Average number of shares used to compute diluted earnings per share 1,256.1 1,256.4 1,256.9

Debt, cash and cash equivalen_2

Debt, cash and cash equivalents and lease liabilities (Tables)	12 Months Ended
	Dec. 31, 2024
Financial Instruments [Abstract]
Summary of Changes in Financial Position	Changes in Sanofi's financial position during the period were as follows: (€ million) 2024 2023 2022 Long-term debt 11,791 14,347 14,857 Short-term debt and current portion of long-term debt 4,209 2,045 4,174 Interest rate and currency derivatives used to manage debt 137 139 187 Total debt 16,137 16,531 19,218 Cash and cash equivalents (7,441) (8,710) (12,736) Interest rate and currency derivatives used to manage cash and cash equivalents 76 (28) (45) Net debt (a) 8,772 7,793 6,437 (a) Net debt does not include lease liabilities, which amounted to €1,906 million as of December 31, 2024 , € 2,030 million as of December 31, 2023 , and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.) .
Summary of Reconciliation of Carrying Amount to Value on Redemption	Reconciliation of carrying amount to value on redemption Value on redemption (€ million) Carrying amount at December 31, 2024 Amortized cost Adjustment to debt measured at fair value December 31, 2024 December 31, 2023 December 31, 2022 Long-term debt 11,791 30 119 11,940 14,546 15,143 Short-term debt and current portion of long-term debt 4,209 4 5 4,218 2,045 4,178 Interest rate and currency derivatives used to manage debt 137 (124) 13 (18) (48) Total debt 16,137 34 — 16,171 16,573 19,273 Cash and cash equivalents (7,441) (7,441) (8,710) (12,736) Interest rate and currency derivatives used to manage cash and cash equivalents 76 76 (28) (45) Net debt 8,772 34 — 8,806 7,835 6,492
Disclosure of Movement In Total Debt	The table below shows the movement in total debt during the period: Cash flows from financing activities Non-cash items (€ million) December 31, 2023 Repayments New borrowings Other cash flows (a) Currency translation differences (b) Reclassification from non-current to current Other items (c) December 31, 2024 Long-term debt 14,347 (67) — — 63 (2,599) 47 11,791 Short-term debt and current portion of long-term debt 2,045 (605) — 242 9 2,599 (81) 4,209 Interest rate and currency derivatives used to manage debt 139 — — (132) 146 — (16) 137 Total debt 16,531 (672) — 110 218 — (50) 16,137 (a)These amounts mainly comprise €262 million related to the US commercial paper program. (b) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone. (c) These amounts mainly comprise changes in accrued interest balances, and fair value adjustments. The table below shows the movement in total debt during prior periods: Cash flows from financing activities Non-cash items (€ million) December 31, 2022 Repayments New borrowings Other cash flows (a) Currency translation differences (b) Reclassification from non-current to current Other items (c) December 31, 2023 Long-term debt 14,857 (12) 48 — (30) (604) 88 14,347 Short-term debt and current portion of long-term debt 4,174 (3,672) — 903 (21) 604 57 2,045 Interest rate and currency derivatives used to manage debt 187 — — (8) 29 — (69) 139 Total debt 19,218 (3,684) 48 895 (22) — 76 16,531 (a) These amounts mainly comprise €946 million related to the US commercial paper program. (b) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone. (c) These amounts mainly comprise changes in accrued interest balances, and fair value adjustments. Cash flows from financing activities Non-cash items (€ million) December 31, 2021 Repayments New borrowings Other cash flows Currency translation differences (a) Reclassification from non-current to current Other items (b) December 31, 2022 Long-term debt 17,123 (11) 1,549 — 56 (3,632) (228) 14,857 Short-term debt and current portion of long-term debt 3,183 (2,707) — 43 20 3,632 3 4,174 Interest rate and currency derivatives used to manage debt (56) — — (373) 366 7 243 187 Total debt 20,250 (2,718) 1,549 (330) 442 7 18 19,218 (a) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone. (b) These amounts include changes in accrued interest balances and fair value adjustments.
Summary of Debt by Type Valuation of Redemption	2024 2023 2022 (€ million) Non- current Current Total Non- current Current Total Non- current Current Total Bond issues 11,876 2,716 14,592 14,416 718 15,134 15,044 3,817 18,861 Other bank borrowings 64 1,290 1,354 130 1,118 1,248 99 187 286 Other borrowings — 3 3 — 6 6 — 6 6 Bank credit balances — 209 209 — 203 203 — 168 168 Interest rate and currency derivatives used to manage debt — 13 13 — (18) (18) — (48) (48) Total debt 11,940 4,231 16,171 14,546 2,027 16,573 15,143 4,130 19,273 Cash and cash equivalents — (7,441) (7,441) — (8,710) (8,710) — (12,736) (12,736) Interest rate and currency derivatives used to manage cash and cash equivalents — 76 76 — (28) (28) — (45) (45) Net debt (a) 11,940 (3,134) 8,806 14,546 (6,711) 7,835 15,143 (8,651) 6,492 (a) Net debt does not include lease liabilities (see the maturity schedule in Note D.17.2.)
Summary of Bond Issues	Bond issues denominated in euros carried out by Sanofi are as follows: Issuer ISIN code Issue date Maturity Annual interest rate Amount (€ million) Type Sanofi FR0013505104 March 2020 April 2025 1.000% 1,000 EMTN program Sanofi FR0014009KS6 April 2022 April 2025 0.875% 850 Standalone Prospectus Sanofi FR0012969038 September 2015 September 2025 1.500% 750 EMTN program Sanofi FR0013324340 March 2018 March 2026 1.000% 1,500 EMTN program Sanofi FR0012146801 September 2014 September 2026 1.750% 1,510 EMTN program Sanofi FR0013201639 September 2016 January 2027 0.500% 1,150 EMTN program Sanofi FR0013144003 April 2016 April 2028 1.125% 700 EMTN program Sanofi FR0013409844 March 2019 March 2029 0.875% 650 EMTN program Sanofi FR0014009KQ0 April 2022 April 2029 1.250% 650 Standalone Prospectus Sanofi FR0013324357 March 2018 March 2030 1.375% 2,000 EMTN program Sanofi FR0013505112 March 2020 April 2030 1.500% 1,000 EMTN program Sanofi FR0013409851 March 2019 March 2034 1.250% 500 EMTN program Sanofi FR0013324373 March 2018 March 2038 1.875% 1,250 EMTN program Bond issues denominated in US dollars carried out by Sanofi under the public bond issue program (shelf registration statement) registered with the US Securities and Exchange Commission (SEC) comprise: Issuer ISIN code Issue date Maturity Annual interest rate Amount ($ million) Type Sanofi US801060AD60 June 2018 June 2028 3.625% 1,000 SEC registered
Summary of Debt by Maturity at Value on Redemption	December 31, 2024 Current Non-current (€ million) Total 2025 2026 2027 2028 2029 2030 and later Bond issues 14,592 2,716 3,010 1,150 1,666 1,300 4,750 Other bank borrowings 1,354 1,290 32 1 1 1 29 Other borrowings 3 3 — — — — — Bank credit balances 209 209 — — — — — Interest rate and currency derivatives used to manage debt 13 13 — — — — — Total debt 16,171 4,231 3,042 1,151 1,667 1,301 4,779 Cash and cash equivalents (7,441) (7,441) — — — — — Interest rate and currency derivatives used to manage cash and cash equivalents 76 76 — — — — — Net debt (a) 8,806 (3,134) 3,042 1,151 1,667 1,301 4,779 (a) Net debt does not include lease liabilities, which amounted to € 1,906 million as of December 31, 2024; € 2,030 million as of December 31, 2023; and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.). As of December 31, 2024 , the main undrawn confirmed general-purpose credit facilities at holding company level amounted to €8 billion , half of which expired in 2027 and the other half of which expires in 2030. As of December 31, 2024 , no single counterparty represented more than 6% of Sanofi’s undrawn confirmed credit facilities. December 31, 2023 Current Non-current (€ million) Total 2024 2025 2026 2027 2028 2029 and later Bond issues 15,134 718 2,600 3,010 1,150 1,606 6,050 Other bank borrowings 1,248 1,118 98 1 1 1 29 Other borrowings 6 6 — — — — — Bank credit balances 203 203 — — — — — Interest rate and currency derivatives used to manage debt (18) (18) — — — — — Total debt 16,573 2,027 2,698 3,011 1,151 1,607 6,079 Cash and cash equivalents (8,710) (8,710) — — — — — Interest rate and currency derivatives used to manage cash and cash equivalents (28) (28) — — — — — Net debt 7,835 (6,711) 2,698 3,011 1,151 1,607 6,079 December 31, 2022 Current Non-current (€ million) Total 2023 2024 2025 2026 2027 2028 and later Bond issues 18,861 3,817 600 2,600 4,160 — 7,684 Other bank borrowings 286 187 61 — — — 38 Other borrowings 6 6 — — — — — Bank credit balances 168 168 — — — — — Interest rate and currency derivatives used to manage debt (48) (48) — — — — — Total debt 19,273 4,130 661 2,600 4,160 — 7,722 Cash and cash equivalents (12,736) (12,736) — — — — — Interest rate and currency derivatives used to manage cash and cash equivalents (45) (45) — — — — — Net debt 6,492 (8,651) 661 2,600 4,160 — 7,722
Summary of Debt by Interest Rate	The table below splits net debt between fixed and floating rate, and by maturity, as of December 31, 2024 . The figures shown are values on redemption, before the effects of derivative instruments: (€ million) Total 2025 2026 2027 2028 2029 2030 and later Fixed-rate debt 14,592 2,716 3,010 1,150 1,666 1,300 4,750 of which euro 13,626 of which US dollar 966 % fixed-rate 90% Floating-rate debt 1,566 1,502 32 1 1 1 29 of which euro — of which US dollar 1,221 % floating-rate 10% Debt 16,158 4,218 3,042 1,151 1,667 1,301 4,779 Cash and cash equivalents (7,441) (7,441) — — — — — of which euro (2,945) of which US dollar (4,204) % floating-rate 100% Net debt 8,717 (3,223) 3,042 1,151 1,667 1,301 4,779 To optimize the cost of debt or reduce the volatility of debt and manage its exposure to financial foreign exchange risk, Sanofi uses derivative instruments (interest rate swaps, currency swaps, foreign exchange swaps and forward contracts) that alter the fixed/floating rate split and the currency split of its net debt: (€ million) Total 2025 2026 2027 2028 2029 2030 and later Fixed-rate debt 11,098 (778) 3,010 1,150 1,666 1,300 4,750 of which euro 11,098 of which US dollar — % fixed-rate 69% Floating-rate debt 5,074 5,010 32 1 1 1 29 of which euro 174 of which US dollar 3,507 % floating-rate 31% Debt 16,171 4,231 3,042 1,151 1,667 1,301 4,779 Cash and cash equivalents (7,365) (7,365) — — — — — of which euro (3,987) of which US dollar (1,005) of which Singapore dollar (822) % floating-rate 100% Net debt 8,806 (3,134) 3,042 1,151 1,667 1,301 4,779
Summary of Interest Rate of Net Debt at Value on Redemption	The table below shows the fixed/floating rate split of net debt at value on redemption after taking account of derivative instruments as of December 31, 2023 and December 31, 2022 : (€ million) 2023 % 2022 % Fixed-rate debt 11,382 69% 16,386 85% Floating-rate debt 5,191 31% 2,886 15% Debt 16,573 100% 19,273 100% Cash and cash equivalents (8,738) (12,781) Net debt 7,835 6,492
Summary of Interest Rate Fluctuations of Debt Net of Cash and Cash Equivalents	The projected full-year sensitivity of net debt to interest rate fluctuations for 2025 is as follows: Change in short-term interest rates Impact on pre-tax net income (€ million) Impact on pre-tax income/(expense) recognized directly in equity (€ million) +100 bp 34 — +25 bp 8 — -25 bp (8) — -100 bp (34) —
Summary of Debt by Currency Before and After Derivative Instrument	The table below shows net debt by currency at December 31, 2024 , before and after derivative instruments contracted to convert the foreign-currency net debt of exposed entities into their functional currency: (€ million) Before derivative instruments After derivative instruments Euro 10,681 7,285 US dollar (2,017) 2,502 Singapore dollar (3) (822) Hungarian forint — (641) Chinese yuan renminbi (10) 226 Other currencies 65 256 Net debt 8,717 8,806
Summary of Debt by Currency After Derivative Instruments	The table below shows net debt by currency at December 31, 2023 and 2022 , after derivative instruments contracted to convert the foreign currency net debt of exposed entities into their functional currency: (€ million) 2023 2022 Euro 6,852 10,489 US dollar 1,169 (2,404) Other currencies (186) (1,593) Net debt 7,835 6,492
Summary of Market Value of Net Debt	The market value of Sanofi’s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows: (€ million) 2024 2023 2022 Market value 8,165 7,086 5,227 Value on redemption 8,806 7,835 6,492
Amount of Future Undiscounted Contractual Cash Flows Relating to Debt and Derivative Instruments Designated as Hedges of Debt	The table below shows the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt: December 31, 2024 Payments due by period (€ million) Total 2025 2026 2027 2028 2029 2030 and later Debt 17,077 4,328 3,226 1,288 1,780 1,388 5,067 Principal 16,049 4,105 3,047 1,151 1,667 1,300 4,779 Interest (a) 1,028 223 179 137 113 88 288 Net cash flows related to derivative instruments 161 71 34 34 21 1 — Total 17,238 4,399 3,260 1,322 1,801 1,389 5,067 (a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2024 . The tables below show the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt as of December 31, 2023 and 2022 : December 31, 2023 Payments due by period (€ million) Total 2024 2025 2026 2026 2028 2029 and later Debt 17,710 2,153 2,912 3,187 1,285 1,719 6,454 Principal 16,468 1,917 2,703 3,011 1,151 1,607 6,079 Interest (a) 1,242 236 209 176 134 112 375 Net cash flows related to derivative instruments 143 47 32 23 24 16 1 Total 17,853 2,200 2,944 3,210 1,309 1,735 6,455 (a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2023 . December 31, 2022 Payments due by period (€ million) Total 2023 2024 2025 2026 2026 2028 and later Debt 20,408 4,206 868 2,803 3,184 1,283 8,064 Principal 18,932 3,928 661 2,601 3,011 1,151 7,580 Interest (a) 1,476 278 207 202 173 132 484 Net cash flows related to derivative instruments 209 24 60 38 31 31 25 Total 20,617 4,230 928 2,841 3,215 1,314 8,089 (a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2022 .
Disclosure of Lease Liabilities	A maturity analysis of lease liabilities as of December 31, 2024 , 2023 and 2022 is set forth below: Undiscounted future minimum lease payments (€ million) Total Less than 1 year From 1 to 3 years From 3 to 5 years More than 5 years Discounting effect Total lease liabilities as of December 31, 2024 (a) 1,906 377 498 386 819 (174) Total lease liabilities as of December 31, 2023 2,030 291 448 360 989 (58) Total lease liabilities as of December 31, 2022 2,181 320 515 436 1,129 (219) (a) 2024 amounts exclude Opella discontinued operations, while 2023 and 2022 include them. Lease liabilities include leases relating to real estate assets located at Cambridge, MA (United States), which have a lease term of 15 years .

Liabilities related to busine_2

Liabilities related to business combinations and to non-controlling interests (Tables)	12 Months Ended
	Dec. 31, 2024
Business Combination [Abstract]
Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests	Movements in liabilities related to business combinations and to non-controlling interests are shown below: (€ million) Bayer contingent consideration arising from the acquisition of Genzyme MSD contingent consideration (European Vaccines business) Shire contingent consideration arising from the acquisition of Translate Bio Contingent consideration arising from acquisition of Amunix Other Total (a) Balance at January 1, 2022 59 269 354 — 32 714 New transactions — — — 156 — 156 Payments made (29) (79) — — (28) (136) Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (b) (9) 14 2 (2) — 5 Other movements — — — — — — Currency translation differences 5 — 24 11 — 40 Balance at December 31, 2022 26 204 380 165 4 779 New transactions — — — — — — Payments made (21) (77) — (69) — (167) Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (b) (5) — 74 45 — 114 Other movements — — — — — — Currency translation differences — — (13) (4) — (17) Balance at December 31, 2023 — 127 441 137 4 709 New transactions — — — — — — Payments made — (70) — — (1) (71) Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (b) — 16 94 — 1 109 Other movements — — — (137) (3) (139) Currency translation differences — (1) 33 — — 33 Balance at December 31, 2024 — 72 568 — 1 641 (a) Portion due after more than one year: €569 million as of December 31, 2024 ( €501 million as of December 31, 2023 and €674 million as of December 31, 2022 ); portion due within less than one year: €72 million as of December 31, 2024 ( €208 million as of December 31, 2023 and €105 million as of December 31, 2022 ). (b) Amounts reported within the income statement line item Fair value remeasurement of contingent consideration , and mainly comprising unrealized gains and losses .
Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests	T he table below sets forth the maximum amount of contingent consideration payable in respect of already-marketed products: December 31, 2024 Payments due by period (€ million) Total Less than 1 year From 1 to 3 years From 3 to 5 years More than 5 years Commitments relating to contingent consideration in connection with business combinations 72 72 — — —

Provisions, income tax liabil_2

Provisions, income tax liabilities and other liabilities (Tables)	12 Months Ended
	Dec. 31, 2024
Subclassifications of assets, liabilities and equities [abstract]
Summary of Non Current Provisions and Other Non-current Liabilities	The line item Non current provisions and other non-current liabilities comprises the following: (€ million) 2024 2023 2022 Provisions 5,762 5,262 5,822 Other non-current liabilities (a) 2,334 2,340 519 Total 8,096 7,602 6,341 (a) Includes derivative financial instruments: € 121 million as of December 31, 2024 , €164 million as of December 31, 2023 , €232 million as of December 31, 2022 . The figure as of December 31, 2024 includes € 2,007 million for the liability in respect of royalties payable to Sobi on net sales of Beyfortus (nirsevimab) in the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is € 1,140 million; the nominal value of payments estimated to be due after more than five years is € 2,792 million.
Summary of Movements in Non-current Provisions	The table below sets forth movements in non-current provisions for the reporting periods presented: (€ million) Provisions for pensions and other post- employment benefits (D.19.1.) Provisions for other long-term benefits Restructuring provisions (D.19.2.) Other provisions (D.19.3.) Total Balance at January 1, 2022 2,947 935 524 2,024 6,430 Changes in scope of consolidation (96) (28) — (76) (200) Increases in provisions 193 (a) 40 521 531 1,285 Provisions utilized (275) (a) (119) (12) (122) (528) Reversals of unutilized provisions (66) (a) (20) (11) (191) (288) Transfers 10 4 (265) (23) (274) Net interest related to employee benefits, and unwinding of discount 43 4 5 12 64 Currency translation differences 63 28 (1) 23 113 Actuarial gains and losses on defined-benefit plans (780) — — — (780) Balance at December 31, 2022 2,039 844 761 2,178 5,822 Increases in provisions 141 (a) 185 315 311 952 Provisions utilized (162) (a) (107) (25) (114) (408) Reversals of unutilized provisions (21) (a) (190) (159) (388) (758) Transfers (1) — (361) (210) (572) Net interest related to employee benefits, and unwinding of discount 70 3 23 24 120 Currency translation differences (23) (17) — (25) (65) Actuarial gains and losses on defined-benefit plans 171 — — — 171 Balance at December 31, 2023 2,214 718 554 1,776 5,262 Changes in scope of consolidation — — — 11 11 Increases in provisions 145 (a) 199 548 730 1,622 Provisions utilized (173) (a) (118) (20) (135) (446) Reversals of unutilized provisions (108) (a) — (8) (126) (242) Transfers (89) — (270) (157) (516) Net interest related to employee benefits, and unwinding of discount 65 2 19 36 122 Currency translation differences 43 34 (3) 42 116 Actuarial gains and losses on defined-benefit plans (13) — — — (13) Opella reclassification (b) (92) (14) (21) (27) (154) Balance at December 31, 2024 1,992 821 799 2,150 5,762 (a) In the case of “Provisions for pensions and other post-employment benefits”, the “Increases in provisions” line corresponds to rights vesting in employees during the period, and past service cost; the “Provisions utilized” line corresponds to contributions paid into pension funds and to beneficiaries; and the “Reversals of unutilized provisions” line corresponds to plan curtailments, settlements and amendments. (b) The liabilities of Opella, which in 2022 and 2023 were presented in the relevant balance sheet line item for each class of liability, were reclassified in 2024 to Liabilities related to assets held for sale in accordance with IFRS 5 (see Note D.1.) .
Summary of Financial and Demographic Assumptions	Those calculations were based on the following financial and demographic assumptions: 2024 2023 2022 France Germany US UK France Germany US UK France Germany US UK Discount rate (a)(b) 2.95% to 3.40% 2.95% to 3.40% 5.45% 5.50% 2.95% to 3.15% 2.95% to 3.15% 4.75% 4.50% 3.55% to 3.75% 3.55% to 3.75% 4.90% 4.75% General inflation rate (c) 2.10% 2.10% — 3.20% 2.20% 2.20% — 3.05% 2.50% 2.50% — 3.25% Pension benefit indexation 2.10% 2.10% — 3.00% 2.20% 2.20% — 2.90% 2.50% 2.50% — 3.00% Healthcare cost inflation rate (d) — — 4.00% to 5.93% — — — 4.00% to 9.75% — — — 3.29% to 6.56% — Retirement age 62 to 67 63 55 to 70 60 to 65 62 to 67 63 55 to 70 60 to 65 62 to 67 63 55 to 70 60 to 65 Mortality table TGH/ TGF 05 Heubeck RT 2018 G RP2012 Proj. MP2021 White Collar SAPS S3 TGH/ TGF 05 Heubeck RT 2018 G RP2012 Proj. MP2021 White Collar SAPS S3 TGH/ TGF 05 Heubeck RT 2018 G RP2012 Proj. MP2021 White Collar SAPS S3 (a) The discount rates used were based on market rates for high quality corporate bonds with a duration close to that of the expected benefit payments under the plans. The benchmarks used to determine discount rates were the same for all periods presented. (b) The rate depends on the duration of the plan ( 0 to 7 years, 7 to 10 years, or more than 10 years). (c) Inflation for the euro zone is determined using a multi-criterion method. (d) No post-employment healthcare benefits are provided in France since 2020, Germany and UK .
Summary of Weighted Average Duration of Obligation for Pensions and Other Long-term Benefits in Principal Countries	The table below shows the duration of Sanofi’s obligations in the principal countries: 2024 2023 2022 (years) France Germany US UK France Germany US UK France Germany US UK Weighted average duration 11 12 10 11 10 12 11 13 10 12 11 13
Summary of Sensitivity for Pensions and Other Post-employment Benefits to Changes in Key Actuarial Assumptions	The table below shows the sensitivity of Sanofi’s obligations for pensions and other post-employment benefits to changes in key actuarial assumptions: (€ million) Pensions and other post-employment benefits, by principal country Measurement of defined-benefit obligation Change in assumption France Germany US UK Discount rate -0.50% +90 +190 +103 +161 General inflation rate +0.50% +56 +267 — +95 Pension benefit indexation +0.50% +57 +264 — +93 Healthcare cost inflation rate +0.50% — — +41 +43 Mortality table +1 year +56 +86 +59 +118
Reconciliation of Net Obligation in Respect of Sanofi's Pension and Other Post-Employment Benefit Plans	The table below reconciles the net obligation in respect of Sanofi’s pension and other post-employment benefit plans with the amounts recognized in the consolidated financial statements: Pensions and other post-employment benefits (€ million) 2024 2023 2022 Measurement of the obligation: Beginning of period 8,930 8,651 12,175 Current service cost 138 140 193 Interest cost 335 346 206 Actuarial losses/(gains) due to changes in demographic assumptions (45) (34) (219) Actuarial losses/(gains) due to changes in financial assumptions (380) 157 (3,006) Actuarial losses/(gains) due to experience adjustments (4) 256 177 Plan amendments, curtailments or settlements not specified in the terms of the plan (b) (181) (36) (229) Plan settlements specified in the terms of the plan (59) (40) (84) Benefits paid (502) (483) (463) Changes in scope of consolidation and transfers 4 (14) (114) Currency translation differences 181 (13) 15 Opella reclassification (188) — — Obligation at end of period 8,229 8,930 8,651 Fair value of plan assets: Beginning of period 6,993 6,899 9,651 Interest income on plan assets 271 276 163 Difference between actual return and interest income on plan assets (c) (416) 197 (2,398) Administration costs (13) (7) (6) Plan settlements specified in the terms of the plan (58) (40) (84) Plan settlements not specified in the terms of the plan (71) (17) (161) Contributions from plan members 5 6 6 Employer’s contributions 127 122 238 Benefits paid (456) (446) (426) Changes in scope of consolidation and transfers (20) (8) (32) Currency translation differences 132 11 (52) Opella reclassification (97) — — Fair value of plan assets at end of period 6,397 6,993 6,899 Net amount shown in the balance sheet: Net obligation 1,832 1,937 1,752 Effect of asset ceiling 4 6 18 Net amount shown in the balance sheet at end of period 1,836 1,943 1,770 Amounts recognized in the balance sheet: Pre-funded obligations (see Note D.7.) (a) (156) (271) (269) Obligations provided for 1,992 2,214 2,039 Net amount recognized at end of period 1,836 1,943 1,770 Benefit cost for the period: (d) Current service cost 138 140 193 (Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan (110) (22) (68) Net interest (income)/cost 64 71 43 Contributions from plan members (5) (6) (6) Administration costs and taxes paid during the period 13 7 6 Expense recognized directly in profit or loss 100 190 168 Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses) (b) (13) 171 (650) Expense/(gain) for the period 87 361 (482) (a) For 2023, this line includes €66 million of assets in the United Kingdom (versus €99 million for 2022); those amounts are not subject to any asset ceiling, in accordance with IFRIC 14. (b) Amounts recognized in Other comprehensive income (see Note D.15.7.). (c) In 2024, this line includes the effects of the partial buy-in in the United Kingdom for €(204) million . (d) Benefit cost for the total Group including Opella on all the periods .
Net Liability in Respect of Pension Plans and Other Post-employment Benefits by Geographical Region	The tables below show Sanofi’s net liability in respect of pension plans and other post-employment benefits by geographical region: (€ million) Pensions and other post-employment benefits by geographical region December 31, 2024 France Germany US UK Other Total Measurement of obligation 1,228 2,651 1,427 1,994 929 8,229 Fair value of plan assets 667 2,239 744 1,891 856 6,397 Effect of asset ceiling — — — — (4) (4) Net amount shown in the balance sheet at end of period 561 412 683 103 77 1,836 (€ million) Pensions and other post-employment benefits by geographical region December 31, 2023 France Germany US UK Other Total Measurement of obligation 1,322 2,911 1,528 2,174 995 8,930 Fair value of plan assets 675 2,401 825 2,235 857 6,993 Effect of asset ceiling — — — — (6) (6) Net amount shown in the balance sheet at end of period 647 510 703 (61) 144 1,943 (€ million) Pensions and other post-employment benefits by geographical region December 31, 2022 France Germany US UK Other Total Measurement of obligation 1,324 2,730 1,546 2,080 971 8,651 Fair value of plan assets 697 2,317 860 2,175 850 6,899 Effect of asset ceiling — — — — (18) (18) Net amount shown in the balance sheet at end of period 627 413 686 (95) 139 1,770
Fair Value of Plans Assets relating to Pension Plans and Other Post-employment Plans	The table below shows the fair value of plan assets relating to Sanofi’s pension and other post-employment plans, split by asset category: 2024 2023 2022 Securities quoted in an active market 63.1% 84.9% 84.4% Cash and cash equivalents 0.8% 0.8% 0.7% Equity instruments 19.3% 22.3% 21.7% Bonds and similar instruments 35.8% 54.3% 52.4% Real estate 2.9% 3.4% 4.0% Derivatives (0.2%) —% 0.1% Commodities 1.1% 0.9% 0.9% Other 3.4% 3.2% 4.6% Other securities 36.9% 15.1% 15.6% Hedge funds —% —% —% Insurance policies 36.9% 15.1% 15.6% Total 100.0% 100.0% 100.0%
Service Cost for Pension and Other post-employment Benefit Plans, by Geographical Region	The tables below show the service cost for Sanofi’s pension and other post-employment benefit plans, by geographical region: (€ million) Pensions and other post-employment benefits by geographical region Service cost for 2024 France Germany US UK Other Total Current service cost 48 30 22 — 38 138 (Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan (82) — (20) — (8) (110) Net interest cost/(income) including administration costs and taxes paid during the period 13 20 36 (1) 9 77 Contributions from plan members — — — — (5) (5) Expense/(gain) recognized directly in profit or loss (21) 50 38 (1) 34 100 Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses) (31) (134) (46) 212 (14) (13) Expense/(gain) for the period (52) (84) (8) 211 20 87 (€ million) Pensions and other post-employment benefits by geographical region Service cost for 2023 France Germany US UK Other Total Current service cost 50 30 20 — 40 140 (Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan (20) — 1 — (3) (22) Net interest cost/(income) including administration costs and taxes paid during the period 22 15 35 (5) 11 78 Contributions from plan members — — — — (6) (6) Expense/(gain) recognized directly in profit or loss 52 45 56 (5) 42 190 Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses) 3 98 26 44 — 171 Expense/(gain) for the period 55 143 82 39 42 361 (€ million) Pensions and other post-employment benefits by geographical region Service cost for 2022 France Germany US UK Other Total Current service cost 61 44 50 — 38 193 (Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan (60) 2 1 (6) (5) (68) Net interest cost/(income) including administration costs and taxes paid during the period 10 7 30 (7) 9 49 Contributions from plan members — — — — (6) (6) Expense/(gain) recognized directly in profit or loss 11 53 81 (13) 36 168 Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses) (156) (204) (382) 130 (38) (650) Expense/(gain) for the period (145) (151) (301) 117 (2) (482)
Remeasurement of Net Defined-benefit (Asset)/Liability (Actuarial Gains and Losses)	An analysis of the “Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)” line in the preceding tables is set forth below: (€ million) 2024 2023 2022 France Germany US UK France Germany US UK France Germany US UK Actuarial gains/(losses) arising during the period 29 135 47 (212) (3) (98) (25) (44) 156 205 382 (131) Comprising: Gains/(losses) on experience adjustments (a) 18 46 (42) (472) 16 (54) (7) (12) (120) (620) (287) (1,328) Gains/(losses) on demographic assumptions — — 11 50 — — 18 11 — — 129 54 Gains/(losses) on financial assumptions 11 89 78 210 (19) (44) (36) (43) 276 825 540 1,143 (a) Experience adjustments are mainly due to the effect on plan assets of trends in the financial markets .
Summary of Net Pre-tax Actuarial Loss	The net pre-tax actuarial loss (excluding investments accounted for using the equity method) recognized directly in equity is presented below: (€ million) 2024 2023 2022 Net pre-tax actuarial loss (2,258) (2,259) (2,090)
Summary of Present Value of Pension and Other Post Employement Benefits	The present value of Sanofi’s obligations in respect of pension and other post-employment benefit plans at the end of each reporting period is shown below: (€ million) 2024 2023 2022 Present value of wholly or partially funded obligations in respect of pension and other post-employment benefit plans 7,192 7,693 7,463 Present value of unfunded obligations 1,037 1,237 1,188 Total 8,229 8,930 8,651
Total Expense for Pensions and Other Post-employment Benefits Allocated between Income Statement Line Items	The total expense for pensions and other post-employment benefits ( €100 million in 2024 ) is allocated between income statement line items as follows: (€ million) 2024 2023 2022 Cost of sales 32 33 53 Research and development expenses 17 28 51 Selling and general expenses 42 57 78 Other operating (income)/expenses, net 4 5 (2) Restructuring costs (64) (9) (59) Financial expenses 60 67 42 Net income from discontinued operations 9 9 5 Total 100 190 168
Estimated Amounts of Employer's Contributions to Plan Assets	The estimated amounts of employer’s contributions to plan assets in 2025 are as follows: (€ million) France Germany US UK Other Total Employer’s contributions in 2024 (estimate): 2025 — — 2 48 27 77
Expected Timing of Benefit Payments under Pension and Other Post-employment Benefit Plans	The table below shows the expected timing of benefit payments under pension and other post-employment benefit plans for future years: (€ million) France Germany US UK Other Total Estimated future benefit payments 2025 94 210 97 126 38 565 2026 59 210 98 130 41 538 2027 71 208 100 134 40 553 2028 75 207 103 139 42 566 2029 81 209 107 143 44 584 2030 to 2034 497 893 543 785 241 2,959
Timing of Future Payments in Respect of Unfunded Pension and Other Post-employment Benefit Plans	The table below shows estimates as of December 31, 2024 for the timing of future payments in respect of unfunded pension and other post-employment benefit plans: Payments due by period (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Estimated payments 1,035 67 122 131 715
Movements in Restructuring Provisions Classified in Non-current and Current Liabilities	The table below shows movements in restructuring provisions classified in non-current and current liabilities: (€ million) 2024 2023 2022 Balance, beginning of period 1,132 1,233 1,118 Of which: • Classified in non-current liabilities 554 761 524 • Classified in current liabilities 578 472 594 Change in provisions recognized in profit or loss for the period 999 435 636 Provisions utilized (a) (582) (561) (522) Transfers (33) 3 — Unwinding of discount 19 31 5 Currency translation differences 1 (9) (4) Opella reclassification (b) (84) — — Balance, end of period 1,452 1,132 1,233 Of which: • Classified in non-current liabilities 799 554 761 • Classified in current liabilities 653 578 472 (a) Provisions utilized mainly correspond to payments related to employees affected by separation programs. (b) This line comprises the restructuring provisions of Opella, reclassified to Liabilities related to assets held for sale as of December 31, 2024 (see Note D.1.).
Timing of Future Termination Benefit Payments	The timing of future termination benefit payments is as follows: December 31, 2024 Benefit payments by period (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Employee termination benefits • France 862 312 416 126 8 • Other countries 456 304 144 7 1 Total 1,318 616 560 133 9 December 31, 2023 Benefit payments by period (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Employee termination benefits • France 611 215 315 79 2 • Other countries 357 302 47 7 1 Total 968 517 362 86 3 December 31, 2022 Benefit payments by period (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Employee termination benefits • France 804 185 412 207 — • Other countries 235 189 36 8 2 Total 1,039 374 448 215 2
Summary of Other Provisions	Other provisions include provisions for risks and litigation relating to environmental, tax, commercial and product liability matters. (€ million) 2024 2023 2022 Environmental risks 474 493 526 Product liability risks, litigation and other 1,676 1,283 1,652 Total 2,150 1,776 2,178
Current Provisions and Other Current Liabilities	Current provisions and other current liabilities comprise the following: (€ million) 2024 2023 2022 Taxes payable, other than corporate income taxes 437 395 420 Employee-related liabilities 1,929 2,106 2,158 Restructuring provisions (see Note D.19.2.) 653 578 472 Interest rate derivatives (see Note D.20.) 7 1 — Currency derivatives (see Note D.20.) 330 126 94 Equity derivatives (see Note D.20.) — — — Amounts payable for acquisitions of non-current assets 878 945 714 Customer contract liabilities (a) — — 269 Other current liabilities (b)(c) 10,007 9,590 7,894 Total 14,241 13,741 12,021 (a) See Note A.5. , “Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK” . The year-on-year change in this item between 2023 and 2022 includes revenue of € 269 million recognized in profit or loss during 2023 (previously included in “ Customer contract liabilities ” as of December 31, 2022 ). (b) “Other current liabilities” mainly comprises provisions and liabilities for customer rebates and returns; provisions for discounts and rebates granted to healthcare authorities and governmental programs (see Note D.23.); and the liability payable at each reporting date under the Monoclonal Antibody Alliance with Regeneron. (c) As of December 31, 2024 includes € 273 million (nominal value: € 290 million) for the current liability relating to royalties payable to Sobi on net sales of Beyfortus (nirsevimab) in the United States (see Note C.2.)

Derivative financial instrume_2

Derivative financial instruments and market risks (Tables)	12 Months Ended
	Dec. 31, 2024
Financial Instruments [Abstract]
Summary of Fair Value of Derivative Instruments	The table below shows the fair value of derivative instruments as of December 31, 2024 , 2023 and 2022 : (€ million) Non- current assets Current assets Total assets Non-current liabilities Current liabilities Total liabilities Market value at December 31, 2024 (net) Market value at December 31, 2023 (net) Market value at December 31, 2022 (net) Currency derivatives — 217 217 — (330) (330) (113) 75 112 operating — 81 81 — (111) (111) (30) 22 22 financial — 136 136 — (219) (219) (83) 53 90 Interest rate derivatives — — — (121) (7) (128) (128) (165) (232) Equity derivatives — — — — — — — — Total — 217 217 (121) ( 337) (458) (241) ( 90) ( 120)
Summary of Operating Currency Hedging Instruments	The table below shows operating currency hedging instruments in place as of December 31, 2024 , with the notional amount translated into euros at the relevant closing exchange rate: December 31, 2024 Of which derivatives designated as cash flow hedges Of which derivatives not eligible for hedge accounting (€ million) Notional amount Fair value Notional amount Fair value Of which recognized in equity Notional amount Fair value Forward currency sales 7,521 (67) — — — 7,521 (67) of which US dollar 3,974 (59) — — — 3,974 (59) of which Chinese yuan renminbi 703 (5) — — — 703 (5) of which Pound sterling 368 (1) — — — 368 (1) of which Japanese yen 241 2 — — — 241 2 of which Turkish lira 216 (23) — — — 216 (23) Forward currency purchases 4,796 37 — — — 4,796 37 of which US dollar 2,660 24 — — — 2,660 24 of which Singapore dollar 484 3 — — — 484 3 of which Chinese yuan renminbi 451 2 — — — 451 2 of which Turkish lira 203 19 — — — 203 19 of which Canadian dollar 126 — — — — 126 — Total 12,317 (30) — — — 12,317 (30) The table below shows operating currency hedging instruments in place as of December 31, 2023 , with the notional amount translated into euros at the relevant closing exchange rate: December 31, 2023 Of which derivatives designated as cash flow hedges Of which derivatives not eligible for hedge accounting (€ million) Notional amount Fair value Notional amount Fair value Of which recognized in equity Notional amount Fair value Forward currency sales 6,112 30 — — — 6,112 30 of which US dollar 2,981 35 — — — 2,981 35 of which Chinese yuan renminbi 788 7 — — — 788 7 of which Singapore dollar 419 (1) — — — 419 (1) of which Japanese yen 339 (6) — — — 339 (6) of which Korean won 192 (4) — — — 192 (4) Forward currency purchases 4,246 (8) — — — 4,246 (8) of which US dollar 2,022 (12) — — — 2,022 (12) of which Singapore dollar 876 — — — — 876 — of which Chinese yuan renminbi 364 (1) — — — 364 (1) of which Korean won 137 2 — — — 137 2 of which Japanese yen 123 1 — — — 123 1 Total 10,358 22 — — — 10,358 22 The table below shows operating currency hedging instruments in place as of December 31, 2022 , with the notional amount translated into euros at the relevant closing exchange rate: December 31, 2022 Of which derivatives designated as cash flow hedges Of which derivatives not eligible for hedge accounting (€ million) Notional amount Fair value Notional amount Fair value Of which recognized in equity Notional amount Fair value Forward currency sales 5,403 49 — — — 5,403 49 of which US dollar 2,732 56 — — — 2,732 56 of which Chinese yuan renminbi 576 2 — — — 576 2 of which Japanese yen 240 (5) — — — 240 (5) of which Singapore dollar 180 1 — — — 180 1 of which Korean won 179 (14) — — — 179 (14) Forward currency purchases 3,459 (27) — — — 3,459 (27) of which US dollar 2,047 (21) — — — 2,047 (21) of which Singapore dollar 375 (7) — — — 375 (7) of which Chinese yuan renminbi 142 — — — — 142 — of which Korean won 130 4 — — — 130 4 of which Taiwan dollar 84 — — — — 84 — Total 8,862 22 — — — 8,862 22
Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated	The table below shows financial currency hedging instruments in place, with the notional amount translated into euros at the relevant closing exchange rate: 2024 2023 2022 (€ million) Notional amount Fair value Expiry Notional amount Fair value Expiry Notional amount Fair value Expiry Forward currency sales 10,377 (195) 10,279 111 7,559 66 of which US dollar 8,923 (a) (176) 2025 6,628 101 2024 6,114 59 2023 of which Japanese yen 371 4 2025 157 (1) 2024 111 — 2023 of which Chinese yuan renminbi 235 (1) 2025 513 4 2024 203 2 2023 Forward currency purchases 6,884 112 7,055 (58) 4,997 24 of which US dollar 4,397 (b) 123 2025 3,073 (52) 2024 2,011 (4) 2023 of which Singapore dollar 819 2 2025 2,696 (10) 2024 2,154 22 2023 of which Hungarian forint 641 (9) 2025 99 1 2024 59 1 2023 Total 17,261 (83) 17,334 53 12,556 90 (a) Includes forward sales with a notional amount of $3,615 million expiring in 2025 , designated as a hedge of Sanofi’s net investment in Bioverativ. As of December 31, 2024 , the fair value of these forward contracts represented a liability of €88 million ; the opposite entry was recognized in "Other comprehensive income", with the impact on financial income and expense being immaterial. (b) Includes forward purchases with a notional amount of $ 1,000 million expiring in 2025 , designated as a fair value hedge of the exposure of $ 1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of December 31, 2024 , the fair value of the contracts was an asset of € 75 million , the opposite entry for €0.2 million of which was debited to “Other comprehensive income” under the cost of hedging accounting treatment.
Disclosure of Instruments	The table below shows interest rate hedging instruments in place as of December 31, 2024 : Notional amounts by expiry date as of December 31, 2024 Of which designated as fair value hedges Of which designated as cash flow hedges (€ million) 2025 2026 2027 2028 2029 2030 and later Total Fair value Notional amount Fair value Notional amount Fair value Of which recognized in equity Interest rate swaps pay capitalized SOFR USD/ receive 1.03% — — — 483 — — 483 (47) 483 (47) — — — pay capitalized SOFR USD/ receive 1.32% — — — 483 — — 483 (43) 483 (43) — — — pay capitalized Ester/receive 0.69% 850 — — — — — 850 (7) 850 (7) — — — pay capitalized Ester/receive 0.92% — — — — 650 650 (31) 650 (31) — — — Total 850 — — 966 650 — 2,466 (128) 2,466 (128) — — — The table below shows interest rate hedging instruments in place as of December 31, 2023 : Notional amounts by expiry date as of December 31, 2023 Of which designated as fair value hedges Of which designated as cash flow hedges (€ million) 2024 2025 2026 2027 2028 2029 and later Total Fair value Notional amount Fair value Notional amount Fair value Of which recognized in equity Interest rate swaps pay capitalized SOFR USD/ receive 1.03% — — — — 453 — 453 (49) 453 (49) — — — pay capitalized SOFR USD/ receive 1.32% — — — — 453 — 453 (43) 453 (43) — — — pay capitalized Ester/receive 0.69% — 850 — — — — 850 (28) 850 (28) — — — pay capitalized Ester/receive 0.92% — — — — — 650 650 (44) 650 (44) — — — pay capitalized Ester/receive 3.43% 999 — — — — — 999 (1) 999 (1) — — — Total 999 850 — — 906 650 3,405 (165) 3,405 (165) — — — The table below shows interest rate hedging instruments in place as of December 31, 2022 : Notional amounts by expiry date as of December 31, 2022 Of which designated as fair value hedges Of which designated as cash flow hedges (€ million) 2023 2024 2025 2026 2027 2028 and later Total Fair value Notional amount Fair value Notional amount Fair value Of which recognized in equity Interest rate swaps pay capitalized SOFR USD/ receive 1.03% — — — — — 467 467 (62) 467 (62) — — — pay capitalized SOFR USD/ receive 1.32% — — — — — 467 467 (56) 467 (56) — — — pay capitalized Ester/ receive 0.69% — — 850 — — — 850 (43) 850 (43) — — — pay capitalized Ester/ receive 0.92% — — — — — 650 650 (71) 650 (71) — — — Total — — 850 — — 1,584 2,434 (232) 2,434 (232) — — —
Disclosure of Actual or Potential Effects of Netting Arrangements	The table below is prepared in accordance with the accounting policies described in Note B.8.3.: (€ million) 2024 2023 2022 Derivative financial assets Derivative financial liabilities Derivative financial assets Derivative financial liabilities Derivative financial assets Derivative financial liabilities Gross carrying amounts before offset (a) 217 (458) 201 (291) 206 (326) Gross amounts offset (in accordance with IAS 32) (b) — — — — — — Net amounts as reported in the balance sheet (a) - (b) = (c) 217 (458) 201 (291) 206 (326) Effects of other netting arrangements (not fulfilling the IAS 32 criteria for offsetting) (d) Financial instruments (201) 201 (171) 171 (160) 160 Fair value of financial collateral N/A N/A N/A N/A N/A N/A Net exposure (c) + (d) 16 (257) 30 (120) 46 (166)

Off balance sheet commitments (

Off balance sheet commitments (Tables)	12 Months Ended
	Dec. 31, 2024
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Summary of Off Balance Sheet Commitments Relating to Operating Activities	Off balance sheet commitments relating to Sanofi ’s operating activities, not including as of December 31, 2024 the commitments of the Opella held-for-sale operation, comprise the following: December 31, 2024 Payments due by period (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced (a) 554 28 34 41 451 Irrevocable purchase commitments (b) • given (c) 3,683 1,152 1,195 442 894 • received (391) (288) (96) (7) — Research and development license agreements - commitments given • commitments related to R&D and other commitments (d) 84 42 29 6 7 • contingent milestone payments in connection with development programs in progress (e) 4,230 941 635 470 2,184 Total - net commitments given 8,160 1,875 1,797 952 3,536 (a) Includes the variable portion of future lease payments not recognized as lease liabilities as of December 31, 2024 ; the equivalent amount of these commitments as of December 31, 2023 was € 221 million. During 2023 , Sanofi signed a 15-year lease which will take effect in 2025 and to which Sanofi is committed for a minimum period of 12 years , corresponding to a commitment of $ 0.2 billion. The lease includes two extension options of five years each. During 2024 , Sanofi signed a 12-year lease in France which will take effect in 2027, representing a commitment of € 0.2 billion. (b) These comprise irrevocable commitments to suppliers of (i) property, plant and equipment, net of down-payments (see Note D.3.) and (ii) goods and services. As of December 31, 2023 , irrevocable commitments amounted to €6,141 million given (including €754 million related to Opella) and € 550 million received (zero related to Opella). (c) Irrevocable purchase commitments given as of December 31, 2024 include € 749 million of commitments to joint ventures. This line also includes (i) the commitment to EUROAPI as described in Note D.1. and amounting to € 535 million as of December 31, 2024, and (ii) commitments related to long-term renewable energy purchase contracts lasting between 15 and 20 years giving rise to the physical supply of electricity mainly in France for an estimated total annual volume of 329 GWh. (d) Commitments related to research and development, and other commitments, amounted to € 381 million as of December 31, 2023 . (e) This line only includes contingent milestone payments on development projects in progress. The equivalent amount as of December 31, 2023 was € 4,886 million .
Summary of Undrawn Credit Facilities	Undrawn credit facilities are as follows: December 31, 2024 Expiry (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years General-purpose credit facilities 8,000 — 4,000 — 4,000
Summary of Amount of Guarantees Given and Received	The table below shows the amount of guarantees given and received: (€ million) 2024 2023 2022 Guarantees given: 4,298 3,936 3,815 • Guarantees provided to banks in connection with credit facilities 1,130 1,067 1,007 • Other guarantees given 3,168 2,869 2,808 Guarantees received (1,288) (1,272) (1,229)

Provisions for discounts, reb_2

Provisions for discounts, rebates and sales returns (Tables)	12 Months Ended
	Dec. 31, 2024
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Summary of Movement in Provisions for Discounts, Rebates and Sales Returns	The table below shows movements in these items: (€ million) Government and State programs (a) Managed care and GPO programs (b) Chargeback incentives Rebates and discounts Sales returns Other deductions Total Balance at January 1, 2022 2,596 931 303 1,425 610 34 5,899 Provision related to current period sales 6,744 3,246 4,147 7,244 578 182 22,141 Net change in provision related to prior period sales (120) (47) (21) (138) (8) 19 (315) Payments made (6,824) (3,208) (4,093) (6,809) (599) (166) (21,699) Currency translation differences 207 99 26 83 48 1 464 Balance at December 31, 2022 (c) 2,603 1,021 362 1,805 629 70 6,490 Changes in scope of consolidation 2 — (1) (6) (2) 4 (3) Provision related to current period sales 7,758 3,590 3,861 8,177 654 256 24,296 Net change in provision related to prior period sales (74) (12) (9) (58) (25) 23 (155) Payments made (7,251) (3,446) (3,564) (7,603) (511) (278) (22,653) Currency translation differences (76) (34) (12) (46) (30) (15) (213) Balance at December 31, 2023 (c) 2,962 1,119 637 2,269 715 60 7,762 Provision related to current period sales 5,401 3,961 3,093 9,758 595 482 23,290 Net change in provision related to prior period sales (177) (5) (26) (34) (54) 14 (282) Payments made (5,599) (3,882) (3,336) (9,678) (491) (496) (23,482) Currency translation differences 143 77 36 8 41 (2) 303 Opella reclassification (d) (d) (24) — (6) (201) (30) (3) (264) Balance at December 31, 2024 (c) 2,706 1,270 398 2,122 776 56 7,328 (a) Primarily US government programs: Medicaid ( €1,193 million in 2024 , €1,421 million in 2023 , €1,307 million in 2022 ) and Medicare ( €722 million in 2024 , €1,099 million in 2023 and €775 million in 2022 ). (b) Mainly rebates and other price reductions granted to healthcare authorities in the United States (including Managed Care: €1,097 million in 2024 , €1,028 million in 2023 and € 934 million in 2022 ). (c) Provisions related to US net sales amounted to €4,823 million as of December 31, 2024 , €5,124 million as of December 31, 2023 and €4,270 million as of December 31, 2022 . (d) This line comprises provisions for discounts, rebates and sales returns related to Opella, reclassified as of December 31 ,2024 within Liabilities for assets held for sale in accordance with I FRS 5 (see Note D.1.) .

Personnel costs (Tables)

Personnel costs (Tables)	12 Months Ended
	Dec. 31, 2024
Employee Benefits [Abstract]
Summary of Personal Costs	Total personnel costs (other than termination benefits, presented in Note D.27.) include the following items: (€ million) 2024 2023 2022 Salaries 7,236 7,183 7,145 Social security charges (including defined-contribution pension plans) 2,189 2,100 2,098 Other employee benefits ( a) 766 531 748 Total (b) 10,191 9,814 9,991 (a) Includes expenses related to share-based payments and defined-benefit plans. (b) Includes personnel costs related to Opella of €886 million for 2024, €826 million for 2023, and €794 million for 2022 .

Other operating expenses (Table

Other operating expenses (Tables)	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Schedule Other Operating Expenses	For 2024 , this line item includes €3,955 million of expenses related to Regeneron (see Note C.1.), compared with €3,206 million for 2023 and €2,378 million for 2022 (as shown in the table below): (€ million) 2024 2023 2022 Income & expense related to sharing of (profits)/losses under the Monoclonal Antibody Alliance (4,143) (3,321) (2,325) Additional share of profit paid by Regeneron towards development costs (a) 833 668 434 Reimbursement to Regeneron of selling expenses incurred (637) (543) (476) Total - Monoclonal Antibody Alliance (3,947) (3,196) (2,367) Immuno-Oncology Alliance — — 16 Other (mainly Zaltrap and Libtayo) 158 217 1,120 Other operating income/(expenses), net related to Regeneron (3,789) (2,979) (1,231) of which amount presented in Other operating income (Note D.25.) 166 227 1,147 (a) As of December 31, 2024, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to € 1.6 billion , compared with € 2.1 billion as of December 31, 2023 (see Note D.21.).

Restructuring costs and simil_2

Restructuring costs and similar items (Tables)	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Summary of Restructuring Costs and Similar Items	Restructuring costs and similar items amounted to € 1,396 million in 2024 , € 1,030 million in 2023 and € 1,077 million in 2022 , and were comprised of the following items: (€ million) 2024 2023 (a) 2022 (a) Employee-related expenses 963 404 471 Charges, gains or losses on assets (b) 4 273 261 Costs related to transformation programs 285 330 325 Other 144 23 20 Total 1,396 1,030 1,077 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sano fi .

Financial expenses and income (

Financial expenses and income (Tables)	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Summary of Analysis of Financial Income and Expenses	An analysis of Financial expenses and Financial income is set forth below: (€ million) 2024 2023 (a) 2022 (a) Cost of debt (b) (599) (552) (362) Interest income (c) 413 527 239 Cost of net debt (186) (25) (123) Non-operating foreign exchange gains/(losses) 6 (2) (3) Unwinding of discounting of provisions (d) (44) (51) (17) Net interest cost related to employee benefits (64) (70) (46) Gains/(losses) on disposals of financial assets — (1) 1 Net interest expense on lease liabilities (42) (37) (40) Other (e) (224) (523) 3 Net financial income/(expenses) (554) (709) (225) comprising: Financial expenses (1,073) (1,293) (430) Financial income 519 584 205 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) Includes net gains/(losses) on interest rate and currency derivatives used to manage debt: €(45) million in 2024 , €(67) million in 2023 , €(11) million in 2022 . (c) Includes net gains on interest rate and currency derivatives used to manage cash and cash equivalents: €(25) million in 2024 , €(13) million in 2023 , €68 million in 2022 . (d) Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note D.19.). (e) Includes a financial expense of € 291 million for the remeasurement of the liability recognized in the balance sheet for estimated future royalties on Beyfortus sales in the US. In 2023 , that expense amounted to € 541 million, reflecting the successful launch of Beyfortus (see Note C.2.). T

Income tax expense (Tables)

Income tax expense (Tables)	12 Months Ended
	Dec. 31, 2024
Income Taxes [Abstract]
Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes	The table below shows the allocation of income tax expense between current and deferred taxes: (€ million) 2024 2023 (a) 2022 (a) Current taxes (2,152) (2,251) (2,631) Deferred taxes 948 1,234 722 Total (1,204) (1,017) (1,909) Income before tax and investments accounted for using the equity method 6,698 6,251 9,937 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate	The difference between the effective tax rate and the standard corporate income tax rate applicable in France is explained as follows: (%) 2024 2023 (a) 2022 (a) Standard tax rate applicable in France 25.8 25.8 25.8 Difference between the standard French tax rate and the rates applicable to Sanofi (b) (13.3) (15.3) (6.9) Revisions to tax exposures and settlements of tax disputes 2.8 3.1 (0.8) Fair value remeasurement of contingent consideration 0.1 (0.2) Other items (c) 2.7 2.6 1.3 Effective tax rate 18.0 16.3 19.2 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France. For the year ended December 31, 2024, this line includes a tax expense of €58 million , representing the estimated impact of Pillar Two based on Sanofi’s current understanding of Pillar Two rules. (c) In determining the amount of the deferred tax liability for 2024 , 2023 and 2022 , Sanofi took into account changes in the ownership structure of certain subsidiaries .

Net income attributable to no_2

Net income attributable to non-controlling interests (Tables)	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Summary of Trends in Net Income Attributable to Non-Controlling Interests	The table below shows Net income attributable to non-controlling interests for the reporting periods presented: (€ million) 2024 2023 2022 Share of net income attributable to non-controlling interests 58 36 113 Total 58 36 113

Related party transactions (Tab

Related party transactions (Tables)	12 Months Ended
	Dec. 31, 2024
Related Party [Abstract]
Schedule of Compensation Paid to Key Management Personnel	The table below shows, by type, the compensation paid to key management personnel: (€ million) 2024 2023 2022 Short-term benefits (a) 37 36 31 Post-employment benefits 2 2 2 Share-based payment 21 8 19 Total recognized in profit or loss 60 46 52 (a) Compensation, employer’s social security contributions, directors’ compensation, and any termination benefits (net of reversals of termination benefit obligations).
Summary of Aggregate Amounts Payable to Key Management Personnel	The table below shows the aggregate obligation as of December 31 for each period presented for individuals who hold or have held executive positions within Sanofi during that period. (€ million) 2024 2023 2022 Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members 9 10 10 Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel 7 6 5

Segment information (Tables)

Segment information (Tables)	12 Months Ended
	Dec. 31, 2024
Operating Segments [Abstract]
Schedule of Segment Results	The table below shows Sanofi’s segment results for the years ended December 31, 2024 , December 31, 2023 and December 31, 2022 : 2024 (€ million) Biopharma Other Total 2024 Change vs. 2023 on a reported basis (IFRS) Change vs. 2023 at constant exchange rates (non- IFRS) 2024 Change vs. 2023 on a reported basis (IFRS) Change vs. 2023 at constant exchange rates (non- IFRS) 2024 Change vs. 2023 on a reported basis (IFRS) Change vs. 2023 at constant exchange rates (non- IFRS) Net sales 41,081 8.6% 11.3% — 41,081 8.6% 11.3% Other revenues 2,866 (18.2%) (16.3%) 339 14.5% 23.3% 3,205 (15.7%) (13.3%) Cost of sales (12,973) 4.5% 5.7% (222) 8.8% 20.1% (13,195) 4.6% 6.0% Research and development expenses (7,393) 13.7% 14.6% (1) (50.0%) (50.0%) (7,394) 13.6% 14.6% Selling and general expenses (9,113) 2.9% 4.6% (70) (11.4%) (3.8%) (9,183) 2.8% 4.5% Other operating income and expenses (3,305) 12 (3,293) Share of profit/(loss) from investments accounted for using the equity method 136 — 136 Net income attributable to non-controlling interests (14) — (14) Business operating income 11,285 1.2% 7.3% 58 152.2% 160.9% 11,343 1.5% 7.6% As % of net sales 27.5% 27.6% 2023 (a) (€ million) Biopharma Other Total Net sales 37,817 — 37,817 Other revenues 3,505 296 3,801 Cost of sales (12,415) (204) (12,619) Research and development expenses (6,505) (2) (6,507) Selling and general expenses (8,854) (79) (8,933) Other operating income and expenses (2,476) 12 (2,464) Share of profit/(loss) from investments accounted for using the equity method 101 — 101 Net income attributable to non-controlling interests (18) — (18) Business operating income 11,155 23 11,178 (a) Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. 2022 (a)(b) (€ million) Biopharma Other Total Net sales 37,651 — 37,651 Other revenues 2,534 376 2,910 Cost of sales (11,682) (197) (11,879) Research and development expenses (6,499) (2) (6,501) Selling and general expenses (8,536) (203) (8,739) Other operating income and expenses (764) 55 (709) Share of profit/(loss) from investments accounted for using the equity method 76 — 76 Net income attributable to non-controlling interests (16) — (16) Business operating income 12,764 29 12,793 (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax).
Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method	The table below, presented in compliance with IFRS 8, shows a reconciliation between aggregated “Business operating income” for the segment and Income before tax and investments accounted for using the equity method : (€ million) 2024 2023 (a) 2022 (a)(h) Business operating income 11,343 11,178 12,793 Share of profit/(loss) from investments accounted for using the equity method (b) (136) (101) (76) Net income attributable to non-controlling interests (c) 14 18 16 Amortization and impairment of intangible assets (d) (1,997) (2,807) (1,375) Fair value remeasurement of contingent consideration (96) (93) 27 Expenses arising from the impact of acquisitions on inventories (e) (10) (9) (3) Restructuring costs and similar items (f) (1,396) (1,030) (1,077) Other gains and losses, and litigation (g) (470) (196) (143) Operating income 7,252 6,960 10,162 Financial expenses (1,073) (1,293) (430) Financial income 519 584 205 Income before tax and investments accounted for using the equity method 6,698 6,251 9,937 ( a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) Joint ventures and associates with which Sanofi has entered into a strategic alliance. (c) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (d) For 2024, this line includes a net impairment charge of € 248 million mainly due to a recognition of impairment losses of € 640 million against on various research and development projects – including a €239 million loss resulting from the decision taken in February 2025 to discontinue a phase 3 clinical study investigating of a vaccine candidate to prevent invasive E.coli disease - partially offset by impairment losses reversals , recognized in connection with the disposals of the ProXTen platform and Enjaymo, for € 225 million and € 167 million respectively. For 2023, this amount mainly comprises an impairment loss of €833 million , reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and ProXTen technology platforms. For 2022, this line includes a reversal of €2,154 million on Eloctate franchise products following FDA approval of ALTUVIIIO on February 22, 2023, partially offset by an impairment loss of €1,586 million on intangible assets relating to SAR444245 (non- alpha interleukin-2). (e) This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date. (f) See note D.27 . (g) See note D.28. (h) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax) .
Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment	Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period. Biopharma (€ million) 2024 2023 2022 Investments accounted for using the equity method (a) 234 234 248 Acquisitions of property, plant and equipment 1,733 1,619 1,529 Acquisitions of other intangible assets 1,462 1,287 574 (a) Carrying amount at the end of the reporting period.
Summary of Geographical Information on Net Sales and Non-Current Assets	The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with IFRS 8, the non-current assets reported below exclude right-of-use assets relating to leases as determined under IFRS 16, investments accounted for using the equity method, other non-current assets, non-current income tax assets, and deferred tax assets. 2024 (€ million) Total Europe of which France United States Other countries Net sales 41,081 9,027 1,814 19,986 12,068 Non-current assets: • property, plant and equipment owned 10,091 5,550 3,112 2,411 2,130 • goodwill 43,384 — — — — ▪ other intangible assets 22,629 3,307 — 18,711 611 (€ million) 2023 Total Europe of which France United States Other countries Net sales (a) 37,817 8,816 1,910 17,262 11,739 Non-current assets: • property, plant and equipment owned 10,160 5,659 3,085 2,322 2,179 • goodwill 49,404 — — — — • other intangible assets 24,319 5,566 — 17,850 903 (a) Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (€ million) 2022 Total Europe of which France United States Other countries Net sales (a) 37,651 8,490 1,830 16,986 12,175 Non-current assets: • property, plant and equipment owned 9,869 5,365 2,875 2,457 2,047 • goodwill 49,892 — — — — • other intangible assets 21,640 6,257 — 14,174 1,209 (a) Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Non-current asset held for sa_2

Non-current asset held for sale and discontinued operations (Tables)	12 Months Ended
	Dec. 31, 2024
DisclosureOfDiscontinuedOperationsAbstract [Abstract]
Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures Text Block	An analysis of those line items is provided below: (€ million) 2024 Assets Property, plant and equipment owned 760 Right-of-use assets 116 Goodwill 7,255 Other intangible assets 2,928 Inventories 600 Accounts receivable 989 Other assets 841 Total assets held for sale 13,489 Liabilities Llease liabilities 112 Non-current provisions and other non-current liabilities 204 Accounts payable 797 Current provisions and other current liabilities 570 Other liabilities 448 Total liabilities related to assets held for sale 2,131 In accordance with IFRS 5, the Opella held for sale asset group, and the related liabilities, have been measured at the lower of carrying amount and fair value less costs to sell. This valuation did not result in the recognition of any impairment. The table below details the main items presented within Net income from discontinued operations : (€ million) 2024 2023 2022 Net sales 5,031 4,884 4,781 Operating income 305 915 494 Income before tax and investments accounted for using the equity method 288 902 485 Income tax expense (240) (585) (97) Net income from discontinued operations (Opella) 64 338 401 The table below presents basic and diluted earnings per share from discontinued operations (Opella, in accordance with IAS 33 (Earnings per Share): (€ million) 2024 2023 2022 Net income from discontinued operations (Opella) 64 338 401 Average number of shares outstanding (million) 1,251.4 1,251.7 1,251.9 Average number of shares after dilution (million) 1,256.1 1,256.4 1,256.9 Basic earnings per share (in euros) 0.04 0.25 0.31 Diluted earnings per share (in euros) 0.04 0.25 0.31 Off balance sheet commitments relating to Opella operating activities break down as follows: December 31, 2024 Payments due by period (€ million) Total Less than 1 year 1 to 3 years 3 to 5 years More than 5 years Irrevocable purchase commitments 704 159 225 204 116 • given 705 160 225 204 116 • received (1) (1) Research and development license agreements - commitments given 676 6 560 77 33 Total 1,380 165 785 281 149

Principal accountants' fees a_2

Principal accountants' fees and services (Tables)	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Disclosure of Accountants' Fees and Services	The table below shows fees charged by those firms and member firms of their networks to Sanofi and consolidated subsidiaries in the years ended December 31, 2024 and 2023 . Forvis Mazars PricewaterhouseCoopers Ernst & Young 2024 2024 2023 2023 (€ million) Amount % Amount % Amount % Amount % Statutory audit of separate and consolidated financial statements (a) 11.5 93% 19.7 73% 14.7 72% 15.1 74% Limited review of sustainability statement (b) 0.6 5% 1.0 4% — —% — —% Services other than statutory audit (c) 0.2 2% 6.4 23% 5.8 28% 5.4 26% Audit-related services (d)(e) 0.2 6.4 5.8 5.3 Tax 0.0 0.0 — — Other — — — 0.1 Total 12.3 100% 27.1 100% 20.5 100% 20.5 100% (a) Includes services provided by the independent auditors of the parent company and French subsidiaries: Forvis Mazars €4.8 million in 2024 ; PricewaterhouseCoopers Audit €12.5 million in 2024 , €8.3 million in 2023 and Ernst & Young €7.9 million in 2023 . (b) For SEC purposes, these Services are classified as Other. (c) Services other than statutory audit provided by Forvis Mazars during 2024 comprised: - assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy. Services other than statutory audit provided by PricewaterhouseCoopers during 2024 comprised: - contractual audits, including on the combined financial statements of the Opella business; - additional procedures to enable reports previously signed by the firm to be incorporated by reference; and - assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy. (d) Includes services provided by the independent auditors of the parent company and French subsidiaries: Forvis Mazars: €0.1 million in 2024 ,; PricewaterhouseCoopers Audit €3.5 million in 2024 , €3.6 million in 2023 and Ernst & Young €5.2 million in 2023 . (e) Includes €0.5 million for services that can only be provided by the statutory auditors, such as comfort letters, attestation services required by regulation (which qualify as audit fees under SEC rules).

List of principal companies i_2

List of principal companies included in the scope of consolidation during 2023 (Tables)	12 Months Ended
	Dec. 31, 2024
Interests In Other Entities [Abstract]
Summary of Principal Companies and their Country of Incorporation	The table below shows Sanofi’s principal subsidiaries and their country of incorporation : Europe Financial interest (%) as of December 31, 2024 Hoechst GmbH * Germany 100.0 Sanofi-Aventis Deutschland GmbH Germany 100.0 A. Nattermann & Cie GmbH Germany 100.0 Sanofi-Aventis GmbH Austria 100.0 Sanofi Belgium Belgium 100.0 Ablynx NV Belgium 100.0 Genzyme Flanders BV Belgium 100.0 Sanofi A/S Denmark 100.0 Sanofi-Aventis SA Spain 100.0 Opella Healthcare Spain, SL Spain 100.0 Sanofi Oy Finland 100.0 Sanofi France 100.0 Sanofi Winthrop Industrie * France 100.0 Sanofi-Aventis Recherche & Développement France 100.0 Sanofi-Aventis Groupe France 100.0 Sanofi-Aventis Participations * France 100.0 Sanofi Pasteur France 100.0 Aventis Pharma SA France 100.0 Aventis Agriculture France 100.0 Sanofi Biotechnology * France 100.0 Sanofi Pasteur NVL France 100.0 Sanofi Pasteur Europe France 100.0 Opella Healthcare France 100.0 Sanofi Pasteur Merieux SAS France 100.0 Opella Healthcare International SAS France 100.0 Opella Healthcare France SAS France 100.0 Opella Healthcare Group SAS France 100.0 Genzyme Polyclonals SAS France 100.0 Sanofi-Aventis AEBE Greece 100.0 Sanofi-Aventis Private Co Ltd Hungary 99.6 Chinoin Private Co Ltd Hungary 99.6 Opella Healthcare Hungary Commercial KFT Hungary 100.0 Opella Healthcare Hungary KFT Hungary 100.0 Carraig Insurance DAC Ireland 100.0 Genzyme Ireland Limited Ireland 100.0 Sanofi-Aventis Ireland Ltd Ireland 100.0 Sanofi-aventis Holdings (Ireland) Ltd Ireland 100.0 Sanofi SRL Italy 100.0 Opella Healthcare Italy SRL Italy 100.0 Genzyme Global Sarl Luxembourg 100.0 Genzyme Luxembourg Sarl Luxembourg 100.0 Le Rock Re Luxembourg 100.0 Sanofi-aventis Norge AS Norway 100.0 Sanofi BV * Netherlands 100.0 Sanofi Foreign Participations BV * Netherlands 100.0 Europe Financial interest (%) as of December 31, 2024 Opella Healthcare Participation BV Netherlands 100.0 Sanofi-Aventis Sp zoo Poland 100.0 Opella Healthcare Poland sp.ZOO Poland 100.0 Sanofi Produtos Farmaceuticos Lda Portugal 100.0 Sanofi sro Czech Republic 100.0 Sanofi Romania SRL Romania 100.0 Opella Healthcare Romania SRL Romania 100.0 Sanofi-Aventis UK Holdings Limited United Kingdom 100.0 Aventis Pharma Limited United Kingdom 100.0 Sanofi-Synthelabo UK Ltd United Kingdom 100.0 Aventis Pharma Holdings Ltd United Kingdom 100.0 Opella Healthcare UK Limited United Kingdom 100.0 AO Sanofi Russia Russia 100.0 Opella Healthcare LLC Russia 100.0 Sanofi AB Sweden 100.0 Sanofi-Aventis (Suisse) SA Switzerland 100.0 Genzyme Global Sarl Baar Intellectual Property Branch Switzerland 100.0 Sanofi Ilac Sanayi ve Ticaret AS Turkey 100.0 Sanofi Pasteur Asi Ticaret AS Turkey 100.0 Opella Healthcare Tüketici Sağlığı Anonim Şirketi Turkey 100.0 Sanofi Saglik Urunleri Limited Sirketi Turkey 100.0 United States Financial interest (%) as of December 31, 2024 Genzyme Therapeutic Products Limited Partnership United States 100.0 Aventis Inc * United States 100.0 Sanofi US Services Inc United States 100.0 Sanofi-Aventis U.S. LLC United States 100.0 Chattem, Inc United States 100.0 Aventisub LLC United States 100.0 Genzyme Corporation * United States 100.0 Sanofi Pasteur Inc * United States 100.0 VaxServe, Inc United States 100.0 Bioverativ Inc United States 100.0 Bioverativ U.S.LLC United States 100.0 Bioverativ USA Inc United States 100.0 Bioverativ Therapeutics Inc United States 100.0 Principia Biopharma Inc United States 100.0 Sanofi Ventures LLC United States 100.0 Sanofi Bioverativ Holdings LLC United States 100.0 RPR US Ltd United States 100.0 Kadmon Pharmaceuticals LLC United States 100.0 Kadmon Corporation, LLC United States 100.0 Synthorx, Inc United States 100.0 Provention Bio United States 100.0 QRIB Intermediate Holding United States 100.0 QRI United States 100.0 Gold Bond Co LLC United States 100.0 Chattem (GB) Holding United States 100.0 Sanofi AATD, Inc United States 100.0 Translate Bio, Inc United States 100.0 Other Countries Financial interest (%) as of December 31, 2024 Sanofi-Aventis South Africa (Pty) Ltd South Africa 100.0 Sanofi-Aventis Algérie Algeria 100.0 Sanofi Arabia Trading Company Limited Saudi Arabia 100.0 Sanofi-Aventis Argentina SA Argentina 100.0 Opella Healthcare Argentina SAU Argentina 100.0 Genzyme de Argentina SA Argentina 100.0 Sanofi-Aventis Healthcare Pty Ltd Australia 100.0 Sanofi-Aventis Australia Pty Ltd Australia 100.0 Sanofi Medley Farmaceutica Ltda Brazil 100.0 Opella Healthcare Brazil Ltda Brazil 100.0 Sanofi-Aventis Canada Inc Canada 100.0 Sanofi Pasteur Limited Canada 100.0 Merieux Canada Holdings ULC (Canada) Canada 100.0 Sanofi Vaccines Chile SA Chile 100.0 Sanofi (Hangzhou) Pharmaceuticals Co Ltd China 100.0 Opella Healthcare Shanghai LTD China 100.0 Sanofi (China) Investment Co Ltd China 100.0 Sanofi (Beijing) Pharmaceuticals Co Ltd China 100.0 Sanofi (Jiangsu) Biologics Co Ltd China 100.0 Shenzhen Sanofi pasteur Biological Products Co Ltd China 100.0 Shanghai Rongheng Pharmaceutical Co Ltd China 100.0 Opella Healthcare Colombia SAS Colombia 100.0 Sanofi-Aventis de Colombia SA Colombia 100.0 Sanofi-Aventis Korea Co Ltd South Korea 100.0 Sanofi-Aventis Gulf FZE United Arab Emirates 100.0 Sanofi Egypt Egypt 99.8 Sanofi Hong-Kong Limited Hong Kong 100.0 Sanofi India Limited India 60.4 Sanofi Healthcare India Private Limited India 99.9 Sanofi-Aventis Israël Ltd Israel 100.0 Sanofi KK Japan 100.0 SSP Co Ltd Japan 100.0 Sanofi-Aventis (Malaysia) SDN BHD Malaysia 100.0 Sanofi-Aventis Maroc Morocco 100.0 Sanofi-Aventis de Mexico SA de CV Mexico 100.0 Sanofi Pasteur SA de CV Mexico 100.0 Azteca Vacunas SA de CV Mexico 100.0 Sanofi-Aventis de Panama SA Panama 100.0 Opella Healthcare Panama SA Panama 100.0 sanofi-aventis Puerto Rico Inc Puerto Rico 100.0 Sanofi-Aventis Philippines Inc Philippines 100.0 Opella Healthcare Philippines Inc Philippines 100.0 Sanofi-Aventis Singapore Pte Ltd * Singapore 100.0 Aventis Pharma (Manufacturing) Pte Ltd Singapore 100.0 Sanofi Manufacturing Pte Ltd Singapore 100.0 Sanofi Taiwan Co Ltd Taiwan 100.0 Sanofi-Aventis (Thailand) Ltd Thailand 100.0 Sanofi-Aventis de Venezuela SA Venezuela 100.0 Sanofi-aventis Vietnam Company Limited Vietnam 100.0 Sanofi Vietnam Shareholding Company Limited Vietnam 85.0 * Main significant subsidiaries as of December 31, 2024 .
Summary of Principal Investments Accounted for Using the Equity Method	Financial interest (%) as of December 31, 2024 Haleon US, LP United States 11.7 Infraserv GmbH & Co. Höchst KG Germany 31.2 Maphar Morocco 48.3 MCM Vaccine BV Netherlands 50.0 MSP Vaccine Company (formerly MCM company) United States 50.0 EUROAPI France 29.6

Basis of preparation (Details)

Basis of preparation (Details) € in Millions, vaccine_dose in Millions		1 Months Ended	12 Months Ended
		Jul. 31, 2020 vaccine_dose	Dec. 31, 2024 EUR (€) scenario emission	Dec. 31, 2023 EUR (€)		Dec. 31, 2022 EUR (€)		Dec. 31, 2021 EUR (€)
Disclosure of initial application of standards or interpretations [line items]
Average effective tax rate			18%	16.30%	[1]	19.20%	[1]
Planet Care Program, net emissions by 2045 | emission			0
Planet Care Program, percentage of reduction in scope 1 and 2 greenhouse gas by 2030			55%
Planet Care Program, percentage of reduction in scope 3 greenhouse gas by 2030			30%
Planet Care Program, percentage of reduction in all scopes greenhouse gas by 2030			90%
Planet Care Program, percentage of renewably-sourced energy in all sites by 2030			100%
Planet Care Program, number of global warming scenarios | scenario			3
Other revenues			€ 3,205	€ 3,801	[2],[3]	€ 2,910	[2],[3]
Current contract liabilities	[4]		0	0		269
Collaboration agreement with GSK
Disclosure of initial application of standards or interpretations [line items]
Current contract liabilities						269		€ 319
Other revenue, doses no longer an obligation to be delivered				94
Collaboration agreement with GSK | US Government
Disclosure of initial application of standards or interpretations [line items]
Number of vaccine doses to be supplied | vaccine_dose		100
Other revenues				411
Government grant recognised as deduction from development expenses			€ 58	€ 59		€ 265
Argentina
Disclosure of initial application of standards or interpretations [line items]
Cumulative inflation rate over three years				100%
Turkey
Disclosure of initial application of standards or interpretations [line items]
Cumulative inflation rate over three years				100%
[1] (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) See Note A.5. , “Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK” . The year-on-year change in this item between 2023 and 2022 includes revenue of € 269 million recognized in profit or loss during 2023 (previously included in “ Customer contract liabilities ” as of December 31, 2022 ).

Summary of significant accoun_4

Summary of significant accounting policies - Other Intangible Assets not Acquired in Business Combination (Details)	12 Months Ended
	Dec. 31, 2024
Bottom of range
Disclosure of detailed information about intangible assets [line items]
Useful life, intangible assets other than goodwill (in years)	1 year
Bottom of range | Software
Disclosure of detailed information about intangible assets [line items]
Useful life, intangible assets other than goodwill (in years)	3 years
Top of range
Disclosure of detailed information about intangible assets [line items]
Useful life, intangible assets other than goodwill (in years)	25 years
Top of range | Software
Disclosure of detailed information about intangible assets [line items]
Useful life, intangible assets other than goodwill (in years)	5 years

Summary of significant accoun_5

Summary of significant accounting policies - Summary of Useful Lives of Property Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2024
Bottom of range | Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Useful lives or depreciation rates, property, plant and equipment (in years)	15 years
Bottom of range | Fixtures
Disclosure of detailed information about property, plant and equipment [line items]
Useful lives or depreciation rates, property, plant and equipment (in years)	10 years
Bottom of range | Machinery and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Useful lives or depreciation rates, property, plant and equipment (in years)	5 years
Bottom of range | Other
Disclosure of detailed information about property, plant and equipment [line items]
Useful lives or depreciation rates, property, plant and equipment (in years)	3 years
Top of range | Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Useful lives or depreciation rates, property, plant and equipment (in years)	40 years
Top of range | Fixtures
Disclosure of detailed information about property, plant and equipment [line items]
Useful lives or depreciation rates, property, plant and equipment (in years)	20 years
Top of range | Machinery and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Useful lives or depreciation rates, property, plant and equipment (in years)	15 years
Top of range | Other
Disclosure of detailed information about property, plant and equipment [line items]
Useful lives or depreciation rates, property, plant and equipment (in years)	15 years

Summary of significant accoun_6

Summary of significant accounting policies - Treasury Shares (Details)	12 Months Ended
	Dec. 31, 2023 EUR (€)
Corporate information and statement of IFRS compliance [abstract]
Gain (loss) recognized on purchase of treasury shares	€ 0
Gain (loss) recognized on sale of treasury shares	0
Gain (loss) recognized on impairment of treasury shares	0
Gain (loss) recognized on cancellation of treasury shares	€ 0

Summary of significant accoun_7

Summary of significant accounting policies - Provision for Risks (Details)	12 Months Ended
	Dec. 31, 2023 EUR (€)
Corporate information and statement of IFRS compliance [abstract]
Provisions recorded for future operating losses	€ 0

Summary of significant accoun_8

Summary of significant accounting policies - Income Tax Expense (Details) - EUR (€)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022	[1]
Disclosure Of Detailed Information About Income Taxes [Line Items]
Deferred tax expense	€ (948,000,000)	€ (1,234,000,000)	[1]	€ (722,000,000)
Temporary differences subject to GILTI
Disclosure Of Detailed Information About Income Taxes [Line Items]
Deferred tax expense		€ 0
[1] (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Summary of significant accoun_9

Summary of significant accounting policies - Share-Based Payment (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Stock option plans
Disclosure Of Detailed Information About Share-Based Payment [Line Items]
Option vesting period (in years)		4 years
Restricted share plans
Disclosure Of Detailed Information About Share-Based Payment [Line Items]
Award vesting period (in years)	3 years

Principal alliances - Collabora

Principal alliances - Collaboration agreements on human therapeutic antibodies (Details) € in Millions, $ in Millions

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Apr. 01, 2020

Jul. 01, 2015 agreement

Jul. 31, 2023 EUR (€)

Nov. 30, 2022 EUR (€)

Nov. 30, 2007 agreement

Mar. 31, 2022

Dec. 31, 2022 Rate

Dec. 31, 2024 EUR (€) Rate

Dec. 31, 2023 EUR (€) Rate

Dec. 31, 2023 USD ($) Rate

Dec. 31, 2022 EUR (€) bond

Dec. 31, 2022 USD ($) bond

Dec. 31, 2015

Disclosure of detailed information about Principal Alliances [Line Items]

Net sales | €

€ 41,081

€ 37,817

[1]

€ 37,651

[1]

US

Disclosure of detailed information about Principal Alliances [Line Items]

Net sales | €

€ 19,986

€ 17,262

[2]

€ 16,986

[3]

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement

Disclosure of detailed information about Principal Alliances [Line Items]

Number of agreements signed | agreement

2

Phase III costs, responsibility percentage

80%

Phase III costs, responsibility percentage for Regeneron

20%

Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)

10%

20%

Percentage of cumulative development costs reimbursed

50%

50%

50%

Period before scheduled launch date

24 months

Number of payments | bond

2

2

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, first achievement

Disclosure of detailed information about Principal Alliances [Line Items]

Payment related to attainment of goal

$ 50

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, first achievement | Antibodies

Disclosure of detailed information about Principal Alliances [Line Items]

Net sales

2,000

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, second achievement

Disclosure of detailed information about Principal Alliances [Line Items]

Payment related to attainment of goal

50

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, second achievement | Antibodies

Disclosure of detailed information about Principal Alliances [Line Items]

Net sales

$ 2,500

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Prior agreement

Disclosure of detailed information about Principal Alliances [Line Items]

Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) | Rate

10%

10%

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | New agreement

Disclosure of detailed information about Principal Alliances [Line Items]

Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) | Rate

20%

20%

20%

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales Of Antibodies, Third Achievement

Disclosure of detailed information about Principal Alliances [Line Items]

Payment related to attainment of goal

$ 50

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales Of Antibodies, Third Achievement | Antibodies

Disclosure of detailed information about Principal Alliances [Line Items]

Net sales

$ 3,000

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | US

Disclosure of detailed information about Principal Alliances [Line Items]

Percentage of profits and losses arising from commercial operations

50%

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Outside the United States

Disclosure of detailed information about Principal Alliances [Line Items]

Percentage of losses arising from commercial operations

55%

Royalty expense, percentage (percentage)

5%

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Outside the United States | Bottom of range

Disclosure of detailed information about Principal Alliances [Line Items]

Percentage of profits arising from commercial operations

55%

Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Outside the United States | Top of range

Disclosure of detailed information about Principal Alliances [Line Items]

Percentage of profits arising from commercial operations

65%

Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement

Disclosure of detailed information about Principal Alliances [Line Items]

Number of agreements signed | agreement

2

Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)

10%

Percentage of cumulative development costs reimbursed

50%

Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Major Collaboration Agreement

Disclosure of detailed information about Principal Alliances [Line Items]

Proceeds from collaboration agreements | €

€ 117

€ 196

€ 952

AstraZeneca | Antibodies Collaboration agreement

Disclosure of detailed information about Principal Alliances [Line Items]

Collaboration agreements, regulatory milestone payment | €

€ 65

€ 25

Collaboration Agreements, Amount Paid | €

€ 25

[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (a) Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Principal alliances - Immuno-On

Principal alliances - Immuno-Oncology Agreement with Regeneron Pharmaceuticals, Inc. (Details) € in Millions, $ in Millions			1 Months Ended				12 Months Ended
	Sep. 30, 2021 USD ($)	Jul. 01, 2015 agreement	Nov. 30, 2022 EUR (€)	Nov. 30, 2022 USD ($)	Jul. 31, 2022 EUR (€)	Jul. 31, 2022 USD ($)	Dec. 31, 2024 EUR (€)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2015 USD ($)
Disclosure of Principal Alliances [Line Items]
Other operating income/(expenses), net related to Regeneron							€ (3,789)	€ (2,979)	€ (1,231)
Non-current assets or disposal groups classified as held for sale							13,489	15	85
Regeneron Pharmaceuticals, INC
Disclosure of Principal Alliances [Line Items]
Non-current assets or disposal groups classified as held for sale									226
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement
Disclosure of Principal Alliances [Line Items]
Number of agreements signed | agreement		2
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)										10%
Percentage of cumulative development costs reimbursed										50%
Regular milestone payments for projects under collaboration agreements			€ 96	$ 100
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Major Collaboration Agreement
Disclosure of Principal Alliances [Line Items]
Upfront payments for projects under collaboration agreements					€ 856	$ 900
Royalty income percentage (percentage)					11%	11%
Other operating income/(expenses), net related to Regeneron								116	111
Proceeds from collaboration agreements							€ 117	€ 196	€ 952
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Development of cemiplimab (REGN2810)
Disclosure of Principal Alliances [Line Items]
Prior development budget in total | $										$ 1,640
Contractual agreement for anti-programmed cell death protein										5,000%
Maximum additional funding for PD1 - part of each company | $	$ 1,840									$ 820
PD1 sales milestone payment from Sanofi | $										375
Minimum sales of PD1 in 12-month period to be achieved for milestone payment | $										$ 2,000

Principal alliances - Investor

Principal alliances - Investor Agreement with Regeneron Pharmaceuticals, Inc. (Details) - shares		1 Months Ended
	May 29, 2020	Jan. 31, 2014
Public offering | Regeneron
Disclosure of detailed information about Principal Alliances [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	13,000,000
Regeneron Pharmaceuticals, INC | 2014 Amended Investment Agreement
Disclosure of detailed information about Principal Alliances [Line Items]
Maximum ownership percentage allowed to acquire		30%

Principal alliances - Agreement

Principal alliances - Agreements on the commercialization of Beyfortus™ (nirsevimab, previously MEDI8897) in the US (Details) - EUR (€) € in Millions		1 Months Ended			3 Months Ended	12 Months Ended
		Jul. 31, 2023	Nov. 30, 2022	Mar. 31, 2017	Sep. 30, 2019	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Principal Alliances [Line Items]
Collaboration agreements, upfront payment				€ 120
Other non-current liabilities	[1]					€ 2,334	€ 2,340	€ 519
Antibodies Collaboration agreement | AstraZeneca
Disclosure of Principal Alliances [Line Items]
Collaboration agreements, development milestone payment					€ 30
Collaboration agreements, regulatory milestone payment		€ 65	€ 25
Commitments related to milestone payments for projects under collaboration agreements							375
Accruals						100
Collaboration Agreements, Amount Paid						25
Collaboration Agreements, Amount Made						€ 50
Intangible assets and goodwill							1,600
Total financial liabilities measured at fair value							1,600
Antibodies Collaboration agreement | AstraZeneca | Major territories
Disclosure of Principal Alliances [Line Items]
Percentage of profits arising from commercial operations						5,000%
Antibodies Collaboration agreement | AstraZeneca | Other territories
Disclosure of Principal Alliances [Line Items]
Percentage of profits arising from commercial operations						25%
Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB
Disclosure of Principal Alliances [Line Items]
Other non-current liabilities						€ 2,007
Increase through remeasurement of financial liability						291	541
Immuno-oncology collaboration agreement | Regeneron Pharmaceuticals, INC | Major Collaboration Agreement
Disclosure of Principal Alliances [Line Items]
Proceeds from collaboration agreements						€ 117	€ 196	€ 952
[1] (a) Includes derivative financial instruments: € 121 million as of December 31, 2024 , €164 million as of December 31, 2023 , €232 million as of December 31, 2022 . The figure as of December 31, 2024 includes € 2,007 million for the liability in respect of royalties payable to Sobi on net sales of Beyfortus (nirsevimab) in the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is € 1,140 million; the nominal value of payments estimated to be due after more than five years is € 2,792 million.

Principal changes in the scop_3

Principal changes in the scope of consolidation in 2023 - Additional Information (Details) $ / shares in Units, € in Millions, $ in Millions

12 Months Ended

Dec. 31, 2024 EUR (€)

Dec. 31, 2024 USD ($)

Dec. 31, 2023 EUR (€)

Dec. 31, 2023 USD ($)

Dec. 31, 2022 EUR (€)

May 30, 2024 USD ($) $ / shares

Sep. 29, 2023 EUR (€)

Sep. 29, 2023 USD ($)

Apr. 27, 2023 USD ($)

Mar. 13, 2023 USD ($) $ / shares

Disclosure of detailed information about business combination [line items]

Net cash flow on acquisition | €

[1]

€ 1,901

€ 2,535

[2]

€ 987

[2]

Goodwill, tax deductible period

15 years

15 years

Other intangible assets | €

€ 22,629

€ 24,319

€ 21,640

Assets Acquisition

Disclosure of detailed information about business combination [line items]

Consideration transferred, acquisition-date fair value

$ 2,035

Net cash flow on acquisition

$ 2,035

Other intangible assets

$ 1,885

Cash payment per non-transferable contingent value right (in USD per share) | $ / shares

$ 5

Contingent consideration recognised as of acquisition date

$ 300

Provention Bio, Inc

Disclosure of detailed information about business combination [line items]

Purchase price per share (in euro/usd per share) | $ / shares

$ 25

Cash transferred

$ 2,800

Equity interest in acquiree held before acquisition date

$ 68

Consideration transferred, acquisition-date fair value

$ 2,806

Net cash flow on acquisition

$ 2,722

Other intangible assets

$ 2,810

QRIB Intermediate Holding

Disclosure of detailed information about business combination [line items]

Consideration transferred, acquisition-date fair value

€ 1,343

$ 1,419

Identifiable intangible assets recognised as of acquisition date | €

774

Goodwill recognised as of acquisition date | €

€ 484

[1] This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2024, it includes the net cash outflow relating to the acquisition of Inhibrx, Inc. (see Note D.1..1). For 2023, it includes the net cash outflow on the acquisitions of Provention Bio (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note D.1.) Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).

Principal changes in the scop_4

Principal changes in the scope of consolidation in 2023 - Summary of Provisional Purchase Price Allocation (Details) € in Millions, $ in Millions		12 Months Ended
		Dec. 31, 2024 EUR (€)	Dec. 31, 2023 EUR (€)	[2]	Dec. 31, 2022 EUR (€)	[2]	Sep. 29, 2023 EUR (€)	Sep. 29, 2023 USD ($)
Disclosure of detailed information about business combination [line items]
Net cash flow on acquisition	[1]	€ 1,901	€ 2,535		€ 987
QRIB Intermediate Holding
Disclosure of detailed information about business combination [line items]
Identifiable intangible assets recognised as of acquisition date							€ 774
Other Current Assets And Current Liabilities As Of Acquisition Date							80
Cash and cash equivalents recognised as of acquisition date							8
Deferred tax liabilities recognised as of acquisition date							(3)
Net assets							859
Goodwill recognised as of acquisition date							484
Consideration transferred, acquisition-date fair value							€ 1,343	$ 1,419
[1] This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2024, it includes the net cash outflow relating to the acquisition of Inhibrx, Inc. (see Note D.1..1). For 2023, it includes the net cash outflow on the acquisitions of Provention Bio (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note D.1.) Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).

Principal changes in the scop_5

Principal changes in the scope of consolidation in 2022 and 2021 - Additional Information (Details) € / shares in Units, $ / shares in Units, € in Millions, $ in Millions

1 Months Ended

8 Months Ended

11 Months Ended

12 Months Ended

Nov. 29, 2024 EUR (€)

Nov. 29, 2024 USD ($)

Sep. 29, 2023 EUR (€)

Jun. 17, 2022 EUR (€)

May 10, 2022 EUR (€) € / shares shares

May 03, 2022

Mar. 17, 2022 EUR (€)

Nov. 30, 2022 EUR (€)

Nov. 30, 2022 USD ($)

Jul. 31, 2022 EUR (€)

Jul. 31, 2022 USD ($)

Dec. 31, 2022 EUR (€)

Dec. 31, 2022 EUR (€)

Dec. 31, 2024 EUR (€)

Dec. 31, 2024 USD ($)

Dec. 31, 2023 EUR (€)

Dec. 31, 2023 USD ($)

Dec. 31, 2022 EUR (€)

Dec. 31, 2021 EUR (€)

May 30, 2024 USD ($)

Sep. 29, 2023 USD ($)

Apr. 27, 2023 USD ($)

Mar. 13, 2023 USD ($) $ / shares

Feb. 08, 2022 EUR (€)

Feb. 08, 2022 USD ($)

Oct. 01, 2021 EUR (€)

Disclosure of detailed information about business combination [line items]

Net cash flow on acquisition

[1]

€ 1,901

€ 2,535

[2]

€ 987

[2]

Net sales

41,081

37,817

[3]

37,651

[3]

Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi

[4]

793

Investments accounted for using the equity method

€ 677

€ 677

316

424

677

Other gains, (losses) and litigation

(470)

(196)

[3]

(143)

[3]

Tax expense (income)

(1,204)

(1,017)

[3],[5]

(1,909)

[3],[5]

Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax

[6]

0

42

[2]

134

[2]

Other intangible assets

21,640

21,640

22,629

24,319

21,640

Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax

[7]

1,461

807

[2]

1,340

[2]

Goodwill

€ 49,892

49,892

43,384

49,404

49,892

Cash flows from (used in) investing activities, discontinued operations

[8]

€ (109)

(1,250)

[2]

42

[2]

Enjaymo global rights | Major Collaboration Agreement

Disclosure of detailed information about business combination [line items]

Upfront payments for projects under collaboration agreements | $

$ 825

Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax

€ 768

Goodwill

€ 276

Regular milestone payments for projects under collaboration agreements | $

$ 250

Assets Acquisition

Disclosure of detailed information about business combination [line items]

Contingent consideration recognised as of acquisition date | $

$ 300

Net cash flow on acquisition | $

$ 2,035

Consideration transferred, acquisition-date fair value | $

2,035

Other intangible assets | $

$ 1,885

Provision for decommissioning, restoration and rehabilitation costs

Disclosure of detailed information about business combination [line items]

Other provisions

€ 14

Regulatory compliance costs

Disclosure of detailed information about business combination [line items]

Other provisions

€ 15

Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement

Disclosure of detailed information about business combination [line items]

Regular milestone payments for projects under collaboration agreements

€ 96

$ 100

Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Major Collaboration Agreement

Disclosure of detailed information about business combination [line items]

Upfront payments for projects under collaboration agreements

€ 856

$ 900

AstraZeneca | Antibodies Collaboration agreement

Disclosure of detailed information about business combination [line items]

Commitments related to milestone payments for projects under collaboration agreements

€ 375

AstraZeneca | Antibodies Collaboration agreement | Major territories

Disclosure of detailed information about business combination [line items]

Percentage of profits arising from commercial operations

5,000%

5,000%

EUROAPI

Disclosure of detailed information about business combination [line items]

Proportion of ownership interest in associate (in percent)

30.10%

29.60%

[9]

29.60%

[9]

Ownership interest in subsidiary, minimum holding period

2 years

Investments accounted for using the equity method

€ 413

413

413

EUROAPI | EPIC BPIFrance

Disclosure of detailed information about business combination [line items]

Consideration transferred, valuation period

30 days

EUROAPI

Disclosure of detailed information about business combination [line items]

Exceptional supplementary dividend proposed, percentage of share capital

58%

Exceptional supplementary dividend, percentage of share capital

5,800%

58%

Special distribution, number of shares converted (in shares) | shares

23

Special distribution, percentage of share capital distributed

57.88%

Net sales

€ 486

Decrease through loss of control of subsidiary, net assets

€ 1,227

Decrease through loss of control of subsidiary, intangible assets and goodwill

€ 164

Weighted average share price (in EUR per share) | € / shares

€ 14.58

Net foreign exchange loss

€ 35

Other gains, (losses) and litigation

3

Tax expense (income)

111

Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax

€ 101

101

EUROAPI | Manufacture and supply collaboration agreement

Disclosure of detailed information about business combination [line items]

Collaboration agreement, annual net sales target

€ 300

Collaboration agreement, commitment amount

€ 1,100

1,100

1,100

EUROAPI | EPIC BPIFrance

Disclosure of detailed information about business combination [line items]

Percentage of voting equity interests divested

12%

12%

Consideration transferred, maximum amount

€ 150

€ 150

Opella Business

Disclosure of detailed information about business combination [line items]

Tax expense (income)

€ (122)

Financial interest in principal fully consolidated companies

50%

50%

Valuation of Subsidiary

€ 16,000

Attributable to equity holders of Sanofi

Disclosure of detailed information about business combination [line items]

Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi

[4]

€ 793

Amunix Pharmaceuticals, Inc

Disclosure of detailed information about business combination [line items]

Cash transferred

€ 970

Commitments related to milestone payments, business combinations | $

$ 225

Contingent consideration recognised as of acquisition date

156

Net cash flow on acquisition

€ 852

Identifiable intangible assets recognised as of acquisition date

493

Consideration transferred, acquisition-date fair value

1,126

Goodwill recognised as of acquisition date

€ 609

Provention Bio, Inc

Disclosure of detailed information about business combination [line items]

Cash transferred | $

$ 2,800

Net cash flow on acquisition | $

$ 2,722

Purchase price per share (in euro/usd per share) | $ / shares

$ 25

Financial interest in principal fully consolidated companies

3%

Consideration transferred, acquisition-date fair value | $

$ 2,806

Other intangible assets | $

$ 2,810

QRIB Intermediate Holding

Disclosure of detailed information about business combination [line items]

Identifiable intangible assets recognised as of acquisition date

€ 774

Consideration transferred, acquisition-date fair value

1,343

$ 1,419

Goodwill

484

Cash flows from (used in) investing activities, discontinued operations

1,410

Goodwill recognised as of acquisition date

€ 484

[1] This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2024, it includes the net cash outflow relating to the acquisition of Inhibrx, Inc. (see Note D.1..1). For 2023, it includes the net cash outflow on the acquisitions of Provention Bio (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note D.1.) Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation This a mount includes the valuation of the shares distributed as a dividend in kind, at a price of €14.58 per share, as of May 10, 2022 (see Note D.1.3). (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. For 2022, this line item includes the net cash inflows (before taxes) of €101 million on the divestment of EUROAPI (see Note D.1.). For 2024 , this line item includes the sale of the Enjaymo global rights to Recordati for pre-tax proceeds of €768 million . For 2023 and 2022 , this line item mainly comprises disposals of assets and activities related to portfolio streamlining, and disposals of equity and debt instruments. For 2023, this line item includes the net cash outflow on the acquisition of QRIB (see Note D.1.) (a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€ 2.88 as of December 31, 2024, and € 5.73 as of December 31, 2023)

Principal changes in the scop_6

Principal changes in the scope of consolidation in 2022 and 2021 - Summary of Purchase Price Allocation (Details) - Amunix Pharmaceuticals, Inc € in Millions	Feb. 08, 2022 EUR (€)
Disclosure of detailed information about business combination [line items]
Identifiable intangible assets recognised as of acquisition date	€ 493
Other Current Assets And Current Liabilities As Of Acquisition Date	(13)
Cash and cash equivalents recognised as of acquisition date	118
Deferred tax liabilities recognised as of acquisition date	(81)
Net assets	517
Goodwill recognised as of acquisition date	609
Consideration transferred, acquisition-date fair value	€ 1,126

Property, plant and equipment -

Property, plant and equipment - Schedule of Property, Plant and Equipment (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		€ 10,160	€ 9,869
Acquisitions and other increases		1,717	1,693	€ 1,748
Property, plant and equipment, ending balance		10,091	10,160	9,869
Gross value
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		24,770	23,924	24,810
Changes in scope of consolidation		0	(51)	(2,104)
Acquisitions and other increases		1,717	1,693	1,748
Disposals and other decreases		(974)	(502)	(559)
Currency translation differences		349	(245)	347
Transfers	[1]	5	(49)	(318)
Increase (decrease) through Opella reclassification	[2]	(1,806)
Property, plant and equipment, ending balance		24,061	24,770	23,924
Accumulated depreciation & impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		(14,610)	(14,055)	(14,782)
Changes in scope of consolidation		0	24	1,533
Depreciation expense		(1,041)	(1,080)	(1,142)
Impairment losses, net of reversals		(105)	(130)	(186)
Disposals and other decreases		914	488	518
Currency translation differences		(189)	112	(138)
Transfers	[1]	15	31	142
Increase (decrease) through Opella reclassification	[2]	1,046
Property, plant and equipment, ending balance		(13,970)	(14,610)	(14,055)
Land
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		220	227
Property, plant and equipment, ending balance		201	220	227
Land | Gross value
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		228	237	240
Changes in scope of consolidation		0	0	(17)
Acquisitions and other increases		0	0	0
Disposals and other decreases		(3)	(2)	(1)
Currency translation differences		13	(5)	17
Transfers	[1]	(1)	(2)	(2)
Increase (decrease) through Opella reclassification	[2]	(36)
Property, plant and equipment, ending balance		201	228	237
Land | Accumulated depreciation & impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		(8)	(10)	(9)
Changes in scope of consolidation		0	0	0
Depreciation expense		0	0	0
Impairment losses, net of reversals		0	0	(1)
Disposals and other decreases		1	0	0
Currency translation differences		1	2	0
Transfers	[1]	0	0	0
Increase (decrease) through Opella reclassification	[2]	6
Property, plant and equipment, ending balance		0	(8)	(10)
Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		3,181	3,103
Property, plant and equipment, ending balance		3,034	3,181	3,103
Buildings | Gross value
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		7,681	7,328	7,170
Changes in scope of consolidation		0	(11)	(294)
Acquisitions and other increases		13	27	11
Disposals and other decreases		(209)	(50)	(161)
Currency translation differences		163	(94)	122
Transfers	[1]	335	481	480
Increase (decrease) through Opella reclassification	[2]	(539)
Property, plant and equipment, ending balance		7,444	7,681	7,328
Buildings | Accumulated depreciation & impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		(4,500)	(4,225)	(4,190)
Changes in scope of consolidation		0	5	201
Depreciation expense		(325)	(321)	(356)
Impairment losses, net of reversals		(47)	(30)	(50)
Disposals and other decreases		197	48	133
Currency translation differences		(77)	45	(52)
Transfers	[1]	9	(22)	89
Increase (decrease) through Opella reclassification	[2]	333
Property, plant and equipment, ending balance		(4,410)	(4,500)	(4,225)
Machinery and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		3,039	3,211
Property, plant and equipment, ending balance		3,002	3,039	3,211
Machinery and equipment | Gross value
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		10,912	10,848	11,648
Changes in scope of consolidation		0	(29)	(1,480)
Acquisitions and other increases		36	47	54
Disposals and other decreases		(510)	(340)	(240)
Currency translation differences		126	(71)	144
Transfers	[1]	764	457	722
Increase (decrease) through Opella reclassification	[2]	(866)
Property, plant and equipment, ending balance		10,462	10,912	10,848
Machinery and equipment | Accumulated depreciation & impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		(7,873)	(7,637)	(8,340)
Changes in scope of consolidation		0	16	1,202
Depreciation expense		(580)	(620)	(622)
Impairment losses, net of reversals		(23)	(46)	(58)
Disposals and other decreases		507	334	201
Currency translation differences		(95)	44	(69)
Transfers	[1]	5	36	49
Increase (decrease) through Opella reclassification	[2]	599
Property, plant and equipment, ending balance		(7,460)	(7,873)	(7,637)
Fixtures, fittings and other
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		463	500
Property, plant and equipment, ending balance		460	463	500
Fixtures, fittings and other | Gross value
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		2,500	2,515	2,655
Changes in scope of consolidation		0	(7)	(163)
Acquisitions and other increases		36	36	41
Disposals and other decreases		(173)	(100)	(155)
Currency translation differences		30	(30)	29
Transfers	[1]	142	86	108
Increase (decrease) through Opella reclassification	[2]	(154)
Property, plant and equipment, ending balance		2,381	2,500	2,515
Fixtures, fittings and other | Accumulated depreciation & impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		(2,037)	(2,015)	(2,115)
Changes in scope of consolidation		0	3	130
Depreciation expense		(136)	(139)	(164)
Impairment losses, net of reversals		(3)	(4)	(2)
Disposals and other decreases		172	98	153
Currency translation differences		(18)	21	(22)
Transfers	[1]	4	(1)	5
Increase (decrease) through Opella reclassification	[2]	97
Property, plant and equipment, ending balance		(1,921)	(2,037)	(2,015)
Property, plant and equipment in process
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		3,257	2,828
Property, plant and equipment, ending balance		3,394	3,257	2,828
Property, plant and equipment in process | Gross value
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		3,449	2,996	3,097
Changes in scope of consolidation		0	(4)	(150)
Acquisitions and other increases		1,632	1,583	1,642
Disposals and other decreases		(79)	(10)	(2)
Currency translation differences		17	(45)	35
Transfers	[1]	(1,235)	(1,071)	(1,626)
Increase (decrease) through Opella reclassification	[2]	(211)
Property, plant and equipment, ending balance		3,573	3,449	2,996
Property, plant and equipment in process | Accumulated depreciation & impairment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, beginning balance		(192)	(168)	(128)
Changes in scope of consolidation		0	0	0
Depreciation expense		0	0	0
Impairment losses, net of reversals		(32)	(50)	(75)
Disposals and other decreases		37	8	31
Currency translation differences		0	0	5
Transfers	[1]	(3)	18	(1)
Increase (decrease) through Opella reclassification	[2]	11
Property, plant and equipment, ending balance		€ (179)	€ (192)	€ (168)
[1] (a) This line mainly comprises property, plant and equipment in process brought into service during the period, and reclassification of assets (other than Opella assets) to Assets held for sale . (b) This line comprises property, plant and equipment owned by Opella, reclassified to Assets held for sale as of December 31, 2024 in accordance with IFRS 5 (see Note D.1.)

Property, plant and equipment_2

Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of acquisitions of property plant and equipment by operating segments [line items]
Acquisitions	€ 1,717	€ 1,693	€ 1,748
Capitalized interest	51	26	17
Biopharma (operating segment)
Disclosure of acquisitions of property plant and equipment by operating segments [line items]
Acquisitions	1,554	1,592	1,678
Biopharma (operating segment) | Manufacturing & Supply
Disclosure of acquisitions of property plant and equipment by operating segments [line items]
Acquisitions	1,114	1,188	1,129
Opella Business
Disclosure of acquisitions of property plant and equipment by operating segments [line items]
Acquisitions		163	101	€ 70
Opella Business | Manufacturing & Supply
Disclosure of acquisitions of property plant and equipment by operating segments [line items]
Acquisitions	€ 135	€ 90	€ 63

Property, plant and equipment_3

Property, plant and equipment - Summary of Off Balance Sheet Commitments Relating to Property, Plant and Equipment (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, plant and equipment [abstract]
Firm orders of property, plant and equipment	€ 422	€ 638	€ 861
Property, plant and equipment pledged as security for liabilities	€ 21	€ 16	€ 0

Property, plant and equipment_4

Property, plant and equipment - Summary of Impairment Losses Recognised in Property, Plant and Equipment (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, plant and equipment [abstract]
Net impairment losses on property, plant and equipment	[1]	€ 105	€ 130	€ 186
[1] (a) These amounts mainly comprise impairment losses recognized as a result of decisions taken during the periods presented, relating primarily to shutdowns or changes in use of industrial sites.

Property, plant and equipment_5

Property, plant and equipment - Summary of Property, Plant and Equipment Leased (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets at beginning of period		€ 1,654	€ 1,815
Right-of-use assets at end of period		1,510	1,654	€ 1,815
Right-of-use assets		1,510	1,654	1,815
Lease liabilities		€ 1,906	2,030	2,181
Cambridge, Massachusetts
Disclosure of detailed information about property, plant and equipment [line items]
Initial lease term		15 years
Gross value
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets at beginning of period		€ 2,672	2,872	2,745
Changes in scope of consolidation				(26)
Acquisitions and other increases		442	247	292
Disposals and other decreases		(375)	(314)	(232)
Currency translation differences		89	(58)	101
Transfers	[1]	(60)	(75)	(8)
Increase (Decrease) Through Reclassification, Property, Plant and Equipment, Right Of Use Assets	[2]	(155)
Right-of-use assets at end of period		2,613	2,672	2,872
Right-of-use assets		2,613	2,672	2,872
Accumulated depreciation & impairment
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets at beginning of period		(1,018)	(1,057)	(797)
Changes in scope of consolidation				14
Depreciation and impairment charged in the period		(315)	(292)	(341)
Disposals and other decreases		183	276	82
Currency translation differences		(30)	21	(17)
Transfers	[1]	38	34	2
Increase (Decrease) Through Reclassification, Property, Plant and Equipment, Right Of Use Assets	[2]	39
Right-of-use assets at end of period		(1,103)	(1,018)	(1,057)
Right-of-use assets		€ (1,103)	€ (1,018)	€ (1,057)
[1] (a) This line also includes the effect of the reclassification of assets (other than Opella assets) to Assets held for sale (b) This line comprises the Opella right-of-use assets, reclassified to Assets held for sale as of December 31, 2024 in accordance with IFRS 5 (see Note D.1.)

Property, plant and equipment_6

Property, plant and equipment - Additional Information (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]
Expense relating to short-term leases and low value assets	€ 16	€ 19	€ 26
Cash outflow for leases, excluding short-term leases	€ 348	€ 315	€ 389
Office and industrial premises
Disclosure of detailed information about property, plant and equipment [line items]
Leased assets, percentage	90%
Vehicle fleet
Disclosure of detailed information about property, plant and equipment [line items]
Leased assets, percentage	10%

Goodwill and other intangible_3

Goodwill and other intangible assets - Schedule of Movements in Goodwill (Details) € in Millions, $ in Millions		12 Months Ended
		Dec. 31, 2024 EUR (€)		Dec. 31, 2024 USD ($)	Dec. 31, 2023 EUR (€)		Dec. 31, 2023 USD ($)	Dec. 31, 2022 EUR (€)
Gross value
Disclosure of reconciliation of changes in goodwill [line items]
Acquisitions and other increases		€ 1,554	[1]		€ 3,112	[1]		€ 571
Gross value | Products, trademarks and other rights
Disclosure of reconciliation of changes in goodwill [line items]
Acquisitions and other increases		444	[1]		1,970	[1]		195
Antibodies Collaboration agreement | Gross value | Products, trademarks and other rights | Teva Pharmaceuticals
Disclosure of reconciliation of changes in goodwill [line items]
Acquisitions and other increases | $							$ 500
Antibodies Collaboration agreement | Gross value | Products, trademarks and other rights | Janssen Pharmaceuticals, Inc
Disclosure of reconciliation of changes in goodwill [line items]
Acquisitions and other increases | $							$ 175
Antibodies Collaboration agreement | Gross value | Products, trademarks and other rights | Novavax
Disclosure of reconciliation of changes in goodwill [line items]
Acquisitions and other increases | $				$ 500
Antibodies Collaboration agreement | Gross value | Products, trademarks and other rights | Corxel Pharmaceuticals
Disclosure of reconciliation of changes in goodwill [line items]
Acquisitions and other increases | $				$ 300
Goodwill
Disclosure of reconciliation of changes in goodwill [line items]
Beginning balance		49,404			49,892			48,056
Acquisitions during the period		0			475	[2]		609
Other movements during the period	[3]	(351)			(90)			(258)
Currency translation differences		1,586			(873)			1,485
Increase (decrease) through reclassification, intangible assets other than goodwill	[4]	(7,255)
Ending balance		€ 43,384			€ 49,404			€ 49,892
[1] (f) This line mainly comprises: In 2023: – the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April 2023 in respect of the agreements on Beyfortus (nirsevimab) (see Note C.2.); – an upfront payment of $500 million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co- commercialization of TEV’574;and – an upfront payment of $175 million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli. In 2024: – an upfront payment of $500 million for the rights acquired under the agreement with Novavax relating to the co-exclusive license agreement for the co-commercialization of a COVID-19 vaccine and the development of a combined flu-COVID-19 vaccine; and – an upfront payment of $300 million for the rights acquired under an agreement with Corxel Pharmaceuticals for the development and commercialization rights to aficamten in China. (c) The final purchase price allocation for QRIB Intermediate Holdings, LLC resulted in the recognition of intangible assets (other than goodwill) of €774 million as of the acquisition date (September 29, 2023) and of goodwill measured at €484 million as of the acquisition date (see Note D.1.). (a) This line mainly comprises the amount of goodwill allocated to divested operations in accordance with paragraph 86 of IAS 36, including in 2024 the allocated goodwill relating to the divestment of the Enjaymo activity to Recordati (see Note D.1.). For 2022, this line includes the loss of control of EUROAPI (see Note D.1.). (b) The Opella goodwill is presented within Assets held for sale (see Note D.1.).

Goodwill and other intangible_4

Goodwill and other intangible assets - Schedule of Allocation of Goodwill (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill	€ 43,384	€ 49,404	€ 49,892

Goodwill and other intangible_5

Goodwill and other intangible assets - Additional Information (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2022	Sep. 29, 2023	Feb. 08, 2022
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill	€ 43,384		€ 49,404		€ 49,892
Intangible assets other than goodwill	22,629		24,319		21,640
Gross value
Disclosure of reconciliation of changes in goodwill [line items]
Acquisitions and other increases	1,554	[1]	3,112	[1]	571
Marketed products
Disclosure of reconciliation of changes in goodwill [line items]
Intangible assets other than goodwill	12,700		€ 16,600		12,700
Useful life, intangible assets other than goodwill (in years)			10 years
Technological platforms
Disclosure of reconciliation of changes in goodwill [line items]
Intangible assets other than goodwill	€ 1,100		€ 1,200		€ 2,200
Useful life, intangible assets other than goodwill (in years)	18 years
QRIB Intermediate Holding
Disclosure of reconciliation of changes in goodwill [line items]
Identifiable intangible assets recognised as of acquisition date						€ 774
Goodwill						€ 484
Amunix [Member]
Disclosure of reconciliation of changes in goodwill [line items]
Identifiable intangible assets recognised as of acquisition date							€ 493
Goodwill							€ 609
[1] (f) This line mainly comprises: In 2023: – the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April 2023 in respect of the agreements on Beyfortus (nirsevimab) (see Note C.2.); – an upfront payment of $500 million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co- commercialization of TEV’574;and – an upfront payment of $175 million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli. In 2024: – an upfront payment of $500 million for the rights acquired under the agreement with Novavax relating to the co-exclusive license agreement for the co-commercialization of a COVID-19 vaccine and the development of a combined flu-COVID-19 vaccine; and – an upfront payment of $300 million for the rights acquired under an agreement with Corxel Pharmaceuticals for the development and commercialization rights to aficamten in China.

Goodwill and other intangible_6

Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details) € in Millions, $ in Millions		12 Months Ended
		Dec. 31, 2024 EUR (€)		Dec. 31, 2023 EUR (€)		Dec. 31, 2023 USD ($)	Dec. 31, 2022 EUR (€)
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance		€ 24,319		€ 21,640
Amortization expense(e)		(1,749)		(1,911)	[1]		€ (1,804)	[1]
Other intangible assets, ending balance		22,629		24,319			21,640
Gross value
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance		85,313		81,716			78,865	[2]
Changes in scope of consolidation	[3]	1,745		3,401			464
Acquisitions and other increases		1,554	[4]	3,112	[4]		571
Disposals and other decreases		(1,514)		(683)			(543)
Currency translation differences		3,331		(1,837)			2,533
Transfers	[5]	3		(396)			(174)
Increase (decrease) through reclassification, intangible assets other than goodwill	[2]	(9,366)
Other intangible assets, ending balance		81,066		85,313			81,716
Accumulated amortization & impairment
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance		(60,994)		(60,076)			(57,458)	[2]
Changes in scope of consolidation				33	[3]		11
Amortization expense(e)		(2,200)		(2,345)			(2,196)	[6]
Impairment losses, net of reversals	[7]	(264)		(932)			454
Disposals and other decreases		722		629			525
Currency translation differences		(2,134)		1,287			(1,591)
Transfers	[5]	(5)		410			179
Increase (decrease) through reclassification, intangible assets other than goodwill	[2]	6,438
Other intangible assets, ending balance		(58,437)		(60,994)			(60,076)
Acquired R&D
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance		6,038		6,226
Other intangible assets, ending balance		8,369		6,038			6,226
Acquired R&D | Gross value
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance		9,772		10,354			11,207	[2]
Changes in scope of consolidation	[3]	1,745		113			0
Acquisitions and other increases		1,006	[4]	1,062	[4]		277
Disposals and other decreases		(58)		(262)			(72)
Currency translation differences		606		(242)			518
Transfers	[5]	(52)		(1,253)			(1,576)
Increase (decrease) through reclassification, intangible assets other than goodwill	[2]	(153)
Other intangible assets, ending balance		12,866		9,772			10,354
Acquired R&D | Accumulated amortization & impairment
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance		(3,734)		(4,128)			(3,477)	[2]
Changes in scope of consolidation				0	[3]		0
Amortization expense(e)		0		0			0	[6]
Impairment losses, net of reversals	[7]	(638)		(90)			(1,107)
Disposals and other decreases		58		262			75
Currency translation differences		(191)		94			(7)
Transfers	[5]	(2)		128			388
Increase (decrease) through reclassification, intangible assets other than goodwill	[2]	10
Other intangible assets, ending balance		(4,497)		(3,734)			(4,128)
Products, trademarks and other rights
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance		17,825		14,927
Other intangible assets, ending balance		13,841		17,825			14,927
Products, trademarks and other rights | Gross value
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance		73,733		69,579			65,906	[2]
Changes in scope of consolidation	[3]	0		3,287			499
Acquisitions and other increases		444	[4]	1,970	[4]		195
Disposals and other decreases		(1,447)		(380)			(423)
Currency translation differences		2,708		(1,584)			1,994
Transfers	[5]	66		861			1,408
Increase (decrease) through reclassification, intangible assets other than goodwill	[2]	(9,156)
Other intangible assets, ending balance		66,348		73,733			69,579
Products, trademarks and other rights | Gross value | Antibodies Collaboration agreement | Teva Pharmaceuticals
Disclosure of detailed information about intangible assets [line items]
Acquisitions and other increases | $						$ 500
Products, trademarks and other rights | Gross value | Antibodies Collaboration agreement | Janssen Pharmaceuticals, Inc
Disclosure of detailed information about intangible assets [line items]
Acquisitions and other increases | $						$ 175
Products, trademarks and other rights | Accumulated amortization & impairment
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance		(55,908)		(54,652)			(52,744)	[2]
Changes in scope of consolidation				33	[3]		0
Amortization expense(e)		(2,094)		(2,225)			(2,099)	[6]
Impairment losses, net of reversals	[7]	373		(842)			1,561
Disposals and other decreases		655		326			411
Currency translation differences		(1,928)		1,184			(1,567)
Transfers	[5]	(3)		268			(214)
Increase (decrease) through reclassification, intangible assets other than goodwill	[2]	6,398
Other intangible assets, ending balance		(52,507)		(55,908)			(54,652)
Products, trademarks and other rights | Accumulated amortization & impairment | IO License and Collaboration agreement
Disclosure of detailed information about intangible assets [line items]
Amortization expense(e)							(226)
Software
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance		456		487
Other intangible assets, ending balance		419		456			487
Software | Gross value
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance		1,808		1,783			1,752	[2]
Changes in scope of consolidation	[3]	0		1			(35)
Acquisitions and other increases		104	[4]	80	[4]		99
Disposals and other decreases		(9)		(41)			(48)
Currency translation differences		17		(11)			21
Transfers	[5]	(11)		(4)			(6)
Increase (decrease) through reclassification, intangible assets other than goodwill	[2]	(57)
Other intangible assets, ending balance		1,852		1,808			1,783
Software | Accumulated amortization & impairment
Disclosure of detailed information about intangible assets [line items]
Other intangible assets, beginning balance		(1,352)		(1,296)			(1,237)	[2]
Changes in scope of consolidation				0	[3]		11
Amortization expense(e)		(106)		(120)			(97)	[6]
Impairment losses, net of reversals	[7]	1		0			0
Disposals and other decreases		9		41			39
Currency translation differences		(15)		9			(17)
Transfers	[5]	0		14			5
Increase (decrease) through reclassification, intangible assets other than goodwill	[2]	30
Other intangible assets, ending balance		€ (1,433)		€ (1,352)			€ (1,296)
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (a) Comprises the other intangible assets of Opella, now reclassified to Assets held for sale at December 31, 2024 in accordance with IFRS 5 (see note D.1.). (c) The “Changes in scope of consolidation” line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during the period (see Note D.1.) (f) This line mainly comprises: In 2023: – the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April 2023 in respect of the agreements on Beyfortus (nirsevimab) (see Note C.2.); – an upfront payment of $500 million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co- commercialization of TEV’574;and – an upfront payment of $175 million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli. In 2024: – an upfront payment of $500 million for the rights acquired under the agreement with Novavax relating to the co-exclusive license agreement for the co-commercialization of a COVID-19 vaccine and the development of a combined flu-COVID-19 vaccine; and – an upfront payment of $300 million for the rights acquired under an agreement with Corxel Pharmaceuticals for the development and commercialization rights to aficamten in China. (b) The “Transfers” line mainly comprises (i) acquired R&D that came into commercial use during the period and (ii) reclassifications of assets (other than Opella assets) as Assets held for sale . (e) The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of €226 million in 2022 (see Note C.1.) (d) See Note D.5.

Goodwill and other intangible_7

Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		€ 22,629	€ 24,319	€ 21,640
Marketed products
Disclosure of detailed information about intangible assets [line items]
Concentration risk percentage		95%
Other intangible assets		€ 12,700	€ 16,600	12,700
Useful life, intangible assets other than goodwill (in years)			10 years
Total: principal marketed products incl. Opella products presented in "Assets held for sale"
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		14,795	€ 15,927	11,863
Intangible Assets Other Than Goodwill, Discontinued Operations		12,002	13,055	9,429
Genzyme
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	€ 59	208	621
Useful life, intangible assets other than goodwill (in years)	[1],[2]	10 years
Remaining amortisation period of intangible assets material to entity	[1],[3]	2 years
Boehringer Ingelheim Consumer Healthcare
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	€ 1,764	1,806	2,037
Useful life, intangible assets other than goodwill (in years)	[1],[2]	17 years
Remaining amortisation period of intangible assets material to entity	[1],[3]	10 years
Aventis
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	€ 39	43	58
Useful life, intangible assets other than goodwill (in years)	[1],[2]	9 years
Remaining amortisation period of intangible assets material to entity	[1],[3]	10 years
Chattem
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	€ 482	501	574
Useful life, intangible assets other than goodwill (in years)	[1],[2]	23 years
Remaining amortisation period of intangible assets material to entity	[1],[3]	10 years
Protein Sciences
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	€ 381	420	498
Useful life, intangible assets other than goodwill (in years)	[1],[2]	13 years
Remaining amortisation period of intangible assets material to entity	[1],[3]	6 years
Ablynx
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	€ 1,083	1,220	1,357
Useful life, intangible assets other than goodwill (in years)	[1],[2]	14 years
Remaining amortisation period of intangible assets material to entity	[1],[3]	8 years
Bioverativ
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	€ 4,349	5,152	4,836
Useful life, intangible assets other than goodwill (in years)	[1],[2]	13 years
Remaining amortisation period of intangible assets material to entity	[1],[3]	8 years
Rezurock
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		€ 1,513	1,580	1,702
Useful life, intangible assets other than goodwill (in years)	[2]	12 years
Remaining amortisation period of intangible assets material to entity	[3]	9 years
Tzield
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		€ 2,339	2,405	0
Useful life, intangible assets other than goodwill (in years)	[2]	12 years
Remaining amortisation period of intangible assets material to entity	[3]	11 years
Beyfortus
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		€ 2,087	1,870	180
Useful life, intangible assets other than goodwill (in years)	[2]	17 years
Remaining amortisation period of intangible assets material to entity	[3]	16 years
Qunol
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		€ 699	€ 722	€ 0
Useful life, intangible assets other than goodwill (in years)	[2]	10 years
Remaining amortisation period of intangible assets material to entity	[3]	8 years
Gross value | Total: principal marketed products incl. Opella products presented in "Assets held for sale"
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		€ 68,753
Intangible Assets Other Than Goodwill, Discontinued Operations		60,214
Gross value | Genzyme
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	10,600
Gross value | Boehringer Ingelheim Consumer Healthcare
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	3,520
Gross value | Aventis
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	34,175
Gross value | Chattem
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	1,406
Gross value | Protein Sciences
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	886
Gross value | Ablynx
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	1,966
Gross value | Bioverativ
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	8,375
Gross value | Rezurock
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		2,033
Gross value | Tzield
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		2,714
Gross value | Beyfortus
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		2,288
Gross value | Qunol
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		790
Accumulated amortization & impairment | Total: principal marketed products incl. Opella products presented in "Assets held for sale"
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		(53,958)
Intangible Assets Other Than Goodwill, Discontinued Operations		(48,212)
Accumulated amortization & impairment | Genzyme
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	(10,541)
Accumulated amortization & impairment | Boehringer Ingelheim Consumer Healthcare
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	(1,756)
Accumulated amortization & impairment | Aventis
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	(34,136)
Accumulated amortization & impairment | Chattem
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	(924)
Accumulated amortization & impairment | Protein Sciences
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	(505)
Accumulated amortization & impairment | Ablynx
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	(883)
Accumulated amortization & impairment | Bioverativ
Disclosure of detailed information about intangible assets [line items]
Other intangible assets	[1]	(4,026)
Accumulated amortization & impairment | Rezurock
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		(520)
Accumulated amortization & impairment | Tzield
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		(375)
Accumulated amortization & impairment | Beyfortus
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		(201)
Accumulated amortization & impairment | Qunol
Disclosure of detailed information about intangible assets [line items]
Other intangible assets		€ (91)
Bottom of range
Disclosure of detailed information about intangible assets [line items]
Useful life, intangible assets other than goodwill (in years)		1 year
Top of range
Disclosure of detailed information about intangible assets [line items]
Useful life, intangible assets other than goodwill (in years)		25 years
[1] (c) Commercialized products derived from the acquisition of these companies. In the case of Bioverativ, the product Enjaymo was sold to Recordati in 2024 (see Note D.1.). (a) Weighted averages. The amortization periods for these products vary between 1 and 25 years. (b) Weighted averages.

Goodwill and other intangible_8

Goodwill and other intangible assets - Amortization of Softwares Recognized in Income Statement (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Disclosure of detailed information about intangible assets [line items]
Cost of sales	€ 13,205	€ 12,628	[1]	€ 11,882	[1]
Research and development expenses	7,394	6,507	[1]	6,501	[1]
Selling and general expenses	9,183	8,933	[1]	8,739	[1]
Other operating expenses	4,382	3,443	[1]	2,523	[1]
Net income excluding the exchanged/held-for-exchange Animal Health business	64	338	[1]	401	[1]
Amortization expense	1,749	1,911	[1]	1,804	[1]
Amortization of computer software and other rights of an industrial or operational nature
Disclosure of detailed information about intangible assets [line items]
Cost of sales	16	14	[2]	9
Research and development expenses	1	3	[2]	1
Selling and general expenses	87	100	[2]	82
Other operating expenses	1	2	[2]	4
Net income excluding the exchanged/held-for-exchange Animal Health business	1	1	[2]	1
Amortization expense	€ 106	€ 120	[2]	€ 97
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation

Impairment of intangible asse_3

Impairment of intangible assets and property, plant and equipment - Additional Information (Details) - EUR (€)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of goodwill recognized	€ 0	€ 0	€ 0
Bottom of range
Disclosure of impairment loss and reversal of impairment loss [line items]
After tax discount rates	7.25%
Top of range
Disclosure of impairment loss and reversal of impairment loss [line items]
After tax discount rates	8.25%
Opella (discontinued operation, see Note D.1.) | Cash-generating units
Disclosure of impairment loss and reversal of impairment loss [line items]
Rate used for Impairment of goodwill	7.25%
Biopharma (operating segment) | Goodwill
Disclosure of impairment loss and reversal of impairment loss [line items]
Perpetual growth rates applied to future cash flows	0%
Biopharma (operating segment) | Cash-generating units
Disclosure of impairment loss and reversal of impairment loss [line items]
Pre-tax discount rates	9.80%

Impairment of intangible asse_4

Impairment of intangible assets and property, plant and equipment - Summary of Net Impairment Losses of Other Intangible Assets (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of intangible assets		€ 248	€ 896	[1]	€ (429)	[1]
Eloctate [Member]
Disclosure of impairment loss and reversal of impairment loss [line items]
Reversal amount					2,154
Biopharma (operating segment)
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)		415
ALTUVIIIO
Disclosure of impairment loss and reversal of impairment loss [line items]
Reversal amount					2,800
Other intangible assets
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)		265	932		(454)
Other intangible assets | Biopharma (operating segment)
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)		225
Other intangible assets | Marketed products
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)		(167)	0		(1,561)
Other intangible assets | Research and development projects and technology platforms
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)	[2],[3],[4]	415	896		1,107
Other intangible assets | Others
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)		17	36		0
Research and development projects and technology platforms | Eloctate [Member]
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)					600
Reversal amount					600
Research and development projects and technology platforms | SAR444245
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)					1,586
Research and development projects and technology platforms | NK Cell and ProXTen technology platforms
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)			833
Research and development projects and technology platforms | Biopharma (operating segment)
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)		640
Marketed products | Eloctate [Member]
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)					1,554
Marketed products | Enjaymo
Disclosure of impairment loss and reversal of impairment loss [line items]
Reversal amount		167
Clinical Study | Biopharma (operating segment)
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)		239
Biopharma (operating segment) | Other intangible assets | Marketed products
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)	[5]	(167)	0		(1,526)
Opella (discontinued operation, see Note D.1.) | Other intangible assets | Marketed products
Disclosure of impairment loss and reversal of impairment loss [line items]
Impairment of other intangible assets, net of reversals (excluding software)		€ 0	€ 0		€ (35)
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (c) For 2023, this amount mainly comprises an impairment loss of €833 million , reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and ProXTen technology platforms. (b) For 2024, the monitoring of impairment indicators for other intangible assets led to the recognition of net impairment losses of €415 million , comprising (i) impairment losses of €640 million against various research and development projects - including a €239 million loss resulting from the decision taken in February 2025 to discontinue a phase 3 clinical study investigating of a vaccine candidate to prevent invasive E.coli disease - and (ii) an impairment reversal of €225 million recognized in connection with the disposal of the ProXTen technology platform. (d) For 2022, this amount mainly comprises: – an impairment loss of €1,586 million taken against the development project for SAR444245 (non-alpha interleukin-2), recognized following revised cash flow projections reflecting unfavorable developments in the launch schedule; – the €600 million reversal relating to the BIVV001 project (see above). As required by IFRS 5, the other intangible assets of Opella were measured in accordance with IAS 36 immediately before their reclassification as assets held for sale; this assessment did not result in any impairment of their carrying amount being recognized. (a) For 2024, this comprises a reversal of €167 million in connection with the disposal of Enjaymo. For 2022, this amount mainly comprises a reversal of €2,154 million of impairment losses taken against Eloctate and BIVV001 (assets belonging to the Eloctate franchise), consisting of €1,554 million for marketed products and €600 million for research and development projects respectively. In 2019, the launch of competing products for Eloctate led Sanofi to update its sales forecasts for products belonging to the franchise, as a result of which impairment losses of €2.8 billion were recognized against the assets in question. The reversal reflects the approval by the FDA on February 22, 2023 of ALTUVIIIO (the commercial name of efanesoctocog alpha, corresponding to the BIVV001 project), which was submitted in 2022.

Investments accounted for usi_3

Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details) - EUR (€) € / shares in Units, € in Millions		8 Months Ended	12 Months Ended
		Dec. 31, 2022	Dec. 31, 2024		Dec. 31, 2023
Disclosure of transactions between related parties [line items]
Investments in subsidiaries, joint ventures and associates		€ 677	€ 316		€ 424
EUROAPI
Disclosure of transactions between related parties [line items]
Stock price			€ 2.88		€ 5.73
Infraserv GmbH & Co. Höchst KG
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in joint venture (in percent)	[1]		31.20%
Investments in joint ventures	[1]	97	€ 102		€ 90
MSP Vaccine Company (formerly MCM company)
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in joint venture (in percent)	[2]		50%
Investments in joint ventures	[2]	104	€ 81		96
Other investments
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in joint venture (in percent)			0%
Investments in joint ventures		€ 84	€ 51		76
EUROAPI
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in associate (in percent)		30.10%	29.60%	[3]
Investments in joint ventures	[3]	€ 392	€ 82		€ 162
Impairment loss recognised in profit or loss			€ (77)
MCM Vaccine BV | MSP Vaccine Company (formerly MCM company)
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in joint venture (in percent)			100%
[1] (b) Joint venture. (c) Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV (a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€ 2.88 as of December 31, 2024, and € 5.73 as of December 31, 2023)

Investments accounted for usi_4

Investments accounted for using the equity method - Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures (Details) - EUR (€) € / shares in Units, € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
EUROAPI
Disclosure of transactions between related parties [line items]
Stock price		€ 2.88	€ 5.73
Joint ventures
Disclosure of transactions between related parties [line items]
Share of profit/(loss) from investments accounted for using the equity method	[1]	€ 134	€ 101	€ 73
Share of other comprehensive income from investments accounted for using the equity method		3	(7)	(3)
Total		137	94	70
Associates
Disclosure of transactions between related parties [line items]
Share of profit/(loss) from investments accounted for using the equity method	[1]	(74)	(237)	(18)
Share of other comprehensive income from investments accounted for using the equity method		(5)	7	(1)
Total		(79)	€ (230)	€ (19)
EUROAPI
Disclosure of transactions between related parties [line items]
Impairment loss recognised in profit or loss		€ (77)
[1] (a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€ 2.88 as of December 31, 2024, and € 5.73 as of December 31, 2023).

Investments accounted for usi_5

Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details) - Associates and joint ventures - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of transactions between related parties [line items]
Sales(d)	[1]	€ 103	€ 157	€ 131	[2]
Royalties and other income(d)	[1]	71	14	21	[2]
Accounts receivable and other receivables	[3]	184	249	330	[2]
Other Assets, Related Party Transactions	[4]	189	0	0	[2]
Purchases and other expenses (including research expenses)(d)	[1]	600	573	472	[2]
Accounts payable and other liabilities		160	€ 190	258	[2]
EUROAPI
Disclosure of transactions between related parties [line items]
Subordinate Hybrid Bond, Related Party Transactions		€ 189		€ 200
[1] (d) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) In 2022, these items include Sanofi's transactions with EUROAPI from May 10, 2022 (see Note D.1.). (b) Includes loans to joint ventures and associates. (c) In October 2024, Sanofi raised its investment in EUROAPI by € 200 million in the form of a perpetual subordinated hybrid bon d. The fair value of this investment as of December 31, 2024 is € 189 million.

Investments accounted for usi_6

Investments accounted for using the equity method - Additional Information (Details) - EUR (€)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Associates and joint ventures
Disclosure of transactions between related parties [line items]
Funding commitments to associates and joint ventures	€ 0	€ 0	€ 0

Other non-current assets - Summ

Other non-current assets - Summary of Other Non-current Assets (Details) - EUR (€) € in Millions		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Other Non Current Assets [Line Items]
Other financial assets at fair value through profit or loss		€ 1,027	€ 808	€ 823
Pre-funded pension obligations		156	271	269
Long-term prepaid expenses		152	114	286
Non current loans and receivables	[1]	502	591	452
Derivative financial instruments		0	0	0
Other non-current assets		3,753	3,218	3,095
Non-current finance lease receivables		116	132
Other current assets		3,826	3,455	3,532
Non-current finance lease receivables, gross		181	195
BioAtrium
Disclosure Of Other Non Current Assets [Line Items]
Other current assets				156
Trading equity securities
Disclosure Of Other Non Current Assets [Line Items]
Fair value through other comprehensive income		1,559	1,088	936
Debt securities
Disclosure Of Other Non Current Assets [Line Items]
Fair value through other comprehensive income		€ 357	€ 346	€ 329
[1] (a) As of December 31, 2024 , this line includes: – Loan of € 149 million to the BioAtrium joint venture which matures on December 1, 2031, of which €156 million was recognized in "Other current assets" as of December 31, 2022; – a receivable under a sub-lease amounting to € 116 million ( € 181 million before discounting), versus € 132 million (or € 195 million before discounting) as of December 31, 2023

Other non-current assets - Addi

Other non-current assets - Additional Information (Details) € in Millions, $ in Millions	1 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($)	Dec. 31, 2024 EUR (€)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Aug. 31, 2022 EUR (€)
Disclosure Of Other Non Current Assets [Line Items]
Pre-tax impact on other comprehensive income		€ 47
Non-current finance lease receivables		116	€ 132
Non-current finance lease receivables, gross		181	195
BioAtrium
Disclosure Of Other Non Current Assets [Line Items]
Non-current Loans And Receivable		149
EUROAPI | Associates and joint ventures
Disclosure Of Other Non Current Assets [Line Items]
Subordinate Hybrid Bond, Related Party Transactions		€ 189		€ 200
Fair value of SPMSD contingent consideration
Disclosure Of Other Non Current Assets [Line Items]
Increase In Contingent Consideration		700%
Quoted euro denominated senior bonds
Disclosure Of Other Non Current Assets [Line Items]
Debt instruments at fair value through other comprehensive income		€ 357
Senior bond
Disclosure Of Other Non Current Assets [Line Items]
Financial assets held for investments				329
Held-to-maturity investment			346
Financial instruments held to fund deferred compensation plan
Disclosure Of Other Non Current Assets [Line Items]
Financial investments		688	572	512
Trading equity securities
Disclosure Of Other Non Current Assets [Line Items]
Fair value through other comprehensive income		1,559	1,088	936
Trading equity securities | Level 1
Disclosure Of Other Non Current Assets [Line Items]
Fair value through other comprehensive income		467	470	387
Unquoted equity investments
Disclosure Of Other Non Current Assets [Line Items]
Investments in equity instruments designated at fair value through OCI		1,092	618	549
Unquoted equity investments | Quoted euro denominated senior bonds
Disclosure Of Other Non Current Assets [Line Items]
Exchange for financial assets held to meet obligations to employees under post-employment benefit plans		110
Commitments related to unquoted debt securities
Disclosure Of Other Non Current Assets [Line Items]
Investments in equity instruments designated at fair value through OCI		360	65
Financial assets at fair value through profit or loss		168	159
Commitments related to unquoted debt securities | Orano Med
Disclosure Of Other Non Current Assets [Line Items]
Investments in equity instruments designated at fair value through OCI		300
Quoted equity securities
Disclosure Of Other Non Current Assets [Line Items]
Unrealized after-tax losses		342	349	256
SPMSD contingent consideration asset
Disclosure Of Other Non Current Assets [Line Items]
Fair value of the contingent consideration		113	214	303
Non-current assets | Fair value of SPMSD contingent consideration
Disclosure Of Other Non Current Assets [Line Items]
Fair value of the contingent consideration			104	196
Unquoted debt securities not meeting the definition of equity instruments
Disclosure Of Other Non Current Assets [Line Items]
Financial assets at fair value through profit or loss		165	€ 132	115
Discovery Design and Clinical Development | Orano Med
Disclosure Of Other Non Current Assets [Line Items]
Investments in equity instruments designated at fair value through OCI		€ 1,900
Proportion of ownership interests held by non-controlling interests		16%
Non Current Asset
Disclosure Of Other Non Current Assets [Line Items]
Fair value of the contingent consideration		€ 104
Increase of ten percent basis point in market interest rate | Debt instruments
Disclosure Of Other Non Current Assets [Line Items]
Other comprehensive income before tax		1
Increase of ten percent basis point in market interest rate | Quoted debt instruments
Disclosure Of Other Non Current Assets [Line Items]
Other comprehensive income before tax		€ 1
Regeneron
Disclosure Of Other Non Current Assets [Line Items]
Proceeds from sales of investments accounted for using equity method | $	$ 174
Innovent Biologics
Disclosure Of Other Non Current Assets [Line Items]
Investments in equity instruments designated at fair value through other comprehensive income, transaction amount				€ 228	€ 250

Assets held for sale or excha_3

Assets held for sale or exchange and liabilities related to assets held for sale or exchange - Summary of Assets Held for Sale or Exchange, and Liabilities Related to Assets Held for Sale or Exchange (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Non-current assets or disposal groups classified as held for sale	€ 13,489	€ 15	€ 85
Liabilities included in disposal groups classified as held for sale	2,131	13	10
Disclosure of analysis of single amount of discontinued operations [line items]
Non-current assets or disposal groups classified as held for sale	13,489	15	85
Liabilities included in disposal groups classified as held for sale	2,131	13	10
Opella Business
Subclassifications of assets, liabilities and equities [abstract]
Non-current assets or disposal groups classified as held for sale	13,489	0	0
Liabilities included in disposal groups classified as held for sale	2,131	0	0
Disclosure of analysis of single amount of discontinued operations [line items]
Non-current assets or disposal groups classified as held for sale	13,489	0	0
Liabilities included in disposal groups classified as held for sale	2,131	0	0
Others
Subclassifications of assets, liabilities and equities [abstract]
Non-current assets or disposal groups classified as held for sale	0	15	85
Liabilities included in disposal groups classified as held for sale	0	13	10
Disclosure of analysis of single amount of discontinued operations [line items]
Non-current assets or disposal groups classified as held for sale	0	15	85
Liabilities included in disposal groups classified as held for sale	€ 0	€ 13	€ 10

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of inventories [line items]
Raw materials	€ 1,453	€ 1,550	€ 1,474
Work in process	5,296	5,316	4,985
Finished goods	2,682	2,800	2,501
Total	9,431	9,666	8,960
Gross value
Disclosure of inventories [line items]
Raw materials	1,588	1,676	1,613
Work in process	5,777	5,869	5,663
Finished goods	2,899	3,045	2,748
Total	10,264	10,590	10,024
Allowances
Disclosure of inventories [line items]
Raw materials	135	126	139
Work in process	481	553	678
Finished goods	217	245	247
Total	€ 833	€ 924	€ 1,064

Inventories - Additional Inform

Inventories - Additional Information (Details) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Inventories pledged as security for liabilities	€ 0	€ 3

Accounts receivable - Summary o

Accounts receivable - Summary of Accounts Receivable (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of accounts receivable [line items]
Accounts receivable	€ 7,677	€ 8,433	€ 8,424
Gross value
Disclosure of accounts receivable [line items]
Accounts receivable	7,777	8,528	8,537
Allowances
Disclosure of accounts receivable [line items]
Accounts receivable	€ 100	€ 95	€ 113

Accounts receivable - Additiona

Accounts receivable - Additional Information (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Impairment loss recognised in profit or loss, trade receivables	€ 19	€ 8	€ 1
Gross value of overdue receivables	650	689	452
Derecognized receivables	€ 14	€ 761	€ 131

Accounts receivable - Summary_2

Accounts receivable - Summary of Gross Value of Overdue Receivables (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of financial assets that are either past due or impaired [line items]
Overdue receivables gross value	€ 650	€ 689	€ 452
Less than 1 month
Disclosure of financial assets that are either past due or impaired [line items]
Overdue receivables gross value	316	269	118
Overdue by 1 to 3 months
Disclosure of financial assets that are either past due or impaired [line items]
Overdue receivables gross value	194	154	161
Overdue by 3 to 6 months
Disclosure of financial assets that are either past due or impaired [line items]
Overdue receivables gross value	87	123	87
Overdue by 6 to 12 months
Disclosure of financial assets that are either past due or impaired [line items]
Overdue receivables gross value	9	62	35
Later than 12 months
Disclosure of financial assets that are either past due or impaired [line items]
Overdue receivables gross value	€ 44	€ 81	€ 51

Other current assets (Details)

Other current assets (Details) - EUR (€) € in Millions		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Tax receivables, other than corporate income taxes		€ 782	€ 768	€ 660
Prepaid expenses		895	768	714
Other receivables	[1]	1,446	1,448	1,289
Currency derivatives measured at fair value (see Note D.20.)		217	201	206
Other Financial Assets At Fair Value Through Profit Or Loss		115	112	146
Other current financial assets	[2]	371	158	517
Total		€ 3,826	€ 3,455	€ 3,532
[1] (a) This line mainly comprises advance payments to suppliers, and receivables relating to Sanofi's activities as agent under a transitional services agreement. (b) This item mainly comprises bank loans and receivables maturing in less than one year with high-grade counterparties

Financial assets and liabilit_3

Financial assets and liabilities measured at fair value - Summary of Assets and Liabilities Measured at Fair Value (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Level 1
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	€ 5,673	€ 6,737	€ 10,765
Total financial liabilities measured at fair value	0	0	0
Level 1 | Bayer contingent purchase consideration arising from the acquisition of Genzyme
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 1 | MSD contingent consideration (European vaccines business)
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 1 | Shire contingent consideration arising from the acquisition of Translate Bio
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 1 | Contingent consideration arising from acquisition of Amunix
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 1 | Other contingent consideration arising from business combinations and acquisitions
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 1 | Non-current derivatives
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 1 | Current derivatives
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 1 | Quoted equity investments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	467	470	387
Level 1 | Unquoted equity investments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 1 | Quoted debt securities
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	357	346	329
Level 1 | Unquoted debt securities not meeting the definition of equity instruments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 1 | Contingent consideration relating to divestments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 1 | Financial assets held to meet obligations under deferred compensation plans
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	688	572	512
Level 1 | Non-current derivatives
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 1 | Current derivatives
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 1 | Mutual fund investments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	4,161	5,349	9,537
Level 2
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	217	201	206
Total financial liabilities measured at fair value	458	291	326
Level 2 | Bayer contingent purchase consideration arising from the acquisition of Genzyme
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 2 | MSD contingent consideration (European vaccines business)
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 2 | Shire contingent consideration arising from the acquisition of Translate Bio
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 2 | Contingent consideration arising from acquisition of Amunix
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 2 | Other contingent consideration arising from business combinations and acquisitions
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 2 | Non-current derivatives
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	121	164	232
Level 2 | Current derivatives
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	337	127	94
Level 2 | Quoted equity investments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 2 | Unquoted equity investments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 2 | Quoted debt securities
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 2 | Unquoted debt securities not meeting the definition of equity instruments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 2 | Contingent consideration relating to divestments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 2 | Financial assets held to meet obligations under deferred compensation plans
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 2 | Non-current derivatives
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 2 | Current derivatives
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	217	201	206
Level 2 | Mutual fund investments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 3
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	1,717	964	967
Total financial liabilities measured at fair value	641	709	779
Level 3 | Bayer contingent purchase consideration arising from the acquisition of Genzyme
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	26
Level 3 | MSD contingent consideration (European vaccines business)
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	72	127	204
Level 3 | Shire contingent consideration arising from the acquisition of Translate Bio
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	568	441	380
Level 3 | Contingent consideration arising from acquisition of Amunix
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	137	165
Level 3 | Other contingent consideration arising from business combinations and acquisitions
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	1	4	4
Level 3 | Non-current derivatives
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 3 | Current derivatives
Disclosure of information on income statement [line items]
Total financial liabilities measured at fair value	0	0	0
Level 3 | Quoted equity investments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 3 | Unquoted equity investments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	1,092	618	549
Level 3 | Quoted debt securities
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 3 | Unquoted debt securities not meeting the definition of equity instruments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	339	132	115
Level 3 | Contingent consideration relating to divestments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	286	214	303
Level 3 | Financial assets held to meet obligations under deferred compensation plans
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 3 | Non-current derivatives
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 3 | Current derivatives
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	0	0	0
Level 3 | Mutual fund investments
Disclosure of information on income statement [line items]
Total financial assets measured at fair value	€ 0	€ 0	€ 0

Cash and cash equivalents (Deta

Cash and cash equivalents (Details) - EUR (€)		Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021	[2]
Subclassifications of assets, liabilities and equities [abstract]
Cash		€ 1,270,000,000	€ 1,461,000,000		€ 1,385,000,000
Cash equivalents	[1]	6,171,000,000	7,249,000,000		11,351,000,000
Cash and cash equivalents		7,441,000,000	8,710,000,000	[2]	12,736,000,000	[2]	€ 10,098,000,000
Cash equivalents, money market mutual funds		4,161,000,000	5,349,000,000		9,537,000,000
Cash equivalents, term deposits		1,293,000,000	1,191,000,000		1,167,000,000
Cash equivalents, commercial paper		0	0
Cash equivalents, captive insurance and reinsurance companies		€ 446,000,000	€ 476,000,000		€ 439,000,000
[1] (a) As of December 31, 2024 , cash equivalents mainly comprised the following: (i) €4,161 million invested in euro and US dollar denominated money-market mutual funds ( December 31, 2023 : €5,349 million ; December 31, 2022 : €9,537 million ); (ii) €1,293 million of term deposits ( December 31, 2023 : €1,191 million ; December 31, 2022 : €1,167 million ) and (iii) zero commercial paper ( December 31, 2023 : zero ; December 31, 2022 : zero ). Cash equivalents also include €446 million held by captive insurance and reinsurance companies in accordance with insurance regulations ( December 31, 2023 : €476 million ; December 31, 2022 : €439 million ). Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).

Net deferred tax position - Sum

Net deferred tax position - Summary of Net Deferred Tax Position (Details) - EUR (€) € in Millions		Dec. 31, 2024		Dec. 31, 2023	Dec. 31, 2022
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Net deferred tax asset/(liability)		€ 5,801		€ 4,570	€ 3,540
Deferred tax liabilities		2,166		1,857	1,841
Reserves likely to be distributed in the foreseeable future		64,900
Deferred tax assets		7,967		6,427	5,381
Consolidation adjustments (intragroup margin in inventory)
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Net deferred tax asset/(liability)		1,927		1,525	1,388
Provision for pensions and other employee benefits
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Net deferred tax asset/(liability)		787		853	850
Remeasurement of other acquired intangible assets
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Net deferred tax asset/(liability)		(2,079)	[1]	(2,795)	(3,269)
Remeasurement of other acquired intangible assets | Bioverativ(c)
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities		987
Remeasurement of other acquired intangible assets | Principia
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities		648
Remeasurement of other acquired intangible assets | Genzyme
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities		15
Remeasurement of other acquired intangible assets | Ablynx NV
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities		178
Recognition of acquired property, plant and equipment at fair value
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Net deferred tax asset/(liability)		(10)		(21)	(24)
Equity interests in subsidiaries and investments in other entities
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Net deferred tax asset/(liability)	[2]	(1,044)		(1,023)	(617)
Tax losses available for carry-forward
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Net deferred tax asset/(liability)		971		1,526	1,506
Stock options and other share-based payments
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Net deferred tax asset/(liability)		103		84	92
Accrued expenses and provisions deductible at time of payments
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Net deferred tax asset/(liability)	[3]	2,277		1,994	1,859
Other
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Net deferred tax asset/(liability)	[4]	2,869		2,427	1,755
Deferred tax relating to restructuring provisions
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets		319		286	256
Deferred tax relating to capitalisation of R&D expenses
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets		€ 2,053		€ 1,331	€ 742
[1] ( a ) A s of December 31, 2024 , includes remeasurements of the acquired intangible assets of Bioverativ ( €987 million ), Principia (€ 648 million ), Ablynx (€ 178 million ) and Genzyme ( €15 million ). (b) In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a deferred tax liability on the reserves of French and foreign subsidiaries (approximately € 64.9 billion ) which it regards as likely to be distributed in the foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2024 , Sanofi took into account changes in the ownership structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of the European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December 31, 2023, this line includes a deferred tax liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Opella business, as announced in October 2023 (see Note D.30.). (c) Includes deferred tax assets related to restructuring provisions, amounting to €319 million as of December 31, 2024 , €286 million as of December 31, 2023 , and €256 million as of December 31, 2022 . (d) Includes deferred taxes arising on the spread tax deduction of R&D expenses, amounting to € 2,053 million as of December 31, 2024 , € 1,331 million as of December 31, 2023 , and €742 million as of December 31, 2022 .

Net deferred tax position - Add

Net deferred tax position - Additional information (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Abstract]
Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised	€ 10,500	€ 10,000	€ 10,600
Total deferred tax assets for tax loss carryforwards	3,010	2,729	2,650
Unused tax losses for which no deferred tax asset recognised	2,039	1,203	1,144
Deferred tax assets not recognized as future recovery not probable	€ 2,117	€ 1,261	€ 1,197

Net deferred tax position - S_2

Net deferred tax position - Summary of Tax Losses Available for Carry-forward (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of tax losses available for carryforward [line items]
Tax losses available for carry-forward	[1]	€ 9,812	€ 8,933	€ 8,503
Tax loss carry-forwards on asset disposals		40	€ 5	€ 5
Year 1
Disclosure of tax losses available for carryforward [line items]
Tax losses available for carry-forward	[1]	1
Year 2
Disclosure of tax losses available for carryforward [line items]
Tax losses available for carry-forward	[1]	17
Year 3
Disclosure of tax losses available for carryforward [line items]
Tax losses available for carry-forward	[1]	12
Year 4
Disclosure of tax losses available for carryforward [line items]
Tax losses available for carry-forward	[1]	30
Year 5
Disclosure of tax losses available for carryforward [line items]
Tax losses available for carry-forward	[1]	187
Year 5 and later
Disclosure of tax losses available for carryforward [line items]
Tax losses available for carry-forward	[1]	€ 9,565
[1] (a) Excluding tax loss carry-forwards on asset disposals. Such carry-forwards amounted to €40 million as of December 31, 2024 , €5 million as of December 31, 2023 and €5 million as of December 31, 2022

Consolidated shareholders_ eq_3

Consolidated shareholders’ equity - Additional Information (Details) - EUR (€)	12 Months Ended
	Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2022
Disclosure of classes of share capital [line items]
Share capital			€ 2,526,245,442
Number of shares (in shares)			1,263,122,721
Par value per share (in euros per share)			€ 2
Hedges of net investments in foreign operations	€ (679,000,000)		€ (574,000,000)		€ (580,000,000)
Currency translation differences	218,000,000	[1]	€ (22,000,000)	[2]	€ 442,000,000	[3]
Opella Business
Disclosure of classes of share capital [line items]
Currency translation differences	€ (300,000,000)
May 25, 2023
Disclosure of classes of share capital [line items]
Period of share repurchase program			18 months
May 3, 2022
Disclosure of classes of share capital [line items]
Period of share repurchase program					18 months
April 30, 2021
Disclosure of classes of share capital [line items]
Period of share repurchase program	18 months
Stock subscription option plan
Disclosure of classes of share capital [line items]
Increase in shareholders equity due to exercise of stock purchase option	€ 75,000,000
Number of shares issued by exercice of each option (in shares)	1
[1] (b) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone. (b) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone. (a) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.

Consolidated shareholders_ eq_4

Consolidated shareholders’ equity - Summary of Treasury Shares Held (Details) - shares shares in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share Capital, Reserves And Other Equity Interest [Abstract]
Number of shares (in shares)	9,530	13,450	8,200	11,020
% of share capital for the period	0.755%	1.063%	0.65%	0.872%

Consolidated shareholders_ eq_5

Consolidated shareholders’ equity - Summary of Movements Share Capital (Details) - shares						12 Months Ended
		Jul. 24, 2024	Jul. 27, 2023	Dec. 14, 2022	Jul. 27, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of classes of share capital [line items]
Beginning balance (in shares)						1,263,122,721
Ending balance (in shares)							1,263,122,721
Share capital | Sanofi
Disclosure of classes of share capital [line items]
Beginning balance (in shares)						1,264,799,969	1,260,835,732	1,263,560,695
Capital increase by exercise of stock subscription options (in shares)	[1]					398,569	504,956	490,373
Capital increase by issuance of restricted shares (in shares)	[2]					1,479,787	1,330,558	1,499,987
Capital increase reserved for employees (in shares)		2,244,396	2,128,723		2,027,057
Reduction in share capital by cancellation of treasury shares (in shares)				6,742,380		(5,800,000)
Ending balance (in shares)						1,263,122,721	1,264,799,969	1,260,835,732
[1] (a) Shares issued on exercise of Sanofi stock subscription options. (b) Shares vesting under restricted share plans and issued in the period

Consolidated shareholders_ eq_6

Consolidated shareholders’ equity - Principal Characteristics of Restricted Share Plans (Details) € / shares in Units, € in Millions		1 Months Ended						12 Months Ended
		Dec. 31, 2024 shares	Apr. 30, 2024 shares	Dec. 31, 2023 shares	May 31, 2023 shares	Dec. 31, 2022 shares	May 31, 2022 shares	Dec. 31, 2024 EUR (€) shares € / shares	Dec. 31, 2023 EUR (€) shares € / shares	Dec. 31, 2022 EUR (€) shares € / shares
Performance share plan one | With market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares								147,894	126,935	123,940
Restricted share plan 2023 | Performance share plan one
Disclosure of classes of share capital [line items]
Service period									3 years
Total number of shares awarded (in shares) | shares	[1]								3,838,434
Fair value of plan at the date of grant | €									€ 326
Restricted share plan 2023 | Performance share plan one | Without market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares									2,425,047
Fair value per share awarded (in euros per share)	[2]								€ 87.69
Restricted share plan 2023 | Performance share plan one | With market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares									1,413,387
Fair value per share awarded (in euros per share)	[3]								€ 83.74
Fair value per share awarded for three year service period, additional shares (in euros per share)	[4]								43.60
Fair value per share awarded for three year service period, to chief executive officer (in euros per share)	[3]								€ 82.17
Restricted share plan 2023 | Performance share plan two
Disclosure of classes of share capital [line items]
Service period									3 years
Total number of shares awarded (in shares) | shares	[1]								65,129
Fair value of plan at the date of grant | €									€ 5
Restricted share plan 2023 | Performance share plan two | Without market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares									944
Fair value per share awarded (in euros per share)	[2]								€ 77.42
Restricted share plan 2023 | Performance share plan two | With market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares				5,838					64,185
Fair value per share awarded (in euros per share)	[3]								€ 74.50
Fair value per share awarded for three year service period, additional shares (in euros per share)	[4]								34.90
Fair value per share awarded for three year service period, to chief executive officer (in euros per share)	[3]								€ 0
Restricted share plan 2022 | Performance share plan one
Disclosure of classes of share capital [line items]
Service period										3 years
Total number of shares awarded (in shares) | shares	[1]									3,344,432
Fair value of plan at the date of grant | €										€ 294
Restricted share plan 2022 | Performance share plan one | Without market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares										2,000,627
Fair value per share awarded (in euros per share)	[2]									€ 91.19
Restricted share plan 2022 | Performance share plan one | With market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares							114,874			1,343,805
Fair value per share awarded (in euros per share)	[3]									€ 86.65
Fair value per share awarded for three year service period, additional shares (in euros per share)	[4]									49
Fair value per share awarded for three year service period, to chief executive officer (in euros per share)	[3]									€ 84.46
Restricted share plan 2022 | Performance share plan two
Disclosure of classes of share capital [line items]
Service period										3 years
Total number of shares awarded (in shares) | shares	[1]									109,981
Fair value of plan at the date of grant | €										€ 8
Restricted share plan 2022 | Performance share plan two | Without market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares										10,335
Fair value per share awarded (in euros per share)	[2]									€ 79.17
Restricted share plan 2022 | Performance share plan two | With market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares						9,066				99,646
Fair value per share awarded (in euros per share)	[3]									€ 69.60
Fair value per share awarded for three year service period, additional shares (in euros per share)	[4]									54.70
Fair value per share awarded for three year service period, to chief executive officer (in euros per share)	[3]									€ 0
Restricted share plan 2021 | Performance share plan one | With market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares					121,097
Restricted share plan 2021 | Performance share plan two | With market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares		8,229
Restricted Share Plan 2024 Member | Performance share plan one
Disclosure of classes of share capital [line items]
Service period								3 years
Total number of shares awarded (in shares) | shares	[1]							4,505,145
Fair value of plan at the date of grant | €								€ 346
Restricted Share Plan 2024 Member | Performance share plan one | Without market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares								2,888,502
Fair value per share awarded (in euros per share)	[2]							€ 81.84
Restricted Share Plan 2024 Member | Performance share plan one | With market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares			139,665					1,616,643
Fair value per share awarded (in euros per share)	[3]							€ 72.79
Fair value per share awarded for three year service period, additional shares (in euros per share)	[4]							13.50
Fair value per share awarded for three year service period, to chief executive officer (in euros per share)	[3]							€ 72.38
Restricted Share Plan 2024 Member | Performance share plan two
Disclosure of classes of share capital [line items]
Service period								3 years
Total number of shares awarded (in shares) | shares	[1]							97,100
Fair value of plan at the date of grant | €								€ 7
Restricted Share Plan 2024 Member | Performance share plan two | Without market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares								6,649
Fair value per share awarded (in euros per share)	[2]							€ 79.51
Restricted Share Plan 2024 Member | Performance share plan two | With market condition
Disclosure of classes of share capital [line items]
Total number of shares awarded (in shares) | shares								90,451
Fair value per share awarded (in euros per share)	[3]							€ 75.11
Fair value per share awarded for three year service period, additional shares (in euros per share)	[4]							32.09
Fair value per share awarded for three year service period, to chief executive officer (in euros per share)	[3]							€ 0
[1] (a) Includes shares awarded in an additional tranche subject to a higher level of market conditions: 139,665 additional shares awarded in April 2024 and 8,229 awarded in December 2024 (versus 121,097 awarded in May 2023 and 5,838 awarded in December 2023 ). (b) Market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period. (c) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period. (d) Additional tranche subject to a higher level of market conditions: 139,665 additional shares awarded in April 2024 and 8,229 awarded in December 2024 (versus 121,097 awarded in May 2023 , 5,838 awarded in December 2023 , 114,874 awarded in May 2022 and 9,066 awarded in December 2022 ).

Consolidated shareholders_ eq_7

Consolidated shareholders’ equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details) € in Millions		1 Months Ended			12 Months Ended
		Apr. 30, 2024 shares	May 31, 2023 shares	May 31, 2022 shares	Dec. 31, 2024 EUR (€) shares	Dec. 31, 2023 EUR (€) shares	Dec. 31, 2022 EUR (€) shares
With market condition | Performance share plan one
Disclosure of classes of share capital [line items]
Number of options granted (in shares)					147,894	126,935	123,940
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)					147,894	126,935	123,940
Restricted shares
Disclosure of classes of share capital [line items]
Total expense for restricted share plans | €	[1]				€ 260	€ 231	€ 206
Number of shares not yet fully vested (in shares)	[1]				10,914,134	9,773,084	9,245,513
Restricted Share Plan 2024 Member
Disclosure of classes of share capital [line items]
Number of shares not yet fully vested (in shares)	[1]				4,454,299	0	0
Restricted Share Plan 2024 Member | Performance share plan one
Disclosure of classes of share capital [line items]
Number of options granted (in shares)	[2]				4,505,145
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)	[2]				4,505,145
Restricted Share Plan 2024 Member | With market condition | Performance share plan one
Disclosure of classes of share capital [line items]
Number of options granted (in shares)		139,665			1,616,643
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)		139,665			1,616,643
Restricted share plan 2023
Disclosure of classes of share capital [line items]
Number of shares not yet fully vested (in shares)	[1]				3,501,088	3,780,513	0
Restricted share plan 2023 | Performance share plan one
Disclosure of classes of share capital [line items]
Number of options granted (in shares)	[2]					3,838,434
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)	[2]					3,838,434
Restricted share plan 2023 | With market condition | Performance share plan one
Disclosure of classes of share capital [line items]
Number of options granted (in shares)						1,413,387
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)						1,413,387
Restricted share plan 2022
Disclosure of classes of share capital [line items]
Number of shares not yet fully vested (in shares)	[1]				2,958,747	3,099,158	3,330,801
Restricted share plan 2022 | Performance share plan one
Disclosure of classes of share capital [line items]
Number of options granted (in shares)	[2]						3,344,432
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)	[2]						3,344,432
Restricted share plan 2022 | With market condition | Performance share plan one
Disclosure of classes of share capital [line items]
Number of options granted (in shares)				114,874			1,343,805
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)				114,874			1,343,805
Restricted share plan 2021
Disclosure of classes of share capital [line items]
Number of shares not yet fully vested (in shares)	[1]				0	2,893,413	3,097,531
Restricted share plan 2021 | With market condition | Performance share plan one
Disclosure of classes of share capital [line items]
Number of options granted (in shares)			121,097
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)			121,097
Restricted share plan 2020
Disclosure of classes of share capital [line items]
Number of shares not yet fully vested (in shares)	[1]				0	0	2,817,181
[1] (a) Includes shares awarded in an additional tranche subject to a higher level of market conditions: 147,894 additional shares awarded in 2024 , versus 126,935 awarded in 2023 and 123,940 awarded in 2022 (a) Includes shares awarded in an additional tranche subject to a higher level of market conditions: 139,665 additional shares awarded in April 2024 and 8,229 awarded in December 2024 (versus 121,097 awarded in May 2023 and 5,838 awarded in December 2023 ).

Consolidated shareholders_ eq_8

Consolidated shareholders’ equity - Summary of Characteristics of Employee Share Ownership Plans Awarded (Details) - € / shares		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jan. 31, 2024	Feb. 02, 2023	Feb. 03, 2022
Disclosure of classes of share capital [line items]
Subscription price (as a percent)		80%	80%	80%
Number of trading days preceding plan approval		20 days	20 days	20 days
Employees share ownership plan
Disclosure of classes of share capital [line items]
Subscription price (in euros per share)	[1]				€ 72.87	€ 79.58	€ 80.21
Number of shares subscribed (in shares)					2,124,445	2,009,306	1,909,008
Number of shares issued immediately as employer's contribution (in shares)					119,951	119,417	118,049
[1] (a) Subscription price representing 80% of the average of the opening quoted market prices of Sanofi shares during the 20 trading days preceding May 30, 2024, May 31, 2023 and June 6, 2022, respectively

Consolidated shareholders_ eq_9

Consolidated shareholders’ equity - Summary of Expenses (Details) - Employees share ownership plan - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of classes of share capital [line items]
Expense recognized	€ 45	€ 52	€ 39
Expense recognized of which employers' contribution	€ 11	€ 12	€ 11

Consolidated shareholders_ e_10

Consolidated shareholders’ equity - Summary of Repurchases Program (Details) - EUR (€) € in Millions		12 Months Ended
	Feb. 02, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of classes of share capital [line items]
Number of shares (in shares)	29,556,650
Value	€ 3,000
Hedges of net investments in foreign operations		€ (679)	€ (574)	€ (580)
2024
Disclosure of classes of share capital [line items]
Number of shares (in shares)		0
Value		€ 0
2023
Disclosure of classes of share capital [line items]
Number of shares (in shares)		3,215,460	2,584,540
Value		€ 302	€ 230
2022
Disclosure of classes of share capital [line items]
Number of shares (in shares)			4,000,204	1,510,000
Value			€ 363	€ 137
2021
Disclosure of classes of share capital [line items]
Number of shares (in shares)				3,976,992
Value				€ 360

Consolidated shareholders_ e_11

Consolidated shareholders’ equity - Summary of Currency Translation Differences (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of classes of share capital [line items]
Attributable to equity holders of Sanofi	€ 77,507	€ 74,040	€ 74,784
Attributable to non-controlling interests	350	313	368
Total equity	77,857	74,353	75,152	€ 69,031
Reserve of exchange differences on translation
Disclosure of classes of share capital [line items]
Attributable to equity holders of Sanofi	2,408	(31)	1,499
Attributable to non-controlling interests	(17)	(37)	(37)
Total equity	€ 2,391	€ (68)	€ 1,462

Consolidated shareholders_ e_12

Consolidated shareholders’ equity - Summary of Movements within Other Comprehensive Income (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of analysis of other comprehensive income by item [line items]
Items subsequently reclassifiable to profit or loss(e)		€ 2,488	€ (1,448)	€ 2,367
Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss
Disclosure of analysis of other comprehensive income by item [line items]
Actuarial gains/(losses) excluding investments accounted for using the equity method (see Note D.19.1.)		13	(171)	650
Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes		(2)	0	4
Tax effects		(27)	18	(212)
Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss | Equity instruments included in financial assets
Disclosure of analysis of other comprehensive income by item [line items]
Change in fair value (excluding investments accounted for using the equity method)		(21)	97	(4)
Change in fair value (investments accounted for using the equity method, net of taxes)		0	0	0
Equity risk hedging instruments designated as fair value hedges		0	0	17
Tax effects		9	(21)	(4)
Other Comprehensive Income That Will Not Be Reclassified to Continued Operations Profit or Loss, Net of Tax	[1]	(28)	(77)	451
Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss | Equity instruments included in financial assets | Opella Business
Disclosure of analysis of other comprehensive income by item [line items]
Other Comprehensive Income That Will Not Be Reclassified to Continued Operations Profit or Loss, Net of Tax		(1)		20
Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss
Disclosure of analysis of other comprehensive income by item [line items]
Change in fair value (excluding investments accounted for using the equity method)	[2]	(3)	1	5
Change in fair value (investments accounted for using the equity method, net of taxes)		(3)	(2)	2
Tax effects		2	0	(1)
Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)	[3]	2,560	(1,551)	2,643
Currency translation differences (investments accounted for using the equity method)	[3]	3	3	(11)
Hedges of net investments in foreign operations	[3]	(121)	8	(354)
Tax effects		17	(2)	91
Other Comprehensive Income That Will Be Reclassified to Continued Operations Profit or Loss, Net of Tax	[4]	2,460	(1,526)	2,313
Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Opella Business
Disclosure of analysis of other comprehensive income by item [line items]
Other Comprehensive Income That Will Be Reclassified to Continued Operations Profit or Loss, Net of Tax		(28)	(78)	(54)
Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Debt instruments
Disclosure of analysis of other comprehensive income by item [line items]
Change in fair value (excluding investments accounted for using the equity method)	[5]	5	21	(77)
Tax effects		0	(4)	15
Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Cash Flow And Fair Value Hedge
Disclosure of analysis of other comprehensive income by item [line items]
Items subsequently reclassifiable to profit or loss(e)		1	1	2
Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Foreign Currency Translation
Disclosure of analysis of other comprehensive income by item [line items]
Items subsequently reclassifiable to profit or loss(e)		€ 5	€ (56)	(40)
Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | EUROAPI | Foreign Currency Translation
Disclosure of analysis of other comprehensive income by item [line items]
Items subsequently reclassifiable to profit or loss(e)				€ (35)
[1] (a) Items not subsequently reclassifiable to profit or loss and attributable to Opella: € (1) million in 2024, immaterial amount in 2023 and € 20 million in 2022. (c) Amounts reclassified to profit or loss: €1 million in 2024 , €1 million in 2023 and € 2 million in 2022 . (d) Amounts reclassified to profit or loss: € 5 million in 2024 , € (56) million in 2023 and € (40) million in 2022 (including € (35) million relating to the deconsolidation of EUROAPI). Currency translation differences arise from the translation into euros of the financial statements of foreign subsidiaries, and are mainly due to the appreciation of the dollar against the euro. (e) Items subsequently reclassifiable to profit or loss and attributable to Opella (currency translation differences): € (28) million in 2024, € (78) million in 2023, € (54) million in 2022 (b) Amounts reclassified to profit or loss were immaterial in 2024 , 2023 and 2022 .

Consolidated shareholders_ e_13

Consolidated shareholders’ equity - Disclosure of Stock Subscription Option Plan Outstanding and Option Exercised (Details) € / shares in Units, € in Millions							12 Months Ended
	Apr. 30, 2019 shares	May 02, 2018 shares	May 10, 2017 shares	May 04, 2016 shares	Jun. 24, 2015 shares	Mar. 05, 2014 shares	Dec. 31, 2024 EUR (€) shares € / shares	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Items subsequently reclassifiable to profit or loss(e) | €							€ 2,488	€ (1,448)	€ 2,367
Stock subscription option plan
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options outstanding (in shares)							934,444
Stock subscription option plan five
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)						1,009,250
Exercise price (in euros per share) | € / shares							€ 73.48
Number of options outstanding (in shares)							0
Stock subscription option plan six
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)					435,000
Exercise price (in euros per share) | € / shares							€ 89.38
Number of options outstanding (in shares)							159,250
Stock subscription option plan seven
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)				402,750
Exercise price (in euros per share) | € / shares							€ 75.90
Number of options outstanding (in shares)							136,000
Stock subscription option plan eight
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)			378,040
Exercise price (in euros per share) | € / shares							€ 88.97
Number of options outstanding (in shares)							257,010
Stock subscription option plan nine
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)		220,000
Exercise price (in euros per share) | € / shares							€ 65.84
Number of options outstanding (in shares)							168,784
Stock subscription option plan ten
Disclosure of stock subscription option plan outstanding and option exercised [line items]
Number of options granted (in shares)	220,000
Exercise price (in euros per share) | € / shares							€ 76.71
Number of options outstanding (in shares)							213,400

Consolidated shareholders_ e_14

Consolidated shareholders’ equity - Summary of Stock Options Outstanding at Each Balance Sheet Date (Details) - Total stock option plans € / shares in Units, € in Millions	12 Months Ended
	Dec. 31, 2024 EUR (€) shares € / shares	Dec. 31, 2023 EUR (€) shares € / shares	Dec. 31, 2022 EUR (€) shares € / shares		Dec. 31, 2021 EUR (€) shares € / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options, beginning balance (in shares) | shares	1,333,013	1,837,969	2,337,968
Number of options, options exercisable (in shares) | shares	934,444	1,333,013	1,624,569		1,949,184
Number of options, options exercised (in shares) | shares	(398,569)	(504,956)	(490,373)
Number of options, options cancelled (in shares) | shares			(9,626)	[1]
Number of options, ending balance (in shares) | shares	934,444	1,333,013	1,837,969		2,337,968
Average exercise price per share, beginning balance (in euros per share) | € / shares	€ 80.53	€ 78.64	€ 77.13
Average exercise price per share, options exercisable (in euros per share) | € / shares	80.16	80.53	78.89		€ 78.15
Average exercise price per share, options exercised (in euros per share) | € / shares	81.38	73.65	71.39
Average exercise price per share, options cancelled (in euros per share) | € / shares			80.56	[1]
Average exercise price per share, ending balance (in euros per share) | € / shares	€ 80.16	€ 80.53	€ 78.64		€ 77.13
Total, beginning balance | €	€ 107	€ 144	€ 180
Total, options exercisable | €	75	107	128		€ 152
Total, options exercised | €	(32)	(37)	(35)
Total, options cancelled | €			(1)	[1]
Total, ending balance | €	€ 75	€ 107	€ 144		€ 180
[1] (a) Mainly due to the grantees leaving Sanofi

Consolidated shareholders_ e_15

Consolidated shareholders’ equity - Summary of Options Outstanding and Exercisable (Details) - Stock Option Plan	12 Months Ended
	Dec. 31, 2024 shares € / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Number of options (in shares) | shares	934,444
Exercisable, number of options (in shares) | shares	934,444
Exercise price range two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Number of options (in shares) | shares	168,784
Weighted average residual life (years)	3 years 4 months 2 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)	€ 65.84
Exercisable, number of options (in shares) | shares	168,784
Weighted average exercise price per share, Options exercisable (in euros per share)	€ 65.84
Exercise price range three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Number of options (in shares) | shares	349,400
Weighted average residual life (years)	3 years 2 months 1 day
Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)	€ 76.39
Exercisable, number of options (in shares) | shares	349,400
Weighted average exercise price per share, Options exercisable (in euros per share)	€ 76.39
Exercise price range four
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, Number of options (in shares) | shares	416,260
Weighted average residual life (years)	1 year 7 months 20 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)	€ 89.13
Exercisable, number of options (in shares) | shares	416,260
Weighted average exercise price per share, Options exercisable (in euros per share)	€ 89.13
Bottom of range | Exercise price range two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	60
Bottom of range | Exercise price range three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	70
Bottom of range | Exercise price range four
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	80
Top of range | Exercise price range two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	70
Top of range | Exercise price range three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	80
Top of range | Exercise price range four
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	€ 90

Consolidated shareholders_ e_16

Consolidated shareholders’ equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021	[1]
Share Capital, Reserves And Other Equity Interest [Abstract]
Average number of shares outstanding (in shares)	1,251.4	1,251.7	[1]	1,251.9	[1]
Adjustment for stock options with dilutive effect (in shares)	0.1	0.2		0.3
Adjustment for restricted shares (in shares)	4.6	4.5		4.7
Average number of shares used to compute diluted earnings per share (in shares)	1,256.1	1,256.4	[1]	1,256.9		1,256.9
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation

Debt, cash and cash equivalen_3

Debt, cash and cash equivalents and lease liabilities - Summary of Changes in Financial Position (Details) - EUR (€) € in Millions		Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Financial Instruments [Abstract]
Long-term debt		€ 11,791	€ 14,347		€ 14,857
Short-term debt and current portion of long-term debt		4,209	2,045		4,174
Interest rate and currency derivatives used to manage debt		137	139		187
Total debt		16,137	16,531		19,218		€ 20,250
Cash and cash equivalents		(7,441)	(8,710)	[1]	(12,736)	[1]	€ (10,098)	[1]
Interest rate and currency derivatives used to manage cash and cash equivalents		76	(28)		(45)
Net debt	[2]	8,772	7,793		6,437
Lease liabilities		€ 1,906	€ 2,030		€ 2,181
[1] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). (a) Net debt does not include lease liabilities, which amounted to €1,906 million as of December 31, 2024 , € 2,030 million as of December 31, 2023 , and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.)

Debt, cash and cash equivalen_4

Debt, cash and cash equivalents and lease liabilities - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details) - EUR (€) € in Millions		Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt		€ 11,791		€ 14,347		€ 14,857
Short-term debt and current portion of long-term debt		4,209		2,045		4,174
Interest rate and currency derivatives used to manage debt		137		139		187
Total debt		16,137		16,531		19,218		€ 20,250
Cash and cash equivalents		(7,441)		(8,710)	[1]	(12,736)	[1]	€ (10,098)	[1]
Interest rate and currency derivatives used to manage cash and cash equivalents		76		(28)		(45)
Net debt	[2]	8,772		7,793		6,437
Amortized cost
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt		30
Short-term debt and current portion of long-term debt		4
Interest rate and currency derivatives used to manage debt
Total debt		34
Cash and cash equivalents
Interest rate and currency derivatives used to manage cash and cash equivalents
Net debt		34
Adjustment to debt measured at fair value
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt		119
Short-term debt and current portion of long-term debt		5
Interest rate and currency derivatives used to manage debt		(124)
Total debt		0
Cash and cash equivalents
Interest rate and currency derivatives used to manage cash and cash equivalents
Net debt		0
Value on redemption
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt		11,940		14,546		15,143
Short-term debt and current portion of long-term debt		4,218		2,045		4,178
Interest rate and currency derivatives used to manage debt		13		(18)		(48)
Total debt		16,171		16,573		19,273
Cash and cash equivalents		(7,441)		(8,710)		(12,736)
Interest rate and currency derivatives used to manage cash and cash equivalents		76		(28)		(45)
Net debt	[4]	€ 8,806	[3]	€ 7,835		€ 6,492
[1] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). (a) Net debt does not include lease liabilities, which amounted to €1,906 million as of December 31, 2024 , € 2,030 million as of December 31, 2023 , and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.) (a) Net debt does not include lease liabilities, which amounted to € 1,906 million as of December 31, 2024; € 2,030 million as of December 31, 2023; and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.). (a) Net debt does not include lease liabilities (see the maturity schedule in Note D.17.2.)

Debt, cash and cash equivalen_5

Debt, cash and cash equivalents and lease liabilities - Disclosure of Movement In Total Debt (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2022
Disclosure of debt [line items]
Borrowings at beginning of period		€ 16,531		€ 19,218		€ 20,250
Repayments		(672)		(3,684)		(2,718)
New borrowings		0		48		1,549
Other cash flows		110	[1]	895	[2]	(330)
Currency translation differences		218	[3]	(22)	[4]	442	[5]
Reclassification from non-current to current		0		0		7
Other items		(50)	[6]	76	[7]	18	[8]
Borrowings at end of period		16,137		16,531		19,218
Net change in short-term debt and other financial instruments	[9]	59		751	[10]	216	[10]
Commercial paper program in USA
Disclosure of debt [line items]
Net change in short-term debt and other financial instruments		262
Long-term debt
Disclosure of debt [line items]
Borrowings at beginning of period		14,347		14,857		17,123
Repayments		(67)		(12)		(11)
New borrowings		0		48		1,549
Other cash flows		0	[1]	0	[2]	0
Currency translation differences		63	[3]	(30)	[4]	56	[5]
Reclassification from non-current to current		(2,599)		(604)		(3,632)
Other items		47	[6]	88	[7]	(228)	[8]
Borrowings at end of period		11,791		14,347		14,857
Short-term debt and current portion of long-term debt
Disclosure of debt [line items]
Borrowings at beginning of period		2,045		4,174		3,183
Repayments		(605)		(3,672)		(2,707)
New borrowings		0		0		0
Other cash flows		242	[1]	903	[2]	43
Currency translation differences		9	[3]	(21)	[4]	20	[5]
Reclassification from non-current to current		2,599		604		3,632
Other items		(81)	[6]	57	[7]	3	[8]
Borrowings at end of period		4,209		2,045		4,174
Interest rate and currency derivatives used to manage debt
Disclosure of debt [line items]
Borrowings at beginning of period		139		187		(56)
Repayments		0		0		0
New borrowings		0		0		0
Other cash flows		(132)	[1]	(8)	[2]	(373)
Currency translation differences		146	[3]	29	[4]	366	[5]
Reclassification from non-current to current		0		0		7
Other items		(16)	[6]	(69)	[7]	243	[8]
Borrowings at end of period		€ 137		139		€ 187
Commercial paper program in USA
Disclosure of debt [line items]
Other cash flows				€ 946
[1] (a)These amounts mainly comprise €262 million related to the US commercial paper program. (a) These amounts mainly comprise €946 million related to the US commercial paper program. (b) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone. (b) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone. (a) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone. (c) These amounts mainly comprise changes in accrued interest balances, and fair value adjustments. (c) These amounts mainly comprise changes in accrued interest balances, and fair value adjustments. (b) These amounts include changes in accrued interest balances and fair value adjustments. For 2024, this line item mainly includes a US commercial paper program for €262 million . For 2024 , 2023 and 2022 , it also includes realized foreign exchange differences on (i) cash and cash equivalents in non-functional currencies (primarily the US dollar) and (ii) derivative instruments used to manage such cash and cash equivalents. Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).

Debt, cash and cash equivalen_6

Debt, cash and cash equivalents and lease liabilities - Additional Information (Details)	12 Months Ended
	Dec. 31, 2024 EUR (€) performance_indicator currency credit_facility shares	Dec. 31, 2024 USD ($)	Dec. 31, 2023 EUR (€) program credit_facility bond	Dec. 31, 2024 USD ($) performance_indicator currency credit_facility shares	Mar. 31, 2023 EUR (€)	Mar. 31, 2018 EUR (€)
Disclosure of detailed information about borrowings [line items]
Number of bond issues redeemed | bond			1
Number of credit facilities | credit_facility	2		2	2
Number of sustainable development performance indicators | performance_indicator	2			2
Number of commercial paper programs | program			2
Number of currencies debt is issued in | currency	2			2
Sanofi Euro Medium Term Notes (EMTN) bonds | Weighted average interest rate before derivative instruments
Disclosure of detailed information about borrowings [line items]
Annual interest rate	1.70%			1.70%
Cash and cash equivalents, invested rate	4.20%			4.20%
Sanofi Euro Medium Term Notes (EMTN) bonds | Weighted average interest rate after derivative instruments
Disclosure of detailed information about borrowings [line items]
Annual interest rate	2.10%			2.10%
Cash and cash equivalents, invested rate	4.10%			4.10%
€1,750 million bonds maturing March 2023
Disclosure of detailed information about borrowings [line items]
Credit facilities, amount drawable						€ 600,000,000
€4 billion facility maturing March 2029
Disclosure of detailed information about borrowings [line items]
Credit facilities, amount drawable	€ 4,000,000,000
€4 billion facility maturing March 2029 | Sanofi Euro Medium Term Notes (EMTN) bonds
Disclosure of detailed information about borrowings [line items]
Credit facilities, amount drawable			€ 4,000,000,000
€4 billion facility maturing December 2027
Disclosure of detailed information about borrowings [line items]
Credit facilities, amount drawable	€ 4,000,000,000
€4 billion facility maturing December 2027 | Sanofi Euro Medium Term Notes (EMTN) bonds
Disclosure of detailed information about borrowings [line items]
Credit facilities, amount drawable			€ 4,000,000,000
1983 to 1987 participating shares issued | Sanofi Euro Medium Term Notes (EMTN) bonds
Disclosure of detailed information about borrowings [line items]
Number of participating shares outstanding (in shares) | shares	57,844			57,844
Participating shares carrying amount	€ 9,000,000
Commercial paper program in France | Sanofi Euro Medium Term Notes (EMTN) bonds
Disclosure of detailed information about borrowings [line items]
Commercial paper programs	6,000,000,000
Borrowing, average drawdown	0.1
Borrowing, maximum drawdown	€ 0.4
Commercial paper program in USA | Sanofi Euro Medium Term Notes (EMTN) bonds
Disclosure of detailed information about borrowings [line items]
Commercial paper programs | $				$ 10,000,000,000
Borrowing, average drawdown | $		$ 5.8
Borrowing, maximum drawdown | $		$ 8.9
Borrowing, drawdown | $				$ 1.3
Syndicated Credit Facility One
Disclosure of detailed information about borrowings [line items]
Credit facilities, amount drawable					€ 4,000,000,000

Debt, cash and cash equivalen_7

Debt, cash and cash equivalents and lease liabilities - Summary of Net Debt by Type Valuation of Redemption (Details) - EUR (€) € in Millions		Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Interest rate and currency derivatives used to manage debt		€ 137		€ 139		€ 187
Total debt		16,137		16,531		19,218		€ 20,250
Cash and cash equivalents		(7,441)		(8,710)	[1]	(12,736)	[1]	€ (10,098)	[1]
Interest rate and currency derivatives used to manage cash and cash equivalents		76		(28)		(45)
Net debt	[2]	8,772		7,793		6,437
Value on redemption
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues		14,592		15,134		18,861
Other bank borrowings		1,354		1,248		286
Other borrowings		3		6		6
Bank credit balances		209		203		168
Interest rate and currency derivatives used to manage debt		13		(18)		(48)
Total debt		16,171		16,573		19,273
Cash and cash equivalents		(7,441)		(8,710)		(12,736)
Interest rate and currency derivatives used to manage cash and cash equivalents		76		(28)		(45)
Net debt	[4]	8,806	[3]	7,835		6,492
Value on redemption | Less than 1 year
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues		2,716		718		3,817
Other bank borrowings		1,290		1,118		187
Other borrowings		3		6		6
Bank credit balances		209		203		168
Interest rate and currency derivatives used to manage debt		13		(18)		(48)
Total debt		4,231		2,027		4,130
Cash and cash equivalents		(7,441)		(8,710)		(12,736)
Interest rate and currency derivatives used to manage cash and cash equivalents		76		(28)		(45)
Net debt		(3,134)	[3]	(6,711)		(8,651)
Value on redemption | 1 to 2 years
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues		3,010		2,600		600
Other bank borrowings		32		98		61
Other borrowings		0		0		0
Bank credit balances		0		0		0
Interest rate and currency derivatives used to manage debt		0		0		0
Total debt		3,042		2,698		661
Cash and cash equivalents		0		0		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0		0		0
Net debt		3,042	[3]	2,698		661
Value on redemption | 2 to 3 years
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues		1,150		3,010		2,600
Other bank borrowings		1		1		0
Other borrowings		0		0		0
Bank credit balances		0		0		0
Interest rate and currency derivatives used to manage debt		0		0		0
Total debt		1,151		3,011		2,600
Cash and cash equivalents		0		0		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0		0		0
Net debt		1,151	[3]	3,011		2,600
Value on redemption | 3 to 4 years
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues		1,666		1,150		4,160
Other bank borrowings		1		1		0
Other borrowings		0		0		0
Bank credit balances		0		0		0
Interest rate and currency derivatives used to manage debt		0		0		0
Total debt		1,667		1,151		4,160
Cash and cash equivalents		0		0		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0		0		0
Net debt		1,667	[3]	1,151		4,160
Value on redemption | 4 to 5 years
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues		1,300		1,606		0
Other bank borrowings		1		1		0
Other borrowings		0		0		0
Bank credit balances		0		0		0
Interest rate and currency derivatives used to manage debt		0		0		0
Total debt		1,301		1,607		0
Cash and cash equivalents		0		0		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0		0		0
Net debt		1,301	[3]	1,607		0
Value on redemption | More than 5 years
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues		4,750		6,050		7,684
Other bank borrowings		29		29		38
Other borrowings		0		0		0
Bank credit balances		0		0		0
Interest rate and currency derivatives used to manage debt		0		0		0
Total debt		4,779		6,079		7,722
Cash and cash equivalents		0		0		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0		0		0
Net debt		4,779	[3]	6,079		7,722
Value on redemption | Non-current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Cash and cash equivalents		0		0		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0		0		0
Net debt	[4]	11,940		14,546		15,143
Value on redemption | Current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Cash and cash equivalents		(7,441)		(8,710)		(12,736)
Interest rate and currency derivatives used to manage cash and cash equivalents		76		(28)		(45)
Net debt	[4]	(3,134)		(6,711)		(8,651)
Value on redemption | Non-current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues		11,876		14,416		15,044
Other bank borrowings		64		130		99
Other borrowings		0		0		0
Bank credit balances		0		0		0
Interest rate and currency derivatives used to manage debt		0		0		0
Total debt		11,940		14,546		15,143
Value on redemption | Current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues		2,716		718		3,817
Other bank borrowings		1,290		1,118		187
Other borrowings		3		6		6
Bank credit balances		209		203		168
Interest rate and currency derivatives used to manage debt		13		(18)		(48)
Total debt		€ 4,231		€ 2,027		€ 4,130
[1] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). (a) Net debt does not include lease liabilities, which amounted to €1,906 million as of December 31, 2024 , € 2,030 million as of December 31, 2023 , and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.) (a) Net debt does not include lease liabilities, which amounted to € 1,906 million as of December 31, 2024; € 2,030 million as of December 31, 2023; and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.). (a) Net debt does not include lease liabilities (see the maturity schedule in Note D.17.2.)

Debt, cash and cash equivalen_8

Debt, cash and cash equivalents and lease liabilities - Summary of Bond Issues (Details) € in Millions, $ in Millions	Apr. 30, 2022 EUR (€)	Mar. 31, 2020 EUR (€)	Mar. 31, 2019 EUR (€)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 EUR (€)	Sep. 30, 2016 EUR (€)	Apr. 30, 2016 EUR (€)	Sep. 30, 2015 EUR (€)	Sep. 30, 2014 EUR (€)
Sanofi Euro Medium Term Notes (EMTN) bonds | March 2020 EMTN ISIN FR0013505104
Disclosure of detailed information about borrowings [line items]
Annual interest rate		1%
Amount		€ 1,000
Sanofi Euro Medium Term Notes (EMTN) bonds | April 2022 EMTN ISIN FR0014009KS6
Disclosure of detailed information about borrowings [line items]
Annual interest rate	0.875%
Amount	€ 850
Sanofi Euro Medium Term Notes (EMTN) bonds | September 2015 EMTN ISIN FR0012969038
Disclosure of detailed information about borrowings [line items]
Annual interest rate								1.50%
Amount								€ 750
Sanofi Euro Medium Term Notes (EMTN) bonds | March 2018 EMTN ISIN FR0013324340
Disclosure of detailed information about borrowings [line items]
Annual interest rate					1%
Amount					€ 1,500
Sanofi Euro Medium Term Notes (EMTN) bonds | September 2014 EMTN ISIN FR0012146801
Disclosure of detailed information about borrowings [line items]
Annual interest rate									1.75%
Amount									€ 1,510
Sanofi Euro Medium Term Notes (EMTN) bonds | September 2016 EMTN ISIN FR0013201639
Disclosure of detailed information about borrowings [line items]
Annual interest rate						0.50%
Amount						€ 1,150
Sanofi Euro Medium Term Notes (EMTN) bonds | April 2016 EMTN ISIN FR0013144003
Disclosure of detailed information about borrowings [line items]
Annual interest rate							1.125%
Amount							€ 700
Sanofi Euro Medium Term Notes (EMTN) bonds | March 2019 EMTN ISIN FR0013409844
Disclosure of detailed information about borrowings [line items]
Annual interest rate			0.875%
Amount			€ 650
Sanofi Euro Medium Term Notes (EMTN) bonds | April 2022 EMTN ISIN FR0014009KQ0
Disclosure of detailed information about borrowings [line items]
Annual interest rate	1.25%
Amount	€ 650
Sanofi Euro Medium Term Notes (EMTN) bonds | March 2018 EMTN ISIN FR0013324357
Disclosure of detailed information about borrowings [line items]
Annual interest rate					1.375%
Amount					€ 2,000
Sanofi Euro Medium Term Notes (EMTN) bonds | March 2020 EMTN ISIN FR0013505112
Disclosure of detailed information about borrowings [line items]
Annual interest rate		1.50%
Amount		€ 1,000
Sanofi Euro Medium Term Notes (EMTN) bonds | March 2019 EMTN ISIN FR0013409851
Disclosure of detailed information about borrowings [line items]
Annual interest rate			1.25%
Amount			€ 500
Sanofi Euro Medium Term Notes (EMTN) bonds | March 2018 EMTN ISIN FR0013324373
Disclosure of detailed information about borrowings [line items]
Annual interest rate					1.875%
Amount			€ 1,250
Shelf registration statement program | June 2018 SNF ISIN US801060AD60
Disclosure of detailed information about borrowings [line items]
Annual interest rate				3.625%
Amount | $				$ 1,000

Debt, cash and cash equivalen_9

Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Maturity at Value on Redemption (Details) - EUR (€) € in Millions		Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Disclosure of detailed information about borrowings [line items]
Interest rate and currency derivatives used to manage debt		€ 137		€ 139		€ 187
Total debt		16,137		16,531		19,218		€ 20,250
Cash and cash equivalents		(7,441)		(8,710)	[1]	(12,736)	[1]	€ (10,098)	[1]
Interest rate and currency derivatives used to manage cash and cash equivalents		76		(28)		(45)
Net debt	[2]	8,772		7,793		6,437
Lease liabilities		1,906		2,030		2,181
Sanofi Euro Medium Term Notes (EMTN) bonds | Main undrawn confirmed general purpose credit facilities
Disclosure of detailed information about borrowings [line items]
Credit facilities, amount drawable		8,000
Less than 1 year
Disclosure of detailed information about borrowings [line items]
Lease liabilities		377		291		320
More than 5 years
Disclosure of detailed information about borrowings [line items]
Lease liabilities		819		989		1,129
Value on redemption
Disclosure of detailed information about borrowings [line items]
Bond issues		14,592		15,134		18,861
Other bank borrowings		1,354		1,248		286
Other borrowings		3		6		6
Bank credit balances		209		203		168
Interest rate and currency derivatives used to manage debt		13		(18)		(48)
Total debt		16,171		16,573		19,273
Cash and cash equivalents		(7,441)		(8,710)		(12,736)
Interest rate and currency derivatives used to manage cash and cash equivalents		76		(28)		(45)
Net debt	[4]	8,806	[3]	7,835		6,492
Value on redemption | Less than 1 year
Disclosure of detailed information about borrowings [line items]
Bond issues		2,716		718		3,817
Other bank borrowings		1,290		1,118		187
Other borrowings		3		6		6
Bank credit balances		209		203		168
Interest rate and currency derivatives used to manage debt		13		(18)		(48)
Total debt		4,231		2,027		4,130
Cash and cash equivalents		(7,441)		(8,710)		(12,736)
Interest rate and currency derivatives used to manage cash and cash equivalents		76		(28)		(45)
Net debt		(3,134)	[3]	(6,711)		(8,651)
Value on redemption | 1 to 2 years
Disclosure of detailed information about borrowings [line items]
Bond issues		3,010		2,600		600
Other bank borrowings		32		98		61
Other borrowings		0		0		0
Bank credit balances		0		0		0
Interest rate and currency derivatives used to manage debt		0		0		0
Total debt		3,042		2,698		661
Cash and cash equivalents		0		0		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0		0		0
Net debt		3,042	[3]	2,698		661
Value on redemption | 2 to 3 years
Disclosure of detailed information about borrowings [line items]
Bond issues		1,150		3,010		2,600
Other bank borrowings		1		1		0
Other borrowings		0		0		0
Bank credit balances		0		0		0
Interest rate and currency derivatives used to manage debt		0		0		0
Total debt		1,151		3,011		2,600
Cash and cash equivalents		0		0		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0		0		0
Net debt		1,151	[3]	3,011		2,600
Value on redemption | 3 to 4 years
Disclosure of detailed information about borrowings [line items]
Bond issues		1,666		1,150		4,160
Other bank borrowings		1		1		0
Other borrowings		0		0		0
Bank credit balances		0		0		0
Interest rate and currency derivatives used to manage debt		0		0		0
Total debt		1,667		1,151		4,160
Cash and cash equivalents		0		0		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0		0		0
Net debt		1,667	[3]	1,151		4,160
Value on redemption | 4 to 5 years
Disclosure of detailed information about borrowings [line items]
Bond issues		1,300		1,606		0
Other bank borrowings		1		1		0
Other borrowings		0		0		0
Bank credit balances		0		0		0
Interest rate and currency derivatives used to manage debt		0		0		0
Total debt		1,301		1,607		0
Cash and cash equivalents		0		0		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0		0		0
Net debt		1,301	[3]	1,607		0
Value on redemption | More than 5 years
Disclosure of detailed information about borrowings [line items]
Bond issues		4,750		6,050		7,684
Other bank borrowings		29		29		38
Other borrowings		0		0		0
Bank credit balances		0		0		0
Interest rate and currency derivatives used to manage debt		0		0		0
Total debt		4,779		6,079		7,722
Cash and cash equivalents		0		0		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0		0		0
Net debt		€ 4,779	[3]	€ 6,079		€ 7,722
[1] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). (a) Net debt does not include lease liabilities, which amounted to €1,906 million as of December 31, 2024 , € 2,030 million as of December 31, 2023 , and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.) (a) Net debt does not include lease liabilities, which amounted to € 1,906 million as of December 31, 2024; € 2,030 million as of December 31, 2023; and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.). (a) Net debt does not include lease liabilities (see the maturity schedule in Note D.17.2.)

Debt, cash and cash equivale_10

Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Interest Rate (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021	[1]
Disclosure of financial instruments by type of interest rate [line items]
Cash and cash equivalents		€ (7,441)	€ (8,710)	[1]	€ (12,736)	[1]	€ (10,098)
Net debt	[2]	8,772	€ 7,793		€ 6,437
Value on redemption before derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		€ 16,158
Debt, percent		100%
Net debt		€ 8,717
Value on redemption before derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		€ 14,592
Debt, percent		90%
Value on redemption before derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		€ 1,566
Debt, percent		10%
Cash and cash equivalents		€ (7,441)
Value on redemption after derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		16,171
Debt, percent			100%		100%
Cash and cash equivalents		(7,365)	€ (8,738)		€ (12,781)
Net debt		8,806	€ 7,835		€ 6,492
Value on redemption after derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		€ 11,098
Debt, percent		69%	69%		85%
Value on redemption after derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		€ 5,074
Debt, percent		31%	31%		15%
Year 1 | Value on redemption before derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		€ 4,218
Net debt		(3,223)
Year 1 | Value on redemption before derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		2,716
Year 1 | Value on redemption before derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,502
Cash and cash equivalents		(7,441)
Year 1 | Value on redemption after derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		4,231
Net debt		(3,134)
Year 1 | Value on redemption after derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		(778)
Year 1 | Value on redemption after derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		5,010
Cash and cash equivalents		(7,365)
Year 2 | Value on redemption before derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		3,042
Net debt		3,042
Year 2 | Value on redemption before derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		3,010
Year 2 | Value on redemption before derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		32
Cash and cash equivalents		0
Year 2 | Value on redemption after derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		3,042
Net debt		3,042
Year 2 | Value on redemption after derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		3,010
Year 2 | Value on redemption after derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		32
Cash and cash equivalents		0
Year 3 | Value on redemption before derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,151
Net debt		1,151
Year 3 | Value on redemption before derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,150
Year 3 | Value on redemption before derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1
Cash and cash equivalents		0
Year 3 | Value on redemption after derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,151
Net debt		1,151
Year 3 | Value on redemption after derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,150
Year 3 | Value on redemption after derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1
Cash and cash equivalents		0
Year 4 | Value on redemption before derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,667
Net debt		1,667
Year 4 | Value on redemption before derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,666
Year 4 | Value on redemption before derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1
Cash and cash equivalents		0
Year 4 | Value on redemption after derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,667
Net debt		1,667
Year 4 | Value on redemption after derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,666
Year 4 | Value on redemption after derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1
Cash and cash equivalents		0
Year 5 | Value on redemption before derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,301
Net debt		1,301
Year 5 | Value on redemption before derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,300
Year 5 | Value on redemption before derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1
Cash and cash equivalents		0
Year 5 | Value on redemption after derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,301
Net debt		1,301
Year 5 | Value on redemption after derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,300
Year 5 | Value on redemption after derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1
Cash and cash equivalents		0
Year 5 and later | Value on redemption before derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		4,779
Net debt		4,779
Year 5 and later | Value on redemption before derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		4,750
Year 5 and later | Value on redemption before derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		29
Cash and cash equivalents		0
Year 5 and later | Value on redemption after derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Debt		4,779
Net debt		4,779
Year 5 and later | Value on redemption after derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		4,750
Year 5 and later | Value on redemption after derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		29
Cash and cash equivalents		0
Euro | Value on redemption before derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Net debt		10,681
Euro | Value on redemption before derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		13,626
Euro | Value on redemption before derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		0
Cash and cash equivalents		(2,945)
Euro | Value on redemption after derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Net debt		7,285	€ 6,852		€ 10,489
Euro | Value on redemption after derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		11,098
Euro | Value on redemption after derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		174
Cash and cash equivalents		(3,987)
US dollar | Value on redemption before derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Net debt		(2,017)
US dollar | Value on redemption before derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		966
US dollar | Value on redemption before derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		1,221
Cash and cash equivalents		(4,204)
US dollar | Value on redemption after derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Net debt		2,502	€ 1,169		€ (2,404)
US dollar | Value on redemption after derivative instruments | Fixed-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		0
US dollar | Value on redemption after derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Debt		3,507
Cash and cash equivalents		(1,005)
Singapore dollar | Value on redemption before derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Net debt		(3)
Singapore dollar | Value on redemption after derivative instruments
Disclosure of financial instruments by type of interest rate [line items]
Net debt		(822)
Singapore dollar | Value on redemption after derivative instruments | Floating-rate debt
Disclosure of financial instruments by type of interest rate [line items]
Cash and cash equivalents		€ (822)
[1] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). (a) Net debt does not include lease liabilities, which amounted to €1,906 million as of December 31, 2024 , € 2,030 million as of December 31, 2023 , and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.)

Debt, cash and cash equivale_11

Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate of Net Debt at Value on Redemption (Details) - EUR (€) € in Millions		Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]
Total debt		€ 16,137	€ 16,531		€ 19,218		€ 20,250
Cash and cash equivalents		(7,441)	(8,710)	[1]	(12,736)	[1]	€ (10,098)	[1]
Net debt	[2]	8,772	7,793		6,437
Value on redemption after derivative instruments
Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]
Total debt			16,573		19,273
Cash and cash equivalents		(7,365)	(8,738)		(12,781)
Net debt		€ 8,806	€ 7,835		€ 6,492
Debt, percent			100%		100%
Value on redemption after derivative instruments | Fixed-rate debt
Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]
Total debt			€ 11,382		€ 16,386
Debt, percent		69%	69%		85%
Value on redemption after derivative instruments | Floating-rate debt
Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]
Total debt			€ 5,191		€ 2,886
Debt, percent		31%	31%		15%
[1] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). (a) Net debt does not include lease liabilities, which amounted to €1,906 million as of December 31, 2024 , € 2,030 million as of December 31, 2023 , and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.)

Debt, cash and cash equivale_12

Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate Fluctuations of Debt Net of Cash and Cash Equivalents (Details) - Change in Euro and US dollar short-term interest rates € in Millions	12 Months Ended
	Dec. 31, 2024 EUR (€)
+100 bp
Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]
Impact on pre-tax net income	€ 34
Impact on pre-tax income/(expense) recognized directly in equity	0
+25 bp
Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]
Impact on pre-tax net income	8
Impact on pre-tax income/(expense) recognized directly in equity	0
-25 bp
Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]
Impact on pre-tax net income	(8)
Impact on pre-tax income/(expense) recognized directly in equity	0
-100 bp
Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]
Impact on pre-tax net income	(34)
Impact on pre-tax income/(expense) recognized directly in equity	€ 0

Debt, cash and cash equivale_13

Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Currency (Details) - EUR (€) € in Millions		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Debt By Currency [Line Items]
Net debt	[1]	€ 8,772	€ 7,793	€ 6,437
Value on redemption before derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		8,717
Value on redemption after derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		8,806	7,835	6,492
Euro | Value on redemption before derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		10,681
Euro | Value on redemption after derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		7,285	6,852	10,489
US dollar | Value on redemption before derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		(2,017)
US dollar | Value on redemption after derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		2,502	1,169	(2,404)
Singapore dollar | Value on redemption before derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		(3)
Singapore dollar | Value on redemption after derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		(822)
Hungarian forint | Value on redemption before derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		0
Hungarian forint | Value on redemption after derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		(641)
Chinese yuan renminbi | Value on redemption before derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		(10)
Chinese yuan renminbi | Value on redemption after derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		226
Other currencies | Value on redemption before derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		65
Other currencies | Value on redemption after derivative instruments
Disclosure Of Debt By Currency [Line Items]
Net debt		€ 256	€ (186)	€ (1,593)
[1] (a) Net debt does not include lease liabilities, which amounted to €1,906 million as of December 31, 2024 , € 2,030 million as of December 31, 2023 , and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.)

Debt, cash and cash equivale_14

Debt, cash and cash equivalents and lease liabilities - Summary of Market Value of Net Debt (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about borrowings [line items]
Total debt	€ 16,137	€ 16,531	€ 19,218	€ 20,250
Market value
Disclosure of detailed information about borrowings [line items]
Total debt	8,165	7,086	5,227
Value on redemption
Disclosure of detailed information about borrowings [line items]
Total debt	16,171	16,573	19,273
Total debt at redemption	€ 8,806	€ 7,835	€ 6,492

Debt, cash and cash equivale_15

Debt, cash and cash equivalents and lease liabilities - Amount of Future Undiscounted Contractual Cash Flows Relating to Debt and Derivative Instruments Designated as Hedges of Debt (Details) - EUR (€) € in Millions	Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2022
Disclosure of maturity analysis for derivative financial liabilities [line items]
Debt	€ 17,077		€ 17,710		€ 20,408
Principal	16,049		16,468		18,932
Interest	1,028	[1]	1,242	[2]	1,476	[3]
Net cash flows related to derivative instruments	161		143		209
Total	17,238		17,853		20,617
Year 1
Disclosure of maturity analysis for derivative financial liabilities [line items]
Debt	4,328		2,153		4,206
Principal	4,105		1,917		3,928
Interest	223	[1]	236	[2]	278	[3]
Net cash flows related to derivative instruments	71		47		24
Total	4,399		2,200		4,230
Year 2
Disclosure of maturity analysis for derivative financial liabilities [line items]
Debt	3,226		2,912		868
Principal	3,047		2,703		661
Interest	179	[1]	209	[2]	207	[3]
Net cash flows related to derivative instruments	34		32		60
Total	3,260		2,944		928
Year 3
Disclosure of maturity analysis for derivative financial liabilities [line items]
Debt	1,288		3,187		2,803
Principal	1,151		3,011		2,601
Interest	137	[1]	176	[2]	202	[3]
Net cash flows related to derivative instruments	34		23		38
Total	1,322		3,210		2,841
Year 4
Disclosure of maturity analysis for derivative financial liabilities [line items]
Debt	1,780		1,285		3,184
Principal	1,667		1,151		3,011
Interest	113	[1]	134	[2]	173	[3]
Net cash flows related to derivative instruments	21		24		31
Total	1,801		1,309		3,215
Year 5
Disclosure of maturity analysis for derivative financial liabilities [line items]
Debt	1,388		1,719		1,283
Principal	1,300		1,607		1,151
Interest	88	[1]	112	[2]	132	[3]
Net cash flows related to derivative instruments	1		16		31
Total	1,389		1,735		1,314
Year 5 and later
Disclosure of maturity analysis for derivative financial liabilities [line items]
Debt	5,067		6,454		8,064
Principal	4,779		6,079		7,580
Interest	288	[1]	375	[2]	484	[3]
Net cash flows related to derivative instruments	0		1		25
Total	€ 5,067		€ 6,455		€ 8,089
[1] (a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2024 (a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2023 (a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2022

Debt, cash and cash equivale_16

Debt, cash and cash equivalents and lease liabilities - Lease Liabilities (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of maturity analysis of finance lease payments receivable [line items]
Lease liabilities	€ 1,906	€ 2,030	€ 2,181
Discounting effect	€ (174)	(58)	(219)
Cambridge, Massachusetts
Disclosure of maturity analysis of finance lease payments receivable [line items]
Initial lease term	15 years
Less than 1 year
Disclosure of maturity analysis of finance lease payments receivable [line items]
Lease liabilities	€ 377	291	320
From 1 to 3 years
Disclosure of maturity analysis of finance lease payments receivable [line items]
Lease liabilities	498	448	515
From 3 to 5 years
Disclosure of maturity analysis of finance lease payments receivable [line items]
Lease liabilities	386	360	436
More than 5 years
Disclosure of maturity analysis of finance lease payments receivable [line items]
Lease liabilities	€ 819	€ 989	€ 1,129

Liabilities related to busine_3

Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Beginning balance	[1]	€ 709	€ 779	€ 714
New transactions	[1]	0	0	156
Payments made	[1]	(71)	(167)	(136)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	[1],[2]	109	114	5
Other movements	[1]	(139)	0	0
Currency translation differences	[1]	33	(17)	40
Ending balance	[1]	641	709	779
Non-current liabilities related to business combinations and to non-controlling interests		569	501	674
Current liabilities related to business combinations and to non-controlling interests		72	208	105
Bayer contingent purchase consideration arising from the acquisition of Genzyme
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Beginning balance		0	26	59
New transactions		0	0	0
Payments made		0	(21)	(29)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	[2]	0	(5)	(9)
Other movements		0	0	0
Currency translation differences		0	0	5
Ending balance		0	0	26
MSD contingent consideration (European vaccines business)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Beginning balance		127	204	269
New transactions		0	0	0
Payments made		(70)	(77)	(79)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	[2]	16	0	14
Other movements		0	0	0
Currency translation differences		(1)	0	0
Ending balance		72	127	204
Shire contingent consideration arising from the acquisition of Translate Bio
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Beginning balance		441	380	354
New transactions		0	0	0
Payments made		0	0	0
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	[2]	94	74	2
Other movements		0	0	0
Currency translation differences		33	(13)	24
Ending balance		568	441	380
Amunix [Member]
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Beginning balance		137	165	0
New transactions		0	0	156
Payments made		0	(69)	0
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	[2]	0	45	(2)
Other movements		(137)	0	0
Currency translation differences		0	(4)	11
Ending balance		0	137	165
Other
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Beginning balance		4	4	32
New transactions		0	0	0
Payments made		(1)	0	(28)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	[2]	1	0	0
Other movements		(3)	0	0
Currency translation differences		0	0	0
Ending balance		€ 1	€ 4	€ 4
[1] (a) Portion due after more than one year: €569 million as of December 31, 2024 ( €501 million as of December 31, 2023 and €674 million as of December 31, 2022 ); portion due within less than one year: €72 million as of December 31, 2024 ( €208 million as of December 31, 2023 and €105 million as of December 31, 2022 ). (b) Amounts reported within the income statement line item Fair value remeasurement of contingent consideration , and mainly comprising unrealized gains and losses

Liabilities related to busine_4

Liabilities related to business combinations and to non-controlling interests - Additional Information (Details) - EUR (€) € in Millions		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Fair value of contingent consideration payable	[1]	€ 641	€ 709	€ 779	€ 714
Commitments relating to contingent consideration in connection with business combinations		72	133	604
MSD contingent consideration (European vaccines business)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Fair value of contingent consideration payable		72	127	204	269
Shire contingent consideration arising from the acquisition of Translate Bio
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Fair value of contingent consideration payable		€ 568	441	380	354
Shire contingent consideration
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Increase in fair value of liability		13%
Amunix [Member]
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Fair value of contingent consideration payable		€ 0	€ 137	€ 165	€ 0
[1] (a) Portion due after more than one year: €569 million as of December 31, 2024 ( €501 million as of December 31, 2023 and €674 million as of December 31, 2022 ); portion due within less than one year: €72 million as of December 31, 2024 ( €208 million as of December 31, 2023 and €105 million as of December 31, 2022 ).

Liabilities related to busine_5

Liabilities related to business combinations and to non-controlling interests - Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]
Commitments relating to contingent consideration in connection with business combinations	€ 72	€ 133	€ 604
Less than 1 year
Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]
Commitments relating to contingent consideration in connection with business combinations	72
From 1 to 3 years
Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]
Commitments relating to contingent consideration in connection with business combinations	0
From 3 to 5 years
Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]
Commitments relating to contingent consideration in connection with business combinations	0
More than 5 years
Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]
Commitments relating to contingent consideration in connection with business combinations	€ 0

Provisions, income tax liabil_3

Provisions, income tax liabilities and other liabilities - Summary of Non Current Provisions and Other Non-current Liabilities (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2020	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Non-current Provisions [line items]
Provisions		€ 5,762		€ 5,262	€ 5,822	€ 6,430
Other non-current liabilities	[1]	2,334		2,340	519
Total		8,096		7,602	6,341
Non-current liabilities		121		164	232
Increase Decrease Through Reclassification of Business, Other Provisions	[2]	(154)
US legal restructuring
Disclosure Of Non-current Provisions [line items]
Percentage of capital losses used			33.33%
Restructuring provisions
Disclosure Of Non-current Provisions [line items]
Provisions		799		554	761	524
Increase Decrease Through Reclassification of Business, Other Provisions	[2]	(21)
Provisions for other long-term benefits
Disclosure Of Non-current Provisions [line items]
Provisions		821		718	844	935
Increase Decrease Through Reclassification of Business, Other Provisions	[2]	(14)
Provisions for pensions and other post-employment benefits
Disclosure Of Non-current Provisions [line items]
Provisions		1,992		2,214	2,039	2,947
Increase Decrease Through Reclassification of Business, Other Provisions	[2]	(92)
Other provisions
Disclosure Of Non-current Provisions [line items]
Provisions		2,150		€ 1,776	€ 2,178	€ 2,024
Increase Decrease Through Reclassification of Business, Other Provisions	[2]	(27)
Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB
Disclosure Of Non-current Provisions [line items]
Other non-current liabilities		2,007
Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB | Later than one year and not later than five years
Disclosure Of Non-current Provisions [line items]
Other non-current liabilities		1,140
Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB | More than 5 years
Disclosure Of Non-current Provisions [line items]
Other non-current liabilities		€ 2,792
[1] (a) Includes derivative financial instruments: € 121 million as of December 31, 2024 , €164 million as of December 31, 2023 , €232 million as of December 31, 2022 . The figure as of December 31, 2024 includes € 2,007 million for the liability in respect of royalties payable to Sobi on net sales of Beyfortus (nirsevimab) in the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is € 1,140 million; the nominal value of payments estimated to be due after more than five years is € 2,792 million. (b) The liabilities of Opella, which in 2022 and 2023 were presented in the relevant balance sheet line item for each class of liability, were reclassified in 2024 to Liabilities related to assets held for sale in accordance with IFRS 5 (see Note D.1.)

Provisions, income tax liabil_4

Provisions, income tax liabilities and other liabilities - Summary of Movements in Non-current Provisions (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Reconciliation of changes in other provisions [abstract]
Beginning balance		€ 5,262	€ 5,822	€ 6,430
Changes in scope of consolidation		11		(200)
Increases in provisions		1,622	952	1,285
Provisions utilized		(446)	(408)	(528)
Reversals of unutilized provisions		(242)	(758)	(288)
Transfers		(516)	(572)	(274)
Net interest related to employee benefits, and unwinding of discount		122	120	64
Currency translation differences		116	(65)	113
Actuarial gains and losses on defined-benefit plans		(13)	171	(780)
Ending balance		5,762	5,262	5,822
Provisions for pensions and other post-employment benefits
Reconciliation of changes in other provisions [abstract]
Beginning balance		2,214	2,039	2,947
Changes in scope of consolidation		0		(96)
Increases in provisions	[1]	145	141	193
Provisions utilized	[1]	(173)	(162)	(275)
Reversals of unutilized provisions	[1]	(108)	(21)	(66)
Transfers		(89)	(1)	10
Net interest related to employee benefits, and unwinding of discount		65	70	43
Currency translation differences		43	(23)	63
Actuarial gains and losses on defined-benefit plans		(13)	171	(780)
Ending balance		1,992	2,214	2,039
Provisions for other long-term benefits
Reconciliation of changes in other provisions [abstract]
Beginning balance		718	844	935
Changes in scope of consolidation		0		(28)
Increases in provisions		199	185	40
Provisions utilized		(118)	(107)	(119)
Reversals of unutilized provisions		0	(190)	(20)
Transfers		0	0	4
Net interest related to employee benefits, and unwinding of discount		2	3	4
Currency translation differences		34	(17)	28
Actuarial gains and losses on defined-benefit plans		0	0	0
Ending balance		821	718	844
Restructuring provisions
Reconciliation of changes in other provisions [abstract]
Beginning balance		554	761	524
Changes in scope of consolidation		0		0
Increases in provisions		548	315	521
Provisions utilized		(20)	(25)	(12)
Reversals of unutilized provisions		(8)	(159)	(11)
Transfers		(270)	(361)	(265)
Net interest related to employee benefits, and unwinding of discount		19	23	5
Currency translation differences		(3)	0	(1)
Actuarial gains and losses on defined-benefit plans		0	0	0
Ending balance		799	554	761
Other provisions
Reconciliation of changes in other provisions [abstract]
Beginning balance		1,776	2,178	2,024
Changes in scope of consolidation		11		(76)
Increases in provisions		730	311	531
Provisions utilized		(135)	(114)	(122)
Reversals of unutilized provisions		(126)	(388)	(191)
Transfers		(157)	(210)	(23)
Net interest related to employee benefits, and unwinding of discount		36	24	12
Currency translation differences		42	(25)	23
Actuarial gains and losses on defined-benefit plans		0	0	0
Ending balance		€ 2,150	€ 1,776	€ 2,178
[1] (a) In the case of “Provisions for pensions and other post-employment benefits”, the “Increases in provisions” line corresponds to rights vesting in employees during the period, and past service cost; the “Provisions utilized” line corresponds to contributions paid into pension funds and to beneficiaries; and the “Reversals of unutilized provisions” line corresponds to plan curtailments, settlements and amendments.

Provisions, income tax liabil_5

Provisions, income tax liabilities and other liabilities - Additional Information (Details) € in Millions, $ in Millions		12 Months Ended
		Dec. 31, 2024 EUR (€) Country age plan	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2018 USD ($)	Dec. 31, 2021 EUR (€)
Provisions And Other Current And Non-Current Liabilities [Line Items]
Number of major countries included in pension obligations | Country		4
Pension obligation, percentage to defined benefit liability		88%
Pension obligations, percentage to plan assets		87%
Employee termination benefits		€ 1,318	€ 968	€ 1,039
Average residual holding periods		2 years 2 months 4 days	2 years 2 months 19 days	2 years 7 months 6 days
Non-current income tax liabilities		€ 1,512	€ 1,842	€ 1,979
Other non-current liabilities	[1]	€ 2,334	€ 2,340	519
Liability recognized representing the estimated cost | $						$ 1,092
Tax charge on deemed repatriation attributable to accumulated earnings payable period		8 years
Mortality table
Provisions And Other Current And Non-Current Liabilities [Line Items]
Possible increase in mortality table (in years)			1 year
US legal restructuring
Provisions And Other Current And Non-Current Liabilities [Line Items]
Unused capital losses for which no deferred tax asset recognised					€ 3,000
Capital losses, carry back period					3 years
Percentage of capital losses used					33.33%
Later than 12 months
Provisions And Other Current And Non-Current Liabilities [Line Items]
Other non-current liabilities			€ 247	459
Other environment related provision
Provisions And Other Current And Non-Current Liabilities [Line Items]
Identified environmental risks provisions estimated obligation period		30 years
Other provisions, expected utilized amount in 2022		€ 67
Other provisions, expected utilized amount in 2023 through 2026		203
Greenhouse Gas Emission
Provisions And Other Current And Non-Current Liabilities [Line Items]
Provision Recognised		1
Uncertainties over income tax treatments
Provisions And Other Current And Non-Current Liabilities [Line Items]
Non-current income tax liabilities		1,512	1,595	1,520
France
Provisions And Other Current And Non-Current Liabilities [Line Items]
Employee termination benefits		€ 862	611	804
US
Provisions And Other Current And Non-Current Liabilities [Line Items]
Number of types of defined-benefit plan | plan		2
UK
Provisions And Other Current And Non-Current Liabilities [Line Items]
Retirement age | age		65
Notional retirement age | age		60
UK | Plan assets
Provisions And Other Current And Non-Current Liabilities [Line Items]
Net amount shown in the balance sheet at end of period		€ (204)
UK | Bottom of range
Provisions And Other Current And Non-Current Liabilities [Line Items]
Vesting right percentage		1.25%
UK | Top of range
Provisions And Other Current And Non-Current Liabilities [Line Items]
Vesting right percentage		1.50%
Lump-sum retirement benefit plans | France
Provisions And Other Current And Non-Current Liabilities [Line Items]
Pension obligation, percentage to defined benefit liability		38%
Defined benefit pension plans | France
Provisions And Other Current And Non-Current Liabilities [Line Items]
Pension obligation, percentage to defined benefit liability		62%
Defined benefit pension plans | US | Qualified defined benefit pension plans
Provisions And Other Current And Non-Current Liabilities [Line Items]
Pension obligation, percentage to defined benefit liability		57%
Defined benefit pension plans | US | Non qualified defined benefit pension plans
Provisions And Other Current And Non-Current Liabilities [Line Items]
Pension obligation, percentage to defined benefit liability		16%
Defined benefit pension plans | UK
Provisions And Other Current And Non-Current Liabilities [Line Items]
Pension obligation, percentage to defined benefit liability		100%
Top-up defined-benefit pension plan | Germany
Provisions And Other Current And Non-Current Liabilities [Line Items]
Pension obligation, percentage to defined benefit liability		61%
Sanofi-Aventis Plus | Germany
Provisions And Other Current And Non-Current Liabilities [Line Items]
Employer's contribution percentage		14%
Multi-employer plan (Pensionskasses) | Germany
Provisions And Other Current And Non-Current Liabilities [Line Items]
Pension obligation, percentage to defined benefit liability		26%
Employee termination benefits		€ 682	744	652
Healthcare Cover And Life Insurance | US
Provisions And Other Current And Non-Current Liabilities [Line Items]
Pension obligation, percentage to defined benefit liability		27%
Employee termination benefits		€ 381
Healthcare Cover And Life Insurance | US | Plan assets
Provisions And Other Current And Non-Current Liabilities [Line Items]
Pension obligations, percentage to plan assets		3%
Net amount shown in the balance sheet at end of period		€ 20
Pensions and other post-employment benefits
Provisions And Other Current And Non-Current Liabilities [Line Items]
Employee termination benefits		8,229	8,930	8,651
Net amount shown in the balance sheet at end of period		1,836	1,943	1,770
Pensions and other post-employment benefits | Plan assets
Provisions And Other Current And Non-Current Liabilities [Line Items]
Net amount shown in the balance sheet at end of period		(6,397)	(6,993)	(6,899)			€ (9,651)
Difference between actual return and interest income on plan assets(c)	[2]	(416)	197	(2,398)
Pensions and other post-employment benefits | France
Provisions And Other Current And Non-Current Liabilities [Line Items]
Employee termination benefits		1,228	1,322	1,324
Net amount shown in the balance sheet at end of period		561	647	627
Pensions and other post-employment benefits | Germany
Provisions And Other Current And Non-Current Liabilities [Line Items]
Employee termination benefits		2,651	2,911	2,730
Net amount shown in the balance sheet at end of period		412	510	413
Pensions and other post-employment benefits | US
Provisions And Other Current And Non-Current Liabilities [Line Items]
Employee termination benefits		1,427	1,528	1,546
Net amount shown in the balance sheet at end of period		683	703	686
Pensions and other post-employment benefits | UK
Provisions And Other Current And Non-Current Liabilities [Line Items]
Employee termination benefits		1,994	2,174	2,080
Net amount shown in the balance sheet at end of period		103	€ (61)	€ (95)
Pensions and other post-employment benefits | UK | Plan assets
Provisions And Other Current And Non-Current Liabilities [Line Items]
Difference between actual return and interest income on plan assets(c)		€ (204)
[1] (a) Includes derivative financial instruments: € 121 million as of December 31, 2024 , €164 million as of December 31, 2023 , €232 million as of December 31, 2022 . The figure as of December 31, 2024 includes € 2,007 million for the liability in respect of royalties payable to Sobi on net sales of Beyfortus (nirsevimab) in the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is € 1,140 million; the nominal value of payments estimated to be due after more than five years is € 2,792 million. (c) In 2024, this line includes the effects of the partial buy-in in the United Kingdom for €(204) million .

Provisions, income tax liabil_6

Provisions, income tax liabilities and other liabilities - Summary of Financial and Demographic Assumptions (Details)		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of defined benefit plans [line items]
Weighted average duration of defined benefit obligation		10 years
Minimum Plan 1
Disclosure of defined benefit plans [line items]
Weighted average duration of defined benefit obligation		0 years
Maximum Plan 1
Disclosure of defined benefit plans [line items]
Weighted average duration of defined benefit obligation		7 years
Minimum plan 2
Disclosure of defined benefit plans [line items]
Weighted average duration of defined benefit obligation		7 years
Maximum plan 2
Disclosure of defined benefit plans [line items]
Weighted average duration of defined benefit obligation		10 years
France
Disclosure of defined benefit plans [line items]
General inflation rate	[1]	2.10%	2.20%	2.50%
Pension benefit indexation		2.10%	2.20%
Weighted average duration of defined benefit obligation		11 years	10 years	10 years
France | Bottom of range
Disclosure of defined benefit plans [line items]
Discount rate	[2],[3]	2.95%	2.95%	3.55%
Pension benefit indexation				2.50%
Retirement age		62 years	62 years	62 years
France | Top of range
Disclosure of defined benefit plans [line items]
Discount rate	[2],[3]	3.40%	3.15%	3.75%
Retirement age		67 years	67 years	67 years
Germany
Disclosure of defined benefit plans [line items]
General inflation rate	[1]	2.10%	2.20%	2.50%
Pension benefit indexation		2.10%	2.20%	2.50%
Retirement age		63 years	63 years	63 years
Weighted average duration of defined benefit obligation		12 years	12 years	12 years
Germany | Bottom of range
Disclosure of defined benefit plans [line items]
Discount rate	[2],[3]	2.95%	2.95%	3.55%
Germany | Top of range
Disclosure of defined benefit plans [line items]
Discount rate	[2],[3]	3.40%	3.15%	3.75%
US
Disclosure of defined benefit plans [line items]
Discount rate	[2],[3]	5.45%	4.75%	4.90%
Weighted average duration of defined benefit obligation		10 years	11 years	11 years
US | Bottom of range
Disclosure of defined benefit plans [line items]
Healthcare cost inflation rate	[4]	4%	4%	3.29%
Retirement age		55 years	55 years	55 years
US | Top of range
Disclosure of defined benefit plans [line items]
Healthcare cost inflation rate	[4]	5.93%	9.75%	6.56%
Retirement age		70 years	70 years	70 years
UK
Disclosure of defined benefit plans [line items]
Discount rate	[2],[3]	5.50%	4.50%	4.75%
General inflation rate	[1]	3.20%	3.05%	3.25%
Pension benefit indexation		3%	2.90%	3%
Weighted average duration of defined benefit obligation		11 years	13 years	13 years
UK | Bottom of range
Disclosure of defined benefit plans [line items]
Retirement age		60 years	60 years	60 years
UK | Top of range
Disclosure of defined benefit plans [line items]
Retirement age		65 years	65 years	65 years
[1] (c) Inflation for the euro zone is determined using a multi-criterion method. (a) The discount rates used were based on market rates for high quality corporate bonds with a duration close to that of the expected benefit payments under the plans. The benchmarks used to determine discount rates were the same for all periods presented. (b) The rate depends on the duration of the plan ( 0 to 7 years, 7 to 10 years, or more than 10 years). (d) No post-employment healthcare benefits are provided in France since 2020, Germany and UK

Provisions, income tax liabil_7

Provisions, income tax liabilities and other liabilities - Summary of Weighted Average Duration of Obligation for Pensions and Other Long-term Benefits in Principal Countries (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of defined benefit plans [line items]
Weighted average duration in main countries	10 years
France
Disclosure of defined benefit plans [line items]
Weighted average duration in main countries	11 years	10 years	10 years
Germany
Disclosure of defined benefit plans [line items]
Weighted average duration in main countries	12 years	12 years	12 years
US
Disclosure of defined benefit plans [line items]
Weighted average duration in main countries	10 years	11 years	11 years
UK
Disclosure of defined benefit plans [line items]
Weighted average duration in main countries	11 years	13 years	13 years

Provisions, income tax liabil_8

Provisions, income tax liabilities and other liabilities - Summary of Sensitivity for Pensions and Other Post-Employment Benefits to Changes in Key Actuarial Assumptions (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2024
Discount rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Possible decrease in actuarial assumption		(0.50%)
General inflation rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Possible increase in actuarial assumption		0.50%
Pension benefit indexation
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Possible increase in actuarial assumption		0.50%
Healthcare cost inflation rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Possible increase in actuarial assumption		0.50%
Mortality table
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Possible increase in mortality table (in years)	1 year
France | Discount rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		€ 90
France | General inflation rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		56
France | Pension benefit indexation
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		57
France | Healthcare cost inflation rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		0
France | Mortality table
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		56
Germany | Discount rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		190
Germany | General inflation rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		267
Germany | Pension benefit indexation
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		264
Germany | Healthcare cost inflation rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		0
Germany | Mortality table
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		86
US | Discount rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		103
US | General inflation rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		0
US | Pension benefit indexation
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		0
US | Healthcare cost inflation rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		41
US | Mortality table
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		59
UK | Discount rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		161
UK | General inflation rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		95
UK | Pension benefit indexation
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		93
UK | Healthcare cost inflation rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		43
UK | Mortality table
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Measurement of defined-benefit obligation		€ 118

Provisions, income tax liabil_9

Provisions, income tax liabilities and other liabilities - Reconciliation of Net Amount Recognized in Respect of Pension and Other Post-employment Benefit Plans (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of net defined benefit liability (asset) [line items]
Actuarial losses/(gains) due to changes in financial assumptions		€ 11	€ (168)	€ 622
Pre-funded pension obligations		156	271	269
Obligations provided for		5,762	5,262	5,822	€ 6,430
UK
Disclosure of net defined benefit liability (asset) [line items]
Actuarial losses/(gains) due to changes in demographic assumptions		(50)	(11)	(54)
Actuarial losses/(gains) due to changes in financial assumptions		(210)	43	(1,143)
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)		(212)	(44)	(131)
Plan assets | UK
Disclosure of net defined benefit liability (asset) [line items]
End of period		(204)
Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [line items]
Beginning of period		1,943	1,770
Current service cost	[1]	138	140	193
Interest (income)/cost	[1]	64	71	43
Plan amendments, curtailments or settlements not specified in the terms of the plan	[1]	(110)	(22)	(68)
Administration costs and taxes paid during the period	[1]	(13)	(7)	(6)
Contributions from plan members	[1]	5	6	6
Net obligation		1,832	1,937	1,752
Pre-funded pension obligations	[2]	156	271	269
Expense recognized directly in profit or loss	[1]	100	190	168
End of period		1,836	1,943	1,770
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)	[1],[3]	(13)	171	(650)
Expense/(gain) for the period	[1]	87	361	(482)
Pensions and other post-employment benefits | UK
Disclosure of net defined benefit liability (asset) [line items]
Beginning of period		(61)	(95)
Current service cost		0	0	0
Contributions from plan members		0	0	0
Pre-funded pension obligations			66	99
Expense recognized directly in profit or loss		(1)	(5)	(13)
End of period		103	(61)	(95)
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)		212	44	130
Pensions and other post-employment benefits | Present value of defined benefit obligation
Disclosure of net defined benefit liability (asset) [line items]
Beginning of period		8,930	8,651	12,175
Current service cost		138	140	193
Interest (income)/cost		335	346	206
Actuarial losses/(gains) due to changes in demographic assumptions		(45)	(34)	(219)
Actuarial losses/(gains) due to changes in financial assumptions		(380)	157	(3,006)
Actuarial losses/(gains) due to experience adjustments		(4)	256	177
Plan amendments, curtailments or settlements not specified in the terms of the plan	[3]	(181)	(36)	(229)
Plan settlements specified in the terms of the plan		(59)	(40)	(84)
Benefits paid		(502)	(483)	(463)
Changes in scope of consolidation and transfers		4	(14)	(114)
Currency translation differences		181	(13)	15
Increase (decrease) in net defined benefit liability (asset) resulting from reclassification, net defined benefit liability (asset)		(188)	0	0
End of period		8,229	8,930	8,651
Pensions and other post-employment benefits | Plan assets
Disclosure of net defined benefit liability (asset) [line items]
Beginning of period		(6,993)	(6,899)	(9,651)
Interest (income)/cost		(271)	(276)	(163)
Plan amendments, curtailments or settlements not specified in the terms of the plan		71	17	161
Plan settlements specified in the terms of the plan		58	40	84
Changes in scope of consolidation and transfers		20	8	32
Currency translation differences		(132)	(11)	52
Increase (decrease) in net defined benefit liability (asset) resulting from reclassification, net defined benefit liability (asset)		97	0	0
Difference between actual return and interest income on plan assets(c)	[4]	(416)	197	(2,398)
Administration costs and taxes paid during the period		(13)	(7)	(6)
Contributions from plan members		5	6	6
Employer’s contributions		127	122	238
Benefits paid		(456)	(446)	(426)
End of period		(6,397)	(6,993)	(6,899)
Pensions and other post-employment benefits | Plan assets | UK
Disclosure of net defined benefit liability (asset) [line items]
Difference between actual return and interest income on plan assets(c)		(204)
Pensions and other post-employment benefits | Effect of asset ceiling
Disclosure of net defined benefit liability (asset) [line items]
Beginning of period		6	18
End of period		4	6	18
Provisions for pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [line items]
Obligations provided for		1,992	2,214	2,039	€ 2,947
Provisions for pensions and other post-employment benefits | Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [line items]
Obligations provided for		€ 1,992	€ 2,214	€ 2,039
[1] (d) Benefit cost for the total Group including Opella on all the periods (a) For 2023, this line includes €66 million of assets in the United Kingdom (versus €99 million for 2022); those amounts are not subject to any asset ceiling, in accordance with IFRIC 14. (b) Amounts recognized in Other comprehensive income (see Note D.15.7.). (c) In 2024, this line includes the effects of the partial buy-in in the United Kingdom for €(204) million .

Provisions, income tax liabi_10

Provisions, income tax liabilities and other liabilities - Net Liability in Respect of Pension Plans and Other Post-employment Benefits by Geographical Region (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of net defined benefit liability (asset) [line items]
Measurement of obligation	€ 1,318	€ 968	€ 1,039
Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [line items]
Measurement of obligation	8,229	8,930	8,651
Fair value of plan assets	6,397	6,993	6,899
Effect of asset ceiling	(4)	(6)	(18)
Net amount shown in the balance sheet at end of period	1,836	1,943	1,770
France
Disclosure of net defined benefit liability (asset) [line items]
Measurement of obligation	862	611	804
France | Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [line items]
Measurement of obligation	1,228	1,322	1,324
Fair value of plan assets	667	675	697
Effect of asset ceiling	0	0	0
Net amount shown in the balance sheet at end of period	561	647	627
Germany | Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [line items]
Measurement of obligation	2,651	2,911	2,730
Fair value of plan assets	2,239	2,401	2,317
Effect of asset ceiling	0	0	0
Net amount shown in the balance sheet at end of period	412	510	413
US | Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [line items]
Measurement of obligation	1,427	1,528	1,546
Fair value of plan assets	744	825	860
Effect of asset ceiling	0	0	0
Net amount shown in the balance sheet at end of period	683	703	686
UK | Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [line items]
Measurement of obligation	1,994	2,174	2,080
Fair value of plan assets	1,891	2,235	2,175
Effect of asset ceiling	0	0	0
Net amount shown in the balance sheet at end of period	103	(61)	(95)
Other
Disclosure of net defined benefit liability (asset) [line items]
Measurement of obligation	456	357	235
Other | Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [line items]
Measurement of obligation	929	995	971
Fair value of plan assets	856	857	850
Effect of asset ceiling	(4)	(6)	(18)
Net amount shown in the balance sheet at end of period	€ 77	€ 144	€ 139

Provisions, income tax liabi_11

Provisions, income tax liabilities and other liabilities - Fair Value of Plans Assets relating to Pension Plans and Other Post-employment Plans (Details)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of fair value of plan assets [line items]
Securities quoted in an active market	63.10%	84.90%	84.40%
Other securities	36.90%	15.10%	15.60%
Total	100%	100%	100%
Cash and cash equivalents
Disclosure of fair value of plan assets [line items]
Securities quoted in an active market	0.80%	0.80%	0.70%
Equity instruments
Disclosure of fair value of plan assets [line items]
Securities quoted in an active market	19.30%	22.30%	21.70%
Bonds and similar instruments
Disclosure of fair value of plan assets [line items]
Securities quoted in an active market	35.80%	54.30%	52.40%
Real estate
Disclosure of fair value of plan assets [line items]
Securities quoted in an active market	2.90%	3.40%	4%
Derivatives
Disclosure of fair value of plan assets [line items]
Securities quoted in an active market	(0.20%)	0%	0.10%
Commodities
Disclosure of fair value of plan assets [line items]
Securities quoted in an active market	1.10%	0.90%	0.90%
Other
Disclosure of fair value of plan assets [line items]
Securities quoted in an active market	3.40%	3.20%	4.60%
Hedge funds
Disclosure of fair value of plan assets [line items]
Other securities	0%	0%	0%
Insurance policies
Disclosure of fair value of plan assets [line items]
Other securities	36.90%	15.10%	15.60%

Provisions, income tax liabi_12

Provisions, income tax liabilities and other liabilities - Service Cost for Pension and Other post-employment Benefit Plans, by Geographical Region (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
France
Disclosure of defined benefit plans [line items]
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)		€ 29	€ (3)	€ 156
Germany
Disclosure of defined benefit plans [line items]
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)		135	(98)	205
US
Disclosure of defined benefit plans [line items]
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)		47	(25)	382
UK
Disclosure of defined benefit plans [line items]
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)		(212)	(44)	(131)
Pensions and other post-employment benefits
Disclosure of defined benefit plans [line items]
Current service cost	[1]	138	140	193
(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan		(110)	(22)	(68)
Net interest cost/(income) including administration costs and taxes paid during the period		77	78	49
Contributions from plan members	[1]	(5)	(6)	(6)
Expense/(gain) recognized directly in profit or loss	[1]	100	190	168
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)	[1],[2]	(13)	171	(650)
Expense/(gain) for the period		87	361	(482)
Pensions and other post-employment benefits | France
Disclosure of defined benefit plans [line items]
Current service cost		48	50	61
(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan		(82)	(20)	(60)
Net interest cost/(income) including administration costs and taxes paid during the period		13	22	10
Contributions from plan members		0	0	0
Expense/(gain) recognized directly in profit or loss		(21)	52	11
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)		(31)	3	(156)
Expense/(gain) for the period		(52)	55	(145)
Pensions and other post-employment benefits | Germany
Disclosure of defined benefit plans [line items]
Current service cost		30	30	44
(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan		0	0	2
Net interest cost/(income) including administration costs and taxes paid during the period		20	15	7
Contributions from plan members		0	0	0
Expense/(gain) recognized directly in profit or loss		50	45	53
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)		(134)	98	(204)
Expense/(gain) for the period		(84)	143	(151)
Pensions and other post-employment benefits | US
Disclosure of defined benefit plans [line items]
Current service cost		22	20	50
(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan		(20)	1	1
Net interest cost/(income) including administration costs and taxes paid during the period		36	35	30
Contributions from plan members		0	0	0
Expense/(gain) recognized directly in profit or loss		38	56	81
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)		(46)	26	(382)
Expense/(gain) for the period		(8)	82	(301)
Pensions and other post-employment benefits | UK
Disclosure of defined benefit plans [line items]
Current service cost		0	0	0
(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan		0	0	(6)
Net interest cost/(income) including administration costs and taxes paid during the period		(1)	(5)	(7)
Contributions from plan members		0	0	0
Expense/(gain) recognized directly in profit or loss		(1)	(5)	(13)
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)		212	44	130
Expense/(gain) for the period		211	39	117
Pensions and other post-employment benefits | Other
Disclosure of defined benefit plans [line items]
Current service cost		38	40	38
(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan		(8)	(3)	(5)
Net interest cost/(income) including administration costs and taxes paid during the period		9	11	9
Contributions from plan members		(5)	(6)	(6)
Expense/(gain) recognized directly in profit or loss		34	42	36
Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)		(14)	0	(38)
Expense/(gain) for the period		€ 20	€ 42	€ (2)
[1] (d) Benefit cost for the total Group including Opella on all the periods (b) Amounts recognized in Other comprehensive income (see Note D.15.7.).

Provisions, income tax liabi_13

Provisions, income tax liabilities and other liabilities - Remeasurement of Net Defined-benefit (Asset)/Liability (Actuarial Gains and Losses) (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of defined benefit plans [line items]
Gains/(losses) on financial assumptions		€ (11)	€ 168	€ (622)
France
Disclosure of defined benefit plans [line items]
Actuarial gains/(losses) arising during the period		29	(3)	156
Gains/(losses) on experience adjustments	[1]	18	16	(120)
Gains/(losses) on demographic assumptions		0	0	0
Gains/(losses) on financial assumptions		11	(19)	276
Germany
Disclosure of defined benefit plans [line items]
Actuarial gains/(losses) arising during the period		135	(98)	205
Gains/(losses) on experience adjustments	[1]	46	(54)	(620)
Gains/(losses) on demographic assumptions		0	0	0
Gains/(losses) on financial assumptions		89	(44)	825
US
Disclosure of defined benefit plans [line items]
Actuarial gains/(losses) arising during the period		47	(25)	382
Gains/(losses) on experience adjustments	[1]	(42)	(7)	(287)
Gains/(losses) on demographic assumptions		11	18	129
Gains/(losses) on financial assumptions		78	(36)	540
UK
Disclosure of defined benefit plans [line items]
Actuarial gains/(losses) arising during the period		(212)	(44)	(131)
Gains/(losses) on experience adjustments	[1]	(472)	(12)	(1,328)
Gains/(losses) on demographic assumptions		50	11	54
Gains/(losses) on financial assumptions		€ 210	€ (43)	€ 1,143
[1] (a) Experience adjustments are mainly due to the effect on plan assets of trends in the financial markets

Provisions, income tax liabi_14

Provisions, income tax liabilities and other liabilities - Summary of Net Pre-tax Actuarial Loss (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Net pre-tax actuarial loss	€ (2,258)	€ (2,259)	€ (2,090)

Provisions, income tax liabi_15

Provisions, income tax liabilities and other liabilities - Summary of Present Value of Pension and Other Post Employment Benefits (Details) - Pensions and other post-employment benefits - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability (asset)	€ 1,836	€ 1,943	€ 1,770
Present value of defined benefit obligation
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability (asset)	8,229	8,930	8,651	€ 12,175
Wholly or partly funded defined benefit plans | Present value of defined benefit obligation
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability (asset)	7,192	7,693	7,463
Wholly unfunded defined benefit plans | Present value of defined benefit obligation
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability (asset)	€ 1,037	€ 1,237	€ 1,188

Provisions, income tax liabi_16

Provisions, income tax liabilities and other liabilities - Total Expense for Pensions and Other Post-employment Benefits Allocated between Income Statement (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Disclosure of defined benefit plans [line items]
Cost of sales	€ 13,205	€ 12,628	[1]	€ 11,882	[1]
Research and development expenses	7,394	6,507	[1]	6,501	[1]
Selling and general expenses	9,183	8,933	[1]	8,739	[1]
Other operating (income)/expenses, net	3,789	2,979		1,231
Financial expenses	1,073	1,293	[1],[2],[3]	430	[1],[2],[3],[4]
Net income excluding the exchanged/held-for-exchange Animal Health business	64	338	[1]	401	[1]
Pensions and other post-employment benefits
Disclosure of defined benefit plans [line items]
Cost of sales	32	33		53
Research and development expenses	17	28		51
Selling and general expenses	42	57		78
Other operating (income)/expenses, net	4	5		(2)
Restructuring costs	(64)	(9)		(59)
Financial expenses	60	67		42
Net income excluding the exchanged/held-for-exchange Animal Health business	9	9		5
Total	€ 100	€ 190		€ 168
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation ( a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax)

Provisions, income tax liabi_17

Provisions, income tax liabilities and other liabilities - Estimated Amounts of Employer's Contributions to Plan Assets (Details) - Year 1 € in Millions	12 Months Ended
	Dec. 31, 2024 EUR (€)
Disclosure of fair value of plan assets [line items]
Estimate of contributions expected to be paid to plan for next annual reporting period	€ 77
France
Disclosure of fair value of plan assets [line items]
Estimate of contributions expected to be paid to plan for next annual reporting period	0
Germany
Disclosure of fair value of plan assets [line items]
Estimate of contributions expected to be paid to plan for next annual reporting period	0
US
Disclosure of fair value of plan assets [line items]
Estimate of contributions expected to be paid to plan for next annual reporting period	2
UK
Disclosure of fair value of plan assets [line items]
Estimate of contributions expected to be paid to plan for next annual reporting period	48
Other
Disclosure of fair value of plan assets [line items]
Estimate of contributions expected to be paid to plan for next annual reporting period	€ 27

Provisions, income tax liabi_18

Provisions, income tax liabilities and other liabilities - Expected Timing of Benefit Payments under Pension and Other Post-employment Benefit Plans (Details) € in Millions	Dec. 31, 2024 EUR (€)
Year 1
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	€ 565
Year 2
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	538
Year 3
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	553
Year 4
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	566
Year 5
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	584
2030 to 2034
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	2,959
France | Year 1
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	94
France | Year 2
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	59
France | Year 3
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	71
France | Year 4
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	75
France | Year 5
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	81
France | 2030 to 2034
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	497
Germany | Year 1
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	210
Germany | Year 2
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	210
Germany | Year 3
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	208
Germany | Year 4
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	207
Germany | Year 5
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	209
Germany | 2030 to 2034
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	893
US | Year 1
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	97
US | Year 2
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	98
US | Year 3
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	100
US | Year 4
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	103
US | Year 5
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	107
US | 2030 to 2034
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	543
UK | Year 1
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	126
UK | Year 2
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	130
UK | Year 3
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	134
UK | Year 4
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	139
UK | Year 5
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	143
UK | 2030 to 2034
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	785
Other | Year 1
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	38
Other | Year 2
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	41
Other | Year 3
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	40
Other | Year 4
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	42
Other | Year 5
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	44
Other | 2030 to 2034
Disclosure of defined benefit plans [line items]
Estimated future benefit payments under pension and other post-employment benefit plans	€ 241

Provisions, income tax liabi_19

Provisions, income tax liabilities and other liabilities - Timing of Future Payments in Respect of Unfunded Pension and Other Post-employment Benefit Plans (Details) € in Millions	12 Months Ended
	Dec. 31, 2024 EUR (€)
Disclosure of defined benefit plans [line items]
Estimated payments	€ 1,035
Less than 1 year
Disclosure of defined benefit plans [line items]
Estimated payments	67
From 1 to 3 years
Disclosure of defined benefit plans [line items]
Estimated payments	122
From 3 to 5 years
Disclosure of defined benefit plans [line items]
Estimated payments	131
More than 5 years
Disclosure of defined benefit plans [line items]
Estimated payments	€ 715

Provisions, income tax liabi_20

Provisions, income tax liabilities and other liabilities - Movements in Restructuring Provisions Classified in Non-current and Current Liabilities (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Restructuring Provisions [line items]
Balance, beginning of period		€ 7,602	€ 6,341
Of which:
Classified in current liabilities		653	578	€ 472
Provisions utilized		(446)	(408)	(528)
Transfers		(516)	(572)	(274)
Increase Decrease Through Reclassification of Business, Other Provisions	[1]	(154)
Currency translation differences		116	(65)	113
Balance, end of period		8,096	7,602	6,341
Restructuring Provision
Disclosure of Restructuring Provisions [line items]
Balance, beginning of period		1,132	1,233	1,118
Of which:
Classified in non-current liabilities		799	554	761	€ 524
Classified in current liabilities		653	578	472	€ 594
Change in provisions recognized in profit or loss for the period		999	435	636
Provisions utilized	[2]	(582)	(561)	(522)
Transfers		(33)	3	0
Increase Decrease Through Reclassification of Business, Other Provisions	[3]	(84)	0	0
Unwinding of discount		19	31	5
Currency translation differences		1	(9)	(4)
Balance, end of period		€ 1,452	€ 1,132	€ 1,233
[1] (b) The liabilities of Opella, which in 2022 and 2023 were presented in the relevant balance sheet line item for each class of liability, were reclassified in 2024 to Liabilities related to assets held for sale in accordance with IFRS 5 (see Note D.1.) (a) Provisions utilized mainly correspond to payments related to employees affected by separation programs. (b) This line comprises the restructuring provisions of Opella, reclassified to Liabilities related to assets held for sale as of December 31, 2024 (see Note D.1.).

Provisions, income tax liabi_21

Provisions, income tax liabilities and other liabilities - Timing of Future Termination Benefit Payments (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of defined benefit plans [line items]
Employee termination benefits	€ 1,318	€ 968	€ 1,039
Less than 1 year
Disclosure of defined benefit plans [line items]
Employee termination benefits	616	517	374
From 1 to 3 years
Disclosure of defined benefit plans [line items]
Employee termination benefits	560	362	448
From 3 to 5 years
Disclosure of defined benefit plans [line items]
Employee termination benefits	133	86	215
More than 5 years
Disclosure of defined benefit plans [line items]
Employee termination benefits	9	3	2
France
Disclosure of defined benefit plans [line items]
Employee termination benefits	862	611	804
France | Less than 1 year
Disclosure of defined benefit plans [line items]
Employee termination benefits	312	215	185
France | From 1 to 3 years
Disclosure of defined benefit plans [line items]
Employee termination benefits	416	315	412
France | From 3 to 5 years
Disclosure of defined benefit plans [line items]
Employee termination benefits	126	79	207
France | More than 5 years
Disclosure of defined benefit plans [line items]
Employee termination benefits	8	2	0
Other
Disclosure of defined benefit plans [line items]
Employee termination benefits	456	357	235
Other | Less than 1 year
Disclosure of defined benefit plans [line items]
Employee termination benefits	304	302	189
Other | From 1 to 3 years
Disclosure of defined benefit plans [line items]
Employee termination benefits	144	47	36
Other | From 3 to 5 years
Disclosure of defined benefit plans [line items]
Employee termination benefits	7	7	8
Other | More than 5 years
Disclosure of defined benefit plans [line items]
Employee termination benefits	€ 1	€ 1	€ 2

Provisions, income tax liabi_22

Provisions, income tax liabilities and other liabilities - Summary of Other Provisions (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of other provisions [abstract]
Environmental risks	€ 474	€ 493	€ 526
Product liability risks, litigation and other	1,676	1,283	1,652
Total	€ 2,150	€ 1,776	€ 2,178

Provisions, income tax liabi_23

Provisions, income tax liabilities and other liabilities - Current Provisions and Other Current Liabilities (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2020	Dec. 31, 2021
Provisions And Other Current And Non-Current Liabilities [Line Items]
Taxes payable, other than corporate income taxes		€ 437	€ 395		€ 420
Employee-related liabilities		1,929	2,106		2,158
Restructuring provisions (see Note D.19.2.)		653	578		472
Interest rate derivatives (see Note D.20.)		7	1		0
Currency derivatives (see Note D.20.)		330	126		94
Equity derivatives (see Note D.20.)		0	0		0
Amounts payable for acquisitions of non-current assets		878	945		714
Customer contract liabilities	[1]	0	0		269
Other current liabilities	[2],[3]	10,007	9,590		7,894
Total		14,241	13,741		12,021
Other revenues		3,205	3,801	[4],[5]	2,910	[4],[5]
Contract liabilities			€ 269
US legal restructuring
Provisions And Other Current And Non-Current Liabilities [Line Items]
Percentage of capital losses used							33.33%
Collaboration agreement with GSK
Provisions And Other Current And Non-Current Liabilities [Line Items]
Customer contract liabilities					€ 269			€ 319
Direct royalty agreement with SOBI on sales of BeyfortusTM in the United States
Provisions And Other Current And Non-Current Liabilities [Line Items]
Other current liabilities		290
Royalties, payable		€ 273
[1] (a) See Note A.5. , “Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK” . The year-on-year change in this item between 2023 and 2022 includes revenue of € 269 million recognized in profit or loss during 2023 (previously included in “ Customer contract liabilities ” as of December 31, 2022 ). (c) As of December 31, 2024 includes € 273 million (nominal value: € 290 million) for the current liability relating to royalties payable to Sobi on net sales of Beyfortus (nirsevimab) in the United States (see Note C.2.) (b) “Other current liabilities” mainly comprises provisions and liabilities for customer rebates and returns; provisions for discounts and rebates granted to healthcare authorities and governmental programs (see Note D.23.); and the liability payable at each reporting date under the Monoclonal Antibody Alliance with Regeneron. Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Derivative financial instrume_3

Derivative financial instruments and market risks - Summary of Fair Value of Derivative Instruments (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Credit Risk Exposure [Line Items]
Non-current assets	€ 0	€ 0	€ 0
Current assets	217
Total assets	217
Non-current liabilities	(121)	(164)	(232)
Current liabilities	(337)
Total liabilities	(458)
Financial instruments designated as hedging instruments, at fair value	(241)	(90)	(120)
Currency derivatives
Disclosure of Credit Risk Exposure [Line Items]
Non-current assets	0
Current assets	217
Total assets	217
Non-current liabilities	0
Current liabilities	(330)
Total liabilities	(330)
Financial instruments designated as hedging instruments, at fair value	(113)	75	112
operating
Disclosure of Credit Risk Exposure [Line Items]
Non-current assets	0
Current assets	81
Total assets	81
Non-current liabilities	0
Current liabilities	(111)
Total liabilities	(111)
Financial instruments designated as hedging instruments, at fair value	(30)	22	22
financial
Disclosure of Credit Risk Exposure [Line Items]
Non-current assets	0
Current assets	136
Total assets	136
Non-current liabilities	0
Current liabilities	(219)
Total liabilities	(219)
Financial instruments designated as hedging instruments, at fair value	(83)	53	90
Interest rate derivatives
Disclosure of Credit Risk Exposure [Line Items]
Non-current assets	0
Current assets	0
Total assets	0
Non-current liabilities	(121)
Current liabilities	(7)
Total liabilities	(128)
Financial instruments designated as hedging instruments, at fair value	(128)	(165)	(232)
Equity derivatives
Disclosure of Credit Risk Exposure [Line Items]
Non-current assets	0
Current assets	0
Total assets	0
Non-current liabilities	0
Current liabilities
Total liabilities	0
Financial instruments designated as hedging instruments, at fair value	€ 0	€ 0	€ 0

Derivative financial instrume_4

Derivative financial instruments and market risks - Summary of Operating Currency Hedging Instruments (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Notional amount
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	€ 12,317	€ 10,358	€ 8,862
Notional amount | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	7,521	6,112	5,403
Notional amount | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	3,974	2,981	2,732
Notional amount | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	703	788	576
Notional amount | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	368	419	180
Notional amount | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	241	339	240
Notional amount | Forward Currency Sales In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	216	192	179
Notional amount | Forward currency sales in Taiwan Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place			84
Notional amount | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	4,796	4,246	3,459
Notional amount | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	2,660	2,022	2,047
Notional amount | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	484	876	375
Notional amount | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	451	364	142
Notional amount | Forward Currency Purchased In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	203	137	130
Notional amount | Forward currency purchases In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	126	123
Notional amount | Cash flow hedges
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Notional amount | Cash flow hedges | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Notional amount | Cash flow hedges | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Notional amount | Cash flow hedges | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Notional amount | Cash flow hedges | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Notional amount | Cash flow hedges | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Notional amount | Cash flow hedges | Forward Currency Sales In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Notional amount | Cash flow hedges | Forward currency sales in Taiwan Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place			0
Notional amount | Cash flow hedges | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Notional amount | Cash flow hedges | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Notional amount | Cash flow hedges | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Notional amount | Cash flow hedges | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Notional amount | Cash flow hedges | Forward Currency Purchased In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Notional amount | Cash flow hedges | Forward currency purchases In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0
Notional amount | Not eligible for hedge accounting
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	12,317	10,358	8,862
Notional amount | Not eligible for hedge accounting | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	7,521	6,112	5,403
Notional amount | Not eligible for hedge accounting | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	3,974	2,981	2,732
Notional amount | Not eligible for hedge accounting | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	703	788	576
Notional amount | Not eligible for hedge accounting | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	368	419	180
Notional amount | Not eligible for hedge accounting | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	241	339	240
Notional amount | Not eligible for hedge accounting | Forward Currency Sales In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	216	192	179
Notional amount | Not eligible for hedge accounting | Forward currency sales in Taiwan Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place			84
Notional amount | Not eligible for hedge accounting | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	4,796	4,246	3,459
Notional amount | Not eligible for hedge accounting | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	2,660	2,022	2,047
Notional amount | Not eligible for hedge accounting | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	484	876	375
Notional amount | Not eligible for hedge accounting | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	451	364	142
Notional amount | Not eligible for hedge accounting | Forward Currency Purchased In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	203	137	130
Notional amount | Not eligible for hedge accounting | Forward currency purchases In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	126	123
Fair value
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(30)	22	22
Fair value | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(67)	30	49
Fair value | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(59)	35	56
Fair value | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(5)	7	2
Fair value | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(1)	(1)	1
Fair value | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	2	(6)	(5)
Fair value | Forward Currency Sales In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(23)	(4)	(14)
Fair value | Forward currency sales in Taiwan Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place			0
Fair value | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	37	(8)	(27)
Fair value | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	24	(12)	(21)
Fair value | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	3	0	(7)
Fair value | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	2	(1)	0
Fair value | Forward Currency Purchased In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	19	2	4
Fair value | Forward currency purchases In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	1
Fair value | Cash flow hedges
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Fair value | Cash flow hedges | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Fair value | Cash flow hedges | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Fair value | Cash flow hedges | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Fair value | Cash flow hedges | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Fair value | Cash flow hedges | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Fair value | Cash flow hedges | Forward Currency Sales In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Fair value | Cash flow hedges | Forward currency sales in Taiwan Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place			0
Fair value | Cash flow hedges | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Fair value | Cash flow hedges | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Fair value | Cash flow hedges | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Fair value | Cash flow hedges | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Fair value | Cash flow hedges | Forward Currency Purchased In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Fair value | Cash flow hedges | Forward currency purchases In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0
Fair value | Not eligible for hedge accounting
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(30)	22	22
Fair value | Not eligible for hedge accounting | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(67)	30	49
Fair value | Not eligible for hedge accounting | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(59)	35	56
Fair value | Not eligible for hedge accounting | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(5)	7	2
Fair value | Not eligible for hedge accounting | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(1)	(1)	1
Fair value | Not eligible for hedge accounting | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	2	(6)	(5)
Fair value | Not eligible for hedge accounting | Forward Currency Sales In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(23)	(4)	(14)
Fair value | Not eligible for hedge accounting | Forward currency sales in Taiwan Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place			0
Fair value | Not eligible for hedge accounting | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	37	(8)	(27)
Fair value | Not eligible for hedge accounting | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	24	(12)	(21)
Fair value | Not eligible for hedge accounting | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	3	0	(7)
Fair value | Not eligible for hedge accounting | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	2	(1)	0
Fair value | Not eligible for hedge accounting | Forward Currency Purchased In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	19	2	4
Fair value | Not eligible for hedge accounting | Forward currency purchases In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	1
Of which recognized in equity | Cash flow hedges
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Of which recognized in equity | Cash flow hedges | Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Of which recognized in equity | Cash flow hedges | Forward currency sales in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Of which recognized in equity | Cash flow hedges | Forward currency sales in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Of which recognized in equity | Cash flow hedges | Forward currency sales in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Of which recognized in equity | Cash flow hedges | Forward currency sales in Japanese Yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Of which recognized in equity | Cash flow hedges | Forward Currency Sales In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Of which recognized in equity | Cash flow hedges | Forward currency sales in Taiwan Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place			0
Of which recognized in equity | Cash flow hedges | Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Of which recognized in equity | Cash flow hedges | Forward currency purchases in US Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Of which recognized in equity | Cash flow hedges | Forward currency purchases in Singapore Dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Of which recognized in equity | Cash flow hedges | Forward currency purchases in Chinese Yuan Renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	0
Of which recognized in equity | Cash flow hedges | Forward Currency Purchased In Korean Won
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0	0	€ 0
Of which recognized in equity | Cash flow hedges | Forward currency purchases In Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	€ 0	€ 0

Derivative financial instrume_5

Derivative financial instruments and market risks - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024 EUR (€)		Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2024 USD ($)
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Derivative financial assets	€ 217
Derivative financial liabilities	458
Change in fair value of cash flow hedges	(6)		€ (1)	€ 7
Forward currency sales in US Dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Notional amount of forward sales | $					$ 3,615
Derivative financial assets	88
Forward currency purchases in US dollar, US bond
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Notional amount of forward sales | $					$ 1,000
Derivative financial liabilities	75
Change in fair value of cash flow hedges	0.2
Notional amount
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	17,261		17,334	12,556
Notional amount | Forward currency sales
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	10,377		10,279	7,559
Notional amount | Forward currency purchases
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	6,884		7,055	4,997
Notional amount | Less than 1 year | Forward currency sales in US Dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	8,923	[1]	6,628	6,114
Notional amount | Less than 1 year | Forward currency sales in Singapore Dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	371		157	111
Notional amount | Less than 1 year | Forward Currency Sales In Chinese Yuan
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	235		513	203
Notional amount | Less than 1 year | Forward currency purchases in US Dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	4,397	[2]	3,073	2,011
Notional amount | Less than 1 year | Forward currency purchases in Singapore Dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	819		2,696	2,154
Notional amount | Less than 1 year | Forward currency purchases In Japanese yen
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	641		99	59
Fair value
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(83)		53	90
Fair value | Forward currency sales
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(195)		111	66
Fair value | Forward currency purchases
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	112		(58)	24
Fair value | Less than 1 year | Forward currency sales in US Dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(176)		101	59
Fair value | Less than 1 year | Forward currency sales in Singapore Dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	4		(1)	0
Fair value | Less than 1 year | Forward Currency Sales In Chinese Yuan
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	(1)		4	2
Fair value | Less than 1 year | Forward currency purchases in US Dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	123		(52)	(4)
Fair value | Less than 1 year | Forward currency purchases in Singapore Dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	2		(10)	22
Fair value | Less than 1 year | Forward currency purchases In Japanese yen
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	€ (9)		€ 1	€ 1
[1] (a) Includes forward sales with a notional amount of $3,615 million expiring in 2025 , designated as a hedge of Sanofi’s net investment in Bioverativ. As of December 31, 2024 , the fair value of these forward contracts represented a liability of €88 million ; the opposite entry was recognized in "Other comprehensive income", with the impact on financial income and expense being immaterial. (b) Includes forward purchases with a notional amount of $ 1,000 million expiring in 2025 , designated as a fair value hedge of the exposure of $ 1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of December 31, 2024 , the fair value of the contracts was an asset of € 75 million , the opposite entry for €0.2 million of which was debited to “Other comprehensive income” under the cost of hedging accounting treatment.

Derivative financial instrume_6

Derivative financial instruments and market risks - Disclosure of Instruments (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 2,466	€ 3,405	€ 2,434
Nominal value of interest rate swaps hedge fixed-rate bonds	12,317	10,358	8,862
Notional amount | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	2,466	3,405	2,434
Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0	0
Nominal value of interest rate swaps hedge fixed-rate bonds	0	0	0
Notional amount | Less than 1 year
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	850	999	0
Notional amount | 1 to 2 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	850	0
Notional amount | 2 to 3 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Notional amount | 2 to 3 years | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			850
Notional amount | 3 to 4 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	966	0	0
Notional amount | 4 to 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	650	906	0
Notional amount | More than 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	650
Notional amount | More than 5 years | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			1,584
Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(128)	(165)	(232)
Nominal value of interest rate swaps hedge fixed-rate bonds	(30)	22	22
Fair value | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(128)	(165)	(232)
Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0	0
Nominal value of interest rate swaps hedge fixed-rate bonds	0	0	0
Of which recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0	0
Nominal value of interest rate swaps hedge fixed-rate bonds	0	€ 0	€ 0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03%
Disclosure of detailed information about financial instruments [line items]
Interest rate		1.03%	1.03%
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	483	€ 453
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	483	453
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | Less than 1 year
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | 1 to 2 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | 2 to 3 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | 3 to 4 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	483	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | 4 to 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	453
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | More than 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(47)	(49)
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Fair value | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(47)	(49)
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Of which recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	€ 0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32%
Disclosure of detailed information about financial instruments [line items]
Interest rate		1.32%	1.32%
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	483	€ 453	€ 850
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	483	453	850
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | Less than 1 year
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | 1 to 2 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | 2 to 3 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0	850
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | 3 to 4 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	483	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | 4 to 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	453	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | More than 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(43)	(43)	(43)
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Fair value | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(43)	(43)	(43)
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Of which recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	€ 0	€ 0
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69%
Disclosure of detailed information about financial instruments [line items]
Interest rate		0.69%	0.69%
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	850	€ 850
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	850	850
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | Less than 1 year
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	850	0
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | 1 to 2 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	850
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | 2 to 3 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | 3 to 4 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | 4 to 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | More than 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(7)	(28)
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Fair value | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(7)	(28)
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Of which recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	€ 0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92%
Disclosure of detailed information about financial instruments [line items]
Interest rate		0.92%	0.92%
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	650	€ 650
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	650	650
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | Less than 1 year
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | 1 to 2 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | 2 to 3 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | 3 to 4 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | 4 to 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	650	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | More than 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		650
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(31)	(44)
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Fair value | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(31)	(44)
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0	0
Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Of which recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 0	0
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			€ 467
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			467
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | Less than 1 year
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | 1 to 2 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | 2 to 3 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | 3 to 4 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | 4 to 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | More than 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			467
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			(62)
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Fair value | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			(62)
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Of which recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			467
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			467
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | Less than 1 year
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | 1 to 2 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | 2 to 3 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | 3 to 4 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | 4 to 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | More than 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			467
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			(56)
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Fair value | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			(56)
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Of which recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives			0
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		999	650
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		999	650
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		0	0
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | Less than 1 year
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		999	0
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | 1 to 2 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		0	0
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | 2 to 3 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		0	0
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | 3 to 4 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		0	0
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | 4 to 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		0	0
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | More than 5 years
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		0	650
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		(1)	(71)
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Fair value | Derivatives designated as fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		(1)	(71)
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Fair value | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		0	0
Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Of which recognized in equity | Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives		€ 0	€ 0

Derivative financial instrume_7

Derivative financial instruments and market risks - Disclosure of Actual or Potential Effects of Netting Arrangements (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Derivative financial assets
Disclosure of Offsetting of Financial Assets and Liabilities [line items]
Gross carrying amounts before offset	€ 217	€ 201	€ 206
Gross amounts offset (in accordance with IAS 32)	0	0	0
Net amounts as reported in the balance sheet	217	201	206
Net exposure	16	30	46
Derivative financial assets | Effects of other netting arrangements not fulfilling the IAS 32 criteria for offsetting
Disclosure of Offsetting of Financial Assets and Liabilities [line items]
Fair value of financial collateral
Financial instruments	(201)	(171)	(160)
Derivative financial liabilities
Disclosure of Offsetting of Financial Assets and Liabilities [line items]
Gross carrying amounts before offset	(458)	(291)	(326)
Gross amounts offset (in accordance with IAS 32)	0	0	0
Net amounts as reported in the balance sheet	(458)	(291)	(326)
Net exposure	(257)	(120)	(166)
Derivative financial liabilities | Effects of other netting arrangements not fulfilling the IAS 32 criteria for offsetting
Disclosure of Offsetting of Financial Assets and Liabilities [line items]
Fair value of financial collateral
Financial instruments	€ 201	€ 171	€ 160

Off balance sheet commitments -

Off balance sheet commitments - Summary of Off Balance Sheet Commitments Relating to Operating Activities (Details) € in Millions, $ in Billions		12 Months Ended
		Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 EUR (€)		Dec. 31, 2023 EUR (€)
Disclosure Of Off Balance Sheet Commitments [Line Items]
Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced				€ 554	[1]	€ 221
Irrevocable purchase commitments given	[2]			3,683
Irrevocable purchase commitments received				(391)
Research and development license agreements - commitments related to R&D and other commitments				84	[3]	381
Research and development license agreements - contingent milestone payments in connection with development programs in progress				4,230	[4]	4,886
Total - net commitments given				8,160
Lease, term		12 years	15 years
Lease, cost | $		$ 0.2	$ 0.2
Lease, extension options, number			2
Lease, extension options, term			5 years
Minimum
Disclosure Of Off Balance Sheet Commitments [Line Items]
Lease, term			12 years
EUROAPI
Disclosure Of Off Balance Sheet Commitments [Line Items]
Irrevocable purchase commitments given				535
Less than 1 year
Disclosure Of Off Balance Sheet Commitments [Line Items]
Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced	[1]			28
Irrevocable purchase commitments given	[2]			1,152
Irrevocable purchase commitments received				(288)
Research and development license agreements - commitments related to R&D and other commitments	[3]			42
Research and development license agreements - contingent milestone payments in connection with development programs in progress	[4]			941
Total - net commitments given				1,875
From 1 to 3 years
Disclosure Of Off Balance Sheet Commitments [Line Items]
Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced	[1]			34
Irrevocable purchase commitments given	[2]			1,195
Irrevocable purchase commitments received				(96)
Research and development license agreements - commitments related to R&D and other commitments	[3]			29
Research and development license agreements - contingent milestone payments in connection with development programs in progress	[4]			635
Total - net commitments given				1,797
From 3 to 5 years
Disclosure Of Off Balance Sheet Commitments [Line Items]
Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced	[1]			41
Irrevocable purchase commitments given	[2]			442
Irrevocable purchase commitments received				(7)
Research and development license agreements - commitments related to R&D and other commitments	[3]			6
Research and development license agreements - contingent milestone payments in connection with development programs in progress	[4]			470
Total - net commitments given				952
More than 5 years
Disclosure Of Off Balance Sheet Commitments [Line Items]
Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced	[1]			451
Irrevocable purchase commitments given	[2]			894
Irrevocable purchase commitments received				0
Research and development license agreements - commitments related to R&D and other commitments	[3]			7
Research and development license agreements - contingent milestone payments in connection with development programs in progress	[4]			2,184
Total - net commitments given				3,536
Suppliers
Disclosure Of Off Balance Sheet Commitments [Line Items]
Irrevocable purchase commitments given						6,141
Irrevocable purchase commitments received						(550)
Suppliers | Opella Business
Disclosure Of Off Balance Sheet Commitments [Line Items]
Irrevocable purchase commitments given						€ 754
Joint ventures
Disclosure Of Off Balance Sheet Commitments [Line Items]
Irrevocable purchase commitments given				€ 749
[1] (a) Includes the variable portion of future lease payments not recognized as lease liabilities as of December 31, 2024 ; the equivalent amount of these commitments as of December 31, 2023 was € 221 million. During 2023 , Sanofi signed a 15-year lease which will take effect in 2025 and to which Sanofi is committed for a minimum period of 12 years , corresponding to a commitment of $ 0.2 billion. The lease includes two extension options of five years each. During 2024 , Sanofi signed a 12-year lease in France which will take effect in 2027, representing a commitment of € 0.2 billion. (c) Irrevocable purchase commitments given as of December 31, 2024 include € 749 million of commitments to joint ventures. This line also includes (i) the commitment to EUROAPI as described in Note D.1. and amounting to € 535 million as of December 31, 2024, and (ii) commitments related to long-term renewable energy purchase contracts lasting between 15 and 20 years giving rise to the physical supply of electricity mainly in France for an estimated total annual volume of 329 GWh. (d) Commitments related to research and development, and other commitments, amounted to € 381 million as of December 31, 2023 . (e) This line only includes contingent milestone payments on development projects in progress. The equivalent amount as of December 31, 2023 was € 4,886 million

Off balance sheet commitments_2

Off balance sheet commitments - Additional Information (Details) € in Millions, $ in Millions

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 12, 2024 EUR (€)

May 10, 2024 USD ($)

Mar. 15, 2022 EUR (€)

Feb. 27, 2017 EUR (€)

Mar. 31, 2022

Dec. 31, 2022 EUR (€)

Dec. 31, 2024 EUR (€)

Dec. 31, 2022 EUR (€)

Dec. 31, 2023 EUR (€)

Apr. 27, 2023 EUR (€)

Nov. 08, 2022 target

Aug. 17, 2022 target

Mar. 29, 2022 target

Jan. 07, 2022 molecule

Feb. 28, 2014

Provisions And Other Current And Non-Current Liabilities [Line Items]

Commitments related to research and development relating to projects in research phase

€ 14,400

€ 16,800

Commitments related to research and development payments contingent upon attainment of sales targets

15,200

17,900

Commitments related to collaboration, discovery, development and commercialization agreements

13,000

10,000

Commitments related to attainment of regulatory and sales milestones for commercialized products

11,200

8,500

Cumulative development costs incurred

9,700

Total credit facilities

€ 8,000

8,000

€ 8,000

8,000

Commitments received in respect of disposals proceeds receivable and contingent consideration on divestments

€ 500

World Health Organization

Provisions And Other Current And Non-Current Liabilities [Line Items]

Percentage of pandemic vaccines agreed to transfer

7.50%

Percentage of pandemic vaccines agreed to reserve

7.50%

Joint ventures

Provisions And Other Current And Non-Current Liabilities [Line Items]

Percentage of future development expense funded by other party

5,000%

Provention Bio, Inc | Maximum

Provisions And Other Current And Non-Current Liabilities [Line Items]

Commitments related to milestone payments for projects under collaboration agreements

€ 946

IGM Biosciences, Inc | Maximum

Provisions And Other Current And Non-Current Liabilities [Line Items]

Number of oncology targets under collaboration agreement | target

3

Number of immunology or inflammation targets under collaboration agreement | target

3

Atomwise | Maximum

Provisions And Other Current And Non-Current Liabilities [Line Items]

Number of drug targets under collaboration agreement | target

5

Insilico Medicine | Maximum

Provisions And Other Current And Non-Current Liabilities [Line Items]

Number of therapeutic targets under collaboration agreement | target

6

Lonza | Joint ventures

Provisions And Other Current And Non-Current Liabilities [Line Items]

Investments in joint ventures

€ 300

Percentage of future development expense funded by company

50%

Amounts payable partners in collaboration agreements

€ 600

Novavax

Provisions And Other Current And Non-Current Liabilities [Line Items]

Commitments related to research and development relating to projects in research phase | $

$ 700,000

Commitments related to attainment of regulatory and sales milestones for commercialized products | $

1,200

Upfront payment | $

500,000

Commitments Related To Attainment Of Additional Regulatory And Sales Milestones For Commercialized Products | $

$ 200,000

Financial interest in principal fully consolidated companies

500%

RadioMedix, Inc. and Orano Med

Provisions And Other Current And Non-Current Liabilities [Line Items]

Commitments related to attainment of regulatory and sales milestones for commercialized products

€ 220

Upfront payment

€ 100

Exscentia | Maximum

Provisions And Other Current And Non-Current Liabilities [Line Items]

Number of novel small molecule candidates developed | molecule

15

Corxel Pharmaceuticals

Provisions And Other Current And Non-Current Liabilities [Line Items]

Commitments Related To Attainment Of Additional Regulatory And Sales Milestones For Commercialized Products | $

$ 150

Antibodies Collaboration agreement | Blackstone Life Sciences

Provisions And Other Current And Non-Current Liabilities [Line Items]

Commitments related to maximum payments for projects under collaboration agreement

€ 300

Antibodies Collaboration agreement | Regeneron Pharmaceuticals, INC

Provisions And Other Current And Non-Current Liabilities [Line Items]

Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)

10%

20%

Percentage of cumulative development costs reimbursed

50%

50%

Commitments received for development costs

€ 1,600

2,100

Ablynx NV

Provisions And Other Current And Non-Current Liabilities [Line Items]

Commitments related to collaboration, discovery, development and commercialization agreements

700

900

Kymab

Provisions And Other Current And Non-Current Liabilities [Line Items]

Commitments related to collaboration, discovery, development and commercialization agreements

300

200

Provention Bio

Provisions And Other Current And Non-Current Liabilities [Line Items]

Commitments related to collaboration, discovery, development and commercialization agreements

€ 400

€ 300

Off balance sheet commitments_3

Off balance sheet commitments - Summary of Undrawn Credit Facilities (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Line of Credit Facility [Line Items]
General-purpose credit facilities	€ 8,000	€ 8,000	€ 8,000
Less than 1 year
Disclosure Of Line of Credit Facility [Line Items]
General-purpose credit facilities	0
From 1 to 3 years
Disclosure Of Line of Credit Facility [Line Items]
General-purpose credit facilities	4,000
From 3 to 5 years
Disclosure Of Line of Credit Facility [Line Items]
General-purpose credit facilities	0
More than 5 years
Disclosure Of Line of Credit Facility [Line Items]
General-purpose credit facilities	€ 4,000

Off balance sheet commitments_4

Off balance sheet commitments - Summary of Amount of Guarantees Given and Received (Details) - EUR (€) € in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Guarantees received
Disclosure of Guarantees [Line Items]
Estimated financial effect of contingent liabilities	€ 1,288	€ 1,272	€ 1,229
Guarantees given
Disclosure of Guarantees [Line Items]
Estimated financial effect of contingent liabilities	4,298	3,936	3,815
Guarantees provided to banks in connection with credit facilities
Disclosure of Guarantees [Line Items]
Estimated financial effect of contingent liabilities	1,130	1,067	1,007
Other guarantees given
Disclosure of Guarantees [Line Items]
Estimated financial effect of contingent liabilities	€ 3,168	€ 2,869	€ 2,808

Legal and arbitral proceedings

Legal and arbitral proceedings (Details) $ in Thousands, € in Millions, $ in Millions

1 Months Ended

12 Months Ended

60 Months Ended

72 Months Ended

Jun. 03, 2022

May 14, 2013 EUR (€)

Sep. 30, 2022 expert

Jul. 31, 2021 manufacturer

Feb. 28, 2021 USD ($)

Sep. 30, 2017 EUR (€)

Dec. 31, 2024 USD ($)

Dec. 31, 2023 EUR (€) lawsuit action

Dec. 31, 2021 trial

Jun. 30, 2021 proceeding

Dec. 31, 2023 EUR (€) action lawsuit

Dec. 31, 2023 EUR (€) lawsuit case action

Dec. 31, 2024 EUR (€) trial claim manufacturer complaint plaintiff family case lawsuit person children

Dec. 31, 2023 AUD ($) lawsuit action

Dec. 31, 2022 EUR (€) claimant case family

Dec. 06, 2022 plaintiff cancer

Nov. 30, 2022 person

Aug. 20, 2022 ruling

Mar. 31, 2022 patient

Dec. 31, 2014 complaint

Nov. 18, 2014 patent

Dec. 31, 1997 EUR (€)

Disclosure of Legal and Arbitral Proceedings [Line Items]

Provisions for product liability risks, litigation and other

€ 1,283

€ 1,283

€ 1,283

€ 1,676

€ 1,652

Environmental risks

€ 493

€ 493

€ 493

€ 474

€ 526

Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of first instance rulings

3

7

Action for which we are defendant | Product liabilities | Minimum

Disclosure of Legal and Arbitral Proceedings [Line Items]

Litigation amount payable

€ 0.1

Action for which we are defendant | Product liabilities | Maximum

Disclosure of Legal and Arbitral Proceedings [Line Items]

Litigation amount payable

€ 0.5

Sanofi Pasteur Hepatitis B Vaccine product litigation | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of civil individual actions | lawsuit

180

Number of ongoing lawsuits | lawsuit

4

4

4

4

Taxotere product litigation in the US | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of bellweather trial held | trial

2

Zantac litigation in the US | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of plaintiffs | plaintiff

24,922

Number of cancers associated with dismissed cases | cancer

5

Number of plaintiffs who filed notices to appeal | plaintiff

12,000

Number of complaints filed | complaint

1,623

Zantac litigation in Canada | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of class actions | action

7

Gold Bond Product litigation in the US | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of class actions | action

700

Number of ongoing trials | action

0

0

0

0

Depakine product litigation in France | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of civil individual actions | claim

79

Number of people exposed | person

133

Number of lawsuits ruled on merits | lawsuit

40

40

40

40

Number of families who filed a civil claim | family

76

Number of claimant | claimant

288

Number of claimant exposed | claimant

111

Number of experts | expert

2

Number of administrative proceedings | proceeding

5

Depakine product litigation in Switzerland | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of people exposed | person

17

Number of families who filed a civil claim | family

11

Number of action declared time-barred | person

1

Depakine product litigation in Spain | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of ongoing trials | trial

7

Number of people exposed | children

15

Number of patients to indemnify | patient

4

Depakine product litigation in Belgium | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of civil individual actions | complaint

2

Depakine product litigation in Ireland | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of pre-action protocol cases | case

2

Number of civil claims on-going | claim

2

Depakine product litigation in Great Britain | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of pre-action protocol cases | case

1

Depakine product litigation in Northern Ireland | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of civil claims on-going | claim

1

Dengvaxia product litigation in the Philippines | Action for which we are defendant | Product liabilities

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of cases | case

8

Ramipril Canada Patent Litigation | Action for which we are a plaintiff | Patents

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of manufacturers with marketing authorization for generic version of drug | manufacturer

8

Praluent (Alirocumab)-related amgen patent litigation in the US | Action for which we are defendant | Patents

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of patent actions initially filed | complaint

4

Number of patents allegedly infringed | patent

7

Plavix litigation (Commonwealth) in Australia | Action for which we are defendant | Minimum | Patents

Disclosure of Legal and Arbitral Proceedings [Line Items]

Reduced amount of compensation claimed

€ 137.8

€ 137.8

€ 137.8

$ 223.3

Reduced amount of compensation claimed, interest included

218

218

218

360.5

Plavix litigation (Commonwealth) in Australia | Action for which we are defendant | Maximum | Patents

Disclosure of Legal and Arbitral Proceedings [Line Items]

Reduced amount of compensation claimed

172.9

172.9

172.9

280.2

Reduced amount of compensation claimed, interest included

€ 294.3

€ 294.3

€ 294.3

$ 487.5

Plavix Attorney General Action in Hawaii | Action for which we are defendant

Disclosure of Legal and Arbitral Proceedings [Line Items]

Total penalty fee incurred by defendants | $

$ 834,000

Penalty fee incurred by Sanofi | $

$ 417,000

Payment of damages claimed by the French CNAM (French Social Security) | $

$ 916,000

Plavix Attorney General Action in Hawaii | Action For Which Sanofi Are Defendant

Disclosure of Legal and Arbitral Proceedings [Line Items]

Payment of damages claimed by the French CNAM (French Social Security) | $

$ 458,000

Plavix related litigation in France | Action for which we are defendant

Disclosure of Legal and Arbitral Proceedings [Line Items]

Penalty fee incurred by Sanofi

€ 40.6

Payment of damages claimed by the French CNAM (French Social Security)

€ 115.8

340B Drug Pricing Program in the United States | Action for which we are defendant

Disclosure of Legal and Arbitral Proceedings [Line Items]

Number of other manufacturers involved in proceedings | manufacturer

3

Aventis Crop Science retained liabilities | Contingencies arising from certain business divestitures

Disclosure of Legal and Arbitral Proceedings [Line Items]

Aggregate participation percentage of legacy companies in ACS

76%

Infraserv Hoechst retained liabilities | Contingencies arising from certain business divestitures

Disclosure of Legal and Arbitral Proceedings [Line Items]

Fund reserves transferred

€ 57

Maximum amount to be reimbursed for current and future environmental expense

€ 143

Provisions for discounts, reb_3

Provisions for discounts, rebates and sales returns - Summary of Movement in Provisions for Discounts, Rebates and Sales Returns (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2022
Disclosure of other provisions [line items]
Provisions for discounts, rebates and sales returns, beginning balance		€ 7,762	[1]	€ 6,490	[1]	€ 5,899
Changes in scope of consolidation	[2]					(3)
Provision related to current period sales		23,290		24,296		22,141
Net change in provision related to prior period sales		(282)		(155)		(315)
Payments made		(23,482)		(22,653)		(21,699)
Currency translation differences		303		(213)		464
Increase Decrease Through Reclassification of Business, Other Provisions	[3]	(264)
Provisions for discounts, rebates and sales returns, ending balance	[1]	7,328		7,762		6,490
Government and State Programs
Disclosure of other provisions [line items]
Provisions for discounts, rebates and sales returns, beginning balance	[2]	2,962	[1]	2,603	[1]	2,596
Changes in scope of consolidation	[2]					2
Provision related to current period sales	[2]	5,401		7,758		6,744
Net change in provision related to prior period sales	[2]	(177)		(74)		(120)
Payments made	[2]	(5,599)		(7,251)		(6,824)
Currency translation differences	[2]	143		(76)		207
Increase Decrease Through Reclassification of Business, Other Provisions	[2],[3]	(24)
Provisions for discounts, rebates and sales returns, ending balance	[1],[2]	2,706		2,962		2,603
Managed care and GPO Programs
Disclosure of other provisions [line items]
Provisions for discounts, rebates and sales returns, beginning balance	[4]	1,119	[1]	1,021	[1]	931
Changes in scope of consolidation	[2]					0
Provision related to current period sales	[4]	3,961		3,590		3,246
Net change in provision related to prior period sales	[4]	(5)		(12)		(47)
Payments made	[4]	(3,882)		(3,446)		(3,208)
Currency translation differences	[4]	77		(34)		99
Increase Decrease Through Reclassification of Business, Other Provisions	[3],[4]	0
Provisions for discounts, rebates and sales returns, ending balance	[1],[4]	1,270		1,119		1,021
Chargeback incentives
Disclosure of other provisions [line items]
Provisions for discounts, rebates and sales returns, beginning balance		637	[1]	362	[1]	303
Changes in scope of consolidation	[2]					(1)
Provision related to current period sales		3,093		3,861		4,147
Net change in provision related to prior period sales		(26)		(9)		(21)
Payments made		(3,336)		(3,564)		(4,093)
Currency translation differences		36		(12)		26
Increase Decrease Through Reclassification of Business, Other Provisions	[3]	(6)
Provisions for discounts, rebates and sales returns, ending balance	[1]	398		637		362
Rebates and discounts
Disclosure of other provisions [line items]
Provisions for discounts, rebates and sales returns, beginning balance		2,269	[1]	1,805	[1]	1,425
Changes in scope of consolidation	[2]					(6)
Provision related to current period sales		9,758		8,177		7,244
Net change in provision related to prior period sales		(34)		(58)		(138)
Payments made		(9,678)		(7,603)		(6,809)
Currency translation differences		8		(46)		83
Increase Decrease Through Reclassification of Business, Other Provisions	[3]	(201)
Provisions for discounts, rebates and sales returns, ending balance	[1]	2,122		2,269		1,805
Sales returns
Disclosure of other provisions [line items]
Provisions for discounts, rebates and sales returns, beginning balance		715	[1]	629	[1]	610
Changes in scope of consolidation	[2]					(2)
Provision related to current period sales		595		654		578
Net change in provision related to prior period sales		(54)		(25)		(8)
Payments made		(491)		(511)		(599)
Currency translation differences		41		(30)		48
Increase Decrease Through Reclassification of Business, Other Provisions	[3]	(30)
Provisions for discounts, rebates and sales returns, ending balance	[1]	776		715		629
Other deductions
Disclosure of other provisions [line items]
Provisions for discounts, rebates and sales returns, beginning balance		60	[1]	70	[1]	34
Changes in scope of consolidation	[2]					4
Provision related to current period sales		482		256		182
Net change in provision related to prior period sales		14		23		19
Payments made		(496)		(278)		(166)
Currency translation differences		(2)		(15)		1
Increase Decrease Through Reclassification of Business, Other Provisions	[3]	(3)
Provisions for discounts, rebates and sales returns, ending balance	[1]	56		60		70
US
Disclosure of other provisions [line items]
Provisions for discounts, rebates and sales returns, beginning balance		5,124		4,270
Provisions for discounts, rebates and sales returns, ending balance		4,823		5,124		4,270
US | Managed care
Disclosure of other provisions [line items]
Provisions for discounts, rebates and sales returns, beginning balance		1,028		934
Provisions for discounts, rebates and sales returns, ending balance		1,097		1,028		934
Medicaid | US | Government and State Programs
Disclosure of other provisions [line items]
Provisions for discounts, rebates and sales returns, beginning balance		1,421		1,307
Provisions for discounts, rebates and sales returns, ending balance		1,193		1,421		1,307
Medicare | US | Government and State Programs
Disclosure of other provisions [line items]
Provisions for discounts, rebates and sales returns, beginning balance		1,099		775
Provisions for discounts, rebates and sales returns, ending balance		€ 722		€ 1,099		€ 775
[1] (c) Provisions related to US net sales amounted to €4,823 million as of December 31, 2024 , €5,124 million as of December 31, 2023 and €4,270 million as of December 31, 2022 . (a) Primarily US government programs: Medicaid ( €1,193 million in 2024 , €1,421 million in 2023 , €1,307 million in 2022 ) and Medicare ( €722 million in 2024 , €1,099 million in 2023 and €775 million in 2022 ). (d) This line comprises provisions for discounts, rebates and sales returns related to Opella, reclassified as of December 31 ,2024 within Liabilities for assets held for sale in accordance with I FRS 5 (see Note D.1.) (b) Mainly rebates and other price reductions granted to healthcare authorities in the United States (including Managed Care: €1,097 million in 2024 , €1,028 million in 2023 and € 934 million in 2022 ).

Personnel costs - Summary of Pe

Personnel costs - Summary of Personal Costs (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Opella Business
Employee Benefits [Line Items]
Total(b)		€ 886	€ 826	€ 794
Salaries		7,236	7,183	7,145
Social security charges (including defined-contribution pension plans)		2,189	2,100	2,098
Other employee expense	[1]	766	531	748
Total(b)	[2]	€ 10,191	€ 9,814	€ 9,991
Personnel costs		Personnel costs Total personnel costs (other than termination benefits, presented in Note D.27.) include the following items: (€ million) 2024 2023 2022 Salaries 7,236 7,183 7,145 Social security charges (including defined-contribution pension plans) 2,189 2,100 2,098 Other employee benefits ( a) 766 531 748 Total (b) 10,191 9,814 9,991 (a) Includes expenses related to share-based payments and defined-benefit plans. (b) Includes personnel costs related to Opella of €886 million for 2024, €826 million for 2023, and €794 million for 2022 . T he total number of registered employees was 84,587 as of December 31, 2024 , compared with 87,994 as of December 31, 2023 and 91,573 as of December 31, 2022 .
[1] (a) Includes expenses related to share-based payments and defined-benefit plans. (b) Includes personnel costs related to Opella of €886 million for 2024, €826 million for 2023, and €794 million for 2022

Personnel costs - Additional In

Personnel costs - Additional Information (Details) - employee	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Employee Benefits [Abstract]
Number of employees	84,587	87,994	91,573

Other operating income (Details

Other operating income (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Disclosure Of Other Operating Income [Line Items]
Other operating income	€ 1,089	€ 979	[1]	€ 1,814	[1]
Other operating income (expense)
Disclosure Of Other Operating Income [Line Items]
Gains on divestment of some mature products	539	484		481
Regeneron | Other operating income (expense)
Disclosure Of Other Operating Income [Line Items]
Other operating income	166	227		1,147
Other related parties | Other operating income (expense)
Disclosure Of Other Operating Income [Line Items]
Other operating income	€ 221	€ 285		€ 1,179
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation

Other operating expenses - Addi

Other operating expenses - Additional Information (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Analysis of income and expense [abstract]
Other operating expense	€ 4,382	€ 3,443	[1]	€ 2,523	[1]
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation

Other operating expenses - Othe

Other operating expenses - Other Income and Expense (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses		€ (4,382)	€ (3,443)	[1]	€ (2,523)	[1]
Other operating income		1,089	979	[1]	1,814	[1]
Other operating income/(expenses), net related to Regeneron		(3,789)	(2,979)		(1,231)
Antibodies Collaboration agreement | Regeneron Pharmaceuticals, INC
Disclosure Of Other Operating Income Expenses [Line Items]
Commitments received for development costs		1,600	2,100
Regeneron
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses		(3,955)	(3,206)		(2,378)
Other operating income (expense) | Regeneron
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income		166	227		1,147
Monoclonal Antibody Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses		(3,947)	(3,196)		(2,367)
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of monoclonal antibodies
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses		(4,143)	(3,321)		(2,325)
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of Zaltrap
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	[2]	833	668		434
Monoclonal Antibody Alliance | Commercialization related expenses
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses		(637)	(543)		(476)
Immuno-Oncology Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income		0	0		16
Others
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income and expenses		€ 158	€ 217		€ 1,120
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (a) As of December 31, 2024, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to € 1.6 billion , compared with € 2.1 billion as of December 31, 2023 (see Note D.21.).

Restructuring costs and simil_3

Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	[1]	Dec. 31, 2022	[1]
Analysis of income and expense [abstract]
Employee-related expenses		€ 963	€ 404		€ 471
Charges, gains or losses on assets	[2]	4	273		261
Costs related to transformation programs		285	330		325
Other		144	23		20
Total		€ 1,396	€ 1,030	[3]	€ 1,077	[3]
[1] (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sano fi Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation

Restructuring costs and simil_4

Restructuring costs and similar items - Additional Information (Details) € in Millions	12 Months Ended
	Dec. 31, 2024 EUR (€)
Analysis of income and expense [abstract]
Increase in restructuring costs	€ 366

Other gains and losses, and l_2

Other gains and losses, and litigation (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Analysis of income and expense [abstract]
Other gains, (losses) and litigation	€ 470	€ 196	[1]	€ 143	[1]
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation

Financial expenses and income_2

Financial expenses and income (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Disclosure of detailed information about finance income expense [Line Items]
Cost of debt	[1]	€ (599)	€ (552)	[2]	€ (362)	[2]
Interest income	[3]	413	527	[2]	239	[2]
Cost of net debt		(186)	(25)	[2]	(123)	[2]
Non-operating foreign exchange gains/(losses)		6	(2)	[2]	(3)	[2]
Unwinding of discounting of provisions	[4]	(44)	(51)	[2]	(17)	[2]
Net interest cost related to employee benefits		(64)	(70)	[2]	(46)	[2]
Gains/(losses) on disposals of financial assets		0	(1)	[2]	1	[2]
Net interest expense on lease liabilities		(42)	(37)	[2]	(40)	[2]
Other	[5]	(224)	(523)	[2]	3	[2]
Net financial income/(expenses)		(554)	(709)	[2]	(225)	[2]
Financial expenses		(1,073)	(1,293)	[2],[6],[7]	(430)	[2],[6],[7],[8]
Financial income		519	584	[2],[6],[7]	205	[2],[6],[7],[8]
Liability recognised for estimated future royalties		(291)	(541)
Interest rate and currency derivatives used to hedge debt
Disclosure of detailed information about finance income expense [Line Items]
Gain on derivatives used to manage debt		(45)	(67)		(11)
Gain on derivatives used to manage cash and cash equivalents		€ (25)	€ (13)		€ 68
[1] (b) Includes net gains/(losses) on interest rate and currency derivatives used to manage debt: €(45) million in 2024 , €(67) million in 2023 , €(11) million in 2022 . (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (c) Includes net gains on interest rate and currency derivatives used to manage cash and cash equivalents: €(25) million in 2024 , €(13) million in 2023 , €68 million in 2022 . (d) Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note D.19.). (e) Includes a financial expense of € 291 million for the remeasurement of the liability recognized in the balance sheet for estimated future royalties on Beyfortus sales in the US. In 2023 , that expense amounted to € 541 million, reflecting the successful launch of Beyfortus (see Note C.2.). ( a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax)

Income tax expense - Summary of

Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Income Taxes [Abstract]
Current taxes		€ (2,152)	€ (2,251)	[1]	€ (2,631)	[1]
Deferred taxes		948	1,234	[1]	722	[1]
Total		(1,204)	(1,017)	[1],[2]	(1,909)	[1],[2]
Income before tax and investments accounted for using the equity method		€ 6,698	€ 6,251	[1],[2],[3]	€ 9,937	[1],[2],[3],[4]
Other items	[5]	2.70%	2.60%	[6]	1.30%	[6]
[1] (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation ( a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax) In determining the amount of the deferred tax liability for 2024 , 2023 and 2022 , Sanofi took into account changes in the ownership structure of certain subsidiaries (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Income tax expense - Summary _2

Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	[1]	Dec. 31, 2022	[1]
Income Taxes [Abstract]
Standard tax rate applicable in France		25.80%	25.80%		25.80%
Difference between the standard French tax rate and the rates applicable to the Sanofi	[2]	(13.30%)	(15.30%)		(6.90%)
Revisions to tax exposures and settlements of tax disputes		2.80%	3.10%		(0.80%)
Fair value remeasurement of contingent consideration			0.10%		(0.20%)
Other items	[3]	2.70%	2.60%		1.30%
Effective tax rate		18%	16.30%		19.20%
Other tax effects for reconciliation between accounting profit and tax expense (income)		€ 58
[1] (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France. For the year ended December 31, 2024, this line includes a tax expense of €58 million , representing the estimated impact of Pillar Two based on Sanofi’s current understanding of Pillar Two rules. In determining the amount of the deferred tax liability for 2024 , 2023 and 2022 , Sanofi took into account changes in the ownership structure of certain subsidiaries

Share of profit_loss from inv_2

Share of profit/loss from investments accounted for using the equity method (Details) € in Millions	12 Months Ended
	Dec. 31, 2024 EUR (€)
EUROAPI
Disclosure of associates [line items]
Impairment loss recognised in profit or loss	€ (77)

Net income attributable to no_3

Net income attributable to non-controlling interests (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Disclosure of net income attributable to non-controlling interests [line items]
Net income attributable to non-controlling interests	€ 58	€ 36	[1],[2]	€ 113	[1],[2]
Share of net income attributable to non-controlling interests
Disclosure of net income attributable to non-controlling interests [line items]
Net income attributable to non-controlling interests	€ 58	€ 36		€ 113
[1] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation

Related party transactions - Ad

Related party transactions - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 executives
Related Party [Abstract]
Average number of members of executive committee	13

Related party transactions - Sc

Related party transactions - Schedule of Compensation Paid to Key Management Personnel (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of compensation paid to key management personnel [abstract]
Short-term benefits	[1]	€ 37	€ 36	€ 31
Post-employment benefits		2	2	2
Share-based payment		21	8	19
Total recognized in profit or loss		€ 60	€ 46	€ 52
[1] (a) Compensation, employer’s social security contributions, directors’ compensation, and any termination benefits (net of reversals of termination benefit obligations).

Related party transactions - Su

Related party transactions - Summary of aggregate amounts Payable to Key Management Personnel (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Related Party [Abstract]
Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members	€ 9	€ 10	€ 10
Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel	€ 7	€ 6	€ 5

Disclosures about major custo_2

Disclosures about major customers and credit risk (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue (in percent)				8%
Net sales	€ 41,081	€ 37,817	[1]	€ 37,651	[1]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	41,081	37,817	[1]	37,651	[1]
Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Net sales	41,081	37,817	[2],[3]	37,651	[3],[4],[5]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	41,081	37,817	[2],[3]	37,651	[3],[4],[5]
Meningitis, Travel And Endemics Vaccines | Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Net sales	1,316	1,266	[3]	1,309	[3]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	1,316	1,266	[3]	1,309	[3]
Launches | Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Net sales	4,535	2,237	[3]	951	[3]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	€ 4,535	€ 2,237	[3]	€ 951	[3]
Largest customers
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue (in percent)	34%
Customer one
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue (in percent)	15%	13%		13%
Customer two
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue (in percent)	11%	10%		9%
Customer three
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue (in percent)	8%	8%
Europe
Disclosure of information about major customers and credit risk [line items]
Net sales	€ 9,027	€ 8,816	[6]	€ 8,490	[7]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	9,027	8,816	[6]	8,490	[7]
Europe | Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Net sales	9,027	8,816		8,490
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	9,027	8,816		8,490
Europe | Meningitis, Travel And Endemics Vaccines | Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Net sales	204	157		112
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	204	157		112
Europe | Launches | Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Net sales	960	491		215
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	960	491		215
US
Disclosure of information about major customers and credit risk [line items]
Net sales	19,986	17,262	[6]	16,986	[7]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	19,986	17,262	[6]	16,986	[7]
US | Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Net sales	19,986	17,262		16,986
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	19,986	17,262		16,986
US | Meningitis, Travel And Endemics Vaccines | Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Net sales	736	730		767
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	736	730		767
US | Launches | Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Net sales	2,998	1,533		623
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	2,998	1,533		623
Other Countries In Segment Results [Member] | Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Net sales	12,068	11,739		12,175
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	12,068	11,739		12,175
Other Countries In Segment Results [Member] | Meningitis, Travel And Endemics Vaccines | Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Net sales	376	379		430
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	376	379		430
Other Countries In Segment Results [Member] | Launches | Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Net sales	577	213		113
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net sales	€ 577	€ 213		€ 113
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation . (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax). (a) Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Other revenue (Details)

Other revenue (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	[2]	Dec. 31, 2022	[2]
Disclosure of information about major customers and credit risk [line items]
Other revenues		€ 3,205	€ 3,801	[1]	€ 2,910	[1]
Disclosure of other revenue [Table]		(€ million) 2024 2023 (a) 2022 (a) VaxServe sales of non-Sanofi products 1,959 2,167 1,567 COVID-19 vaccine related revenues — 509 257 Intragroup sales from continuing to discontinued operations (b) 163 188 208 Royalties 121 107 103 Other (c) 623 534 399 Total Biopharma Other revenues 2,866 3,505 2,534 Sales / Revenues from Opella products (d) 339 296 376 Total Other revenues 3,205 3,801 2,910 (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) Revenues generated by legal entities within the scope of continuing operations from the manufacture of Opella products on behalf of legal entities within the scope of discontinued operations. (c) This line mainly includes revenues received under agreements for Sanofi to provide manufacturing services to third parties. (d) Consumer Healthcare activities that will not be transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements ; (ii) sales made by the dedicated entity Opella Russie, the equity interests in which will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term ; and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).
Biopharma (operating segment)
Disclosure of information about major customers and credit risk [line items]
Other revenues		€ 2,866	3,505	[3]	2,534	[4],[5]
Royalty income		121	107		103
Revenue from COVID-19 vaccine		0	509		257
Revenue from intragroup sales from continuing to discontinued operations	[6]	163	188		208
Miscellaneous other revenue	[7]	623	534		399
Revenue from VaxServe sales of non-Sanofi products		1,959	2,167		1,567
Opella Business
Disclosure of information about major customers and credit risk [line items]
Other revenues	[8]	€ 339	€ 296		€ 376
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax). (b) Revenues generated by legal entities within the scope of continuing operations from the manufacture of Opella products on behalf of legal entities within the scope of discontinued operations. (c) This line mainly includes revenues received under agreements for Sanofi to provide manufacturing services to third parties. (d) Consumer Healthcare activities that will not be transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements ; (ii) sales made by the dedicated entity Opella Russie, the equity interests in which will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term ; and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).

Segment information - Summary o

Segment information - Summary of Net Sales by Segment and Geographical Area (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Disclosure of geographical areas [line items]
Net sales	€ 41,081	€ 37,817	[1]	€ 37,651	[1]
Biopharma (operating segment)
Disclosure of geographical areas [line items]
Net sales	41,081	37,817	[2],[3]	37,651	[3],[4],[5]
Disclosure of operating segments [line items]
Business operating income	11,285	11,155	[2]	12,764	[4],[5]
Biopharma (operating segment) | Dupixent [Member]
Disclosure of geographical areas [line items]
Net sales	13,072	10,715	[3]	8,292	[3]
Biopharma (operating segment) | Aubagio [Member]
Disclosure of geographical areas [line items]
Net sales		379		955	[3]	€ 2,029	[3]
Biopharma (operating segment) | Cerezyme [Member]
Disclosure of geographical areas [line items]
Net sales				686
Biopharma (operating segment) | Fabrazyme [Member]
Disclosure of geographical areas [line items]
Net sales				990
Biopharma (operating segment) | Myozyme Or Lumizyme [Member]
Disclosure of geographical areas [line items]
Net sales				782
Biopharma (operating segment) | Lovenox [Member]
Disclosure of geographical areas [line items]
Net sales				1,122
Biopharma (operating segment) | Industrial Sales [Member]
Disclosure of geographical areas [line items]
Net sales	523	551	[3]	608	[3]
Biopharma (operating segment) | Vaccines [Member]
Disclosure of geographical areas [line items]
Net sales		7,477
Biopharma (operating segment) | Polio Pertussis Hib Vaccines [Member]
Disclosure of geographical areas [line items]
Net sales	2,741	2,766	[3]	2,860	[3]
Biopharma (operating segment) | Influenza Vaccines [Member]
Disclosure of geographical areas [line items]
Net sales	2,555	2,669	[3]	2,977	[3]
Biopharma (operating segment) | RSV Vaccines (Beyfortus)
Disclosure of geographical areas [line items]
Net sales	1,686	547	[3]	0	[3]
Biopharma (operating segment) | Meningitis, Travel And Endemics Vaccines
Disclosure of geographical areas [line items]
Net sales	1,316	1,266	[3]	1,309	[3]
Biopharma (operating segment) | Nexviazyme
Disclosure of geographical areas [line items]
Net sales	667	425	[3]	196	[3]
Biopharma (operating segment) | Sarclisa
Disclosure of geographical areas [line items]
Net sales	471	381	[3]	294	[3]
Biopharma (operating segment) | ALTUVIIIO
Disclosure of geographical areas [line items]
Net sales	682	159	[3]	0	[3]
Biopharma (operating segment) | Rezurock
Disclosure of geographical areas [line items]
Net sales	470	310	[3]	207	[3]
Biopharma (operating segment) | Cablivi
Disclosure of geographical areas [line items]
Net sales	249	227	[3]	211	[3]
Biopharma (operating segment) | Xenpozyme
Disclosure of geographical areas [line items]
Net sales	151	91	[3]	21	[3]
Biopharma (operating segment) | Enjaymo
Disclosure of geographical areas [line items]
Net sales	105	72	[3]	22	[3]
Biopharma (operating segment) | Tzield
Disclosure of geographical areas [line items]
Net sales	54	25	[3]	0	[3]
Libtayo Segment
Disclosure of operating segments [line items]
Business operating income				952
Business Operating Income, Net of Tax				706
Europe
Disclosure of geographical areas [line items]
Net sales	9,027	8,816	[6]	8,490	[7]
Europe | Biopharma (operating segment)
Disclosure of geographical areas [line items]
Net sales	9,027	8,816		8,490
Europe | Biopharma (operating segment) | Dupixent [Member]
Disclosure of geographical areas [line items]
Net sales	1,618	1,224		940
Europe | Biopharma (operating segment) | Aubagio [Member]
Disclosure of geographical areas [line items]
Net sales		152		437		511
Europe | Biopharma (operating segment) | Industrial Sales [Member]
Disclosure of geographical areas [line items]
Net sales	520	528		580
Europe | Biopharma (operating segment) | Polio Pertussis Hib Vaccines [Member]
Disclosure of geographical areas [line items]
Net sales	497	477		479
Europe | Biopharma (operating segment) | Influenza Vaccines [Member]
Disclosure of geographical areas [line items]
Net sales	640	694		681
Europe | Biopharma (operating segment) | RSV Vaccines (Beyfortus)
Disclosure of geographical areas [line items]
Net sales	440	140		0
Europe | Biopharma (operating segment) | Meningitis, Travel And Endemics Vaccines
Disclosure of geographical areas [line items]
Net sales	204	157		112
Europe | Biopharma (operating segment) | Nexviazyme
Disclosure of geographical areas [line items]
Net sales	201	100		17
Europe | Biopharma (operating segment) | Sarclisa
Disclosure of geographical areas [line items]
Net sales	134	111		88
Europe | Biopharma (operating segment) | ALTUVIIIO
Disclosure of geographical areas [line items]
Net sales	0	0		0
Europe | Biopharma (operating segment) | Rezurock
Disclosure of geographical areas [line items]
Net sales	28	5		1
Europe | Biopharma (operating segment) | Cablivi
Disclosure of geographical areas [line items]
Net sales	93	98		94
Europe | Biopharma (operating segment) | Xenpozyme
Disclosure of geographical areas [line items]
Net sales	46	31		15
Europe | Biopharma (operating segment) | Enjaymo
Disclosure of geographical areas [line items]
Net sales	17	6		0
Europe | Biopharma (operating segment) | Tzield
Disclosure of geographical areas [line items]
Net sales	1	0		0
United States
Disclosure of geographical areas [line items]
Net sales	19,986	17,262	[6]	16,986	[7]
United States | Biopharma (operating segment)
Disclosure of geographical areas [line items]
Net sales	19,986	17,262		16,986
United States | Biopharma (operating segment) | Dupixent [Member]
Disclosure of geographical areas [line items]
Net sales	9,544	8,145		6,346
United States | Biopharma (operating segment) | Aubagio [Member]
Disclosure of geographical areas [line items]
Net sales		187		460		1,420
United States | Biopharma (operating segment) | Fabrazyme [Member]
Disclosure of geographical areas [line items]
Net sales				503
United States | Biopharma (operating segment) | Industrial Sales [Member]
Disclosure of geographical areas [line items]
Net sales	1	4		17
United States | Biopharma (operating segment) | Polio Pertussis Hib Vaccines [Member]
Disclosure of geographical areas [line items]
Net sales	679	721		787
United States | Biopharma (operating segment) | Influenza Vaccines [Member]
Disclosure of geographical areas [line items]
Net sales	1,433	1,406		1,737
United States | Biopharma (operating segment) | RSV Vaccines (Beyfortus)
Disclosure of geographical areas [line items]
Net sales	1,068	407		0
United States | Biopharma (operating segment) | Meningitis, Travel And Endemics Vaccines
Disclosure of geographical areas [line items]
Net sales	736	730		767
United States | Biopharma (operating segment) | Nexviazyme
Disclosure of geographical areas [line items]
Net sales	361	272		158
United States | Biopharma (operating segment) | Sarclisa
Disclosure of geographical areas [line items]
Net sales	200	165		127
United States | Biopharma (operating segment) | ALTUVIIIO
Disclosure of geographical areas [line items]
Net sales	617	155		0
United States | Biopharma (operating segment) | Rezurock
Disclosure of geographical areas [line items]
Net sales	425	303		206
United States | Biopharma (operating segment) | Cablivi
Disclosure of geographical areas [line items]
Net sales	136	112		110
United States | Biopharma (operating segment) | Xenpozyme
Disclosure of geographical areas [line items]
Net sales	81	52		5
United States | Biopharma (operating segment) | Enjaymo
Disclosure of geographical areas [line items]
Net sales	58	42		17
United States | Biopharma (operating segment) | Tzield
Disclosure of geographical areas [line items]
Net sales	52	25		0
Other Countries In Segment Results [Member] | Biopharma (operating segment)
Disclosure of geographical areas [line items]
Net sales	12,068	11,739		12,175
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Dupixent [Member]
Disclosure of geographical areas [line items]
Net sales	1,910	1,346		1,006
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Aubagio [Member]
Disclosure of geographical areas [line items]
Net sales		40		58		€ 98
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Cerezyme [Member]
Disclosure of geographical areas [line items]
Net sales				268
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Fabrazyme [Member]
Disclosure of geographical areas [line items]
Net sales				246
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Industrial Sales [Member]
Disclosure of geographical areas [line items]
Net sales	2	19		11
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Polio Pertussis Hib Vaccines [Member]
Disclosure of geographical areas [line items]
Net sales	1,565	1,568		1,594
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Influenza Vaccines [Member]
Disclosure of geographical areas [line items]
Net sales	482	569		559
Other Countries In Segment Results [Member] | Biopharma (operating segment) | RSV Vaccines (Beyfortus)
Disclosure of geographical areas [line items]
Net sales	178	0		0
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Meningitis, Travel And Endemics Vaccines
Disclosure of geographical areas [line items]
Net sales	376	379		430
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Nexviazyme
Disclosure of geographical areas [line items]
Net sales	105	53		21
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Sarclisa
Disclosure of geographical areas [line items]
Net sales	137	105		79
Other Countries In Segment Results [Member] | Biopharma (operating segment) | ALTUVIIIO
Disclosure of geographical areas [line items]
Net sales	65	4		0
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Rezurock
Disclosure of geographical areas [line items]
Net sales	17	2		0
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Cablivi
Disclosure of geographical areas [line items]
Net sales	20	17		7
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Xenpozyme
Disclosure of geographical areas [line items]
Net sales	24	8		1
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Enjaymo
Disclosure of geographical areas [line items]
Net sales	30	24		5
Other Countries In Segment Results [Member] | Biopharma (operating segment) | Tzield
Disclosure of geographical areas [line items]
Net sales	€ 1	€ 0		€ 0
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation . (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax). (a) Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Segment information - Schedule

Segment information - Schedule of Segment Results (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Disclosure of operating segments [line items]
Net sales	€ 41,081	€ 37,817	[1]	€ 37,651	[1]
Other revenues	3,205	3,801	[1],[2]	2,910	[1],[2]
Cost of sales	(13,205)	(12,628)	[1]	(11,882)	[1]
Research and development expenses	(7,394)	(6,507)	[1]	(6,501)	[1]
Selling and general expenses	(9,183)	(8,933)	[1]	(8,739)	[1]
Net income attributable to non-controlling interests	58	36	[1],[3]	113	[1],[3]
Biopharma (operating segment)
Disclosure of operating segments [line items]
Impairment of other intangible assets, net of reversals (excluding software)	415
Biopharma (operating segment) | Research and development projects and technology platforms
Disclosure of operating segments [line items]
Impairment of other intangible assets, net of reversals (excluding software)	640
Total
Disclosure of operating segments [line items]
Net sales	41,081	37,817	[4]	37,651	[5],[6]
Other revenues	3,205	3,801	[4]	2,910	[5],[6]
Cost of sales	(13,195)	(12,619)	[4]	(11,879)	[5],[6]
Research and development expenses	(7,394)	(6,507)	[4]	(6,501)	[5],[6]
Selling and general expenses	(9,183)	(8,933)	[4]	(8,739)	[5],[6]
Other operating income and expenses	(3,293)	(2,464)	[4]	(709)	[5],[6]
Share of profit/(loss) from investments accounted for using the equity method	136	101	[4]	76	[5],[6]
Net income attributable to non-controlling interests	(14)	(18)	[4]	(16)	[5],[6]
Business operating income	11,343	11,178	[4]	12,793	[5],[6]
Biopharma (operating segment)
Disclosure of operating segments [line items]
Net sales	41,081	37,817	[4],[7]	37,651	[5],[6],[7]
Other revenues	2,866	3,505	[2],[4]	2,534	[2],[5],[6]
Cost of sales	(12,973)	(12,415)	[4]	(11,682)	[5],[6]
Research and development expenses	(7,393)	(6,505)	[4]	(6,499)	[5],[6]
Selling and general expenses	(9,113)	(8,854)	[4]	(8,536)	[5],[6]
Other operating income and expenses	(3,305)	(2,476)	[4]	(764)	[5],[6]
Share of profit/(loss) from investments accounted for using the equity method	136	101	[4]	76	[5],[6]
Net income attributable to non-controlling interests	(14)	(18)	[4]	(16)	[5],[6]
Business operating income	11,285	11,155	[4]	12,764	[5],[6]
Other
Disclosure of operating segments [line items]
Net sales	0	0	[4]	0	[5],[6]
Other revenues	339	296	[4]	376	[5],[6]
Cost of sales	(222)	(204)	[4]	(197)	[5],[6]
Research and development expenses	(1)	(2)	[4]	(2)	[5],[6]
Selling and general expenses	(70)	(79)	[4]	(203)	[5],[6]
Other operating income and expenses	12	12	[4]	55	[5],[6]
Share of profit/(loss) from investments accounted for using the equity method	0	0	[4]	0	[5],[6]
Net income attributable to non-controlling interests	0	0	[4]	0	[5],[6]
Business operating income	€ 58	€ 23	[4]	€ 29	[5],[6]
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax). (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation .

Segment information - Schedul_2

Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details) € in Millions, $ in Millions		1 Months Ended		12 Months Ended
		Nov. 30, 2022 EUR (€)	Nov. 30, 2022 USD ($)	Dec. 31, 2024 EUR (€)	Dec. 31, 2023 EUR (€)		Dec. 31, 2022 EUR (€)
Disclosure of operating segments [line items]
Net income attributable to non-controlling interests				€ 58	€ 36	[1],[2]	€ 113	[1],[2]
Fair value remeasurement of contingent consideration				(96)	(93)	[2]	27	[2]
Restructuring costs and similar items				(1,396)	(1,030)	[2],[3]	(1,077)	[2],[3]
Other gains and losses, and litigation				(470)	(196)	[2]	(143)	[2]
Operating income				7,252	6,960	[2],[4]	10,162	[2],[4],[5]
Financial expenses				(1,073)	(1,293)	[2],[4],[6]	(430)	[2],[4],[5],[6]
Financial income				519	584	[2],[4],[6]	205	[2],[4],[5],[6]
Income before tax and investments accounted for using the equity method				6,698	6,251	[2],[4],[7]	9,937	[2],[4],[5],[7]
Immuno-oncology collaboration agreement | Regeneron Pharmaceuticals, INC
Disclosure of operating segments [line items]
Regular milestone payments for projects under collaboration agreements		€ 96	$ 100
Other intangible assets
Disclosure of operating segments [line items]
Impairment of other intangible assets, net of reversals (excluding software)				265	932		(454)
Other intangible assets | NK Cell and ProXTen technology platforms
Disclosure of operating segments [line items]
Impairment of other intangible assets, net of reversals (excluding software)					833
Other intangible assets | SAR444245
Disclosure of operating segments [line items]
Impairment of other intangible assets, net of reversals (excluding software)							1,586
Eloctate [Member]
Disclosure of operating segments [line items]
Reversal amount							2,154
Eloctate [Member] | Research and development projects and technology platforms
Disclosure of operating segments [line items]
Reversal amount							600
Impairment of other intangible assets, net of reversals (excluding software)							600
Biopharma (operating segment)
Disclosure of operating segments [line items]
Impairment of other intangible assets, net of reversals (excluding software)				415
Biopharma (operating segment) | Other intangible assets
Disclosure of operating segments [line items]
Impairment of other intangible assets, net of reversals (excluding software)				225
Biopharma (operating segment) | Research and development projects and technology platforms
Disclosure of operating segments [line items]
Impairment of other intangible assets, net of reversals (excluding software)				640
Biopharma (operating segment) | Clinical Study
Disclosure of operating segments [line items]
Impairment of other intangible assets, net of reversals (excluding software)				239
Operating segments
Disclosure of operating segments [line items]
Business operating income				11,343	11,178	[4]	12,793	[4],[5]
Material reconciling items
Disclosure of operating segments [line items]
Share of profit/(loss) from investments accounted for using the equity method	[8]			(136)	(101)	[4]	(76)	[4],[5]
Net income attributable to non-controlling interests	[9]			14	18	[4]	16	[4],[5]
Amortization and impairment of intangible assets	[10]			(1,997)	(2,807)	[4]	(1,375)	[4],[5]
Fair value remeasurement of contingent consideration				(96)	(93)	[4]	27	[4],[5]
Expenses arising from the impact of acquisitions on inventories	[11]			(10)	(9)	[4]	(3)	[4],[5]
Restructuring costs and similar items	[12]			(1,396)	(1,030)	[4]	(1,077)	[4],[5]
Other gains and losses, and litigation	[13]			€ (470)	€ (196)	[4]	€ (143)	[4],[5]
[1] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. ( a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€ 706 million net of tax) (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b) Joint ventures and associates with which Sanofi has entered into a strategic alliance. (c) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (d) For 2024, this line includes a net impairment charge of € 248 million mainly due to a recognition of impairment losses of € 640 million against on various research and development projects – including a €239 million loss resulting from the decision taken in February 2025 to discontinue a phase 3 clinical study investigating of a vaccine candidate to prevent invasive E.coli disease - partially offset by impairment losses reversals , recognized in connection with the disposals of the ProXTen platform and Enjaymo, for € 225 million and € 167 million respectively. For 2023, this amount mainly comprises an impairment loss of €833 million , reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and ProXTen technology platforms. For 2022, this line includes a reversal of €2,154 million on Eloctate franchise products following FDA approval of ALTUVIIIO on February 22, 2023, partially offset by an impairment loss of €1,586 million on intangible assets relating to SAR444245 (non- alpha interleukin-2). (e) This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date. (f) See note D.27 (g) See note D.28.

Segment information - Schedul_3

Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details) - Biopharma (operating segment) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disclosure of operating segments [line items]
Investments accounted for using the equity method (a)	[1]	€ 234	€ 234	€ 248
Acquisitions of property, plant and equipment		1,733	1,619	1,529
Acquisitions of other intangible assets		€ 1,462	€ 1,287	€ 574
[1] (a) Carrying amount at the end of the reporting period.

Segment information - Summary_2

Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Disclosure of geographical areas [line items]
Net sales	€ 41,081	€ 37,817	[1]	€ 37,651	[1]
Property, plant and equipment owned	10,091	10,160		9,869
Goodwill	43,384	49,404		49,892
Other intangible assets	22,629	24,319		21,640
Total
Disclosure of geographical areas [line items]
Net sales	41,081	37,817	[2]	37,651	[3]
Property, plant and equipment owned	10,091	10,160		9,869
Goodwill	43,384	49,404		49,892
Other intangible assets	22,629	24,319		21,640
Europe
Disclosure of geographical areas [line items]
Net sales	9,027	8,816	[2]	8,490	[3]
Property, plant and equipment owned	5,550	5,659		5,365
Goodwill	0	0		0
Other intangible assets	3,307	5,566		6,257
France
Disclosure of geographical areas [line items]
Net sales	1,814	1,910	[2]	1,830	[3]
Property, plant and equipment owned	3,112	3,085		2,875
Goodwill	0	0		0
Other intangible assets	0	0		0
United States
Disclosure of geographical areas [line items]
Net sales	19,986	17,262	[2]	16,986	[3]
Property, plant and equipment owned	2,411	2,322		2,457
Goodwill	0	0		0
Other intangible assets	18,711	17,850		14,174
Other countries
Disclosure of geographical areas [line items]
Net sales	12,068	11,739	[2]	12,175	[3]
Property, plant and equipment owned	2,130	2,179		2,047
Goodwill	0	0		0
Other intangible assets	€ 611	€ 903		€ 1,209
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (a) Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (a) Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Non-current asset held for sa_3

Non-current asset held for sale and discontinued operations (Details) - EUR (€) € / shares in Units, € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
Disclosure of analysis of single amount of discontinued operations [line items]
Assets Of Disposal Group Including Discontinued Operations	€ 13,489
Lease Liabilities, Disposal Group Including Discontinued Operations	112
Non-Current Provisions And Other Non-Current Liabilities, Disposal Group Including Discontinued Operations	204
Accounts Payable, Disposal Group Including Discontinued Operations	797
Current Provisions And Other Current Liabilities, Disposal Group Including Discontinued Operations	570
Other Liabilities, Disposal Group Including Discontinued Operations	448
Liabilities Of Disposal Group Including Discontinued Operations	2,131
Property, Plant And Equipmenet, Disposal Group Including Discontinued Operations	760
Right Of Use Assets, Disposal Group Including Discontinued Operations	116
Goodwill, Disposal Group Including Discontinued Operations	7,255
Other Intangible Assets, Disposal Group Including Discontinued Operations	2,928
Inventories, Disposal Group Including Discontinued Operations	600
Accounts Receivables, Disposal Group Including Discontinued Operations	989
Other Assets, Disposal Group Including Discontinued Operations	841
Net income excluding the exchanged/held-for-exchange Animal Health business	€ 64	€ 338	[1]	€ 401	[1]
Basic earnings (loss) per share from discontinued operations	€ 0.04	€ 0.25	[1]	€ 0.31	[1]
Revenue From Disposal Group Including Discontinued Operations	€ 5,031	€ 4,884		€ 4,781
Income Tax Expense (Benefit), Disposal Group Including Discontinued Operations	(240)	(585)		(97)
Operating Revenue, Disposal Group Including Discontinued Operations	305	915		494
Income Before Tax And Investments Accounted For Using The Equity Method, Disposal Group Including Discontinued Operations	288	902		485
Irrevocable purchase commitments given	705
Irrevocable Purchase Commitments Received	(1)
Research and development license agreements - contingent milestone payments in connection with development programs in progress	676
Total - net contributions given	1,380
Irrevocable Purchase Commitments, Discontinued Operations	704
Tax expense (income)	1,204	1,017	[1],[2]	1,909	[1],[2]
Deferred tax liability (asset)	(5,801)	€ (4,570)		€ (3,540)
Opella Business
Disclosure of analysis of single amount of discontinued operations [line items]
Tax expense (income)	122
Deferred tax liability (asset)	365
Changes in Profit Loss from Discontinued Operations	274
Less than 1 year
Disclosure of analysis of single amount of discontinued operations [line items]
Irrevocable purchase commitments given	160
Irrevocable Purchase Commitments Received	(1)
Research and development license agreements - contingent milestone payments in connection with development programs in progress	6
Total - net contributions given	165
Irrevocable Purchase Commitments, Discontinued Operations	159
From 1 to 3 years
Disclosure of analysis of single amount of discontinued operations [line items]
Irrevocable purchase commitments given	225
Irrevocable Purchase Commitments Received
Research and development license agreements - contingent milestone payments in connection with development programs in progress	560
Total - net contributions given	785
Irrevocable Purchase Commitments, Discontinued Operations	225
From 3 to 5 years
Disclosure of analysis of single amount of discontinued operations [line items]
Irrevocable purchase commitments given	204
Irrevocable Purchase Commitments Received
Research and development license agreements - contingent milestone payments in connection with development programs in progress	77
Total - net contributions given	281
Irrevocable Purchase Commitments, Discontinued Operations	204
More than 5 years
Disclosure of analysis of single amount of discontinued operations [line items]
Irrevocable purchase commitments given	116
Irrevocable Purchase Commitments Received
Research and development license agreements - contingent milestone payments in connection with development programs in progress	33
Total - net contributions given	149
Irrevocable Purchase Commitments, Discontinued Operations	€ 116
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

Principal accountants' fees a_3

Principal accountants' fees and services (Details) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Disclosure of audit fees and other services [line items]
Auditor's remuneration for comfort letters and attestation services		€ 0.5
Forvis Mazars
Disclosure of audit fees and other services [line items]
Statutory audit of separate and consolidated financial statements	[1]		€ 15.1
Services other than statutory audit	[2]		5.4
Audit-related services	[3],[4]		5.3
Tax			0
Other			0.1
Total			€ 20.5
Statutory audit of separate and consolidated financial statements, percentage	[1]		74%
Percentage Of Auditor Remuneration For Limited Review of Sustainability Statement	[5]		0%
Auditors Remuneration for Limited Review of Sustainability Statement	[5]		€ 0
Services other than statutory audit, percentage	[2]		26%
Total, percentage			100%
Audit of the financial statements of the parent company and its French subsidiaries			€ 7.9
Audit-related services charged to the parent company and its French subsidiaries			5.2
PricewaterhouseCoopers
Disclosure of audit fees and other services [line items]
Statutory audit of separate and consolidated financial statements	[1]	19.7	14.7
Services other than statutory audit	[2]	6.4	5.8
Audit-related services	[3],[4]	6.4	5.8
Tax		0	0
Other		0	0
Total		€ 27.1	€ 20.5
Statutory audit of separate and consolidated financial statements, percentage	[1]	73%	72%
Percentage Of Auditor Remuneration For Limited Review of Sustainability Statement	[5]	4%	0%
Auditors Remuneration for Limited Review of Sustainability Statement	[5]	€ 1	€ 0
Services other than statutory audit, percentage	[2]	23%	28%
Total, percentage		100%	100%
Audit of the financial statements of the parent company and its French subsidiaries		€ 12.5	€ 8.3
Audit-related services charged to the parent company and its French subsidiaries		3.5	€ 3.6
Forvis Mazars
Disclosure of audit fees and other services [line items]
Statutory audit of separate and consolidated financial statements	[1]	11.5
Services other than statutory audit	[2]	0.2
Audit-related services	[3],[4]	0.2
Tax		0
Other		0
Total		€ 12.3
Statutory audit of separate and consolidated financial statements, percentage	[1]	93%
Percentage Of Auditor Remuneration For Limited Review of Sustainability Statement	[5]	5%
Auditors Remuneration for Limited Review of Sustainability Statement	[5]	€ 0.6
Services other than statutory audit, percentage	[2]	2%
Total, percentage		100%
Audit of the financial statements of the parent company and its French subsidiaries		€ 4.8
Audit-related services charged to the parent company and its French subsidiaries		€ 0.1
[1] (a) Includes services provided by the independent auditors of the parent company and French subsidiaries: Forvis Mazars €4.8 million in 2024 ; PricewaterhouseCoopers Audit €12.5 million in 2024 , €8.3 million in 2023 and Ernst & Young €7.9 million in 2023 . (c) Services other than statutory audit provided by Forvis Mazars during 2024 comprised: - assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy. Services other than statutory audit provided by PricewaterhouseCoopers during 2024 comprised: - contractual audits, including on the combined financial statements of the Opella business; - additional procedures to enable reports previously signed by the firm to be incorporated by reference; and - assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy. (e) Includes €0.5 million for services that can only be provided by the statutory auditors, such as comfort letters, attestation services required by regulation (which qualify as audit fees under SEC rules). (d) Includes services provided by the independent auditors of the parent company and French subsidiaries: Forvis Mazars: €0.1 million in 2024 ,; PricewaterhouseCoopers Audit €3.5 million in 2024 , €3.6 million in 2023 and Ernst & Young €5.2 million in 2023 . (b) For SEC purposes, these Services are classified as Other.

List of principal companies i_3

List of principal companies included in the scope of consolidation during 2023 - Summary of Principal Companies and their Country of Incorporation (Details)		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Hoechst GmbH * | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies	[1]	100%
Sanofi-Aventis Deutschland GmbH | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies	[1]	100%
A. Nattermann & Cie GmbH | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis GmbH | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Belgium | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Ablynx NV | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Genzyme Flanders BV | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi A/S | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies			100%
Sanofi-Aventis SA | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Spain, SL | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies			100%
Sanofi Oy | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Winthrop Industrie * | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies	[1]	100%
Sanofi-Aventis Recherche & Développement | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Groupe | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Participations * | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies	[1]	100%
Sanofi Pasteur | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Aventis Pharma SA | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Biotechnology * | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies	[1]	100%
Sanofi Pasteur NVL | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Pasteur Europe | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Pasteur Merieux SAS | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare International SAS | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare France SAS | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Group SAS | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Genzyme Polyclonals SAS | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis AEBE | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Private Co Ltd | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		99.60%
Chinoin Private Co Ltd | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		99.60%
Opella Healthcare Hungary Commercial KFT | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Hungary KFT | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Carraig Insurance DAC | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Genzyme Ireland Limited | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-aventis Holdings (Ireland) Ltd | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi SRL | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Italy SRL | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Genzyme Global Sarl | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Genzyme Luxembourg Sarl | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-aventis Norge AS | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies			100%
Sanofi BV * | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies	[1]	100%
Sanofi Foreign Participations BV * | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies	[1]	100%
Sanofi-Aventis Sp zoo | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies			100%
Opella Healthcare Poland sp.ZOO | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Produtos Farmaceuticos Lda | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi sro | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Romania SRL | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Romania SRL | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis UK Holdings Limited | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Aventis Pharma Limited | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Synthelabo UK Ltd | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Aventis Pharma Holdings Ltd | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare UK Limited | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
AO Sanofi Russia | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare LLC | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi AB | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis (Suisse) SA | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Genzyme Global Sarl Baar Intellectual Property Branch | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Ilac Sanayi ve Ticaret AS | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Pasteur Asi Ticaret AS | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Tüketici Sağlığı Anonim Şirketi | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies			100%
Sanofi Saglik Urunleri Limited Sirketi | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Genzyme Therapeutic Products Limited Partnership | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Aventis Inc * | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies	[1]	100%
Sanofi US Services Inc | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis U.S. LLC | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Chattem, Inc | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Aventisub LLC | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Genzyme Corporation * | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies	[1]	100%
Sanofi Pasteur Inc * | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies	[1]	100%
VaxServe, Inc | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Bioverativ Inc | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Bioverativ U.S.LLC | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Bioverativ Therapeutics Inc | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Principia Biopharma Inc | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Bioverativ Holdings LLC | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
RPR US Ltd | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Kadmon Corporation, LLC | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Synthorx, Inc | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Provention Bio | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
QRIB Intermediate Holding | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
QRI | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Chattem (GB) Holding | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Translate Bio, Inc | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis South Africa (Pty) Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Algérie | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Arabia Trading Company Limited | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Argentina SA | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Healthcare Pty Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Australia Pty Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Medley Farmaceutica Ltda | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Brazil Ltda | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Canada Inc | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Pasteur Limited | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Merieux Canada Holdings ULC (Canada) | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi (Hangzhou) Pharmaceuticals Co Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi (China) Investment Co Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi (Beijing) Pharmaceuticals Co Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Shenzhen Sanofi pasteur Biological Products Co Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Shanghai Rongheng Pharmaceutical Co Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis de Colombia SA | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Korea Co Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Gulf FZE | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Egypt | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		99.80%
Sanofi Hong-Kong Limited | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi India Limited | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		60.40%
Sanofi Healthcare India Private Limited | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		99.90%
Sanofi-Aventis Israël Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi KK | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
SSP Co Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis (Malaysia) SDN BHD | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Maroc | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis de Mexico SA de CV | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Pasteur SA de CV | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Azteca Vacunas SA de CV | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis de Panama SA | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Panama SA | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
sanofi-aventis Puerto Rico Inc | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Philippines Inc | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Philippines Inc | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Singapore Pte Ltd * | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies	[1]	100%
Aventis Pharma (Manufacturing) Pte Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Manufacturing Pte Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Taiwan Co Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis (Thailand) Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis de Venezuela SA | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-aventis Vietnam Company Limited | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Vietnam Shareholding Company Limited | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		85%
Aventis Agriculture France | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare France | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Le Rock Re | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Participation BV Netherlands | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Ventures LLC | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Kadmon Pharmaceuticals LLC | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Gold Bond Co LLC | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi AATD, Inc. | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Argentina S.A.U. | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi Vaccines Chile S.A | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi (Jiangsu) Biologics Co., Ltd | Other countries
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Sanofi-Aventis Ireland Ltd | Europe
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Bioverativ USA Inc | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Genzyme de Argentina SA | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Shanghai LTD | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
Opella Healthcare Colombia SAS | United States
Disclosure of subsidiaries [line items]
Financial interest in principal fully consolidated companies		100%
[1] * Main significant subsidiaries as of December 31, 2024

List of principal companies i_4

List of principal companies included in the scope of consolidation during 2023 - Summary of Principal Investments Accounted for Using the Equity Method (Details)	12 Months Ended
	Dec. 31, 2024
Haleon US, LP
Disclosure of joint operations [line Items]
Financial interest in principal investments accounted for using the equity method	11.70%
Infraserv GmbH & Co. Höchst KG
Disclosure of joint operations [line Items]
Financial interest in principal investments accounted for using the equity method	31.20%
Maphar
Disclosure of joint operations [line Items]
Financial interest in principal investments accounted for using the equity method	48.30%
MCM Vaccine BV
Disclosure of joint operations [line Items]
Financial interest in principal investments accounted for using the equity method	50%
MSP Vaccine Company (formerly MCM company)
Disclosure of joint operations [line Items]
Financial interest in principal investments accounted for using the equity method	50%
EUROAPI
Disclosure of joint operations [line Items]
Financial interest in principal investments accounted for using the equity method	29.60%

Events subsequent to December_2

Events subsequent to December 31, 2023 (Details) - EUR (€) € / shares in Units, € in Billions	Feb. 02, 2025	Feb. 06, 2025	Jan. 29, 2025
Disclosure of non-adjusting events after reporting period [line items]
Value	€ 3
Number of shares (in shares)	29,556,650
Amount Per Share, Shares Repurchased			€ 101.50
Amount Of Shares Repurchased, Maximum Limit		€ 2	€ 5

Cybersecurity Risk Management_2

Cybersecurity Risk Management and Strategy (Details)	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management and Strategy Disclosure Abstract [Abstract]
Cybersecurity Risk Management Processes Integrated	true
Cybersecurity Risk Management Third Party Engaged	true
Cybersecurity Risk Third Party Oversight and Identification Processes	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant	true
Cybersecurity Risk Management Positions or Committees Responsible Report to Board	true